

10-1-2008

# Schmechel v. Dille Clerk's Record v. 4 Dckt. 35050

Follow this and additional works at: [https://digitalcommons.law.uidaho.edu/idaho\\_supreme\\_court\\_record\\_briefs](https://digitalcommons.law.uidaho.edu/idaho_supreme_court_record_briefs)

---

## Recommended Citation

"Schmechel v. Dille Clerk's Record v. 4 Dckt. 35050" (2008). *Idaho Supreme Court Records & Briefs*. 2029.  
[https://digitalcommons.law.uidaho.edu/idaho\\_supreme\\_court\\_record\\_briefs/2029](https://digitalcommons.law.uidaho.edu/idaho_supreme_court_record_briefs/2029)

This Court Document is brought to you for free and open access by Digital Commons @ UIIdaho Law. It has been accepted for inclusion in Idaho Supreme Court Records & Briefs by an authorized administrator of Digital Commons @ UIIdaho Law. For more information, please contact [annablaine@uidaho.edu](mailto:annablaine@uidaho.edu).

LAW CLERK

IN THE  
**SUPREME COURT**  
OF THE  
**STATE OF IDAHO**

VAUGHN SCHEMECHEL, ETAL

Plaintiff/Appellant

and

CLINTON DILLON, ETAL

Defendant/Respondent

and

FIFTH

Appealed from the District Court of the  
Judicial District for the State of Idaho, in and

G. for RICHARD SEVAN County

Hon. District Judge

DAVID COMSTOCK

X

Attorney for Appellant

STEVEN HIPPLER  
RICHARD HALL

X  
Attorney for Respondent

Filed this day of , 20

FILED - COPY

OCT - 1 2008

Clerk

By Supreme Court Court of Appeals Deputy

Entered on ATS by:

IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT OF THE  
STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS

VAUGHN SCHMECHEL, individually and as )  
surviving spouse and Personal Representative )  
of the Estate of Rosie Schmechel, deceased )  
and ROBERT P. LEWIS, KIM HOWARD )  
and TAMARA HALL, natural children of )  
ROSALIE SCHMECHEL, deceased, )

CASE NO. CV 05-4345

Plaintiffs/Appellants, )

vs )

CLINTON DILLE, M.D., SOUTHERN )  
IDAHO PAIN INSTITUTE, an Idaho )  
Corporation, THOMAS BYRNE, P. A., )  
and JOHN DOE and JANE DOE, I through X, )

Defendants/Respondents. )

CLERK'S SUPPLEMENTAL RECORD ON APPEAL  
VOLUME 1

Appeal from the District Court of the Fifth Judicial District  
of the State of Idaho, in and for the County of Twin Falls

HONORABLE G. RICHARD BEVAN  
District Judge

David Comstock  
Byron Foster  
199 N Capitol Blvd., Ste 500  
P. O. Box 2774  
Boise, ID 83701-2774

Steven Hippler  
J. Will Varin  
601 W, Bannock Street  
P. O. Box 2720  
Boise, ID 83701-2720

ATTORNEY FOR APPELLANT

ATTORNEY FOR RESPONDENT

**Supplemental Table of Contents**

**VOLUME 1**

Clerk's Supplemental Record on Appeal, Volume 1 ..... 1  
Supplemental Table of Contents, Volume 1 ..... 2  
Supplemental Index, Volume 1 ..... 4  
Register of Action, Printed September 11, 2008 ..... 6  
Plaintiff's Expert Witness Disclosures, Filed April 20, 2007 ..... 23  
Defendant Thomas J. Byrne's Disclosure of Expert Witnesses, Filed June 18, 2007 ..... 152

**VOLUME 2**

Clerk's Supplemental Record on Appeal, Volume 2 ..... 221  
Supplemental Table of Contents, Volume 2 ..... 222  
Supplemental Index, Volume 2 ..... 224  
Register of Action, Printed September 11, 2008 ..... 226  
Affidavit of Counsel in Support of Defendant Thomas Byrne, P.A.'s Motion in Limine RE:  
Various Issues, Filed September 27, 2007 ..... 243  
Affidavit of J. Will Varin in Support of Clinton Dille and The Southern Idaho Pain Institute's Motions in  
Limine, Filed October 1, 2007 ..... 289  
Defendants Clinton Dille, M.D. and Southern Idaho Pain Institutes' Memorandum in  
Support of Motions in Limine, Filed October 1, 2007 ..... 315  
Memorandum in Support of Thomas J. Byrne's Motion in Limine Re: Various Issues,  
Filed October 1, 2007 ..... 341  
Affidavit of J. Will Varin in Support of Clinton Dille and The Southern Idaho Pain Institute's Response to  
Plaintiffs' Motion in Limine, Filed October 5, 2007 ..... 365

**VOLUME 3**

Clerk's Supplemental Record on Appeal, Volume 3 .....432

Supplemental Table of Contents, Volume 3.....433

Supplemental Index, Volume 3 .....435

Register of Action, Printed September 11, 2008 .....437

Affidavit of Byron Foster in Support of Plaintiffs' Pretrial Memorandum,  
Filed October 9, 2007 .....454

Plaintiffs' Proposed Jury Instructions, Filed October 9, 2007 .....501

Defendant Thomas J. Byrne, P.A.'s Proposed Jury Instructions, Filed October 9, 2007 .....562

Defendant Clinton Dille M.D. and Southern Idaho Pain Institute's Trial Brief,  
Filed October 10, 2007 .....602

**VOLUME 4**

Clerk's Supplemental Record on Appeal, Volume 4 .....627

Supplemental Table of Contents, Volume 4.....628

Supplemental Index, Volume 4 .....630

Register of Action, Printed September 11, 2008 .....632

Defendants Clinton Dille M.D. and Southern Idaho Pain Institute's Jury Instructions,  
Filed October 10, 2007 .....649

Affidavit of Chris D. Comstock Regarding the Parties' Motions in Limine,  
Filed October 15, 2007 .....733

**VOLUME 5**

Clerk's Supplemental Record on Appeal, Volume 5 .....818

Supplemental Table of Contents, Volume 5.....819

Supplemental Index, Volume 5 .....	821
Register of Action, Printed September 11, 2008 .....	823
Supplemental Bench Brief Regarding Jury Instruction on Reckless Conduct, Filed October 23, 2007 .....	840
Affidavit of Byron V. Foster in Support of Plaintiffs' Motion for New Trial, Filed November 17, 2007 .....	869

**VOLUME 6**

Clerk's Record on Appeal, Volume 6 .....	1049
Supplemental Table of Contents, Volume 6 .....	1050
Supplemental Index, Volume 6 .....	1052
Register of Action, Printed September 11, 2008 .....	1054
Defendant Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion for New Trial, Filed December 3, 2007 .....	1071
Affidavit Keely E. Duke in Support of Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion for New Trial, Filed December 3, 2007 .....	1097
Affidavit of Steven J. Hippler in Support of Clinton Dille and the Southern Idaho Pain Institute's Response to Plaintiffs' Motion for New Trial, [ <b>ending with exhibit C</b> ], Filed December 3, 2007 .....	1168

**VOLUME 7**

Clerk's Supplemental Record on Appeal, Volume 7 .....	1275
Supplemental Table of Contents, Volume 7 .....	1276
Supplemental Index, Volume 7 .....	1278
Register of Action, Printed September 11, 2008 .....	1280
Affidavit of Steven J. Hippler in Support of Clinton Dille and the Southern Idaho Pain Institute's Response to Plaintiffs' Motion for New Trial, [ <b>starting with exhibit D</b> ], Filed December 3, 2007 .....	1297

**Supplemental Index**

**VOLUME 1**

Clerk's Supplemental Record on Appeal, Volume 1 .....1  
Defendant Thomas J. Byrne's Disclosure of Expert Witnesses, Filed June 18, 2007 ..... 152  
Plaintiff's Expert Witness Disclosures, Filed April 20, 2007.....23  
Register of Action, Printed September 11, 2008 ..... 6  
Supplemental Index, Volume 1 .....4  
Supplemental Table of Contents, Volume 1 .....2

**VOLUME 2**

Affidavit of Counsel in Support of Defendant Thomas Byrne, P.A.'s Motion in Limine RE:  
Various Issues, Filed September 27, 2007.....243  
  
Affidavit of J. Will Varin in Support of Clinton Dille and The Southern Idaho Pain Institute's Motions in  
Limine, Filed October 1, 2007 ..... 289  
  
Affidavit of J. Will Varin in Support of Clinton Dille and The Southern Idaho Pain Institute's Response to  
Plaintiffs' Motion in Limine, Filed October 5, 2007 ..... 365  
  
Clerk's Supplemental Record on Appeal, Volume 2 .....221  
  
Defendants Clinton Dille, M.D. and Southern Idaho Pain Institutes' Memorandum in  
Support of Motions in Limine, Filed October 1, 2007 .....315  
  
Memorandum in Support of Thomas J. Byrne's Motion in Limine Re: Various Issues,  
Filed October 1, 2007 .....341  
  
Register of Action, Printed September 11, 2008 ..... 226  
Supplemental Index, Volume 2 .....224  
Supplemental Table of Contents, Volume 2 .....222

**VOLUME 3**

Affidavit of Byron Foster in Support of Plaintiffs' Pretrial Memorandum,  
Filed October 9, 2007 .....454

Clerk's Supplemental Record on Appeal, Volume 3 ..... 432

Defendant Clinton Dille M.D. and Southern Idaho Pain Institute's Trial Brief,  
Filed October 10, 2007 .....602

Defendant Thomas J. Byrne, P.A.'s Proposed Jury Instructions, Filed October 9, 2007 .....562

Plaintiffs' Proposed Jury Instructions, Filed October 9, 2007 .....501

Register of Action, Printed September 11, 2008 ..... 437

Supplemental Index, Volume 3 ..... 435

Supplemental Table of Contents, Volume 3.....433

**VOLUME 4**

Affidavit of Chris D. Comstock Regarding the Parties' Motions in Limine,  
Filed October 15, 2007 .....733

Clerk's Supplemental Record on Appeal, Volume 4 .....627

Defendants Clinton Dille M.D. and Southern Idaho Pain Institute's Jury Instructions,  
Filed October 10, 2007 .....649

Register of Action, Printed September 11, 2008 .....632

Supplemental Index, Volume 4 .....630

Supplemental Table of Contents, Volume 4.....628

**VOLUME 5**

Affidavit of Byron V. Foster in Support of Plaintiffs' Motion for New Trial,  
Filed November 17, 2007 .....869

Clerk's Supplemental Record on Appeal, Volume 5 .....	818
Register of Action, Printed September 11, 2008 .....	823
Supplemental Bench Brief Regarding Jury Instruction on Reckless Conduct, Filed October 23, 2007 .....	840
Supplemental Index, Volume 5 .....	821
Supplemental Table of Contents, Volume 5 .....	819

**VOLUME 6**

Affidavit Keely E. Duke in Support of Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion for New Trial, Filed December 3, 2007 .....	1097
Affidavit of Steven J. Hippler in Support of Clinton Dille and the Southern Idaho Pain Institute's Response to Plaintiffs' Motion for New Trial, [ <b>ending with exhibit C</b> ], Filed December 3, 2007 .....	1168
Clerk's Record on Appeal, Volume 6 .....	1049
Defendant Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion for New Trial, Filed December 3, 2007 .....	1071
Register of Action, Printed September 11, 2008 .....	1054
Supplemental Index, Volume 6 .....	1052
Supplemental Table of Contents, Volume 6 .....	1050

**VOLUME 7**

Affidavit of Steven J. Hippler in Support of Clinton Dille and the Southern Idaho Pain Institute's Response to Plaintiffs' Motion for New Trial, [ <b>starting with exhibit D</b> ], Filed December 3, 2007 .....	1297
Clerk's Supplemental Record on Appeal, Volume 7 .....	1275
Register of Action, Printed September 11, 2008 .....	1280
Supplemental Index, Volume 7 .....	1278
Supplemental Table of Contents, Volume 7 .....	1276

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
10/3/2005	NOAP	QUAM	Notice Of Appearance
		QUAM	Filing: A1 - Civil Complaint, More Than \$1000 No Prior Appearance Paid by: Mick Hodges Receipt number: 5024920 Dated: 10/3/2005 Amount: \$82.00 (Check)
	COMP	QUAM	Complaint Filed
	SMIS	QUAM	Summons Issued x 3
11/7/2005		QUAM	Filing: 11A - Civil Answer Or Appear. More Than \$1000 No Prior Appearance Paid by: Givens Pursley, LLP Receipt number: 5027934 Dated: 11/7/2005 Amount: \$52.00 (Check)
	ANSW	QUAM	Answer To Complaint And Demand For Jury Trial
2/14/2005	HRSC	COOPE	Hearing Scheduled (Scheduling Conference 01/04/2006 01:30 PM)
	OSCO	COOPE	Order for Scheduling Conference and Order RE: Motion Practice
2/19/2005	LETT	COOPE	Letter from David Comstock
2/21/2005	HRVC	COOPE	Hearing result for Scheduling Conference held on 01/04/2006 01:30 PM: Hearing Vacated
2/30/2005	AFSV	NIELSEN	Affidavit Of Service
	SMRT	NIELSEN	Summons Returned
1/5/2006		FERCH	Filing: 17A - Civil Answer Or Appear. All Other Actions No Prior Appearance Paid by: Hall Farley Oberrecht Blanton Receipt number: 6000440 Dated: 1/5/2006 Amount: \$52.00 (Check)
	NOAP	FERCH	Notice Of Appearance
	ANSW	FERCH	Defendant Thomas J Byrne's Answer to plaintiffs complaint and demand for jury trial
1/20/2006	SMRT	NIELSEN	Summons Returned Clinton Dille, M.D.
	SMRT	NIELSEN	Summons Returned Southern Idaho Pain Institute
1/6/2006	NOSV	NIELSEN	Notice Of Service
1/14/2006	HRSC	COOPE	Hearing Scheduled (Scheduling Conference 03/06/2006 01:30 PM)
1/15/2006	OSCO	COOPE	Order for Scheduling Conference and Order RE: Motion Practice
1/24/2006	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
1/2/2006	STIP	COOPE	Stipulation for Scheduling and Planning
1/8/2006	HRVC	COOPE	Hearing result for Scheduling Conference held on 03/06/2006 01:30 PM: Hearing Vacated
	HRSC	COOPE	Hearing Scheduled (Jury Trial 10/16/2007 09:00 AM) Excluding Mondays
	HRSC	COOPE	Hearing Scheduled (Civil Pretrial Conference 09/24/2007 02:30 PM)

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
3/8/2006	HRSC	COOPE	Hearing Scheduled (Status/ADR 09/05/2007 01:32 PM)
3/9/2006	NOJT	COOPE	Notice Of Jury Trial Setting, Pretrial Conference And Order Governing Further Proceedings
4/3/2006	NOTR	NIELSEN	Notice Of Preparation Of Transcript
4/6/2006	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Defendant Clinton Dille, M.D.
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Thomas Byrne, PA
4/18/2006	NOSV	NIELSEN	Notice Of Service 04-17-06
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Amber Zaccone
5/1/2006	NOTC	RKLINE	Amended Notice Of Taking Video Deposition Duces Tecum Of Thomas Byrne, PA
	NOTC	RKLINE	Amended Notice Of Taking Video Deposition Duces Tecum Of Defendant Clinton Dille, M.D.
5/10/2006	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
5/9/2006	NOTR	NIELSEN	Notice Of Preparation Of Transcript
	NOTR	NIELSEN	Notice Of Preparation Of Transcript
	NOTR	NIELSEN	Notice Of Preparation Of Transcript
5/19/2006	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum (Timothy Floyd, M.D.)
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum (Julian Nicholson, M.D.)
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum (Records Custodian-Sun Valley Spine Institute)
5/26/2006	NODT	NIELSEN	Amended Notice Of Deposition Duces Tecum (Julian Nicholson, M.D.)
	NODT	NIELSEN	Amended Notice Of Deposition Duces Tecum (Records Custodian - Sun Valley Spine Institute)
5/30/2006	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
7/3/2006	SUBR	NIELSEN	Subpoena Returned
	AFSV	NIELSEN	Affidavit Of Service
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum (Records Custodian - Spine Institute of Idaho)
	SUBR	NIELSEN	Subpoena Returned
	AFFD	NIELSEN	Affidavit of Non-Service
7/13/2006	NOSV	MCMULLEN	Notice Of Service
7/14/2006	NOSV	NIELSEN	Notice Of Service
	NOSV	NIELSEN	Notice Of Service
7/17/2006	NTSD	NIELSEN	Notice Of Service Of Discovery Responses
	NTSD	NIELSEN	Notice Of Service Of Discovery Responses

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
7/25/2006	SUBR	NIELSEN	Subpoena Returned
	AFFD	NIELSEN	Affidavit of Non-Service
8/8/2006	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
8/29/2006	NOSV	NIELSEN	Notice Of Service
8/19/2007	MOTN	NIELSEN	Motion for Leave to Amend Complaint to Include Claim for Punitive Damages fax
8/20/2007	AFFD	NIELSEN	Supplemental Affidavit of Arthur G. Lipman, Pharm.D.
	AFFD	NIELSEN	Affidavit of Arthur G. Lipman, Pharm.d.
	MEMO	NIELSEN	Memorandum in Support of Plaintiffs' Motion for Leave to Amend Complaint to Include Claim for Punitive Damages
		NIELSEN	Plaintiffs' Expert Witness Disclosures
8/26/2007	HRSC	COOPE	Hearing Scheduled (Motion 06/18/2007 09:00 AM) to amend complaint to add punitive damages
	NOHG	NIELSEN	Notice Of Hearing Re: Motion for Leave to Amend Complaint to Include Claim for Punitive Damages
8/11/2007	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Kimberly Vorse, M.D.
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of David Verst, M.D.
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum \$of Juanita Peterson
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Carl Peterson
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Cindy Sheer
8/18/2007		NIELSEN	Defendant Thomas Byrne, P.A.'s Disclosure of Lay Witnesses
8/23/2007		NIELSEN	Plaintiffs' Lay Witness List fax
8/24/2007	NOSV	NIELSEN	Notice Of Service
	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Carl Peterson
	NOTC	NIELSEN	Notice of Vacating Deposition Duces Tecum of Juanita Peterson
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Kenneth Harris, M.D.
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Julian Nicholson, M.D.
	NODT	NIELSEN	amended Notice Of Taking Deposition Duces Tecum of Cindy Sheer

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
5/24/2007	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Kent Jensen
5/25/2007		NIELSEN	Defendant Thomas Byrne, P.a.'s Supplemental Disclosure of Lay Witnesses fax
5/30/2007	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Kimberly Vorse, M.D. Fax
5/4/2007	AFFD	NIELSEN	Second Supplemental Affidavit of Arthur G. Lipman, Pharm.D.
	NOHG	NIELSEN	Notice Of Hearing
	AFFD	NIELSEN	Affidavit of Counsel in Support of Defendant Thomas Byrne's Motion to Strike Portions of the Affidavits of Arthur G. Lipman, Pharm. D.
	MOTN	NIELSEN	Defendant Thomas Byrne's Motion to Strike Portions of the Affidavits of Arthur G. Lipman, Pharm.D.
	AFFD	NIELSEN	Affidavit of Keri Fakata, Pharm.D
		NIELSEN	Defendant Thomas Byrne's Memorandum in Support of Motion to Strike Portions of the Affidavits of Arthur G. Lipman, Pharm.D.
5/6/2007		NIELSEN	Defendant Clinton Dille, M.D.'s Joinder in Motion to Strike Portions of the Affidavit of Arthur G. Lipman Pharm. D. fax
5/11/2007	AFFD	NIELSEN	Affidavit of Byron V. Foster
	AFFD	NIELSEN	Affidavit of Lorraine Shoafkadish BSN, RN
	MEMO	NIELSEN	Plaintiff's Memorandum in Opposition to Defendants' Motion to Strike Portions of the Affidavits of Arthur G. Lipman, Pharm.D.
	AFFD	NIELSEN	Affidavit of William Binegar, M.D. in Opposition to Plaintiffs' Motion to Amend Complaint to Add a Claim for Punitive Damages fax
		NIELSEN	Response to Plaintiffs' Motion for Leave to Amend Complaint to Include Claim for Punitive Damages fax
	AFFD	NIELSEN	Affidavit of Counsel in Support of Defendant Thomas Byrne, P.A.'s Memorandum in Opposition to Plaintiffs' Motion for Leave to Amend Complaint to Include Claim for Punitive Damages
	AFFD	NIELSEN	Affidavit of Rodde Cox, MD fax

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
3/11/2007		NIELSEN	Defendant Thomas Byrne, P.A.'s Memorandum in Opposition to Plaintiffs' Motion for Leave to Amend Complaint to Include Claim for Punitive Damages
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Stephen P. Lordon, M.D.
3/12/2007	AFFD	NIELSEN	Affidavit of Steven J. Hippler
	AFFD	NIELSEN	Affidavit of Bradford Hare, M.D.PH.D in Opposition to Plaintiffs' Motion to Amend Complaint to Add a Claim for Punitive Damages
3/13/2007	NOWD	NIELSEN	Notice Of Withdrawal of Plaintiff's Motion for Leave to Amend Complaint to Include Claim for Punitive Damages
3/14/2007	HRVC	COOPE	Hearing result for Motion held on 06/18/2007 09:00 AM: Hearing Vacated to amend complaint to add punitive damages motion to strike portions of affidavits of Arthur Lipman
	NOTC	NIELSEN	Notice of Vacating Deposition Duces Tecum of Carl Peterson fax
3/15/2007	NOTC	NIELSEN	Notice Vacating Hearing fax
	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Cindy Scheer fax
	NOTC	COOPE	Notice Vacating Hearing fax
3/18/2007		NIELSEN	Plaintiffs' First Supplemental Expert Witness Disclosures
		NIELSEN	Defendant Thomas J. Byrne's Disclosure of Expert Witnesses
	NOTC	NIELSEN	Notice of Compliance fax
	NOTC	COOPE	Notice of Vacating Hearing
3/19/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
3/25/2007	SUBR	NIELSEN	Subpoena Returned fax
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Dennis Chambers fax
	RETN	NIELSEN	Return Of Service 6-16-7 fax
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum fax

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
3/27/2007	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Arthur G. Lipman, Pharm. D. fax
	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Stephen P. Lordon, M.D. fax
	NODT	NIELSEN	Second Amended Notice Of Taking Deposition Duces Tecum of Kimberly Vorse, M.D. fax
7/3/2007	MOTN	NIELSEN	Motion for Protective Order fax
7/20/2007	SUBR	NIELSEN	Subpoena Returned
7/23/2007	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
3/2/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
3/3/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
	NTSD	NIELSEN	Notice Of Service Of Discovery Documents
3/6/2007	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Cornelius Hofman
	NOTC	NIELSEN	Notice of Vacating Deposition Duces Tecum of Dennis Chambers
	NOTC	NIELSEN	Notice of Vacating Deposition Duces Tecum of Shaiyenne Shindle
	NOSV	NIELSEN	Notice Of Service
	NOSV	NIELSEN	Notice Of Service
3/13/2007	NODT	NIELSEN	Second Amended Notice Of Taking Deposition Duces Tecum of Stephen P. Lordon, M.D. (Change of Location)
	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Jim Keller, M.P.H., PA-C
	NODT	NIELSEN	Second Amended Notice Of Taking Deposition Duces Tecum of Arthur G. Lipman, Pharm. D.
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Glen R. Groben
	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Glen R. Groben
	NODT	NIELSEN	Second Amended Notice Of Taking Deposition Duces Tecum of Glen R. Groben
	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
3/22/2007	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Dennis Chambers fax

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
9/22/2007	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Christopher Frey fax G. Richard Bevan
	NODT	NIELSEN	Amended Notice Of Taking Deposition Duces Tecum of Shaiyenne Shindle fax G. Richard Bevan
9/27/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Documents G. Richard Bevan
9/29/2007	CONT	COOPE	Continued (Status/ADR 09/10/2007 11:00 AM) by phone with plaintiff's counsel to initiate G. Richard Bevan
		COOPE	Notice Of Hearing G. Richard Bevan
	NOSV	NIELSEN	Notice Of Service G. Richard Bevan
9/30/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Responses G. Richard Bevan
10/10/2007		NIELSEN	Plaintiffs' Second Supplemental Expert Witness Disclosures G. Richard Bevan
	HRHD	COOPE	Hearing result for Status/ADR held on 09/10/2007 11:00 AM: Hearing Held by phone with plaintiff's counsel to initiate G. Richard Bevan
	LETT	COOPE	Letter from Byron Foster G. Richard Bevan
	CMIN	COOPE	Court Minutes Hearing type: Status/ADR Hearing date: 9/10/2007 Time: 11:03 am Court reporter: Virginia Bailey G. Richard Bevan
10/11/2007	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing G. Richard Bevan
		NIELSEN	Plaintiffs' Third Supplemental Expert Witness Disclosures fax G. Richard Bevan
10/12/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Documents G. Richard Bevan
	NTSD	NIELSEN	Notice Of Service Of Discovery Documents G. Richard Bevan
	NOSV	NIELSEN	Notice Of Service fax G. Richard Bevan
	NOSV	NIELSEN	Notice Of Service fax G. Richard Bevan
	NOSV	NIELSEN	Notice Of Service fax G. Richard Bevan
10/14/2007	NOSV	NIELSEN	Notice Of Service G. Richard Bevan
10/17/2007	NTSD	NIELSEN	Notice Of Service Of Discovery Documents G. Richard Bevan
10/24/2007	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Marty Bright fax G. Richard Bevan
	NODT	NIELSEN	Notice Of Taking Deposition Duces Tecum of Valerie Bothoff fax G. Richard Bevan

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
9/24/2007	NODT	NIELSEN	Second Amended Notice Of Taking Deposition Duces Tecum of Christopher Frey fax
	HRHD	COOPE	Hearing result for Civil Pretrial Conference held on 09/24/2007 02:30 PM: Hearing Held in Chambers
		NIELSEN	Defendant Thomas Byrne, P.A.'s Exhibit List fax
	MISC	COOPE	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute Trial Exhibit List
	MISC	COOPE	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Trial Witness List
9/25/2007	ORDR	COOPE	Pretrial Conference Order Pursuant to I.R.C.P. 16(d)
9/26/2007	MOTN	NIELSEN	Plaintiffs' Motion in Limine fax
	MEMO	NIELSEN	Memorandum in Support of Plaintiffs' Motion in Limine fax
	WITN	NIELSEN	Defendant Thomas Byrne, P.A.'s Witness List fax
	WITN	NIELSEN	Plaintiffs' Witness List fax
		NIELSEN	Plaintiffs' Exhibit List fax
9/27/2007	AFFD	NIELSEN	Affidavit of Counsel in Support of Defendant Thomas Byrne, P.A.'s Motion in Limine Re: Various Issues
9/28/2007	MOTN	NIELSEN	Defendant Clinton Dille, M.D. and Southern Idaho Pain Institutes' Motions in Limine fax
10/1/2007	MEMO	NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institutes' Memorandum in Support of Motions in Limine
	MEMO	NIELSEN	Memorandum in Support of Thomas J. Byrne's Motion in Limine Re: Various Issues
	AFFD	NIELSEN	Affidavit of J. Will Varin in Support of Clinton Dille and the Southern Idaho Pain Institute's Motions in Limine
	NOSV	NIELSEN	Notice Of Service fax
10/2/2007	HRSC	COOPE	Hearing Scheduled (Motion 10/11/2007 10:00 AM) Pretrial
10/3/2007	AFFD	NIELSEN	Affidavit of Counsel in Support of Defendant Thomas Byrne's Motion to Quash Subpoenas Duces Tecum fax

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
0/3/2007	MEMO	NIELSEN	Defendant's Memorandum in Support of Motion to Quash Subpoenas Duces Tecum fax
	MOTN	NIELSEN	Defendant's Motion to Quash Subpoenas Duces Tecum fax
0/4/2007	MOTN	NIELSEN	Defendant's Motion to Shorten Time fax
	NOHG	NIELSEN	Notice Of Hearing fax
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Response to Plaintiffs' Motion in Limine fax
	AFFD	NIELSEN	Affidavit of Counsel in Support of Defendant Thomas Byrne's Memorandum in Opposition to Plaintiffs' Motion in Limine fax
	MEMO	NIELSEN	Defendant Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion in Limine fax
	MOTN	NIELSEN	Defendant Thomas Byrne, P.A.'s Joinder in Clinton Dille, M.D. and Southern Idaho Pain Institute's Motion in Limine fax
		NIELSEN	Amended Plaintiffs' Exhibit List fax
0/5/2007	MEMO	NIELSEN	Memorandum in Response to Defendant's Motions in Limine
	MEMO	NIELSEN	Memorandum in Opposition to Defendant's Motion to Quash Subpoenas Duces Tecum
	AFFD	NIELSEN	Affidavit of Byron V. Foster
	AFFD	NIELSEN	Affidavit of J. Will Varin in Support of Clinton Dille' and the Southern Idaho Pain Institute's Response to Plaintiffs' Motion in Limine
		NIELSEN	Defendant Thomas J. Byrne's Supplemental Disclosure of Expert Witnesses fax
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Joinder in Defendant Byrne's Motion to Quash and Response to Plaintiffs' Opposition to Motion to Quash fax
		NIELSEN	Plaintiffs' Fourth Supplemental Expert Witness Disclosure fax
	SUBR	NIELSEN	Subpoena Returned
	AFSV	NIELSEN	Affidavit Of Service

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
0/9/2007	HRSC	COOPE	Hearing Scheduled (Hearing Scheduled 10/11/2007 09:30 AM)
	MEMO	NIELSEN	Pretrial Memorandum
	AFFD	NIELSEN	Affidavit of Byron V. Foster in Support of Plaintiffs' Pretrial Memorandum
	MEMO	NIELSEN	Reply Memorandum in Support of Plaintiffs' Motion in Limine
		NIELSEN	Plaintiff's Proposed Jury Instructions
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Reply to Plaintiffs' Response to Defendants' Motions in Limine
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Joinder in Defendant Byrne's Motion in Limine
		NIELSEN	Defendant Thomas J. Byrne, P.A.'s Proposed Special Verdict Form
		NIELSEN	Defendant Thomas J. Byrne's Trial Brief
		NIELSEN	Defendant Thomas J. Byrne, P.A.'s Proposed Jury Instructions
0/10/2007	RSPN	COOPE	Defendant's Thomas Bryne, P.A.'s Joinder in Clinton Dille, M.D. and Southern Idaho Pain Institute's Reply to Plaintiff's Reponse to Defendants' Motions in Limine
		NIELSEN	Defendants' Joint Exhibit List fax
		NIELSEN	Defendant Clinton Dille' M.D. and Southern Idaho Pain Institute's Trial Brief
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Jury Instructions
0/11/2007	CMIN	COOPE	Court Minutes Hearing type: Motion in Limines Hearing date: 10/11/2007 Time: 10:07 am Court reporter: Virginia Bailey
	CMIN	COOPE	Court Minutes Hearing type: Jury Numbering Hearing date: 10/11/2007 Time: 9:42 am Court reporter: Virginia Bailey
	NOSV	NIELSEN	Notice Of Service fax
	MISC	COOPE	Jury Seating Chart
	MISC	COOPE	Jury Seating Chart (Hand written)
	HRHD	COOPE	Hearing result for Hearing Scheduled held on 10/11/2007 09:30 AM: Hearing Held
	HRHD	COOPE	Hearing result for Motion held on 10/11/2007 10:00 AM: Hearing Held Pretrial
	JTST	COOPE	Hearing result for Jury Trial held on 10/16/2007 09:00 AM: Jury Trial Started Excluding Mondays

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
10/12/2007		NIELSEN	Pocket Trial Brief Re: Hearsay Issue and Mrs. Schmechel's Identification of Mr. Byrne fax
		NIELSEN	Supplemental Trial Memorandum Re: Dr. Lipman fax
		NIELSEN	Second Supplemental Trial Memorandum Re: Plaintiffs' Expert Jim Keller fax
10/15/2007	AFFD	NIELSEN	Affidavit of Chris D. Comstock Regarding the Parties' Motions in Limine
		NIELSEN	Pocket Trial Brief Re: Hearsay Issue and Mrs. Schmechel's Identification of Mr. Byrne
	MEMO	NIELSEN	Supplemental Trial Memorandum Re: Dr. Lipman
		NIELSEN	Second Supplemental Trial Memorandum Re: Plaintiffs' Expert Jim Keller
		NIELSEN	Defendant Thomas J. Byrne's Reply to Plaintiffs' Pocket Trial Brief Re: Hearsay Issue and Mrs. Schmechel's Identification of Mr. Byrne fax
	JUIN	COOPE	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's First Supplement Jury Instructions
10/16/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 1 Hearing date: 10/16/2007 Time: 9:18 am Court reporter: Virginia Bailey
	MISC	COOPE	Juror Questions Submitted by Defendants Dille and Southern Idaho Pain Institute (in envelope with answers)
	MISC	COOPE	Jury Roll Call
	MISC	COOPE	Peremptory Challenges
	MISC	COOPE	Potential Jury Panel
	ORDR	COOPE	Order Re: Motions in Limine
10/17/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 2 Hearing date: 10/17/2007 Time: 8:45 am Court reporter: Virginia Bailey
	MISC	COOPE	Preliminary Jury Instructions
	MISC	COOPE	Final Jury Panel
10/18/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 3 Hearing date: 10/18/2007 Time: 9:09 am Court reporter: Virginia Bailey Audio tape number: ct rm 1
	JUIN	COOPE	Plaintiff's First Supplemental Proposed Jury Instructions Filed
10/19/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 4 Hearing date: 10/16/2007 Time: 9:00 am Court reporter: Virginia Bailey

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
0/19/2007	BREF	COOPE	Plaintiffs' Bench Brief RE: Proposed "Reckless" Instruction
	OBJC	COOPE	Plaintiffs' Objections to the Defendant's Proposed Jury Instructions
0/23/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 5 Hearing date: 10/23/2007 Time: 9:00 am Court reporter: Virginia Bailey
	BREF	COOPE	Supplemental Bench Brief Regarding Jury Instruction on Reckless Conduct
0/24/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Hearing date: 10/24/2007 Time: 9:00 am Court reporter: Virginia Bailey
0/25/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 7 Hearing date: 10/25/2007 Time: 9:10 am Court reporter: Virginia Bailey
	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
	NOTR	NIELSEN	Notice Of Preparation Of Transcript & Filing
0/26/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 8 Hearing date: 10/26/2007 Time: 9:10 am Court reporter: Virginia Bailey
	JUIN	COOPE	Plaintiffs' Second Supplemental Proposed Jury Instructions Filed
	OBJC	COOPE	Defendants' Joint Objections to Plaintiffs' Proposed Jury Instructions
0/30/2007	CMIN	COOPE	Court Minutes Hearing type: Jury Trial Day 9 Hearing date: 10/30/2007 Time: 8:47 am Court reporter: Virginia Bailey
	MISC	COOPE	Final Jury Instructions
	OBJC	COOPE	Defendants' Joint Objections to Court's Proposed Final Jury Instructions
	OBJC	COOPE	Defendants' Objection to Plaintiffs' Proposed Rebuttal Testimony of Dr. Lipman
	MISC	COOPE	Declaration of Counsel in Support of Defendants' Objection to Proposed Rebuttal Testimony of Dr. Lipman
	MISC	COOPE	Special Verdict Form
0/31/2007	LETT	COOPE	Letter from Comstock and Bush
1/5/2007	JDMT	COOPE	Judgment
1/9/2007	JDMT	COOPE	Judgment
	CDIS	COOPE	Civil Disposition/Judgment entered: entered for: Byrne, Thomas J PA, Defendant; Dille, Clinton L MD, Defendant; Doe, John, Defendant; Jane Doe I -x,, Defendant; Southern Idaho Pain Institute, Defendant; Hall, Tamara, Plaintiff; Howard, Kim Lee, Plaintiff; Lewis, Robert P, Plaintiff; Schmechel, Vaughn, Plaintiff. Filing date: 11/9/2007

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
1/14/2007	AFFD	NIELSEN	Affidavit of Counsel in Support of Memorandum of Costs G. Richard Bevan
	MOTN	NIELSEN	Defendant Thomas Byrne, P.A.'s Motion for Costs G. Richard Bevan
	MEMO	NIELSEN	Defendant Thomas J. Byrne's Verified Memorandum of Costs G. Richard Bevan
1/19/2007	MOTN	NIELSEN	Plaintiffs' Motion for New Trial G. Richard Bevan
	MEMO	NIELSEN	Memorandum in Support of Plaintiffs' Motion for New Trial G. Richard Bevan
	AFFD	NIELSEN	Affidavit of Byron V. Foster in Support of Plaintiffs' Motion for New Trial G. Richard Bevan
1/20/2007	HRSC	COOPE	Hearing Scheduled (Motion for Attorney fees and Costs 12/17/2007 09:00 AM) G. Richard Bevan
	HRSC	COOPE	Hearing Scheduled (Motion 12/17/2007 09:00 AM) for new trial -- Comstock G. Richard Bevan
1/21/2007	NOHG	NIELSEN	Notice Of Hearing re: Motion for New Trial fax G. Richard Bevan
	ORDR	COOPE	Order Returning Property to Investigating Law Enforcement Agency G. Richard Bevan
1/23/2007	MOTN	NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Motion for Costs G. Richard Bevan
	MEMO	NIELSEN	Verified Memorandum of Costs G. Richard Bevan
1/26/2007		NIELSEN	Defendant Thomas J. Byrne's Amended Verified Memorandum of Costs G. Richard Bevan
	NOHG	NIELSEN	Notice Of Hearing fax G. Richard Bevan
1/28/2007	OBJC	NIELSEN	Plaintiffs' Objections to Defendant Thomas J. Byrne's Verified Memorandum of Costs G. Richard Bevan
1/30/2007	NOHG	NIELSEN	Notice Of Hearing G. Richard Bevan
2/3/2007		NIELSEN	Defendant Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion for New Trial G. Richard Bevan
	AFFD	NIELSEN	Affidavit Keely E. Duke in Support of Thomas J. Byrne's Memorandum in Opposition to Plaintiffs' Motion for New Trial G. Richard Bevan
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Response to Plaintiffs' Motion for New Trial G. Richard Bevan
	AFFD	NIELSEN	Affidavit of Steven J. Hippler in Support of Clinton Dille and the Southern Idaho Pain Institute's Response to Plaintiffs' Motion for New Trial G. Richard Bevan
2/4/2007	OBJC	NIELSEN	Plaintiffs' Objections to Defendant Clinton Dille, M.D. and Southern Idaho Pain Institute's Verified Memorandum of Costs fax G. Richard Bevan
2/13/2007		NIELSEN	Defendant Thomas J. Byrne's Reply Memorandum in Support of Motion for Costs G. Richard Bevan

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
12/13/2007	MEMO	NIELSEN	Reply Memorandum in Support of Plaintiffs' Motion for New Trial G. Richard Bevan
12/14/2007	AFFD	NIELSEN	Affidavit of J. Will Varin in Support of Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Reply to Plaintiffs' Objections to Defendants Verified Memorandum of Costs G. Richard Bevan
	MEMO	NIELSEN	Amended Verified Memorandum of Costs G. Richard Bevan
		NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Reply to Plaintiffs' Objections to Defendants Verified Memorandum of Costs G. Richard Bevan
12/17/2007	CMIN	COOPE	Court Minutes Hearing type: Motion for New trial and motion for atty fees Hearing date: 12/17/2007 Time: 9:00 am Court reporter: Virginia Bailey G. Richard Bevan
	HRHD	COOPE	Hearing result for Motion held on 12/17/2007 09:00 AM: Hearing Held for new trial -- Comstock G. Richard Bevan
	HRHD	COOPE	Hearing result for Motion for Attorney fees and Costs held on 12/17/2007 09:00 AM: Hearing Held Dille and Bryne G. Richard Bevan
1/23/2008	OPIN	COOPE	Memorandum Opinion and Order RE: Plaintiffs' Motion for New Trial G. Richard Bevan
1/24/2008	OPIN	COOPE	Memorandum Decision and Order RE: Defendants' Motions for Costs G. Richard Bevan
2/14/2008	JDMT	COOPE	Amended Judgment G. Richard Bevan
	JDMT	COOPE	Judgment Nunc Pro Tunc G. Richard Bevan
3/3/2008	MISC	COOPE	Estimate Cost of Reporter's Transcript 2100 pages G. Richard Bevan
3/5/2008	NTOA	COOPE	Notice Of Appeal G. Richard Bevan
	CCOA	COOPE	Clerk's Certificate Of Appeal G. Richard Bevan
		COOPE	Filing: T - Civil Appeals To The Supreme Court (\$86.00 Directly to Supreme Court Plus this amount to the District Court) Paid by: Comstock, David E. (attorney for Schmechel, Vaughn) Receipt number: 8006054 Dated: 3/5/2008 Amount: \$15.00 (Check) For: Schmechel, Vaughn (plaintiff) G. Richard Bevan
		COOPE	Miscellaneous Payment: For Making Copies Of Transcripts For Appeal Per Page Paid by: Comstock and Bush Receipt number: 8006055 Dated: 3/5/2008 Amount: \$70.00 (Check) G. Richard Bevan
		COOPE	Miscellaneous Payment: Record Covers For Appeals Paid by: Comstock and Bush Receipt number: 8006055 Dated: 3/5/2008 Amount: \$30.00 (Check) G. Richard Bevan
3/14/2008	SCDF	COOPE	Supreme Court Document Filed- Copy of Filing Fee Receipt G. Richard Bevan

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
8/14/2008	SCDF	COOPE	Supreme Court Document Filed- Filing of Clerk's Certificate G. Richard Bevan
	SCDF	COOPE	Supreme Court Document Filed- Notice of Appeal (T) G. Richard Bevan
8/17/2008	REQU	COOPE	Defendant Thomas J. Bryne, P.A.'s Request for Additional Transcript and Record G. Richard Bevan
	REQU	COOPE	Defendants Clinton Dille M.D. and Southern Idaho Pain Institute's Request for Additional Transcripts and Records G. Richard Bevan
8/18/2008	CCOA	COOPE	Amended Clerk's Certificate Of Appeal G. Richard Bevan
8/24/2008	SCDF	COOPE	Supreme Court Document Filed- Order Granting Court Reporter's Motion for Extension of Time G. Richard Bevan
	SCDF	COOPE	Supreme Court Document Filed- Clerk's Record & Transcript Due Date Reset G. Richard Bevan
8/28/2008	SCDF	COOPE	Supreme Court Document Filed- Document(s) G. Richard Bevan
8/2/2008	AFFD	NIELSEN	Affidavit of Byron W. Foster fax G. Richard Bevan
	MOTN	NIELSEN	Plaintiff's Motion to Extend Automatic Stay fax G. Richard Bevan
	AFFD	NIELSEN	Affidavit of Taylor L. Mossman fax G. Richard Bevan
8/8/2008		NIELSEN	Defendants Clinton Dille', M.D. and Southern Idaho Pain Institute's Objection to Plaintiffs' Motion to Extend Automatic Stay fax G. Richard Bevan
	AFFD	NIELSEN	Affidavit of Steven J. Hippler in Support of Defendants' Objection to Plaintiffs' Motion to Extend Automatic Stay fax G. Richard Bevan
8/9/2008		COOPE	Miscellaneous Payment: For Making Copies Of Transcripts For Appeal Per Page Paid by: Givens Pursley Receipt number: 8009231 Dated: 4/9/2008 Amount: \$100.00 (Check) G. Richard Bevan
8/8/2008	HRSC	COOPE	Hearing Scheduled (Motion 05/28/2008 02:00 PM) to stay execution and bond in interesting bearing acct., by phone G. Richard Bevan
	NOTC	COOPE	Plaintiff's Notice of Posting of Cash Bond G. Richard Bevan
	MOTN	COOPE	Plaintiff's Motion to Stay Execution of Judgment Pending the Appeal G. Richard Bevan
	BNDC	COOPE	Bond Posted - Cash (Receipt 8011835 Dated 5/8/2008 for 35603.64) G. Richard Bevan
8/12/2008	OBJC	NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Objection to Plaintiffs' Motion to Stay Execution of Judgment Pending the Appeal G. Richard Bevan
	NOHG	COOPE	Notice Of Telephonic Hearing RE: Plaintiffs' Motion to Stay Execution of Judgment Pending the Appeal and Notice of Posting Cash Bond G. Richard Bevan

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
5/21/2008		NIELSEN	Thomas Byrne, P.A.'s Joinder in Defendants Clinton Dille, M.D. and Souther Idaho Pain Institute's Objection to Plaintiffs' Motion to Stay Execution of Judgment Pending the Appeal fax
5/28/2008	CMIN	COOPE	Court Minutes Hearing type: Motion Hearing date: 5/28/2008 Time: 10:00 am Court reporter: Virginia Bailey Audio tape number: ct rm 1
	DCHH	COOPE	Hearing result for Motion held on 05/28/2008 02:00 PM: District Court Hearing Held Court Reporter: Number of Transcript Pages for this hearing estimated: to stay execution and bond in interest bearing acct., by phone
5/30/2008	ORDR	COOPE	Order Granting Plaintiffs' Motion to Stay Execution of Judgment Pending the Appeal
5/9/2008	SCDF	COOPE	Supreme Court Document Filed- Document
	SCDF	COOPE	Supreme Court Document Filed- Clerk's Record and Transcript Due Date Reset
	SCDF	COOPE	Supreme Court Document Filed- Order Granting Court Reporter's Motion for Extension of Time
	SCDF	COOPE	Supreme Court Document Filed- Clerk's Record & Transcript Due Date Reset
6/13/2008	NOTC	COOPE	Notice of Balance Due on Clerk's Record
	NOTC	COOPE	Notice of Balance Due on Clerk's Record
	NOTC	COOPE	Notice of Balance Due on Clerk's Record
6/24/2008		COOPE	Miscellaneous Payment: Personal Copy Fee Paid by: Comstaock and Bush Receipt number: 8016131 Dated: 6/24/2008 Amount: \$61.70 (Check)
		COOPE	Miscellaneous Payment: For Making Copies Of Transcripts For Appeal Per Page Paid by: Comstaock and Bush Receipt number: 8016131 Dated: 6/24/2008 Amount: \$291.25 (Check)
		COOPE	Miscellaneous Payment: Record Covers For Appeals Paid by: Comstaock and Bush Receipt number: 8016131 Dated: 6/24/2008 Amount: \$30.00 (Check)
		COOPE	Miscellaneous Payment: For Making Copies Of Transcripts For Appeal Per Page Paid by: Hall, Farley, Oberrecht & Blanton P.A. Receipt number: 8016139 Dated: 6/24/2008 Amount: \$269.00 (Check)
		COOPE	Miscellaneous Payment: Personal Copy Fee Paid by: Hall, Farley, Oberrecht & Blanton P.A. Receipt number: 8016140 Dated: 6/24/2008 Amount: \$6.90 (Check)

Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x

Date	Code	User	Judge
3/24/2008		COOPE	Miscellaneous Payment: For Making Copies Of Transcripts For Appeal Per Page Paid by: Hall, Farley, Oberrecht & Blanton P.A. Receipt number: 8016140 Dated: 6/24/2008 Amount: \$47.50 (Check)
		COOPE	Miscellaneous Payment: Personal Copy Fee Paid by: Givens Pursley Receipt number: 8016141 Dated: 6/24/2008 Amount: \$62.00 (Check)
		COOPE	Miscellaneous Payment: For Making Copies Of Transcripts For Appeal Per Page Paid by: Givens Pursley Receipt number: 8016141 Dated: 6/24/2008 Amount: \$211.25 (Check)
7/8/2008	LODG	COOPE	Lodged Transcript Volume 1
	LODG	COOPE	Lodged Transcript Volume 2
7/11/2008	SCDF	COOPE	Supreme Court Document Filed- Notice of Transcript Lodged
3/5/2008	OBJC	NIELSEN	Defendants Clinton Dille, M.D. and Southern Idaho Pain Institute's Objection to Clerk's Record and Request for Additional Items
	OBJC	NIELSEN	Defendant Thomas J. Byrne's Joinder in Defendants Clinton Dille M.D. and Southern Idaho Pain Institute's Objection to Clerk's Record and Request for Additional Items fas
3/6/2008	HRSC	COOPE	Hearing Scheduled (Motion 09/03/2008 09:00 AM) Objection to clerk's record
3/7/2008	NOHG	NIELSEN	Notice Of Hearing
3/12/2008	SCDF	COOPE	Supreme Court Document Filed- Document (s)
	SCDF	COOPE	Supreme Court Document Filed- Clerk's Record/Reporter's Trans. -Suspended-
3/22/2008	STIP	NIELSEN	Stipulation re: to Clerk's Record and Request for Additional Items
	ORDR	COOPE	Order RE: Objection to Clerk's Record and Request for Additional Items and Stipulation RE: Objection to Clerk's Record and Request for Additional Items
3/27/2008	HRVC	COOPE	Hearing result for Motion held on 09/03/2008 09:00 AM: Hearing Vacated Objection to clerk's record
	NOTC	COOPE	Notice of Balance due on Clerk's Record (Supplemental)
9/2/2008	SCDF	COOPE	Supreme Court Document Filed- Document(s)
	SCDF	COOPE	Supreme Court Document Filed- Clerk's Record and Transcript Due Date Reset

ORIGINAL

David E. Comstock  
LAW OFFICES OF COMSTOCK & BUSH  
199 N. Capitol Blvd., Ste 500  
PO Box 2774  
Boise, Idaho 83701  
Telephone: (208) 344-7700  
Facsimile: (208) 344-7721  
ISB # 2455

Byron V. Foster  
Attorney At Law  
199 N. Capitol Blvd., Ste 500  
P.O. Box 1584  
Boise, Idaho 83701  
Telephone: (208) 336-4440  
Facsimile: (208) 344-7721  
ISB #: 2760

Attorneys for Plaintiffs

DISTRICT COURT  
TWIN FALLS CO., IDAHO  
FILED

2007 APR 20 AM 9:32

BY \_\_\_\_\_  
CLERK  
\_\_\_\_\_ DEPUTY

IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT

OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS

VAUGHN SCHMECHEL, individually, and  
as Surviving Spouse and Personal  
Representative of the Estate of ROSALIE  
SCHMECHEL, deceased, and ROBERT P  
LEWIS, KIM HOWARD and TAMARA  
HALL, natural children of ROSALIE  
SCHMECHEL, deceased,

Plaintiffs,

vs.

CLINTON DILLE, M.D., SOUTHERN  
IDAHO PAIN INSTITUTE, an Idaho  
corporation, THOMAS BYRNE, P.A., and  
JOHN DOE and JANE DOE, I through X,

Defendants.

Case No. CV 05-4345

**PLAINTIFFS' EXPERT WITNESS  
DISCLOSURES**

COME NOW Plaintiffs, by and through their attorneys of record, David E. Comstock, of Comstock & Bush, and Byron V. Foster, Attorney at Law, and pursuant to the Court's Scheduling Order and in accordance with I.R.C.P. 26, hereby disclose Plaintiffs' expert witnesses to be called at the trial of this case:

1. **Jim E. Keller, M.P.H., PA-C.**  
**Director, Physician Assistant Program,**  
**Red Rocks Community College,**  
**Lakewood, Colorado, 80228.**

**A. Subject matter of expected testimony.**

Mr. Keller is expected to testify concerning the applicable standard of health care practice for Defendant Thomas Byrne, P.A. The opinions expressed below by Mr. Keller are opinions which he holds to a reasonable degree of medical certainty.

**B. Substance of facts.**

Mr. Keller has reviewed the medical records of Rosalie Schmechel generated by Southern Idaho Pain and Rehabilitation Institute; Sun Valley Pain and Sleep Center; Twin Falls County Coroner Autopsy Report; Twin Falls County Coroner Record of Death; Thomas Byrne, P.A.'s handwritten medical regimen; and the depositions of Defendant Dille, Defendant Byrne, Robert Lewis, Kim Howard and Tamara Hall.

It is expected that Mr. Keller will also review depositions taken in the future of various experts and/or treating health care providers as well as the deposition of Vaughn Schmechel. In addition, Mr. Keller has reviewed Federal guidelines dealing with methadone prescription contained within the code of Federal Regulations as well as various DEA documents, the model policy for use of controlled substances and is expected

to review other literature and materials regarding the subject matter of this litigation.

Mr. Keller will testify as to his understanding as to the facts of this case based upon his review of the above-referenced documents and depositions.

**C. Substance of opinions.**

Mr. Keller is of the opinion that it was a violation of the applicable standard of health care practice for Defendant Byrne to begin Rosalie Schmechel on a new drug regimen on a Friday. The guidelines for medication changes with regard to methadone indicate that during the initial titration stages, the practitioner in charge of the switch in medications should see the patient every day until the methadone reaches a therapeutic level. During that period of time, the practitioner should be watching for any adverse reactions and validating that there are no problems with metabolism of the methadone. Every patient is different with regard to metabolizing methadone and until you understand how the specific patient is going to react, the patient needs to be carefully monitored. Careful monitoring means seeing the patient every day during this period of time.

Mr. Keller is also of the opinion that it was a violation of the applicable standard of health care practice for Mr. Byrne to fail to communicate by telephone with Kimberly Vorse, M.D., Rosalie Schmechel's previous pain management physician. He is also of the opinion that it was a violation of the applicable standard of health care practice to fail to request Dr. Vorse's records. Under circumstances where a switch to methadone from OxyContin is anticipated, it is vitally important to obtain the patient's previous pain care records in order to gain an understanding of the patient's compliance with medications, adverse reactions, therapeutic levels and to validate the information given to the practitioner by the patient.

Mr. Keller is of the opinion that the instructions given to Mrs. Schmechel, as indicated in Mr. Byrne's typewritten office note of September 26, 2003, were confusing when contrasted against the handwritten instruction sheet which he also gave to Mrs. Schmechel. The patient could well have misinterpreted the instructions given and increased the dosage of methadone to 30mg per day too quickly, thus resulting in an overload of methadone based upon methadone's long half-life and the difficulty of ascertaining, in the initial stages, when a therapeutic level has been achieved. Once therapeutic levels are achieved, the practitioner can taper the medication dosage but until that therapeutic level is achieved, the practitioner cannot accurately ascertain how the patient is going to react to the new medication. Thus, the necessity of seeing the patient on a daily basis during this initial switch in medications.

During the initial titration phase of methadone treatment, the patient needs to be seen daily to determine:

1. How much breakthrough pain the patient is experiencing and how much hydrocodone the patient is using for this breakthrough pain; /
2. If the breakthrough episodes are frequent, the methadone dose may be increased;
3. When breakthrough episodes decrease, the practitioner can gain a better understanding whether or not the methadone is achieving a therapeutic level;
4. After five (5) to seven (7) days, the practitioner can usually determine what the maintenance dose will be;
5. The beginning of titration is the most critical time. The initial three (3) to

seven (7) days during titration is when patients encounter the most problems with fluctuating metabolism and relative over or under dosing. Thus, the need to closely monitor.

Another reason why Rosalie Schmechel needed to be closely monitored during the titration phase of her switch to methadone was because of her history of sleep apnea and the use of CPAP. She would be taking a new respiratory depressant (methadone) in conjunction with hydrocodone and the practitioner would need to determine the relative affect of those medications in combination on an individual with severe obstructive sleep apnea. In addition, Mrs. Schmechel was a smoker and suffered from hypertension, two additional reasons for very close monitoring during the titration period.

Mr. Keller is also of the opinion that Defendant Byrne's initial prescription for 90 methadone and 70 hydrocodone was a violation of the applicable standard of health care practice. When titrating methadone, the practitioner should only prescribe the amount needed for initial titration to determine how the patient is going to react to the change in medication. Once the patient metabolizes the drug to a maintenance level, the practitioner should then prescribe sufficient medication to last one (1) week and then see the patient after that one (1) week period of time for a prescription refill. The patient needs to be checked in person by the practitioner in order to verify the maintenance dosage is sufficient, and there are no adverse affects, changes in mentation or sedation level, or other potential adverse reactions or unanticipated side affects encountered.

With regard to the issue of whether or not Defendant Byrne spoke to Rosalie Schmechel on Saturday and/or Sunday September 27 and 28, 2003; Mr. Keller

understands there is a factual dispute based upon his review of the various depositions provided to him. Mr. Keller is of the opinion that had Defendant Byrne spoken by telephone with Mrs. Schmechel on Saturday and Sunday, September 27 and 28, 2003, it would have shown at least some recognition on Defendant Byrne's part that Mrs. Schmechel needed to be closely monitored. However, under these circumstances, a telephone call would not have been sufficient and Defendant Byrne should have seen and examined Mrs. Schmechel in person. Thus, the reason for not beginning titration of methadone as a change in medication on a weekend. However, if telephone calls took place between Defendant Byrne and Mrs. Schmechel on those two dates and the information conveyed as per Robert Lewis' deposition testimony was indeed given to Defendant Byrne, he would have been under an obligation, pursuant to the applicable standard of health care practice, to see and examine Mrs. Schmechel to determine the cause of her nausea and lower extremity edema. Nausea in the setting of a change from OxyContin to methadone is abnormal and would call for further work-up. In addition, lower extremity edema in this same setting is alarming and would call for an examination by the practitioner to determine the cause of the edema and to take steps to remedy the situation.

Mr. Keller is of the opinion that had Defendant Byrne appropriately followed Mrs. Schmechel during the period of time from the inception of methadone titration until the date of her death and appropriately reacted to her developing medical condition as evidenced by the testimony of her family, her death from combined methadone/hydrocodone toxicity could have been prevented.

**D. Witness's credentials.**

Attached hereto as Exhibit "A" is the curriculum vitae of Jim E. Keller. Mr. Keller charges \$125.00 per hour and while at present it is unknown whether he has previously testified by deposition or in trial on other cases where he has been retained as an expert; this information will be forthcoming by supplementation.

2. **Arthur G. Lipman, Pharm. D.**  
Professor, Department of Pharmacotherapy, College of Pharmacy  
Adjunct Professor, Department of Anesthesiology,  
School of Medicine  
Director of Clinical Pharmacology, Pain Management Center,  
University Healthcare  
University of Utah Health Sciences Center  
Salt Lake City, Utah

**A. Subject matter of expected testimony.**

Dr. Lipman is expected to testify regarding the applicable standard of health care practice for individuals who hold themselves out as specialists in pain management. He will testify concerning the pharmacokinetics of methadone, OxyContin, hydrocodone and the other medications which had been prescribed for decedent Rosalie Schmechel by Defendants and her other treating physicians. He will testify and comment on the testimony of Defendants and their disclosed expert witnesses. He will testify, in part, on literature and research conducted by himself and others in his field of expertise. He is expected to utilize, in order to clarify his opinions, various models, graphs and other visual aids dealing with the pharmacokinetics of the medications at issue in this litigation.

**B. Substance of Facts.**

Dr. Lipman has reviewed the medical records of Rosalie Schmechel generated by

Southern Idaho Pain and Rehabilitation Institute; Sun Valley Pain and Sleep Center; Twin Falls County Coroner Record of Death; Thomas Byrne, P.A.'s handwritten medical regimen; and the depositions of Defendant Dille, Defendant Byrne, Robert Lewis, Kim Howard and Tamara Hall. In addition, Dr. Lipman has spoken with Kimberly Vorse, M.D., a physician in Sun Valley, Idaho, who specializes in pain medicine and sleep medicine and discussed the standard of care as it existed in September/October 2003 in both the Wood River Valley (Sun Valley, Ketchum, Hailey) and the Magic Valley (Twin Falls).

It is expected that Dr. Lipman will also review depositions taken in the future of various experts and/or treating health care providers as well as the deposition of Vaughn Schmechel. In addition, Dr. Lipman has reviewed Federal guidelines dealing with pain management and epidemiological publications on methadone toxicity; Federal Regulations; documents generated by the Centers for Disease Control and the MMWR Weekly Newsletter dealing with the incidence of unintentional drug poisoning related to methadone administration in the State of Utah. He is also expected to review other literature and materials regarding the subject matter of this litigation.

Dr. Lipman will testify as to his understanding as to the facts of this case based upon his review of the above-referenced documents and depositions.

**C. Substance of Opinions.**

The opinions expressed by Dr. Lipman herein are opinions he holds to a reasonable medical certainty or probability.

In the early 1990s there began a push, fueled by Medicare and insurance companies, to increase the prescription of methadone because of its relatively decreased

cost compared to OxyContin. However, the increased danger of the use of methadone for pain management appears to have been incompletely understood by some pain management practitioners, including the Defendants herein.

Dr. Lipman is of the opinion that the methodology employed by Defendants Byrne and Dille in switching Rosalie Schmechel from OxyContin to methadone evidenced a lack of understanding of the pharmacokinetics of both medications and this lack of understanding led to her death.

Dr. Dille failed to appropriately supervise Byrne in the change of medications and this lack of supervision resulted in Byrne prescribing an initial titration dosage which called for increasing dosages too soon after inception and a dosing schedule which resulted in inadequate analgesia which would result in inadequate pain relief while at the same time resulting in serum levels of methadone rising too quickly. Thus the level of methadone in Mrs. Schmechel's blood rose to toxic levels at the same time she was obtaining inadequate pain relief, necessitating the use of the short acting opioid, hydrocodone during the titration phase which eventually resulted in lethal and toxic ranges of both medications, ending in overdose.

It is evident from a review of the medical records and depositions of Defendants that neither properly understood how to manage the change in medications. First of all, they failed to gain a detailed understanding of the patient's past treatment by failing to obtain the records of Dr. Kimberly Vorse or speak with her prior to initiating a change to methadone. Second, after noting that Mrs. Schmechel suffered from sleep apnea and utilized a CPAP machine to assist with breathing, they failed to conduct a thorough

investigation to determine whether the patient was compliant in using the machine and how her sleep apnea would potentially interact with methadone. Third, Defendant Dille totally failed in his obligation to supervise the activities of Defendant Byrne. If Byrne was authorized by the State of Idaho to prescribe this change in pain medication, after doing so in a manner violative of the applicable standard of health care practice, Dille then failed to oversee this process when he was informed of the plan of care on September 29<sup>th</sup> of 2003. Whether through inadvertence or ignorance, Dille failed to realize that the verbal instructions given by Byrne, in conjunction with the handwritten instructions given to the patient would result in too rapid a rise in serum levels of methadone in a situation where both Defendants evidenced an inadequate knowledge of the proper methodology for this change in pain management.

The initial dosing regimen of methadone was incorrect because the dosage schedule should have been every 8 hours, not every 12 hours. Methadone's analgesic effects initially may last only 4 to 6 hours and normally have a maximum of 8 hours. If the medication is taken every 12 hours, the effects will wear off before the second dose takes effect. This fact, in conjunction with the confusing and incorrect information contained in Defendant Byrne's handwritten note resulted in Mrs. Schmechel titrating the medication too rapidly. The serum levels rose too quickly under a dosing schedule which made the analgesic effects sub-optimal. Both Dille and Byrne should have known this before they undertook to switch the medications. Dille should certainly have understood this if he talked to Byrne on September 29<sup>th</sup>. At that time the standard of health care practice mandated that Dille take steps to correct the situation before it resulted in Mrs. Schmechel's death.

It can take up to ten days to reach a steady state serum level of methadone. Until the steady state is reached, serum levels continue to rise. This is a critical time in this process and the patient must be closely monitored for any adverse effects or the existence of any new signs or symptoms of impending medical crises. Thus the drug must be titrated very slowly, which was not done here. While Byrne may have indicated verbally for Mrs. Schmechel to titrate slowly, he apparently did not indicate how slowly because he told her she could increase the dose over the weekend. Furthermore, the written instructions he gave her resulted in a too rapid titration.

In their depositions, Both Byrne and Dille talk about the fact that since the patient was a chronic user of pain medications, she should have had a tolerance to those medications. While this may be true in a simplistic sense, the critical issue is that Mrs. Schmechel was naïve to methadone. She therefore had limited if any tolerance to it specifically and the respiratory depressant effects caused by that specific medication. A tolerance to one respiratory depressant does not necessarily equate to a tolerance to methadone and both Defendants should have known that. It takes five to seven days of properly slow titration before the respiratory depressant effects of any opioid provide tolerance to respiratory depression. Methadone appears to preferentially act on a different subtype of the mu-opioid receptor than other opioids she had previously utilized. Therefore, had she been tolerant to OxyContin and/or hydrocodone she would not necessarily have had full tolerance to the respiratory depressant effect of newly initiated methadone.

Dr. Lipman realizes there exists a conflict in the accounts of telephone conversations which took place on Saturday and Sunday, September 27<sup>th</sup> and 28<sup>th</sup>, 2003.

However, if the information was imparted to Defendant Byrne that Rosalie was experiencing nausea, was sick to the stomach, was experiencing lower extremity edema and noticed an increased level of sedation, these factors should have led Defendants to see and examine the patient and modify her medication regimen accordingly.

Another critical factor is the failure of either Defendant to fully investigate and understand specific information regarding Mrs. Schmechel's sleep apnea and her use of CPAP. The danger of potentially fatal respiratory depression under these circumstances is well known and calls for a thorough knowledge of the circumstances surrounding this condition and its treatment.

For all of the above reasons, it is my considered opinion, which I hold to a reasonable medical certainty or probability, that the activities of Defendants Dille and Byrne in the way they changed the patient from OxyContin to methadone; the failure to closely monitor the patient during the initial titration period; the confusing and incorrect dosing and administration schedule; the failure to properly ascertain her past treatment and records; the failure to modify those dosing schedules and intervals; evidence a lack of understanding of appropriate pain management and resulted in the prescription of a medication in a manner which was predictably lethal.

Under the circumstances, the activities of these two health care providers constituted extreme departures from applicable standards of health care practice and constituted reckless conduct.

**D. Witness's credentials.**

Attached hereto as Exhibit "B" is the curriculum vitae of Arthur G. Lipman, and the

record of his testimony. Dr. Lipman charges \$450.00 per hour.

**3. Stephen P. Lordon, M.D.  
Medical Director, Summit Pain Management  
Murray, Utah**

**A. Subject matter of expected testimony.**

Dr. Lordon, who is Board Certified in Anesthesiology and Board Certified in Pain Management, is expected to testify regarding the standard of health care practice applicable to individuals who hold themselves out as specialists in pain management. He will testify concerning the various medications which decedent Rosalie Schmechel was prescribed and the various interactions between those medications. He will testify based upon his review of medical records, depositions, medical literature and his knowledge and experience in treating chronic pain patients. He will testify and comment on the testimony of Defendants, their expert witnesses and other treating health care providers. He will participate in a telephone conference with a pain management specialist practicing in Idaho regarding the applicable standard of health care practice.

**B. Substance of Facts.**

Dr. Lordon has reviewed the medical records of Rosalie Schmechel generated by Southern Idaho Pain and Rehabilitation Institute; Sun Valley Pain and Sleep Center; Twin Falls Coroner Record of Death; Thomas Byrne, P.A.'s handwritten medical regimen; and the depositions of Defendant Dille, Defendant Byrne, Robert Lewis, Kim Howard and Tamara Hall.

It is expected that Dr. Lordon will also review depositions taken in the future of various experts and/or treating health care providers as well as the deposition of Vaughn

Schmechel. In Addition, Dr. Lordon may base his testimony, in part, on medical literature and other documents concerning methadone; methadone dosing guidelines; drug interactions and other subjects at issue in this litigation.

Dr. Lordon will testify as to his understanding of the facts of this case based upon his review of the above-referenced documents and depositions.

**C. Substance of opinions.**

The opinions expressed by Dr. Lordon herein are opinions which he holds to a reasonable degree of medical certainty or probability.

Dr. Lordon is of the opinion that the instructions which Defendant Byrne gave to Mrs. Schmechel concerning the change from OxyContin to methadone were incorrect, inadequate and vague; resulting in a miscommunication of the proper methodology for initial titration of methadone which caused a lethal build-up of methadone in her blood in combination with hydrocodone and amitriptyline. The standard of health care practice applicable to Defendant Byrne required him to possess the knowledge that the proper methodology calls for low levels of methadone to be instituted initially. This regimen is to be maintained for the first seven days until the practitioner determines the effect of the drug and can gauge how optimum serum levels are going to be tolerated. In an individual such as this patient with concomitant medical conditions, this period of time may increase to ten days. The handwritten instructions given by Mr. Byrne to the patient were vague and indicated she could increase the dosage to a total of 30 mg in a short period of time. This is too much methadone in too short a period of time and constituted a violation of the applicable standard of health care practice. To assume Mrs. Schmechel could tolerate

such a high dosage of methadone in such a short period of time is not clinically sound.

Dr. Lordon is aware there are inconsistencies between Mr. Byrne's typed notes, the handwritten note and his deposition testimony, however, Mrs. Schmechel would have been justified in following the written instructions she received and these instructions were, quite simply, not clinically sound.

A compounding factor in Mrs. Schmechel's case is the presence of sleep apnea and the use of CPAP. Mrs. Schmechel stood 5 feet 4 inches in height and weighed 220 pounds. Her body mass index is 37.8. She meets the criteria for morbid obesity which makes the presence of sleep apnea an even greater concern when instituting methadone therapy for pain management. The respiratory depressant effect of methadone cannot be determined without an adequate low, slow titration timetable not evidenced here. In addition Defendants Dille and Byrne took no measures to investigate the patient's past treatment or how she reacted to that treatment; they merely obtained that information from the patient on her first visit without any attempt at verification with her previous treating physician. This was, under the circumstances sub-standard care by both defendants.

The initial titration period is the most dangerous time for the patient and both Defendants do not appear to have appreciated this medical fact resulting in the patient reaching toxic serum levels caused by administration of too much medication over too short a period of time. If anything, Mrs. Schmechel should have been under dosed for the first seven days until her reaction to this new drug regimen could be accurately determined. By giving vague instructions which resulted in the dosage increasing from 10 to 30 mg over a three day period, not enough time was allowed for the original 10 mg dose to stabilize.

It is evident from the methodology utilized by Byrne and Dille that neither appropriately understood the pharmacokinetics and pharmacodynamics of methadone and this constitutes a violation of the standard of health care practice.

One of the critical points in this process is the conversation which Defendant Dille testified to having with Defendant Byrne on Monday, September 29<sup>th</sup>. At that point in time Dille should have instructed Byrne that it was too soon to have the patient on 30mg of methadone per day and the situation should have been immediately rectified. The failure to take this action was a departure from the applicable standard of health care practice and directly resulted in Mrs. Schmechel's death.

Mrs. Schmechel was a complex patient with a complex history of pain management, sleep apnea and CPAP use. Defendant Byrne would have been well advised to ask himself whether it was medically necessary or appropriate to change her medications on the first visit. Other options such as epidural steroids; spinal nerve stimulation or a spinal infusion pump should have been considered. In addition, methadone is an unpredictable medication and its relationship to respiratory depression in a patient like Mrs. Schmechel with sleep apnea is a real cause for concern. Byrne did not have all the information or knowledge to place Mrs. Schmechel on methadone, even if appropriately managed. While the decision of what course of action to take may, in the hands of a knowledgeable practitioner, be a matter of judgment; here Byrne's evident lack of knowledge and understanding of the pharmacokinetics and pharmacodynamics of methadone makes his decision to institute methadone under these circumstances a violation of the applicable standard of health care practice. The first choice of a competent treating health care

provider would have been to consider non opioid treatments, adequately assess her degree of sleep apnea, then consider an increase of the OxyContin dosage to determine if greater pain relief could be achieved without resort to methadone. OxyContin is a much more predictable drug and serum levels increase or decrease much more rapidly than methadone making it, under these circumstances, easier to control and easier to reach optimum pain relief. Evidently neither Byrne nor Dille possessed an understanding of this information.

Dr. Lordon will also discuss the inconsistencies in the testimony of the individuals involved concerning telephone conversations between the patient and Mr. Byrne, which; if those conversations occurred and information was conveyed to Byrne regarding nausea, stomach upset, sedation and lower extremity edema; would have mandated that action be taken by both defendants to examine Mrs. Schmechel and change the course of her treatment.

It is Dr. Lordon's opinion, to a reasonable medical certainty, that the violations of applicable standards of health care practice set forth above directly resulted in the death of Rosalie Schmechel.

**D. Witness's credentials.**

Attached hereto as Exhibit "C" is the curriculum vitae of Stephen P. Lordon, M. D. Dr. Lordon's fee schedule and prior testimony will be provided at a later time through supplementation.

4. **Kimberly Vorse, M.D.**  
**Sun Valley Pain and Sleep Center**  
**180 West First Street**  
**Ketchum, Idaho, 83340**

Dr. Vorse is not a retained expert. She will be called upon to testify regarding her extensive treatment and involvement with Rosalie Schmechel through September 16, 2003. She will also testify that her practice, albeit located in Ketchum, Idaho, in the September/October 2003 time frame, involved treating pain patients from the Wood River Valley and the Magic Valley, including Twin Falls, Idaho. She will also describe how she conferred with and accepted referrals for physicians practicing in Twin Falls. As such, she will describe how she is personally familiar with the standard of care existing in the fall of 2003 for the care and treatment of pain patients like Rosalie Schmechel in the Wood River Valley and Twin Falls.

Dr. Vorse is expected to testify from her medical records regarding the care and treatment she provided, the pain management medications which she had prescribed for Rosalie Schmechel and the CPAP and other treatments she had provided for Rosalie Schmechel's severe sleep apnea. Dr. Vorse will discuss Rosalie Schmechel's medical history, medical conditions and how that history and those conditions impacted Dr. Vorse's treatment decisions with regard to pain management and sleep therapy. Dr. Vorse will discuss the importance of various aspects of Rosalie Schmechel's past medical history to her subsequent treatment decisions.

Dr. Vorse is expected to testify regarding the relationship between sleep apnea, CPAP therapy and respiratory depressant medications. She may also testify with regard to

the pharmacokinetic properties of the various pain medications prescribed for the use of Rosalie Schmechel. It is anticipated that the deposition testimony of Dr. Vorse will be obtained by Defendants and she will testify in accordance with that expected deposition testimony.

5. **Cornelius Hofman**  
**The GEC Group**  
**MBA Economics and Finance**  
**University of Chicago**

**A. Subject matter of expected testimony.**

Mr. Hofman is expected to testify concerning the economic losses to the Plaintiffs.

**B. Substance of facts.**

See Mr. Hofman's report, attached hereto as Exhibit "D."

**C. Substance of opinions.**

See Mr. Hofman's report, attached hereto as Exhibit "D."

**D. Witness's credentials.**


See the curriculum vitae of Cornelius Hofman, his fee schedule and a list of previous cases in which he has testified, attached hereto as Exhibit "E."

**CAVEAT**

It should be understood that Plaintiffs have made a good faith effort to set forth the substance of the opinions to which the above-named treating health care providers and experts will testify. However, it is impossible to specifically set forth every opinion these individuals will express and the exact manner in which those opinions will be expressed.

Plaintiffs reserve the right to elicit from the above-named health care providers / experts, additional testimony and opinions from those individuals based upon information subsequently produced, information gleaned during depositions of Defendants' experts and any subsequent opinions or information developed by the above-named individuals from other sources. As it is anticipated that the Defendants will obtain the deposition testimony of the above-named health care providers / experts, this expert disclosure should not be assumed to be all inclusive in nature. Plaintiffs also reserve the right to amend, modify, delete from or add to by supplementation, this disclosure as further information is developed through discovery. Plaintiffs also reserve the right to name and call as expert witnesses any individuals identified by any party as expert witnesses and also reserves the right to obtain medical testimony from any other health care provider named or identified during the discovery process.

DATED this 19<sup>th</sup> day of April, 2007.

  
David E. Comstock,  
Attorney for Plaintiffs

CERTIFICATE OF SERVICE


I hereby certify that on this 14<sup>th</sup> day of April, 2007, I served a true and correct copy of the above and foregoing instrument, by method indicated below, upon:

Steven J. Hippler  
GIVENS PURSLEY, LLP  
601 W. Bannock St.  
PO Box 2720  
Boise, ID 83701-2720

- U.S. Mail
- Hand Delivery
- Facsimile (208) 388-1300

Richard E. Hall  
HALL FARLEY OBERRECHT &  
BLANTON, PA  
702 West Idaho, Suite 700  
PO Box 1271  
Boise ID 83701

- U.S. Mail
- Hand Delivery
- Facsimile (208) 395-8585

  
David E. Comstock



## CURRICULUM VITAE

### PERSONAL INFORMATION

Name: Jimmie Ellis Keller, M.P.H., PA-C

Home Address: 10251 Pennington Lane  
Highlands Ranch, CO 80126

Home Telephone: (303) 346-5412  
Work Facsimile: (303) 914-6806  
E-mail Address: [Keller50@aol.com](mailto:Keller50@aol.com)  
[jim.keller@rrcc.edu](mailto:jim.keller@rrcc.edu)

Date and Place of Birth: February 13, 1948; Morganton, NC

### EDUCATION

#### Degrees

M.P.H., The George Washington University, Washington, DC, 1989  
B.A., Management/Health Care, Park College, Parkville, MO, 1979  
A.S., Physician Assistant, Baylor University, Waco, TX, 1976

#### Postgraduate Training Fellowships

Graduate, Interagency Institute of Federal Health Care Executives, Washington, DC,  
1992


#### Residencies

Clinical Practicum, Primary Care, U.S. Army-Baylor University Military Physician  
Assistant Program, Moncrief Army Community Hospital, Fort Jackson, SC,  
1975-1976

### EMPLOYMENT HISTORY

December 2001-Present: Director, Physician Assistant Program, Red Rocks Community  
College, Lakewood, CO 80228.  
May 2000-June 2002: Department of the Army Civilian (GS-12), Chief, Nelson Medical  
Clinic, Ireland Army Community Hospital, Fort Knox, KY 40121.  
December 1999-May 2000: Department of the Army Civilian (GS-11) Physician  
Assistant, Red Primary Care Clinic, Ireland Army Community Hospital, Fort  
Knox, KY 40121.

March 2006



- October-November 1999: Physician Assistant, Red Primary Care Clinic, Ireland Army Community Hospital, Fort Knox, Kentucky 40121, via Contract with *CompHealth*, 4021 South 700 East, Suite 300, Salt Lake City, UT 84107.
- October 1999-January 2000: Physician Assistant (part-time), Acute Care of Elizabethtown, 1239 Woodland Drive, Elizabethtown, KY 42701.
- September 1997-June 2001: Coordinating Consultant, PATH Consultation Service, Association of Physician Assistant Programs, 950 North Washington Street, Alexandria, VA 22314-1552.
- August 1997-July 1999: Physician Assistant (part-time), Fayette Urgent Care Center, 105 Yorktown Drive, Fayetteville, GA 30214.
- August 1997-March 1998: Physician Assistant, Family Practice, Fayette Medical Clinic, 4000 Shakerag Hill, Suite 100, Peachtree City, GA 30269.
- April 1997-March 1998: Associate Program Director/Academic Coordinator, Physician Assistant Program, South College, Savannah, GA.
- November 1996-June 1997: Clinical Instructor and Program Planner, Department of Physician Assistant Studies, School of Allied Health Sciences, East Carolina University.
- February 1994-November 1996: Chair and Clinical Instructor, Department of Physician Assistant Studies, School of Allied Health Sciences, East Carolina University.
- March 1995-April 1996: Lead Physician Assistant (part-time), Emergency Department "Fast Track," Department of Emergency Medicine, East Carolina University School of Medicine/Pitt County Memorial Hospital, Greenville, NC.
- October 1988-January 1994: Chief, Physician Assistant Section, Army Medical Specialist Corps, Department of the Army, Office of The Surgeon General, Falls Church, VA.
- February -November 1994: Physician Assistant (part-time), Primary Care, Acute Care Clinic, Naval Hospital, Camp Lejune, NC.
- January 1992-March 1994: Physician Assistant (part-time), Emergency Department "Fast Track," Fredericksburg Emergency Medical Associates, Inc., Mary Washington Hospital, Fredericksburg, VA.
- October 1988-December 1993: Physician Assistant (part-time), Ambulatory/Urgent Care, Prime Care, Annandale, VA.
- October 1988-1995: Instructor and Private Consultant, O'Gara Protective Services, Inc., Chantilly, VA.
- August 1984-September 1988: Administrator and Primary Care Provider, White House Medical Unit, Washington, DC.
- August 1982-July 1984: Career Development Manager, Department of the Army, U.S. Army Medical Department Personnel Support Agency, Office of The Surgeon General, Washington, DC.
- July 1979-June 1982: Medical Officer and Medical Platoon Leader, Aschaffenburg, GE.

July 1976-June 1979: Director of Outpatient Medical Clinic (Officer-In-Charge),  
Moncrief Army Community Hospital, Fort Jackson, SC.  
August 1970-June 1974: Clinical Instructor, Clinical Specialist Course, Fitzsimons Army  
Medical Center, Aurora, CO.  
August 1967-January 1994: Physician Assistant and Primary Health Care Provider,  
Educator, and Administrator in a variety of worldwide assignment locations with  
the U.S. Army. Served as combat medic in Viet Nam (1969). Enlisted Ranks:  
Private - Sergeant First Class. Warrant Officer Ranks: Warrant Officer One -  
Warrant Officer Four. Retired Rank: Major (Promotable).

### CERTIFICATION

Certified, National Commission on Certification of Physician Assistants, Inc. (NCCPA),  
1977-Present. Recertified, 1983, 1989, 1995, 2001.  
(NCCPA Certificate #1003014)

### LICENSURE

Colorado State Board of Medical Examiners, License #2055, December 2004 – Present.  
Colorado High School Athletic Activities Association, Football Official #14206, 2002-  
Present.  
Kentucky High School Athletic Association, Football Official #10896, 2001-2002.  
Kentucky Board of Medical Licensure, License #PA492, December 1999-Present,  
Louisville, KY (Currently in an inactive status).  
Georgia Composite Board of Medical Examiners, License #2996, October 1997-  
December 2000, Atlanta, GA.  
North Carolina Board of Medical Examiners, License #101860, December 1994-June  
1997, Raleigh, NC.  
Commonwealth of Virginia Department of Health Professions, License #0110840375 &  
#0110840375B, June 1993-June 1995, Richmond, VA.

### PROFESSIONAL SOCIETIES

Fellow, American Academy of Physician Assistants, 1977-Present  
Peer-reviewer, *Journal of the American Academy of Physician Assistants*, 2003-  
Present  
Chair, Government Affairs Council, 1991-1993  
Delegate, House of Delegates, 1991-1993  
Teller, Teller Subcommittee, 1989-1990  
Chair, Federal Services Task Force, 1989-1991

Jimmie E. Keller, M.P.H., PA-C

Page 4

Fellow, Association of Family Practice Physician Assistants, 2000-Present  
Fellow, Georgia Association of Physician Assistants, 1997-1999  
Affiliate Member, North Carolina Medical Society, 1995-1997  
Associate Member, Association of Physician Assistant Programs, 1994-Present  
Fellow, North Carolina Academy of Physician Assistants, 1994-1997  
President, Down East Physician Extender Society Regional Chapter, 1995  
Fellow, Virginia Academy of Physician Assistants, 1992-1994  
Fellow, Society of Army Physician Assistants, 1977-Present  
Legislative Coordinator, 1989-1993  
Fellow and Lifetime Member, Society of European Physician Assistants, 1979-Present  
Active Member, Association of Military Surgeons of the United States, 1991-Present  
Fellow and Lifetime Member, Federal Health Care Executives Institute Alumni  
Association, 1992-Present  
Lifetime Member, Veterans of Foreign Wars, 1970-Present  
Lifetime Member, Disabled American Veterans, 1970-Present  
Lifetime Member, Veterans Caucus, American Academy of Physician Assistants,  
1982-Present

#### GRANTS FUNDED

The Colorado Trust, 2005-2008.  
Kate B. Reynolds Charitable Trust, 1996-1999.

#### PROFESSIONAL SERVICE

##### National Commission on Certification of Physician Assistants, Inc.

Director, Board of Directors and Representative of the Department of Defense,  
1990-1993  
Vice Chairman, 1993  
Chair, Strategic Planning Committee, 1993  
Member, Strategic Planning Committee, 1993-1994  
Member, Subcommittee on Evaluation, 1990-1994

##### American Academy of Physician Assistants

Member, Selection Committee for the AAPA/Pfizer Physician Assistant  
Professional Achievement Recognition Program, 1995-1998

Jimmie E. Keller, M.P.H., PA-C  
Page 5

Association of Physician Assistant Programs

Consultant, Program Assistance and Technical Help (PATH) Consultation  
Service, 1995-2001.  
Coordinating Consultant, PATH Consultation Service, 1997-2001.

North Carolina Board of Medical Examiners

Member, Physician Assistant Advisory Committee, 1995-1997

The Center of Excellence for Remote and Medically Under-Served Areas at Saint Francis  
College, Loretto, PA

Member, Best Practices Panel -- Tele-Education, 1995-1997

COMMITTEES

Ireland Army Community Hospital, Fort Knox, KY

Credentials Committee, 1999-2002

East Carolina University

Mid-Level Practitioner Committee, School of Medicine, 1994-1997  
East Carolina-Duke Universities' Grant Planning Committee, Robert Wood  
Johnson Foundation "Partnerships In Training," 1995-1997

School of Allied Health Sciences, East Carolina University

Administrative Council, 1994-1997  
Faculty Council, 1996-1997  
Nominating Committee, 1994, 1995 (Chair), 1996  
Task Force for Clinical Services, 1995-1996

Pitt County Memorial Hospital/University Medical Center of Eastern Carolina, Inc.

Bylaws Work Group, 1995-1996

ADMINISTRATIVE ACTIVITIES

*Director, Physician Assistant Program, Red Rocks Community College,  
Lakewood, CO, December 2001-Present*

Full-time employment as a "Professional-Technical" employee of the State of Colorado with the administrative responsibility for the operation, budget, and curriculum content of a 24-month primary care entry-level physician assistant educational program in one of the 13 community colleges in Colorado. Responsible for supervising several full- and part-time faculty and staff, and teaching a variety of subjects and supervising PA students during clinical practicums and small group learning during the didactic and clinical years of the Program. The Red Rocks Community College PA Program is one of two such programs in Colorado, and one of 134 PA educational programs in the United States.

*Chief, Nelson Troop Medical Clinic, Ireland Army Community Hospital, Fort  
Knox, KY, May 200-June 2002.*

Full-time work as a Department of the Army Civilian with the administrative responsibility for the operation of a primary care clinic for active duty soldiers in entry level training and U.S Army Reserve and National Guard soldiers undergoing annual training at Fort Knox. Responsible for providing primary and urgent care and the oversight and supervision of physician assistants, contract and active duty physicians, a registered nurse, licensed practical nurses, enlisted corpsmen, administrative and medical record clerks, a pharmacist, a podiatrist, and a x-ray technician. Responsible as the liaison for the communication between the commander of the training brigade and the hospital commander for the operation of the clinic and the treatment and referral of soldiers within the brigade. Responsible for the care and treatment of entry level training soldiers who are placed on quarters and bed rest in the hospital infirmary. Responsible for the care and treatment of the inmates confined in the Regional Corrections Facility at Fort Knox.

*Coordinating Consultant, PATH Consultation Service, Association of Physician  
Assistant Programs, September 1997-June 2001.*

Part-time work performed in my home for a national organization to interface with developing and established physician assistant educational programs to offer advice and to coordinate confidential consultative services per the need of the program. Assist with the development of policies and budgeting for the PATH Consultation Service. Coordinate the scheduling and consultation visits of ten consultants located throughout the United States.

Jimmie E. Keller, M.P.H., PA-C  
Page 7

*Associate Director and Academic Coordinator, Physician Assistant Program,  
South College, Savannah, GA, April 1997-March 1998.*

Assisted with the development, design, and implementation of a quality, state-of-the-art Physician Assistant (PA) Program that concentrates curricula in primary care and rural health. Advised on budget and how to obtain grant funding for program operation. Developed didactic courses and scheduling. Assisted with the development of brochures on the PA profession and application materials and brochure on the South College PA Program which outline admission criteria and prerequisite courses to be completed by applicants.

*Chair, Clinical Instructor, and Program Planner, Department of Physician  
Assistant Studies, School of Allied Health Sciences, East Carolina University,  
February 1994-June 1997.*

Developed, designed, and implemented a quality, state-of-the-art PA Program which concentrates curricula in primary care and rural health. Developed budget and obtained grant funding for program operation. Obtained approval for the program from the faculty and administration at ECU, and budgeting and approval from The University of North Carolina (System) Board of Governors. Interviewed and hired program faculty (to include my replacement as department chair). Had advising responsibilities for all students who are currently enrolled, or who wished to enroll, at ECU, and who wished to apply for the ECU PA program. Developed brochures on the PA profession and application materials and brochure on the ECU PA Program which outline admission criteria and prerequisite courses to be completed by applicants.

*Lead Physician Assistant (part-time), Emergency Department "Fast Track,"  
Department of Emergency Medicine, East Carolina University School of  
Medicine/Pitt County Memorial Hospital, March 1995-April 1996.*

Coordinated daily work schedule of PAs and resident physicians. Advised Chair and Attending Physicians in Department of Emergency Medicine on utilization of PAs. Developed and coordinated quality assurance methods and procedures within the Fast Track.

### TEACHING

Program Director, Physician Assistant Program. Red Rocks Community College, December 1, 2001 – Present.

Adjunct Assistant Professor. Duke University School of Nursing, July 1, 1996 – July 31, 2002.

Instructor and Consultant. Developed courses and teach basic life saving skills and basic life support certification to American and foreign nationals for a security protective service, 1988-1995.

Visiting Professorship. The George Washington University, Washington, DC. Guest Lecturer and member of the Admissions Committee, Physician Assistant Program, 1987-Present.

Continuing Medical Education (CME) Coordinator. White House Medical Unit. Developed an extensive CME program for physicians, physician assistants, nurses, medical technicians, and United States Secret Service personnel. Established CME accreditation through the Uniformed Services University of the Health Sciences, 1984-1988.

### POSTGRADUATE EDUCATION

Certified by the National Commission on Certification of Physician Assistants, Inc., continuously since 1977. Certification requires documentation of a minimum of 100 approved hours of continuing medical education every two years in addition to sitting for a written recertification examination every six years. I have always documented in excess of the minimum requirement.

### RESEARCH ACTIVITIES AND INTERESTS

Research activities and interests are centered on understanding adult learning and curriculum development. A summary of this research will be published at a later date, which will chronicle my efforts to establish and implement a physician assistant educational program.

## PUBLICATIONS

### Book Chapters

- Guinn, D.H. and Keller, J.E. "PAs in the Military," The Physician Assistant: A Guide to Clinical Practice, 2d ed., Ballweg et al. (Orlando, FL: W.B. Saunders Company, 1999), pp. 724-732.
- Guinn, D.H. and Keller, J.E. "PAs in the Military," The Physician Assistant: A Guide to Clinical Practice, Ballweg et al. (Orlando, FL: W.B. Saunders Company, 1994), pp. 553-558.

### Articles

- Keller, J.E. "Efforts to Plan and Establish a Physician Assistant Educational Program at East Carolina University," NCAPA News, May/June 1995, supplement.

## PRESENTATIONS

### Panels

- "Allied Health Professional Opportunities," panel discussion, Health Professions Forum, North Carolina Health Careers Access Program, Pembroke State University, Pembroke, NC, February 15, 1995.
- "Primary Care and Mid-Level Practitioners (Physician Assistants)," testimony presented to the North Carolina Health Planning Commission Committee on Primary Care, Greenville, NC, July 11, 1994.

### Presentations

- "Diabetes Mellitus, Type 2, Update," Second Annual Meeting of the Association of Family Practice Physician Assistants, San Antonio, TX, November 19, 2000.
- "2000 PATH Program Enhancement Workshop for Novice Program Leaders," Multiple Topics as a Presenter and Facilitator, San Diego, CA, February 7-10, 2000.
- "Presidential Health," First Annual Meeting of the Association of Family Practice Physician Assistants, San Antonio, TX, November 6, 1999.
- "1999 PATH Program Enhancement Workshop for Novice Program Leaders," Multiple Topics as a Presenter and Facilitator, San Diego, CA, February 3-6, 1999.
- "Presidential Health," Keynote Speaker, Annual Meeting of the New Hampshire Society of Physician Assistants, Manchester, NH, September 26, 1998.
- "Management Issues In Health Care," invited lecturer for students enrolled in health care management program at Clayton State College, Morrow, GA, January 23, 1997.

- "Health Careers: A Changing Workforce," keynote speaker at workshop for health career counselors sponsored by the Eastern Area Health Education Center, Williamston, NC, March 20, 1996.
- "Insomnia and An Integrated Approach to Sleep Management," 13th Annual CME Conference, Virginia Academy of Physician Assistants, Virginia Beach, VA, July 26, 1995.
- "Communication Skills Necessary for Health Care Professionals," D.H. Conley High School, Senior English Classes, Greenville, NC, February 13 and 14, 1995.
- "Health Care Reform and the Use of Physician Assistants and Family Nurse Practitioners in Primary Care," East Carolina University, Graduate Class on Community Health, Greenville, NC, November 8, 1994.
- "Health Care Reform and the Use of Physician Assistants and Family Nurse Practitioners in Primary Care," Pembroke State University, North Carolina Health Careers Access Program, Pembroke, NC, October 12, 1994.
- "Becoming A Physician Assistant," East Carolina University, Health Occupation Students of America, Greenville, NC, September 27, 1994.
- "Developing A Physician Assistant Educational Program at East Carolina University," Eastern Association of Local Health Directors, New Bern, NC, September 1, 1994.
- "Developing A Physician Assistant Educational Program at East Carolina University," Association of Physician Assistant Programs Leadership Conference, Sugarloaf Mountain, ME, August 11, 1994.
- "Becoming A Physician Assistant," East Carolina University, Health Careers Day Symposium, Greenville, NC, June 20, 1994.
- "Developing A Physician Assistant Educational Program at East Carolina University," East Carolina University, North Carolina Community College Counselors' Workshop, Greenville, NC, June 16, 1994.
- "Becoming A Physician Assistant," Martin County Community College, High School Career Day, Williamston, NC, March 3, 1994.
- "Developing A Physician Assistant Educational Program at East Carolina University," North Carolina Primary Health Care Association, Greenville, NC, February 3, 1994.
- "Presidential Health," Symposium on Innovations in the Management of Community-Acquired Infections, Dearborn, MI, September 22, 1993.
- "Presidential Health," Luncheon Meeting, Noble Army Community Hospital, Fort Lee, VA, July 16, 1993.
- "Commissioning and Integration of Army Physician Assistants Into the Army Medical Specialist Corps," Society of Army Physician Assistants' Annual Conference, Fayetteville, NC, April 26, 1993.
- "Presidential Health," Symposium on Innovations in the Management of Community-Acquired Infections, Indianapolis, IN, February 18, 1993.

- "Desert Storm: The Role of Physician Assistants in a Military Crisis," Nevada Academy of Physician Assistants Annual Conference, Las Vegas, NV, February 12, 1993.
- "Commissioning and Integration of Army Physician Assistants Into the Army Medical Specialist Corps," Society of Army Physician Assistants' Annual Conference, Fayetteville, NC, April 27, 1992.
- "Commissioning and Integration of Army Physician Assistants Into the Army Medical Specialist Corps," Series of Commander's Meetings at: Fort Ord, CA; Schofield Barracks, HI; Seoul, Korea; Forts Richardson and Wainwright, AK; and Madigan Army Medical Center, WA, March 9-27, 1992.
- "Desert Storm: The Role of Physician Assistants in a Military Crisis," Maryland Academy of Physician Assistants Annual Conference, Columbia, MD, June 5, 1991.
- "A Case Study: The Effort to Commission the Army Physician Assistants," Society of Army Physician Assistants' Annual Conference, Fayetteville, NC, April 28, 1991.
- "Presidential Health," Society of Army Physician Assistants' Annual Conference, Fayetteville, NC, April 22, 1990.
- "A Case Study: The Effort to Commission the Army Physician Assistants," Society of Army Physician Assistants' Annual Conference, Fayetteville, NC, April 20, 1990.
- "Computer Applications in Public Health: Framingham Heart Study," Master of Public Health Program, The George Washington University, Washington, DC, May 15, 1989.
- "Presidential Health," Indiana Academy of Physician Assistants' Annual Conference, Indianapolis, IN, May 13, 1989.
- "Plan to Increase the Supply and Availability of Very-Low Cost Housing and Related Social Support Structure in the Washington, DC Metropolitan Area," Seminar on the Homeless, The George Washington University, Washington, DC, March 14, 1989.
- "Health Care Policy: Paying the Doctor," Master of Public Health Program, The George Washington University, Washington, DC, July 17, 1988.
- "Medical Ethics and the Law: Euthanasia," Master of Public Health Program, The George Washington University, Washington, DC, May 8, 1988.
- "The Future of Public Health: The IMO Report," Colloquium on Public Health, The George Washington University, March 10, 1988.
- "A Comparison of For-Profit and Nonprofit Hospitals and Problems of the Health Care System," Master of Public Health Program, The George Washington University, Washington, DC, December 11, 1987.

### SPECIAL HONORS AND AWARDS

Commander's Award for Exceptional Service as a Department of the Army Civilian,  
Ireland Army Community Hospital, Fort Knox, KY, 2002.  
Distinguished Member of the Army Medical Department Regiment, 1993.  
Order of Military Medical Merit, 1992.  
Professional Proficiency "A" Designator Awarded by The Surgeon General of the Army,  
1992.  
Robert Scully Memorial Award, Society of Army Physician Assistants, 1992.  
Physician Assistant of the Year Award, Association of Military Surgeons of the United  
States, 1991.  
Physician Assistant Awareness Achievement Award, American Academy of Physician  
Assistants and ICI Pharmaceuticals Group, 1991.  
Outstanding Military Physician Assistant of the Year Award, Veterans Caucus, American  
Academy of Physician Assistants, 1991.  
United States Presidential Service Badge, 1986.  
Numerous U.S. Army Citations, Medals, and Badges, 1967-1994.

### COMMUNITY SERVICE

Member, Colorado Football Officials Association, July 2002-Present.  
Member, Kentuckiana Football Officials Association, July 2001-2002.  
President, Fort Knox High School Baseball Booster Club, 2001-2002.  
Director, Booster Clubs, Fort Knox High School Baseball and Football Teams, February  
2000-2002.  
President, Parent-Teacher Organization, Scott Middle School, Fort Knox, KY, October  
1999-2001.  
Advancement Coordinator, Boy Scouts of America (BSA) Troop 279, Peachtree City,  
GA, February 1998-July 1999.  
Burke Presbyterian Church, Burke, VA. Member, 1985-1994. Elder, 1991-1993.  
Volunteer, Christ House (men's homeless shelter), Washington, DC, 1989-1993.  
Instructor, Basic Cardiac Life Support, American Heart Association, 1984-2000.  
Scoutmaster, BSA Troop 1100, Burke, VA, 1984-1986.  
Assistant Scoutmaster, BSA Troop 1100, Burke, VA, 1983-1984.  
Chair, Health and Safety Committee, George Washington District, National Capitol Area  
Council, BSA, 1983-1984.  
Volunteer coach in youth soccer, baseball, basketball, and football in Colorado, South  
Carolina, Germany, Virginia, Georgia, and Fort Knox, Kentucky, 1970-2000.



CURRICULUM VITAE

**Arthur G. Lipman, Pharm.D.**

Professor, Department of Pharmacotherapy, College of Pharmacy  
Adjunct Professor, Department of Anesthesiology, School of Medicine  
Director of Clinical Pharmacology, Pain Management Center, University Hospitals and Clinics  
University of Utah Health Sciences Center  
Salt Lake City, Utah

30 S 2000 E RM 258  
Salt Lake City UT 84112-5820  
Telephone: (801) 581-5986  
Fax: (801) 585-6160  
E-mail: alipman@hsc.utah.edu

Home Address: 6281 South Havenbrook Circle, Salt Lake City, Utah 84121

Birthplace: New Bedford, Massachusetts

EDUCATION

Bachelor of Science (Pharmacy)  
University of Rhode Island  
Kingston, Rhode Island


Doctor of Pharmacy 1968  
University of Michigan  
Ann Arbor, Michigan

PERSONAL

Married to Patrice M. Arent, J.D.  
2 children: Sarah and Joshua

HONORS

Distinguished Service Award, American Alliance of Cancer Pain Initiatives, 2001.  
Award for Sustained Contributions to the Literature of Pharmacy in Health Systems, American Society of Health-systems Pharmacists Research & Education Foundation, 1999  
Hospice Pioneer Award, Utah Hospice Organization, 1999  
Fellow, American Society of Health-system Pharmacists, 1996  
National Hospice Organization - Clinical Care Giver Heart of Hospice Award, 1994  
Saint George Medal - American Cancer Society National Divisional Award, 1993  
Merrell Dow Lectureship in Clinical Pharmacy, University of Manchester, Manchester, England, 1990  
Rho Chi, Pharmaceutical Honor Society  
Outstanding Teacher of the Year Award, Physicians Assistant Program, University of Utah School of Medicine, 1988  
P.G. Pierpaoli Lecture Award, Connecticut Society of Hospital Pharmacists, 1981  
American Society of Hospital Pharmacists Research & Education Foundation Award for Achievement in Professional Practice, 1980  
Didactic Instructor Award, Jack Cole Society, Yale University School of Medicine, 1978  
Certificate of Special Recognition, Physicians Associate Program, Yale University School of Medicine, 1975  
Connecticut Hospital Pharmacist of the Year Award, 1974  
Squibb Past Presidents Award, Connecticut Society of Hospital Pharmacists, 1974  
Geigy Leadership Award, Connecticut Society of Hospital Pharmacists, 1974  
Lundsford-Richardson National Pharmacy Undergraduate Research Award, 1967  
McKesson and Robins Pharmacy Administration Award, University of Rhode Island, 1967  
Kappa Psi Pharmaceutical Fraternity Scholarship Honors, 1966-1967, 1965-1966



ACADEMIC APPOINTMENTS

1987-present Professor of Pharmacotherapy, College of Pharmacy, University of Utah  
2004-present Research Ethics Faculty Fellow, University of Utah  
2003-present Adjunct Professor of Anesthesiology, School of Medicine, University of Utah  
1982-1987 Professor of Clinical Pharmacy and Chairman, Department of Pharmacy Practice, University of Utah  
1977-1982 Associate Professor of Clinical Pharmacy and Chairman, Department of Pharmacy Practice, University of Utah  
1977 Associate Clinical Professor of Pharmacy, University of Connecticut School of Pharmacy  
1974-1977 Lecturer in Community Health Nursing, Yale University Graduate School of Nursing  
1971-1977 Assistant Clinical Professor of Pharmacy, University of Connecticut School of Pharmacy  
1971-1977 Lecturer in Surgery, Yale University School of Medicine

TEACHING COORDINATOR POSITIONS

1977-present Drug Therapy in Primary Care  
School of Medicine, Physician Assistant Program, University of Utah  
1976-1977 Non-credit Extension Program  
Fairfield University, Fairfield, CT  
1974-1977 Clinical Pharmacology  
Clinical Nurse Practitioner Program, Yale University School of Nursing  
1972-1975 Pharmacology for Inhalation Therapists  
Yale-New Haven Hospital School of Inhalation Therapy  
1971-1977 Medication Nurse Course  
Yale-New Haven Hospital  
1971-1977 Nursing Inservice Education in Drug Therapy  
Yale-New Haven Hospital  
1970-1977 Clinical Pharmacology and Therapeutics  
Physician's Associate Program, Yale University School of Medicine  
1969-1970 Medication Nurse Course  
U.S. Public Health Service Indian Hospital, Tuba City, Arizona

PROFESSIONAL EXPERIENCE

1984-present Director of Clinical Pharmacology  
Pain Management Center, University of Utah Hospitals and Clinics  
1989 (While on Sabbatical leave from the University of Utah): April-June, Research on the development of a cancer pain data system, Sir Michael Sobell House, Churchill Hospital, University of Oxford, England  
1989 (While on Sabbatical leave from the University of Utah): February-April Active Duty, U.S. Public Health Service, Special Projects, Consultation to the Office of the Assistant Surgeon General  
1977-1987 Coordinator of Pharmaceutical Services, University of Utah Health Sciences Center  
1973-1977 Drug Information Director and Associate Director of Pharmacy Services  
Yale-New Haven Hospital  
New Haven, Connecticut  
1970-1973 Drug Information Director  
Department of Pharmacy Services  
Yale-New Haven Hospital  
New Haven, Connecticut  
1968-1970 Commissioned Officer  
United States Public Health Service, Active Duty  
1967 Community Pharmacist, New Bedford, Massachusetts  
1966-1967 Pharmacy Intern, New Bedford, Massachusetts  
1965-1966 Field Auditor, National Prescription Audit

PHARMACIST LICENSURE

Massachusetts, by examination, 1967, No. 14809  
Utah, by reciprocity, No. 3137  
Connecticut, 1970-1995

Rhode Island, by examination, 1967, No. 1851  
New Hampshire, 1983 (honorary)

PUBLICATIONS

Books

1. Drug Use in Assisted Suicide and Euthanasia. MP Battin and AG Lipman, editors, Binghamton NY, Haworth Press, 1996.
2. Evidence-Based Symptom Control in Palliative Care. AG Lipman, LS Tyler and KC Jackson, editors, Binghamton NY, Haworth Press, 2000.
3. Pain and Palliative Care in the Developing World and Marginalized Populations: A Global Challenge. Rajagopal MR, Mazza D, Lipman AG, editors, Binghamton NY, the Haworth Press, 2003.
4. Pain Management for Primary Care Clinicians. Lipman AG, editor. Bethesda MD, ASHP, 2004
5. Drugs and Justice, Dick D, Battin MP, Lipman AG et al. Oxford University Press, in preparation.

Chapters and Monographs

1. Lipman AG. Monitoring and recording drug interactions, in Drug Interactions, University of Connecticut, 1972.
2. Lipman AG. Establishing a drug information service, Hosp Pharm Notes, Eli Lilly and Co., Indianapolis, IN, 1974.
3. Lipman AG. Drug therapy in terminally ill patients, Clinical Pharmacy Sourcebook, American Society of Hospital Pharmacists, Publishing Sciences Group, Acton, MA, 1976.
4. Lipman AG, Decker EL. Therapeutics: H<sub>2</sub> Receptor Antagonists in Peptic Ulcer Disease, Biomedical Information Corporation, New York, 1978.
5. Lipman AG, Molde S. Drug therapy in infectious disease, in Pharmacology and Therapeutics for Nurses, Weiner, Pepper and Romano (eds), McGraw Hill, New York, 1979.
6. Lipman AG. Interactions between diet and drugs, in Handbook of Clinical Dietetics, American Dietetic Association, Yale University Press, New Haven and London, 1980.
7. Lipman AG. Antimicrobial agents, in Pharmacology for the Dental Hygienist, Lewis, Lewis and Mackowiack (eds), Science Research Associates, Chicago, 1980.
8. Anderson J, Freeman HP, Gross SM, Humma KG, Lemberger AP, Leone LA, Lipman AG, Oppenheimer S, Roberts RW, Youngken HW. The Role of the Pharmacist in Cancer Management: Curriculum Guide and Role Definition, American Cancer Society, New York, 1980.
9. Lipman AG. Drug therapy in terminally ill patients, Source Book on Clinical Pharmacy, PSG Publishing Group, Littleton, MA, 1980.
10. Lipman AG. Drugs in pain and symptom management, in Hospice - A Unique Nursing Opportunity, DHEW, USPHS, Health Resources Administration, Division of Nursing, Government Printing Office, Washington, DC, 1981.
11. Lipman AG. On drug and food interactions, Executive Health Report, 18(2), November 1981.
12. Lipman AG. Drug therapy in cancer pain, in Dying Persons and Hospice, Corr CA and Corr DN (eds), Springer Publishing Co., New York, 1982.
13. Lipman AG. Management of pain, in Geriatric Curriculum, American Association of Colleges of Pharmacy, Health Sciences Consortium, Chapel Hill, NC, 1984.
14. Lipman AG. Pain management, in Clinical Pharmacy and Therapeutics, Herfindal CT and Hirschmann JR (eds), 3rd Edition, Williams and Wilkins, Baltimore, 1984.
15. Lipman AG, Mooney KG. Management of pain, in Clinical Pharmacology and Therapeutics in Nursing, 2nd Edition, Weiner M and Pepper G (eds), McGraw Hill, New York, 1985.
16. Lipman AG. Decentralized pharmacy systems for drug use control, in Pharmacy Practice - The Year 2000, Moore RL (ed), Pan Pacific Foundation - United States, Greensboro, NC, 1985.
17. Lipman AG. Formulary development, in Institutional Pharmacy Management, Wertheimer A and Daniels C (eds), Pan American Health Organization, 1988.
18. Lipman AG. Barriers to the development of clinical practice in pharmacy, in the Report of the Western Regional Conference on Clinical Pharmacy Practice, Coto De Caza, CA, 1987.
19. Lipman AG. Newer findings in the pharmacology of opioid analgesics. Norwich-Eaton Pharmaceuticals, 1988.
20. Lipman AG. Pain management. Wellcome Programs in Hospital Pharmacy, Burroughs Wellcome Co., 1988.
21. Hare BD, Lipman AG. Uses and Misuses of Medication in the Treatment of Chronic Pain. In Hare BD, Fine P (editors), Chronic Pain, Problems in Anesthesia, Philadelphia, JB Lippincott Co., 1990.
22. Lipman AG. Pharmacy Services in Hospice. Wellcome Trends in Hospital Pharmacy, New York, Health Education Technologies, June 1990.

continued

Chapters and Monographs (continued)

23. Lipman AG. Drug-Use Management, in Handbook of Institutional Pharmacy Practice, 3rd edition, Brown TR, Smith MC, editors. Bethesda, American Society of Hospital Pharmacists, 1992.
25. Acute Pain Management Guideline Panel. Acute Pain Management: Operative or Medical Procedures and Trauma. Clinical Practice Guideline. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, Feb. 1992.
26. Acute Pain Management Guideline Panel. Acute Pain Management in Adults: Operative Procedures. Quick Reference Guide for Clinicians. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1992.
27. Acute Pain Management Guideline Panel. Acute Pain Management in Infants, Children and Adolescents: Operative and Medical Procedures. Quick Reference Guide for Clinicians. AHCPR Pub. No.92-0020. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1992.
28. Acute Pain Management Guideline Panel. Pain Control After Surgery. A Patient's Guide. AHCPR Pub. No.92-0021. Rockville MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1992.
29. Lipman AG. Curriculum on Pain for Pharmacy Students. International Association for the Study of Pain Newsletter. 1992;May/June:2-4.
30. Lipman AG. Pharmacist involvement and Drug Therapy Issues in State Cancer Pain Initiatives. American Pain Society Bulletin. 1992(Oct/Nov):16,22.
31. Lipman AG. Use of medications in the treatment of pain and injury, in The Psychology of Sport Injury, Heil J (ed), Champagne IL, Human Kinetics Press, 1993.
32. Lipman AG. Current Issues in Pain Management. Syntex Laboratories, 1994.
33. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Clinical Practice Guideline. Rockville MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
34. Jacox A, Carr DB, Payne R, et al. Management of Cancer Pain. Adult Quick Reference Guide. Rockville MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
35. Jacox A, Carr DB, Payne R, et al. Managing Cancer Pain. Patient Guide. Rockville MD, Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services, 1994.
36. Lipman AG, Reisner-Keller LA. The Use of Opioids in Chronic, Non-Malignant Pain, Controversies, Pain Management Pharmacy Newsletter 1994;1(1).
37. Lipman AG and Berry JI. Pharmaceutical Care of Terminally Ill Patients. in Social and Behavioral Aspects of Pharmaceutical Care. Smith M and Wertheimer A (editors), Binghamton NY, Haworth Press, 1996.
38. Lipman AG and Gauthier ME. Pharmacology of Opioid Drugs: Basic Principles. In Topics in Palliative Care: Advances in the Pharmacotherapy of Pain. Portenoy R, Bruerea E. (Editors), New York, Oxford University Press, 1996.
39. Lipman AG. Internal analgesic and antipyretic products. In Handbook of Nonprescription Drugs, 11th edition, Washington DC, American Pharmaceutical Association, 1996.
40. Lipman AG. Pharmaceutical Care of the Acute Pain Patient. GlaxoWellcome Trends in Pharmacy, Helix Online (World Wide Web), <http://www.helix.com/member/mbrhome.html> 1996
41. Lipman AG. Pharmacological Approaches to Pain Management: Nontraditional Analgesics and Analgesic Adjuvants. In Ashburn MA, Rice LF, editors, The Management of Pain. New York, New York, Churchill Livingstone 1997.
42. Lipman AG. Pharmacology of Opioids: Basic Principles. In Portenoy RK, Bruera E, editors, Topics in Palliative Care. New York, Oxford University Press, 1997.
43. Lipman AG, Jackson KC. Headache, Muscle and Joint Pain. in Handbook of Nonprescription Drugs, 12th edition, Washington DC, American Pharmaceutical Association, 2000.
44. Lipman AG, Jackson KC. Fever. in Handbook of Nonprescription Drugs, 12th edition, Washington DC, American Pharmaceutical Association, 2000.
45. Lipman AG, Jackson KC. Use of opioids in chronic noncancer pain. New York, Power-Pak Communications, 2000.
46. Lipman AG, Jackson KC. Opioids. In Warfield C, Bajwa Z, editors, Principles and Practice of Pain Management, 2<sup>nd</sup> edition, New York, McGraw Hill, 2003.
47. Jackson KC, Lipman AG Opioid Analgesics. In Tollison D, editor, Clinical Pain Management: A Practical Approach, 3<sup>rd</sup> Edition, Philadelphia, Lippincott - Williams & Wilkins, 2002.
48. Simon L, Lipman AG, Jacox A et al. Guideline for the Management of Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis Pain. Glenview IL, American Pain Society, 2002.

Chapters and Monographs (continued)

49. Fakata KL, Miaskoski C, Lipman AG. Chronic Malignant Pain Management. In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists, 2004.
50. Ashburn MA, Lipman AG. Pain in Society. . In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists , 2004.
51. Hare BD, Voitanick S, Lipman AG. Pathophysiology of Pain. . In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists, 2004.
53. Jackson KC II, Lipman AG. Nonopioid analgesics. . In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists, 2004.
54. Jackson KC II, Lipman AG. Opioid analgesics. . In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists, 2004.
55. Gitlin MS, Lipman AG. Chronic Nonmalignant Pain. . In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists, 2004.
56. Simon LS, Lipman AG. Managing pain in Osteoarthritis and Rheumatoid Arthritis. In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-Systems Pharmacists, 2004.
57. Mays TA, Thorpe D, Lipman AG. Palliative Care. In Lipman, AG, editor, Pain Management for Primary Care Clinicians. Bethesda MD, American Society of Health-System Pharmacists, 2004.
58. Lipman AG, Rajagopal, MR, Mazza D. Pain and Palliative Care-A Universal Human Imperative: Lessons for the World from the Innovator. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations: A Global Challenge. Binghamton NY, The Haworth Press, 2004.
59. Rajagopal MR, Lipman AG, Mazza D. Commentary: Is Freedom from Pain Truly Possible? In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations, A Global Challenge. Binghamton NY, The Haworth Press, 2004.
60. Rajagopal MR, Lipman AG. Commentary: Documenting Thai Palliative Care. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations, A Global Challenge. Binghamton NY, The Haworth Press, 2004.
61. Rajagopal MR, Lipman AG. Commentary: Acceptance of Palliative Care in Hong Kong. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations, A Global Challenge. Binghamton NY, The Haworth Press, 2004.
62. Lipman AG, Rajagopal MR. Commentary: Hospice Africa- Uganda: A Model for Africa. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations, A Global Challenge. Binghamton NY, The Haworth Press, 2004.
63. Mazza D, Lipman AG. Commentary: Palliative Care in India-More than a Matter of Resources. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations, A Global Challenge. Binghamton NY, The Haworth Press, 2004.
64. Rajagopal MR, Lipman AG. Spirituality and Religion in Palliative Care - Potential Benefits and Risks. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations: A Global Challenge. Binghamton NY, The Haworth Press, 2004.
65. Rajagopal MR, Lipman AG. Commentary: Research is Needed to Improve Practice. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations: A Global Challenge. Binghamton NY, The Haworth Press, 2004.
66. Lipman AG, Rajagopal, MR, Mazza D and Palliative Commentary: The International Association for Hospice Care Traveling Fellowships. In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations: A Global Challenge. Binghamton NY, The Haworth Press, 2004.
66. Rajagopal MR, Lipman AG, Mazza D. Pain and Palliative Care: Where Do We Go From Here? In Rajagopal MR, Mazza D, Lipman AG, editors. Pain and Palliative Care in the Developing World and Marginalized Populations: A Global Challenge. Binghamton NY, The Haworth Press, 2004.
67. Fakata KL, Lipman AG. Gastrointestinal Opioid Physiology and Pharmacology. In Yuan S-H, editor, Opioid Bowel Dysfunction, Binghamton NY, Haworth Medical Press, 2004.
68. Fakata KL, Lipman AG. Opioid Bowel Dysfunction in Acute and Chronic Non-malignant Pain. In Yuan S-H, editor, Opioid Bowel Dysfunction, Binghamton NY, Haworth Medical Press, 2004.

Articles in Refereed Journals

1. Lipman AG, Osborne GE. Medicine and pharmacy aboard New England whaling vessels: the captain, an apothecary-surgeon at sea. *Pharm in Hist* 1969;11:119-131.
2. Lipman AG. Child-resistant medication containers to reduce pediatric drug poisonings. *Conn Med* 1972;38:666-668.
3. Beste DF, McCart GM, Lipman AG. New services generate teaching role. *Hospitals, JAHA* 1973;4:141-146.
4. Lipman AG, Corrison W, Westerman J. Praxalol - foreign drug evaluation. *Hosp Pharm* 1973;8:315-322.
5. Lipman AG, Mullen HF. Quality control for pharmaceutical industry representatives. *Amer J Hosp Pharm* 1974;31:167-70.
6. Lipman AG. The effect of buffering on the incidence and severity of cephalothin induced phlebitis. *Amer J Hosp Pharm* 1974;31:266-268.
7. Lipman AG. Drug therapy in terminally ill patients. *Amer J Hosp Pharm* 1975;32:270-276.
8. Lipman AG, Brooks KJ. Clinical considerations in analgesic therapy: narcotic analgesics. *The PA Journ* 1976;6:68-71.
9. Lipman AG, Bauer E. Pharmaceutical group purchasing cuts costs, expands knowledge. *Hospitals, JAHA* 1976;50:99-104.
10. Lipman AG, Brooks KJ. Clinical considerations in analgesic therapy: non-narcotic analgesics. *The PA Journ* 1976;6:21-4.
11. Kern J, Lipman AG. Rational theophylline therapy: a review of the literature with guide to pharmacokinetics and dosage calculation. *Drug Intell Clin Pharm* 1977;11:144-153.
12. Bennett BS, Lipman AG. A comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. *Amer J Hosp Pharm* 1977;34:931-936.
13. Lipman AG, Madeux B. Computer based formulary service reduces costs, eliminates confusion. *Hospitals, JAHA* 1977;51:109-112.
14. Ponte CD, Lipman AG, Moran CP. Utilization review of nutritionally complete liquid diets. *Amer J Hosp Pharm* 1978;35:159-162.
15. Hutchinson TA, Leventhal JM, Kramer MS, Karch FE, Lipman AG, Feinstein AR. An algorithm for the assessment of adverse drug reactions. *JAMA* 1979;242:633-635.
16. Lipman AG, McMahon JD. The development of program guidelines for community and institutional externships. *Am J Pharm Ed* 1979;43:217-223.
17. Lipman AG, Devenport JK. An integrated, competency based curriculum for doctor of pharmacy students. *Am J Pharm Ed* 1979;43:214-216.
18. Lipman AG, Bair JN, Hibbard FJ, et al. Decentralization of pharmacy services without satellite pharmacies. *Amer J Hosp Pharm* 1979;36:1513-1519.
19. Lipman AG. Drug therapy in chronic pain. *J Cont Ed Clin Hosp Pharm* 1979;1:5:10-22.
20. Lipman AG. Drug therapy in cancer pain. *Cancer Nurs* 1980;3:39-46.
21. Russo J Jr, Lipman AG, Comstock TJ, Page BC, Stephen RL. Lidocaine anesthesia: comparison of iontophoresis, injection, and swabbing. *Amer J Hosp Pharm* 1980;37:843-847.
22. Lipman AG, Bair JN. A graduate program in institutional pharmacy management leading to an MS in hospital pharmacy, MBA and residency. *Am J Pharm Ed* 1981;45:17-20.
23. Phillips RC, Lipman AG. Physician perceptions of clinical pharmacy service. *Hosp Formul* 1981;16:996-1009.
24. Lipman AG, Devenport JK, Page BC. An analysis of information provided by clinical pharmacists. *Amer J Hosp Pharm* 1982;39:71-73.
25. Superstine E, Lipman AG, Bair JN, Baum S. Considerations in selecting a mobile master medication cart. *Amer J Hosp Pharm* 1983;40:293-294.
26. Lipman AG. Motivating faculty. *Am J Pharm Ed* 1983;47:364-366.
27. Lipman AG. Formulary system controversies in the new environment of DRGs. *Hosp Formul* 1985;20:218-232.
28. Yosselson-Superstine S, Lipman AG, Sanders SH. Adjunctive anti-anxiety agents in the management of chronic pain. *Isr J Med Sci* 1985;21:113-117.
29. Lipman AG. Integrating clinical and distributive pharmaceutical services: implications for clinical pharmaceutical education. *Am J Pharm Ed* 1986;50:63-66.
30. Lipman AG. Drug therapy considerations in the renally compromised geriatric patient. *The Consultant Pharmacist* 1987;2(Suppl B):8-11.
31. Kleiman RL, Lipman AG, Hare BD, MacDonald SD. A comparison of morphine administered by patient-controlled analgesia and regularly scheduled intramuscular injection in severe postoperative pain. *J Pain Sympt Manage* 1988;3:15-22.
32. Lipman AG. Documenting Hospice. *American J Hospice Care* 1988;5.
33. Lipman AG. Newer findings in the pharmacology of opiate analgesics. *Contemp Surg* 1988; 33 (Suppl 3A):6-12.
34. Lipman AG. Opioid analgesics in the management of cancer pain: pharmacokinetic considerations. *Am J Hospice Care* 1988;6:(1) 13-28.

Articles in Refereed Journals (continued)

35. Lipman AG. Current information on the use of immunobiologics: comments of the ASHP Commission on Therapeutics. *Clin Pharm* 1989;8:850-851.
36. Lipman AG. Drug therapy in the management of pain. *Br J Pharm Practice*. 1990;12:22-29.
37. Lipman AG. Pain management in the home care and hospice patient. *J Pharm Practice*. 1990;3:1-11.
38. Arter SG, Lipman AG. Hospice Care: a new opportunity for pharmacists. *J Pharm Practice*. 1990;3:28-33.
39. Lipman AG. Clinical advances in the management of pain. *The IHS Primary Care Provider*. 1990;15:54-61.
40. Lipman AG. Clinically relevant differences among the opioid analgesics. *Clin Pharm*. 1990;47(Suppl 1):S7-13.
41. Lipman AG. Specialization in pharmacy education: resources and risks. *Am J Pharm Ed.*; 1990;54:381-382.
42. Lipman AG. Opioid use in the treatment of pain: Refuting 10 common myths. *Pain Management*. 1991;4(4):13-17.
43. Ashburn MA, Lipman AG. Management of Pain in the Cancer Patient. *Anesth Analg*. 1993;76:402-416.
44. Kerrick JM, Fine PG, Lipman AG, Love G. Low-dose amitriptyline as an adjunct to opioids for post-operative orthopedic pain: a placebo-controlled trial. *Pain* 1993;52:325-330.
45. Lipman AG. The argument against therapeutic use of heroin in pain management. *Am J Hosp Pharm*. 1993;50:996-998.
46. Lipman AG. Rational and cost-effective NSAID therapy. *J Pharm Care Pain Symptom Control*. 1994;2(2):39-46.
47. Lipman AG, Berry JI. Pharmaceutical care of terminally ill patients. *J Pharm Care Pain Symptom Control*. 1995;3(2): 31-56.
48. Battin MP, Lipman AG. The need to objectively examine issues in assisted suicide and euthanasia. *J Pharm Care Pain Symptom Control* 1995; 3(3-4): 1-10.
49. Lipman AG. Pharmaceutical Care of The Acute Pain Patient. *Trends in Pharmacy Online*. 1996:December.
50. Lipman AG. Analgesic drugs for neuropathic and sympathetically maintained pain. *Clinics in Geriatric Medicine* 1996;12:501-515.
51. Lipman AG. Pharmacologic approaches to neuropathic pain. *Current Review of Pain* 1997;1:285-295.
52. Doucette WR, Mays-Holland T, Memmott H, Lipman AG. Cancer pain management: pharmacist knowledge and practices. *J Pharm Care Pain Symptom Control* 1997;5(3):17-32.
53. Lipman AG. Pain management in a patient with medication allergy. *Cancer Practice* 1998;6:8-10.
54. Lipman AG. Methadone in the management of pain in cancer patients reviewed. *Oncology* 1999;13:1285-8.
55. Lipman AG. The role of the pharmacist in palliative care. *Trends in Pharmacy Online*. 2000
56. Lipman AG. Evidence-based palliative care. *J Pharm Care Pain Symptom Control* 1999;7(4):1-10.
57. Tyler LS, Lipman AG. Anorexia and cachexia in palliative care patients. *J Pharm Care Pain Symptom Control* 1999;7(4):11-22.
58. Jackson KC, Lipman AG. Anxiety in palliative care patients. *J Pharm Care Pain Symptom Control* 1999;7(4):23-36.
59. Jackson KC, Lipman AG. Delirium in palliative care patients. *J Pharm Care Pain Symptom Control* 1999;7(4):59-70
60. Tyler LS, Lipman AG. Fatigue in palliative care patients. *J Pharm Care Pain Symptom Control* 2000;8(1):129-142.
61. Ferrell BR, Novy D, Sullivan MD, Banja J, Lipman AG et al. Ethical dilemmas in pain management. *J Pain*. 2001; 2:171-80.
62. Lipman AG. Treatment of chronic pain in osteoarthritis: do opioids have a role? *Curr Rheumatol Reports*. 2001;3:513-19.
63. Macario A, Lipman AG. Ketorolac in the Era of COX-2 Inhibitors: Update On Efficacy, Side Effects, and Regulatory Issues. *Pain Med*. 2001;2:336-51
64. Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse events associated with postoperative opioid analgesia: a systematic review. *J Pain* 2002;3: 159-180.
65. Oderda, Evans RS, Lloyd J, Lipman AG, Chen C, Ashburn MA, Burke J, Samore M. Cost of opioid-related adverse events in surgical patients. *J Pain Symptom Manage* 2003;23:64-73.
66. Fakata KL, Lipman AG. Pharmacotherapy for pain in rheumatologic conditions: the neuropathic component. *Curr Pain Headache Rep*. 2003;7:197-205.
67. Rajagopal MR, Lipman AG, Mazza D. Is Freedom from Pain Truly Possible?. *J Pain Palliat Care Pharmacother*. 2003;17(3):11-13.
68. Rajagopal MR, Lipman AG. Commentary: Documenting Thai Palliative Care. *J Pain Palliat Care Pharmacother*. 2003;17(3):63-64.
69. Rajagopal MR, Lipman AG. Commentary: Acceptance of Palliative Care in Hong Kong. *J Pain Palliat Care Pharmacother*. 2003;17(3):75-76.
70. Lipman AG, Rajagopal MR. Commentary: Hospice Africa- Uganda: A Model for Africa. *J Pain Palliat Care Pharmacother* 2003;17(3):119-120.
71. Mazza D, Lipman AG. Commentary: Palliative Care in India-More than a Matter of Resources. *J Pain Palliat Care Pharmacother*. 2003;17(3):129-130.

continued

Articles in Refereed Journals (continued)

72. Rajagopal MR, Lipman AG. Spirituality and Religion in Palliative Care - Potential Benefits and Risks. *J Pain Palliat Care Pharmacother.* 2003;17(3):167-170.
73. Rajagopal MR, Lipman AG. Commentary: Research is Needed to Improve Practice. *J Pain Palliat Care Pharmacother.* 2003;17(3):183-184.
74. Lipman AG, Rajagopal MR, Mazza D and Palliative Commentary: The International Association for Hospice Care Traveling Fellowships. *J Pain Palliat Care Pharmacother.* 2003;17(3):199-200.
75. Rajagopal MR, Lipman AG, Mazza D. Pain and Palliative Care: Where Do We Go From Here *J Pain Palliat Care Pharmacother.* 2003;17(3):239-242.
76. Lipman AG. Pain and the Pharmacist. *Pain MD* 2003;4:193-4.
77. Fakata KL, Lipman AG: Anti-inflammatory Agents for Musculoskeletal Pain and Arthritis. *Current Pain and Headache Rep.* 2004;8:
78. Grahmann PH, Jackson KC, Lipman AG. Clinician Beliefs about Opioid Use and Barriers. *J Pain Palliat Care Pharmacother.* 2004;18(2):7-28.
79. Dalpiaz AS, Lordon SP, Lipman AG. Topical Lidocaine Patch Therapy for Myofascial Pain. *J Pain Palliat Care Pharmacother.* 2004;18(3):15-34.

Abstracts

1. Lipman AG, Osborne GE. Medicine and pharmacy aboard New England whaling vessels, I: the captain, an apothecary-surgeon at sea. American Institute of the History of Pharmacy, Abstracts of the 113th Annual Meeting, American Pharmaceutical Association, Dallas, TX, 1966.
2. McCart GM, Lipman AG, Beste DF. The care of the dying patient - an interdisciplinary approach. Abstracts of the 6th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, 1971.
3. Lipman AG, Deffenbaugh JH Jr. The patient health record: a major means for improving outpatient pharmacy services. Abstracts of the 7th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, 1972.
4. Lipman AG. The effect of buffering on cephalothin induced phlebitis. Abstracts of the 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, 1973.
5. Lipman AG. Providing quality control of pharmaceutical industry representative activities within the institution. Abstracts of the 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, 1973.
6. Lipman AG, Greenberg BR. Drug literature abstract and index services. Abstracts of the 31st Annual Meeting, American Society of Hospital Pharmacists, Chicago, IL, 1974.
7. Rubino MJ, Lipman AG. Critical comparisons of commonly available iodophor solutions and scrubs. Abstracts of the 31st Annual Meeting, American Society of Hospital Pharmacists, Chicago, IL, 1974.
8. Decker EL, Lipman AG, Cote J. The effect of in-line filtration on the incidence and severity of cephalothin-induced infusion phlebitis. Abstracts of the 10th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, 1975.
9. Vengrofski AM, Lipman AG, Miller RF. Utilization review of normal serum albumin. Abstracts of the 11th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1976.
10. Bennett BS, Lipman AG. A comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. Abstracts of the 11th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1976.
11. Ponte CD, Lipman AG. Utilization review of nutritionally complete oral liquid diets. Abstracts of the 11th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1976.
12. Lipman AG, McMahon JD. The development of an auxiliary faculty of practicing pharmacist role models for the provision of meaningful community and hospital general practice externships. Abstracts of the 79th Annual Meeting, American Association of Colleges of Pharmacy, Orlando, FL, 1978.
13. Lipman AG, Devenport JK. An integrated, competency based, clinical curriculum for doctor of pharmacy students. Abstracts of the 79th Annual Meeting, American Association of Colleges of Pharmacy, Orlando, FL, 1978.
14. Lipman AG, Bair JN, Russo J Jr. Planning for decentralization of pharmacy services. Abstracts of the 13th Midyear Clinical Meeting, American Society of Hospital Pharmacists, San Antonio, TX, 1978.
15. Lipman AG. Medicine and pharmacy aboard New England whaling vessels, II: drugs used, their indications, applications, sources and costs. American Institute of the History of Pharmacy, Abstracts of the 126th Annual Meeting, American Pharmaceutical Association, Anaheim, CA, 1979.
16. Lipman AG, Devenport JK, Page B. A multidimensional study of clinical pharmacist process. Abstracts of the 37th Annual Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 1979.
17. Lipman AG, Bair JN. Experience with a graduate program in institutional pharmacy management leading to an M.S. in hospital pharmacy, M.B.A. and residency. Abstracts of the 80th Annual Meeting, American Association of Colleges of Pharmacy, Denver, CO, 1979.
18. Russo J Jr, Lipman AG, Page B, Stephen R. Iontophoresis of lidocaine for topical anesthesia. Abstracts of the 14th Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, 1979.
19. Lipman AG, Wolf HH. A postdoctoral fellowship program for faculty development in clinical pharmacy. Abstracts of the 81st Annual Meeting, American Association of Colleges of Pharmacy, Boston, MA, 1980.
20. Lipman AG, Bair JN, Gisclon LG. Implementation of a comprehensive quality assurance program for pharmaceutical services. Abstracts of the 15th Midyear Clinical Meeting, American Society of Hospital Pharmacists, San Francisco, CA, 1980.
21. Lipman AG, Higbee MD, Devenport JK. Education and service directed toward meeting the needs of the elderly. Abstracts of the 82nd Annual Meeting, American Association of Colleges of Pharmacy, Scottsdale, AZ, 1981.
22. Lipman AG. Drug therapy for symptom control in terminal disease. Abstracts of the 148th National Meeting of the American Association for the Advancement of Science, Washington, DC, 1982.
23. Kleiman R, Lipman A, Hare B. Controlled study of patient controlled analgesia in severe, post-operative pain. Pain 1984;20(Suppl 2):387.

Continued

Abstracts - continued

24. Zbrozek AS, Sudds TW, Bair JN, Lipman AG. Development and marketing of a drug studies pharmacist position. Abstracts of the 43rd Annual Meeting, American Society of Hospital Pharmacists, Denver, CO, 1986.
25. Lipman AG. The formulary review process in the current fiscal environment. Abstracts of the 45th Annual Meeting, American Society of Hospital Pharmacists, San Francisco, CA, 1988.
26. Lipman AG, Czajkowski LA. Pharmacological and psychological considerations in the management of prostatic cancer pain. Abstracts of the Western USA Pain Society Annual Meeting, Santa Fe, NM, 1988.
27. Church RM, Lipman AG, Herrier RN, Smith EB, Boyce RW, Dwight V. Development and implementation of standards of practice for a multiple institution system of hospitals and ambulatory care centers. Abstracts of the 24th ASHP Midyear Clinical Meeting, American Society of Hospital Pharmacists, Atlanta, Georgia, 1989.
28. Lipman AG. Process and outcomes of comprehensive medication histories in chronic pain patients. Abstracts of the Western USA Pain Society Annual Meeting, Park City, UT, 1990.
29. Lipman AG, Twycross RG, Cleeland C, Johns S. A system for concurrent data collection and retrospective analysis of advanced cancer pain and its management. *Pain* 1990;Suppl 5:S374.
30. Lipman AG, Berri JI. Role of the Hospice Pharmacist. Abstracts of the 139th Annual Meeting, American Pharmaceutical Association, San Diego, California, 1992.
31. Lipman AG. New Directions in Pain Management. *International Pharmaceutical Abstracts*. 1993;30:1145.
32. Lipman AG. The cornerstone of the team approach: a case for better pain management. *American Academy of Physician Assistants Annual Conference Abstracts*, 1995.
33. Lipman AG. Adjunctive analgesic drugs in the elderly. Abstracts of the American Society of Consultant Pharmacists Annual Meeting 1995 Educational Sessions, 1995:97.
34. Lipman AG. Pain management: pharmacoeconomic and clinical outcomes. Abstracts of the Academy of Managed Care Pharmacy Annual Meeting, 1996.
35. Lipman AG. Evidence-based drug therapy symptom control guidelines for palliative care. *J Pain Symptom Manage* 1998;15:S:5.
36. Lipman AG. Cancer Pain Management: Pharmacist Knowledge and Practices. *American Pain Society 1998 Annual Meeting Program*:613.
37. Lipman AG, Tyler LS, Jackson II KC. Evidence-based, Drug Therapy Symptom Control Guidelines for Palliative Care. *J Palliative Med*. 1999;2:247
38. Jacobson JA, Lipman AG, Beck SL. A Successful Statewide Collaboration to Improve End of Life Care. *J Palliative Med*. 1999;2:252.
40. Oderda GM, Evans RS, Lloyd J, Lipman AG, Ashburn MA, Chen C, Burke J, Samore M. Cost of opioid related adverse drug events in surgical patients. *International Pharm Abstr*. 2001; 38(21):37.
41. Lipman AG, Dalpiaz A, Lorden SP. Topical lidocaine patch therapy for myofascial pain. *J Pain* 2002;3(2)(Suppl):46
42. Fakata KL, Lipman AG, Mullin S. Systematic Review of the Effects of Opioids and Pain on Human Immune Function-Pain 2003;4: Suppl 1:56.
43. Fakata KL, Lipman AG, Tuteja A, Ho, MJ. Opioid-Induced Bowel Dysfunction: A survey of prevalence and risk factors in Chronic Non-Malignant Pain Patients.- Submitted for poster American Pain Society/Canadian Pain Society Annual Meeting May 2004 Vancouver BC. *J pain* 2004; 5:Suppl 1:

Editorials

1. Lipman AG. Clinical pharmacy: specialty or norm. *Hospital Pharmacy* 1974;9:257.
2. Lipman AG. Concern for dying patients. *American Journal of Hospital Pharmacy* 1974;32:368.
- Lipman AG. *Hospital Formulary* 1979;14
3. Open versus closed formularies: Cost-benefit considerations, March p. 380.
4. A broadened base, July, p. 728.
5. An ounce of protection, August, p. 788.
6. Predetermined standards in use of drug control, September, p. 864.
7. Clinical pharmacokinetics and improved drug therapy, October, p. 948.
8. Congratulations Jere Goyan-the first pharmacist to be FDA commissioner, November, p. 1016.
9. Intravenous infusion pumps: A P&T committee concern, November, p. 1015.
10. Patients' perspective on nonprescription drugs, December, p. 1076.
- Lipman AG. *Hospital Formulary* 1980;15
11. Why a refereed journal? January, p. 66.
12. Therapeutic devices and the P&T committee, February, p. 152.
13. The Hospital Formulary research award: Recognition of excellence, March, p. 228.
14. Debunking some myths about chronic pain therapy, April, p. 328.
15. Letters: A forum for controversies and reports, May, p. 426.
16. Hospital Formulary experience briefs: Another opportunity to share, June, p. 508.
17. Adverse drug reactions and the P&T committee, July, p. 580.
18. From pharmacy department to department of pharmacy services, August, p. 646.
19. Alimentation and hyperalimentation formulae: Drugs or diets, September, p. 724.
20. P&T and IRB: A need for effective communications, October, p. 812.
21. Clinical pharmacy: An evolution, November, p. 914.
22. Our name and our change, December, p. 986.
- Lipman AG. *Hospital Formulary* 1981;16
23. A reaffirmed focus, January, p. 9.
24. Fiscal responsibility and patient care, February, p. 105.
25. Repetition need not be merely redundant, March, p. 239.
26. Collaboration for improved patient care and decreased drug costs, April, p. 371.
27. Hypertension revisited, May, p. 475.
28. What are we doing with our poisons? June, p. 577.
29. Our orphaned outpatients, July, p. 697.
30. The growing menace of drug abuse, August, p. 797.
31. Clinical pharmacy: physicians' friend or foe?, September, p. 923.
32. Rational antimicrobial therapy, October, p. 1105.
33. An international flavor, November, p. 1259.
34. Our biggest and our best, December, p. 1405.
- Lipman AG. *Hospital Formulary* 1982;17
35. Nutritional therapeutics: A P&T committee concern, January, p. 9.
36. Drug information for patients, February, p. 185.
37. An award for safety, March, p. 359.
38. Prophylactic antibiotics, April, p. 503.
39. Consultation in clinical psychopharmacology, May, p. 649.
- Lipman AG. *Hospital Formulary* 1982;17
40. The acceptance of clinical pharmaceutical services, June, p. 783.
41. The P&T committee and the industry, July, p. 907.
42. The formulary and antimicrobial restrictions, August, pp. 1029-1031.
43. The need for a drug information service, September, p. 1159.
44. Hospice care: Science follows practice, October, p. 1289.
45. Consumerism and drugs, November, p. 1417.
46. Prescribing by pharmacists, December, p. 1557.

continued

Editorials- continued

- Lipman AG. Hospital Formulary 1983;18
47. A journal with a mission, January, p. 11.
48. Costs of care, February, p. 139.
49. The third annual Hospital Formulary award, March, p. 241.
50. TEFRA and the P&T committee, April, p. 365.
51. Age: A growing P&T concern, May, p. 469.
52. Philosophy and practice of the P&T committee, June, p. 599.
53. Quality drug therapy at affordable costs, July, p. 673.
54. A new formulary statement and formulary service, August, p. 771.
55. Therapeutic substitution, September, p. 841.
56. Formularies and the feds: The alphabet soup expands, October, p. 941.
57. Prescription drug advertising to the consumer, November, p. 1025.
58. Directions and trends, December, p. 1093.
59. Expanding our editorial expertise, December, p. 1114.
- Lipman AG. Hospital Formulary 1984;19
60. Looking ahead, January, p. 7.
61. Clinical pharmacy service in a long term care facility, February, p. 105.
62. Our litigious environment, March, p. 246.
63. Drug utilization review revisited, April, p. 277.
64. The danger of ignorant patients, May, p. 349.
65. Three hits, no runs and two left on, June, p. 441.
66. P&T committees in the spotlight, July, p. 519.
67. Cost implications of future new drugs, August, p. 635.
68. Patients' perceptions and self medication, September, p. 749.
69. The cost effectiveness of drug therapy, October, p. 875.
70. The cruel hoax of heroin, November, p. 999.
71. Satisfaction from P&T Committee service. December, p. 1097.
72. Lipman AG. The hue and cry for heroin. *Canad J Hosp Pharm* 1984;37:131.
73. Lipman AG. Progress and problems with pain. *Clin Pharm* 1985;4:80-81.
- Lipman AG. Hospital Formulary 1985;20
74. Drug samples in the hospital, January, p. 15.
75. Trends in pharmacy services, February, p. 159.
76. The JCAH and the P&T committee, March, p. 263.
77. What do consumers think about prescription drugs? April, p. 413.
78. Sharing in a newly competitive industry, May, p. 563.
79. Communicating, June, p. 685.
80. Extemporaneous formulations: A continuing need, July, p. 787.
81. Medication compliance, August, p. 876.
82. Advances in pain management, September, p. 951.
83. Nonprescription drug counseling, October, p. 1035.
84. Our changing health care system: Strategies for responding, November, p. 1175.
85. The FDA's plan to action, December, p. 1211.
- Lipman AG. Hospital Formulary 1986;21
86. Direct-to-consumer prescription drug advertising, January, p. 4.
87. The P&T committee and prescribing patterns, March, p. 261.
88. Hospital pharmaceutical services national survey results, April, p. 417.
89. Downsizing while maintaining quality care, May, p. 543.
90. Formulary systems in HMOs, June, p. 637.
91. The pharmacist's role in infection control, July, p. 749.
92. The explosion of generic pharmaceuticals, August, p. 827.
93. New drug delivery systems in the immediate future, September, p. 901.
94. The future is fast upon us, October, p. 987.
96. Changes in pharmacists' functions: Implications for P&T committees, December, p. 1175.

Editorials (continued)

- Lipman AG. Hospital Formulary 1987;22
97. Pain therapy: Time for a change, January, p. 13.
98. Drug samples in the hospital revisited, February, p. 123.
99. Biotechnology and the P&T committee, March, p. 221.
100. Managing the P&T committee agenda, April, p. 331.
101. The new drug diversion bill, May, p. 417.
102. State of the pharmaceutical industry, June, p. 509.
103. Physician dispensing: P&T committee implications, July, pp. 607, 610 (Weintraub M, Lipman AG).
104. Dealing with "me-too" drugs, August, p. 693.
105. The boom in home-use in-vitro diagnostics, September, p. 759.
106. Prescription drug poisonings and the P&T committee, October, p. 817.
107. Pharmacist-conducted drug regimen review, November, p. 999.
108. A year end review of P&T committee accomplishments, December, p. 999.
- Lipman AG. Hospital Formulary 1988;23
109. The paradox of therapeutic progress, January, p. 13.
110. The courage of our convictions, February, p. 117.
111. The FDA drug review process, March, p. 211.
112. JCAH to JCAHO: More than a change in name, April, p. 313.
113. Discharge medications and continuity of care, May, p. 410.
114. The impact of drug usage evaluations, June, p. 499.
115. Physicians' drug knowledge, July, p. 567 (Lipman AG, Weintraub, M).
116. Medication use by older Americans, August, p. 625.
117. The state of the pharmaceutical industry, September, p. 682.
118. The need for soft science, October, p. 769.
119. The case against multidisciplinary health care, November, p. 859.
120. Pharmacy dynamics, December, p. 948.
- Lipman AG. J Pharm Care Pain Symptom Control. 1993;1.
121. Pharmaceutical care and symptom control, number 1, pp. 1-3.
122. Clinical guidelines for symptom control, number 2, pp. 1-4.
123. Perceptions of cancer pain and its treatment, number 3, pp. 1-4.
124. The stepped approach to cancer pain management, Number 4, pp. 1-3.
- Lipman AG. J Pharm Care Pain Symptom Control. 1994;2.
125. The federal cancer pain guideline, Number 1, pp. 1-4.
126. The growth of interdisciplinary pain management is a double edged sword, Number 3, pp. 1-6
127. Practice policies in pain and symptom control, Number 4, pp. 1-4.
- Lipman AG. J Pharm Care Pain Symptom Control. 1995;3.
128. The editorial board. Number 1:1-4.
129. Are pharmacists barriers to cancer pain management? Number 2:1-4
- Lipman, AG. J Pharm Care Pain Symptom Control. 1996;4
130. A tribute to Robert Angarola. Number 3:1-2
131. *Compounded Medications Can Compound Medication Problems.* Number 4:1-3
- Lipman, AG. J Pharm Care Pain Symptom Control. 1997;5
132. Must we make the courts our last resort? Number 1:1-3
133. The reinventing of the agency for health care policy and research ahcpr. Number 2:1-4.
134. Opioids in chronic nonmalignant pain: the debate continues. Number 3: 1-2.
135. *Symptom control: more than the management of pain.* Number 4: 1-2.
- Lipman, AG. J Pharm Care Pain Symptom Control. 1998;6
136. Managing the Information Explosion. Number 1:1-4
137. The Dilemma of Alternative Medicine. Number 2:1-4
138. Constipation Hurts. Number 3:1-3

-continued-

Editorials (continued)

- Lipman, AG. J Pharm Care Pain Symptom Control. 1999;7
139. Science and anecdote: synergistic or antagonistic Number 1:1-1-2
140. A call for more evidence-based pharmacotherapy. Number 2:7-10.
141. Patient empowerment. Number 3:1-4.
142. Silent complicity in assisted death. Number 3:5-6
- Lipman, AG. J Pharm Care Pain Symptom Control. 2000;8
143. Pain Standards Number 2:
144. NIH Consensus Statements, Number 2:
144. Drug-Diet Interactions in Palliative Care, Number 3:
- Lipman AG. J Pharm Care Pain Symptom Control. 2001;9
145. Defining hospice and palliative care. (1):1-3.
146. Are pain clinicians generalists or specialists? (2):1-2
147. Expanding palliative care in society. (2):5-6.
148. Expanding palliative care: Changes in society and in the journal. (3):5-6.
149. Expanding into the Journal of Pain & Palliative Care Pharmacotherapy. (4):1-3.
- Lipman AG. J Pain Palliat Care Pharmacother. 2002;16
150. Clinical trial death form unregulated substance: Johns Hopkins recommends pharmacist and librarian collaboration. (1): 1-4
151. Pain & palliative care pharmacotherapy: A natural synergy. (1):5-7.
152. Evidence-based pain management and palliative care. (2):1-4.
153. Why we need outcomes research and pharmacoeconomics in pain management and palliative care. (3):1-4.
154. Complementary and alternative medicine. (4):1-4.
- Lipman AG. J Pain Palliat Care Pharmacother. 2003;17
155. What have we learned from OxyContin? (1):1-4.
156. Symptom control in advanced disease: Why all the fuss? 92):1-4.
- Lipman AG. J Pain Palliat Care Pharmacother. 2004;18
157. Advance Care Planning can Profoundly Influence Pain and Symptom Management. (1):1-4.
158. Does opiophobia exist among pain specialists? (2):1-4
159. The Federal Ban on Ephedrine Dietary Supplements: An Important Event for Pain Practitioners and Patients. (3):1-5.
160. Pain Professionals' Responsibility for Public Education. (4):1-4.

Drug Therapy Reviews

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1975;43
1. Salicylate-induced drug interactions, Jan. 15, p. 169.
  2. Oral anticoagulant drug interactions I, Feb. 1, p. 139.
  3. Oral anticoagulant drug interactions II, Feb. 15, p. 191. Addendum, April 15, p. 54.
  4. Oral anticoagulant drug interactions III, March 1, p. 127.
  5. Oral anticoagulant drug interactions IV, March 15, p. 199.
  6. Oral anticoagulant drug interactions V, April 1, p. 103.
  7. Drug interactions involving antiepileptic agents I, April 15, p. 151.
  8. Drug interactions involving antiepileptic agents II, May 1, p. 61.
  9. Antidiabetic drug interactions I, May 15, p. 103.
  10. Antidiabetic drug interactions II, June 1, p. 71.
  11. Effects of antidiabetic agents on clinical laboratory test results, June 15, p. 105.
  12. Drug interactions involving diuretics, July 1, p. 119.
  13. Drug interactions with digitalis glycosides, Aug. 1, pp. 111-112.
  14. Drug interactions involving antidepressant agents I, Sept. 1, pp. 79-80.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1975;43
15. Drug interactions involving antidepressant agents II, Sept. 15, pp. 81-82.
  16. Drug interactions involving antidepressant agents III, Oct. 1, p. 69.
  17. Interactions of skeletal muscle relaxants used in surgery, Oct. 15, pp. 73-74.
  18. Drug interactions involving antiarthritic agents, Nov. 15, pp. 79-80.
  19. Drugs for an emergency kit, Dec. 1, pp. 87-88.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1976;44
20. Drugs that may precipitate hemolytic anemia in patients deficient in G-6-PD, Jan. 1, pp. 91-92.
  21. Drug-induced ototoxicity, Jan. 15, pp. 109-110.
  22. Drugs interfering with urinary glucose tests, Feb. 1, pp. 105-106.
  23. Drug interactions with alcohol, Feb. 15, pp. 67-69.
  24. Drug and chemical induced photosensitivity I, March 1, pp. 81-82.
  25. Drug and chemical induced photosensitivity II, March 15, pp. 97-98.
  26. Fiber-free semisynthetic liquid diets, April 1, pp. 99-100.
  27. Drug-induced coloration of the urine, April 15, pp. 83-84.
  28. Drug-induced coloration of the feces, May 1, p. 79.
  29. Drug-induced eosinophilia, May 15, pp. 95-96.
  30. Drug-induced hepatotoxicity I, June 1, pp. 105-106.
  31. Drug-induced hepatotoxicity II, July 1, p. 85.
  32. Hyperuricemia and serum uric acid test changes induced by drugs, Aug. 1, pp. 101-102.
  33. Equivalence of oral theophylline dosage forms, Sept. 1, pp. 79-80.
  34. New nonsteroidal anti-inflammatory agents, Sept. 15, pp. 25-26.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1976;44
35. Drug-induced hypokalemia, Oct. 1, pp. 97-98.
  36. Drug-induced gynecomastia, Oct. 15, pp. 69-70.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1976;44
37. Drug unitage, Nov. 1, pp. 93-94.
  38. Drug-induced thrombocytopenia, Nov. 15, pp. 75-76.
  39. Drug-induced fever, Dec. 1, pp. 87-88.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1977;45
40. Drug-induced ocular toxicity I, Jan. 1, pp. 87-88.
  41. Drug-induced glaucoma, Jan. 15, pp. 103-104.
  42. Drug-induced ocular toxicity II, Feb. 1, pp. 81-82.
  43. Drug-induced optic neuritis, Feb. 15, pp. 55-56.
  44. Immunization and prophylaxis for foreign travel, March 1, p. 67.
  45. Antimicrobial agents in breast milk, March 15, pp. 89-90.
  46. Biological half-lives in antimicrobial agents, April 15, pp. 57-58.
  47. Drugs associated with impotence, May 15, pp. 81-82.

Drug Therapy Reviews – continued

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1977;45
48. Sodium content of commonly used parenteral antibiotics, May 30, pp. 83-84.
49. Sodium content of frequently used analgesics and gastrointestinal drugs, June 15, pp. 59-60.
50. Alcohol content of commonly used drugs, June 15, pp. 43-44.
51. Diabetic sugar urine tests, July 15, p. 109.
52. Temperature requirements for drug storage, August 15, p. 103.
53. Vitamins: Availability and uses, Sept. 15, pp. 63-64.
54. Drug-induced elevations of serum potassium levels, Sept. 30, pp. 59-60.
55. Prescription drugs containing aspirin, Oct. 15, p. 115.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1977;45
56. Drugs that can elevate creatine phosphokinase, Oct. 30, pp. 55-56.
57. Nonprescription drugs containing aspirin, Nov. 15, pp. 79-80.
58. Drug interferences with thyroid function tests, Dec. 15, pp. 97-98.
- Lipman AG. Supplemental Vitamin Therapy. Physician Assistant. 1977;2:23.
60. Lipman AG. Non-steroidal anti-inflammatory agents. Physician Assistant. 1977;2:32.
61. Lipman AG. Amikacin: A new aminoglycoside antibiotic. Physician Assistant. 1977;2:28.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1978;46
62. Dosage schedules for antihypertensive drugs, Jan. 15, pp. 69-70.
63. Potential interactions between monoamine oxidase inhibiting drugs and food, Jan. 30, p. 76-7.
64. Potential interactions between monoamine oxidase inhibitors and nonprescription drugs, Feb. 28, pp. 45-46.
65. Insulin guidelines: Mixing, onset, peak and duration, Mar. 15, pp. 123-124.
66. Comparing the benzodiazepines, Mar. 30, pp. 171-172.
67. Suggested monitoring parameters for total parenteral nutrition, Apr. 15, pp. 125-126.
68. Drug dosage considerations in elderly patients, Apr. 30, pp. 87-88.
69. Effects of maternal drug use near term, May 15, pp. 113-114.
70. Drugs that may cause proteinuria, May 30, p. 155.
71. Malaria prophylaxis for travelers, June 15, pp. 169-170.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1978;46
72. Drugs that interfere with sulfobromophthalein tests, June 30, p. 77.
73. Drugs excreted in breast milk, July 15, pp. 155-156.
74. Drug interferences with urine glucose tests, Aug. 15, pp. 195-196.
75. Drug interactions involving propranolol, Sept. 15, pp. 83-84.
76. Drug interactions with oral contraceptives, Sept. 30, p. 117.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1978;46
77. Drug interactions involving digitalis, Oct. 15, pp. 199-200.
78. What to do about your patient's iron needs, Oct. 30, pp. 69-70.
79. Analgesics in breast milk, Nov. 15, pp. 101-102.
80. Tetracycline drug interactions, Nov. 30, pp. 149-150.
81. Drugs which may induce diabetes, Dec. 15, p. 153.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1979;47
82. Cigarette smoking and drugs, Jan. 15-Jan. 30, pp. 103-104.
83. Drug excretion affected by urinary pH, Jan. 30-Feb. 15, p. 139.
84. Drug interactions with aspirin, Feb. 15-Feb. 28, pp. 187-188.
85. Comparison of theophylline dosage forms, Feb. 28-Mar. 15, pp. 65-66.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1979;47
86. Pharmacologic effects of marijuana, Mar. 15-Mar. 30, pp. 105-106.
87. Drugs affect absorption and excretion of nutrients, Mar. 30-Apr. 15, p. 149.
88. Narcotic analgesic comparisons, Apr. 15-Apr. 30, pp. 195-196.
89. Aspirin's role in preventing emboli, Apr. 30-May 15, p. 77.
90. Smoking's effect on health, May 15-May 30, pp. 91-92.
91. Drug-induced hyperkalemia, May 30-June 15, pp. 153-154.
92. Drug interactions with cardiac antiarrhythmics, June 15-June 30, pp. 173-174.
93. New drugs of 1978, June 30-July 15, pp. 75-76.
94. Drug-induced eosinophilia, July 15-Aug. 15, pp. 179-180.

-continued-

Drug Therapy Reviews (continued)

- Lipman AG. *Drug Actions and Interactions. Modern Medicine. 1979;47*
95. Adverse reactions to cimetidine, Aug. 15-Sept. 15, pp. 163-164.
96. Vitamin toxicity, Sept. 15-Sept. 30, pp. 88-89.
97. Drug-induced serum cholesterol elevations, Sept. 30-Oct. 15, pp. 119-120.
98. Oral anticoagulant interactions with analgesics and anti-inflammatories, Oct. 15-30, pp.185-6.
99. New drugs which may be available soon, Oct. 30-Nov. 15, pp. 73-74.
100. Oral anticoagulant interactions with antiinfective drugs, Nov. 15-Nov. 30, pp. 73-74.
101. New recommendations for the treatment of gonorrhoea, Nov. 30- Dec. 18, pp. 133-134.
102. Oral anticoagulant interactions with hormonal drugs, Dec.15,1979-Jan. 15,1980, pp. 141-142.
- Lipman AG. *Drug Actions and Interactions. Modern Medicine. 1980;48*
103. Drug interferences with urinary pregnancy tests, Jan. 15-Jan. 30, pp. 103-104.
104. Sodium content of some commonly used antacids, Jan. 30-Feb. 15, pp. 123-124.
105. Drug-induced direct positive Coombs' tests, Feb. 15-Feb. 29, pp. 157-158.
106. Prescription analgesics: How much aspirin do they contain, Feb. 29-Mar. 15, pp. 75-76.
107. Which drugs may induce eosinophilia? Mar. 15-Mar. 30, pp. 77-78.
108. Interactions between monoamine oxidase inhibitors and food, Mar. 30-Apr. 15, pp. 133-134.
- Lipman AG. *Drug Actions and Interactions. Modern Medicine. 1980;48*
109. Drug-induced angina pectoris, Apr. 15-Apr. 30, pp. 113-114.
110. Nutritional deficiencies and alcohol abuse, Apr. 30-May 15, pp. 77-78.
111. Drug interference with neuromuscular transmission, May 15-May 30, pp. 71-72.
112. Drug-alcohol interaction, May 30-June 15, pp. 125-130.
113. Effect of drugs in breast milk, June 30-July 15, pp. 71-72.
114. Drug-induced elevation of SGOT and SGPT, II, July 15-Aug. 15, pp. 161-162.
115. A checklist of new drugs, Sept. 15-Sept. 30, pp. 71-72.
116. Marijuana as an antiemetic, Sept. 30-Oct. 15, pp. 121-122.
117. Changes in official drug names, Oct. 15-Oct. 30, pp. 109-110.
- Lipman AG. *Drug Actions and Interactions. Modern Medicine. 1980;48*
118. OTC treatment for hemorrhoids, Oct. 30-Nov. 15, p. 77.
119. Alcohol free cough preparations, Nov. 15-Nov. 30, pp. 81-82.
120. Use of the new rabies vaccine, Nov. 30-Dec. 15, pp. 139-140.
121. Drug-induced deafness, Dec. 15, 1980-Jan. 15, 1981, pp. 147-148.
122. Lipman AG. Wirkungen von Arzneimittel in der Muttermilch, *Extracta Gynecologica (Berlin). 1981;5:239-240.*
- Lipman AG. *Drug Actions and Interactions. Modern Medicine. 1981;49*
123. Single daily doses of drugs to aid compliance, Jan. 15-Jan. 30, pp. 89-90.
124. Drug interactions with aspirin, Jan. 30-Feb. 15, pp. 107-108.
125. Drug interactions with beta-blockers, Feb. 15-Feb. 28, pp. 161-162.
126. Drug-induced impotence, Feb. 28-Mar. 15, pp. 75-76.
127. Drug-induced elevations of serum cholesterol, Mar. 15-Mar. 30, pp. 75-76.
128. Drug-induced hypokalemia, Mar. 30-Apr. 15, pp. 141-142.
129. Drug-induced fever, April, pp. 137-138.
130. Drug-induced hyperkalemia, May, pp. 213-214.
131. Drug-induced photosensitivity, June, pp. 195-196.
132. Drugs which may cause an Antabuse-type reaction, July, pp. 185-186.
133. Tricyclic antidepressant interactions, August, pp. 151-152.
134. Antacids, September, pp. 203-204.
135. Oral anticoagulants: Caution with concurrent drugs, October, pp. 211-212.
136. Oral contraceptive interactions, November, pp. 227-228.
137. Tailoring prescriptions to avoid toxicity in the elderly, December, pp. 179-180.
- Lipman AG. *Drug Actions and Interactions. Modern Medicine. 1982;50*
138. Digitalis glycoside drug interactions, January, pp. 281-282.
139. Drug-induced diabetes, February, pp. 273-274.
140. New drugs of 1980-81, March, pp. 223-224.
141. Drug-induced gynecomastia, April, pp. 179-180.
142. Drug vitamin interactions, May, pp. 257-258.

-continued-

Drug Therapy Reviews (continued)

- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1982;50
143. Active immunizing agents update, June, pp. 229-230.
144. Passive immunizing agents update, July, pp. 199-200.
145. Drug-alcohol interactions, August, pp. 229-230.
146. Non-steroidal antiinflammatory drugs, September, pp. 227-228.
147. Drug-induced angina pectoris, October, pp. 261-264.
148. Propranolol drug interactions, November, pp. 281-282.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1983;51
149. Cardiovascular effects of psychotropic drugs, Feb., pp. 241-242.
150. New drug checklist, March, pp. 289-290.
151. Effects of smoking on drugs, April, pp. 207-208.
152. Drug-induced photosensitivity, May, pp. 279-280.
153. Comparing the benzodiazepines, July, pp. 216-217.
154. Which drugs cause dependence? August, pp. 205-206.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1983;51
155. Drug-induced thrombocytopenia, September, pp. 247-248.
156. Which drugs cause extrapyramidal symptoms? October, pp. 243-244.
157. Benzodiazepines and driving ability, November, pp. 221-222.
158. Drug-induced hyperlipidemia, December, pp. 107-108.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1984;52
159. Comparing the nonsteroidal antiinflammatory drugs, Jan., p. 264.
160. Drug interactions with H<sub>2</sub> receptor blockers, Feb., pp. 259-260.
161. New drugs of the past years, March, pp. 251-252.
162. Clinical drug trials in myocardial infarct patients, April, pp. 210-211.
163. Drug use in pregnancy, labeling categories, May, p. 211.
164. FDA classification system for new drugs, June, pp. 237-238.
165. Caffeine content of common beverages and foods, August, p. 145.
166. Drugs that may cause infertility, September, pp. 231-232.
167. Toxicity linked to vitamins B and C overdose, Oct., pp. 271-272.
168. Rx to OTC: The switch is on, November, pp. 277-278.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1985;53
169. Drugs which may interact with acetaminophen, Jan., pp. 237-238.
170. Drug interactions with marijuana, February, p. 258.
171. New drugs introduced in the past year, March, pp. 274-276.
172. Comparing the benzodiazepines, May, pp. 272-275.
173. Chronic drug use may be linked to bone disease, June, p. 215.
174. Drug-induced photosensitivity, July, pp. 139-140.
175. How smoking interferes with drug therapy, August, pp. 141-142.
176. Recommendations on immunizations, September, pp. 222-225.
177. Drug interactions with antihypertensive agents, Oct., pp. 169-170.
178. Mixing alcohol and drugs, November, pp. 165-166.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1986;54
179. New H<sub>2</sub> receptor blockers interact with other agents, March, pp. 229-230.
180. New drug update, April, pp. 127-128.
181. How drugs effect vitamin metabolism, May, p. 163.
182. Drug interactions with beta blockers, June, pp. 199-201.
183. Managing intractable hiccups, July, pp. 189-190.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1986;54
184. Treatment guidelines for gonorrhoea, November, pp. 175-180.
185. Drugs which may cause hallucinations, December, pp. 153-155.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1987;55
186. Alcohol-drug interactions, February, pp. 165-166.
187. New drug update: The 1986 introductions, March, pp. 212-215.

Drug Therapy Reviews (continued)

188. Drugs affecting oral contraceptive efficacy, May, pp. 189-190.
189. Comparing the benzodiazepines, June, pp. 208-211 (Lipman AG, Pryka RD).
190. Drugs that may damage soft contact lenses, June, p. 205.
191. Comparing the NSAIDs, July, pp. 156-159.
192. Orphan drugs, September, pp. 159-160.
193. Antabuse-type reactions, October, p. 187.
194. Effects of smoking on drug therapy, November, pp. 185-186.
195. Managing pressure sores, December, pp. 157-158.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1988;56
196. Aspirin interactions, January, pp. 203-204.
197. Drug-induced orthostatic hypotension, February, pp. 201-202.
198. New drug update: The 1987 introductions, March, pp. 175-176.
199. Comparing the calcium channel blockers, May, p. 169.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1988;56
200. Comparing oral antidiabetic agents, June, p. 203.
201. Chronic vitamin toxicity, July, pp. 145-146 (Lipman AG, Oliver BS).
202. Antidepressants as analgesics, September (Nielsen J, Lipman AG).
203. Caffeine in oral analgesics, October, pp. 197-198.
204. Comparing the H<sub>2</sub> receptor blockers, November, p. 191.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1989;57
205. Opioid analgesics, January, pp. 161-162.
206. New drug update: The 1988 introductions, March, pp. 203-204.207.
207. Home pregnancy tests, April, p. 175.
208. Comparing the newer cardiac antiarrhythmic agents, May, p. 203.
209. Comparing the NSAIDs, November, pp. 146-149.
- Lipman AG. Drug Actions and Interactions. Modern Medicine. 1990;58.
210. Comparing the hypercholesterolemic agents, February, 145-146.
211. New drug update: the 1989 introductions, March, pp. 129-131.

Book and Media Reviews

1. Lipman AG. *Perspectives on medicines in society*. Edited by AI Wertheimer and PJ Bush, Review. *Inquiry* 1978;15:300-301.
2. Lipman AG. *Therapeutics*. 3rd Edition, by JG Lewis, Review. *PA Journal* 1978;8:255.
3. Lipman AG. *Pills, profits and politics*. By Silverman and RP Lee, Review. *Inquiry* 1979;12:366-367.
4. Lipman AG. *AHFS Drug Formulation 86*. Edited by GK McEvoy. *Hosp Formul* 1986;21:964.
5. Lipman AG. *USP DI, 6th Edition*, United States Pharmacopeial Convention. *Hosp Formul* 1986;21:964.
6. Lipman AG. *Journal of Musculoskeletal Pain*. *J Pharm Care Pain Symptom Control*. 1993;1(4):115-18.
7. Lipman AG. *Cancer Pain* by R. Patt. *J Pharm Care Pain Symptom Control*. 1994;2(4):75-6.
8. Lipman AG. *Martindale, The Extra Pharmacopeia*, Intern *J Pharm Pract*. 1994;2:
9. Lipman AG. *Current and Emerging Issues in Cancer Pain Management*. *Am J Hosp Pharm*. 1994;51:429-430.
10. Lipman AG. *Oxford Textbook of Palliative Medicine*. D Doyle, GWC Hanks, N MacDonald, editors. *J Pharm Care Pain Symptom Control* 1995;4(1/2):349-51.
11. Lipman AG. *IASP Core curriculum for Professional Education in Pain*, H. Fields, ed., *J Pharm Care Pain Symptom Control*. 1996;4(3):129-30.
12. Lipman AG. *Alternative Medicine: When Your Patient Asks*. JS Gordon, WB Jonas. *J Pharm Care Pain Symptom Control*. 1996;4(4):131-4.
13. Lipman AG. *Pain and Palliative Care*, edited by NI Cherny and KM Foley. *J Pharm Care Pain Symptom Control*. 1997;5(2):112-13.
14. Lipman AG. *Advances in headache: neurologic Clinics*. NT Matthew, editor. *J Pharm Care Pain Symptom Control*. 1997;5(4):84-6.
15. Lipman AG. *Pain Relief in Far Advanced Cancer*. RG Twycross. *J Pharm Care Pain Symptom Control*. 1998;6(2):112-21.
16. Lipman AG. *Dying Well. I*. Byock. *J Pharm Care Pain Symptom Control*. 1998;6(3):86-87.
17. Lipman AG. *Approachin gDeath: Improving Care at the End of Life*, MJ Field, C Cassell, editors, *J Pharm Care Pain Symptom Control*. 1998;6(3):87-9.
18. Lipman AG. *Pain in the Elderly*. BF Ferrell, editor, *J Pharm Care Pain Symptom Control*. 1999;7(1):96-8.
19. Lipman AG. *Assessment and Treatment of Cancer Pain*. R. Rayne, Patt RB, Hill CS, editors, *J Pharm Care Pain Symptom Control*. 1999;7(2):84-6.
20. Lipman AG. *Providing a Palliative Care Service: Toward an Evidence Base*. N Bosanquet, C Salisbury, editors, *J Pharm Care Pain Symptom Control*. 2000;8(1):199-201.
21. Lipman AG. *Palliative Medicine 3<sup>rd</sup> edition*, R. Woodruff. *J Pharm Care Pain Symptom Control*, 2000;8(2):88-90.
22. Lipman AG. *Opioids in Pain Control: Basic and Clinical Aspects*, C Stein, editor, *J Pharm Care Pain Symptom Control*. 2000;8(4):75-6.
23. Lipman AG. *American Medical Directors Association Clinical Practice Guidelines for Chronic Pain Management and Pressure Sore Therapy*, *J Pharm Care Pain Symptom Control*. 2001;9(1):112-21.
24. Lipman AG. *Pioneer Programs in Palliative Care: Nine Case Studies*. Robert Wood Johnson foundation and the Millbank Fund., *J Pharm Care Pain Symptom Control*. 2001;9(2):73-5.
25. Lipman AG. *The Internet Pain Guide*, *J Pharm Care Pain Symptom Control*. 2001;9(3):92-4.
26. Lipman AG. *Controlling Cancer Pain*, Johns Hopkins Cancer Center, *J Pharm Care Pain Symptom Control*. 2001;9(4):90-1.
27. Lipman AG. *Implementing the JCAHO Pain Management Standards*. *J Pain Palliat Care Pharmacother*. 2002;16(1):125-9.
28. Lipman AG. *Evidence-based Pharmacy* by P. Wiffen. *J Pain Palliat Care Pharmacother*. 2002;16(2):120-22.
29. Lipman AG. *The medical Care of Terminally Ill Patients*, 2<sup>nd</sup> edition., by R Enck. *J Pain Palliat Care Pharmacother*. 2002;16(4):125-6.
30. Lipman AG. *Issue sin Palliative Care Research*, edited by RK Portenoy and E Bruera, *J Pain Palliat Care Pharmacother*. 2003;17(3/4):252-4.
31. Lipman AG. *Symptom research: Methods and Opportunities*, edited by MB Max and J Lynne, *J Pain Palliat Care Pharmacother*. 2004;18(1):116-18.

Letters

1. Lipman AG. A crack in the door: medical service representatives peer review. *Hospitals, JAHA* 1972;46:8.
2. Lipman AG. Utility of preparations of nitrofurantoin. *New Eng J Med* 1974;290:1436-1437.
3. Lipman AG. Relative potencies of glucocorticosteroids. *Amer J Hosp Pharm* 1974;31:632-633.
4. Lipman AG. *The dilemma of clinical pharmacy*. *Drug Intell Clin Pharm* 1974;8:612.
5. Lipman AG. Judgmental questions and drug information centers. *Amer J Hosp Pharm* 1976;33:20.
6. Lipman AG. Guidelines for prescribers. *Conn Med* 1976;40:289-290.
7. Lipman AG. Drug PRN guidelines. *Conn Med* 1976;40:350-351.
8. Lipman AG. Heparinized solutions in intermittent infusion sets. *Hosp Formul* 1976;11:279.
9. Lipman AG, Decker EL. Rational theophylline therapy. *Drug Intell Clin Pharm* 1977;11:305-306.
10. Yosselson-Superstine S, Lipman AG. Chlordiazepoxide interaction with levodopa. *Annals Intern Med* 1982;96:259-260.
11. Lipman AG. Comment on pain cocktails. *Drug Intell Clin Pharm* 1982;16:332.
12. Lipman AG, Anderson BD. Bioavailability of morphine from rectal suppositories. *Amer J Hosp Pharm* 1984;41:636-7.
13. Lipman AG. Problems with intravenous fluids at the end of life. *Amer J Hospice Care* 1987;4:13.
14. Lipman AG. Hospital-based immunization: a leadership role for hospital pharmacists. *Am J Hosp Pharm*. 1990;47:522-3.
15. Lipman AG. Efficacy of opioids in cancer pain syndromes. *Pain* 1995;63:135.

GRANTS AND CONTRACTSExtramural Grants and Contracts

1972-1973 Connecticut Regional Medical Program  
Connecticut Regional Drug Information Service, Grant No. 5-G03-RM00008, total budget \$88,000, Principal Investigator.

1972-1973 Lilly Research Laboratories  
A study of the incidence and severity of phlebitis secondary to intravenous administration of cephalothin sodium and the effect of buffering the infusion on the incidence and severity of phlebitis. \$3,500, Principal Investigator.

1973 Hospice Inc., Drug Therapy in Dying Patients  
A study and review of pharmacologic management of terminal disease conducted at St. Christopher's Hospice, London, England, \$4,700, Principal Investigator.

1973-1975 Lilly Research Laboratories and McGaw Laboratories  
A study of the effect of in-line filtration of intravenous antibiotic infusions on the incidence and severity of phlebitis. \$3,500, Co-Principal Investigator.

1974-1976 National Cancer Institute  
Continuing Care at Home for Patients with Cancer and Their Families, Contract No. NCI-CN-55053, \$9,900, Consultant.

1975-1977 National Institutes of Health, National Institute of Arthritis, Metabolism and Digestive Diseases  
National Cooperative Gallstone Study, Participation in a study of the efficacy of chenodeoxycholic acid in the treatment of gallstones in situ. Project Staff. Multicenter Patient Compliance Studies. \$7,500, Principal Investigator.

1979 National Center for Health Services Research  
Cost Utilization Review of IV Administration Sets, Grant No. 1-R03-HS-03394-01, direct costs \$34,921, Principal Investigator - approved but not funded.

1980-1982 Burroughs Wellcome Fund  
A Program for Faculty Development in Clinical Pharmacy, direct costs \$175,000, Co-Director.

1980 USPHS, Health Resources Administration  
Drugs in Pain and Symptom Management in Hospice--A Unique Nursing Opportunity, DHEW, No. HRA 232-79-0087, \$2,500.

1980-1981 Utah State Department of Health  
Provision of Clinical Pharmacy Services, \$25,750, Principal Investigator.

1981-1982 Utah State Department of Health  
Provision of Clinical Pharmacy Services, \$19,305, Principal Investigator.

1981-1982 Raleigh Hills Foundation  
Tissue Distribution and Pharmacokinetics of Emetine, \$31,500, Principal Investigator.

1982-1983 Utah State Department of Health  
Provision of Clinical Pharmacy Services, \$22,912, Principal Investigator.

1983 C.R. Bard, Inc.  
Controlled Trial of Patient Controlled Analgesia in Post Operative Pain, \$3,000, Principal Investigator.

1983-1984 Utah State Department of Health  
Provision of Clinical Pharmacy Services, \$27,000, Principal Investigator.

1983-1984 Bard Med Systems: Division of C.R. Bard, Inc.  
Clinical Investigation of New Infusion Pumps, \$8,900, Principal Investigator.

1984-1985 Utah State Department of Health  
Provision of Clinical Pharmacy Services, \$28,500, Principal Investigator.

1985-1986 Utah State Department of Health  
Provision of Clinical Pharmacy Services, \$29,000, Principal Investigator.

1986-1988 National Heart, Lung, Blood Institute, National Institutes of Health  
Genetic and Developmental Determination of Hypertension, Grant No. HL 24855-07, \$18,000, Co-Investigator.

1986-1987 Utah State Department of Health  
Provision of Clinical Pharmacy Service, \$27,000, Principal Investigator.

-continued-

Extramural Grants and Contracts (continued)

1990-1991 Hoechst-Roussel Pharmaceuticals, Inc.  
Development of a data system for advanced cancer pain and its management, \$5,000, Principal investigator.

1994 Syntex Laboratories  
Development of a continuing education program on pathophysiology and management of pain, \$51,425  
Principal investigator.

1996-1997 Vista Hospice Care Foundation  
Postdoctoral training program in pain and palliative care., \$58,000 per year,  
Principal investigator.

1997-1099 VistaCare Foundation, Scottsdale Arizona  
Support for a Post Doctoral Fellowship in Pain and Palliative Care Pharmacy Research, \$66,000 per year,  
Principal Investigator.

1998-1999 Alza Corporation  
Evaluation of E-TRANS (iontophoretic delivery) fentanyl for the treatment of breakthrough pain in conjunction  
with chronic pain, \$22,000 Principle Investigator

1998-1999 Durect Corporation  
Study of subcutaneous sufentanyl in chronic pain management, \$56,000, Principle Investigator

1998-1999 Robert Wood Johnson Foundation  
Utah partnership for improving care at the end of life planning grant, \$75,000, Steering Committee member.

1999-2000 Purdue Pharma  
Physician Perceptions of the Role of Opioids in Chronic Nonmalignant Pain, Principle Investigator, \$ 10,000

1999-2001 American Pain Society  
Development of clinical practice guidelines for pain management in arthritis, Co-Chair-Co Principle  
Investigator, \$25,000

2000-2002 Robert Wood Johnson Foundation  
Utah partnership for improving care at the end of life implementation grant, \$375,000, Steering Committee  
member

2001 Pharmacia Corp,  
Systematic Review Of Adverse Effects of Perioperative, Principle Investigator, \$10,000

2001 Pharmacia Corp.  
Costs of adverse reactions to opioids in post surgical patients, Co-Investigator, \$125,000

2001 American Pain Society Evidence Based Guidelines Program  
Systematic Review of the Effect of Pain and Opioids on Immune Response. Principle Investigator, \$15,000

2001-2002 Janssen Pharmaceutica  
Outcomes study of controlled release opioids in low back pain , Co-investigator, 55,000.

2001-2002 Endo Pharamceuticals  
Dermal Lidocaine for Myofascial Pain, Principle Investigator, \$26,000

2002-2007 NIH/NCI 2R01CA07424906A1  
Pain and the Defense Response  
To study the effects of pharmacological manipulated noradrenergic arousal on the defense response.  
Sub investigator

2003-2004 Progenics Pharmaceuticals MNTX 301  
A double-blind placebo-controlled study of methylnaltrexone (MNTX) for the relief of symptomatic  
constipation due to chronic opioid therapy in patients with advanced medical illness.  
Principal Investigator

2003-2004 Glaxo Smith Kline SB 767905-001  
A randomized, double-blind, placebo-controlled, multicenter phase 3B study to evaluate the efficacy  
and safety of multiple alvimopan dosage regimens for the treatment of opioid-induced bowel  
dysfunction in subjects with chronic pain of non-malignant origin.  
Co-investigator

continued

Extramural Grants and Contracts (continued)

- 2004-2005 Progenics Pharmaceuticals MNTX 302  
A Double Blind Phase 3, Two-Week, Placebo Controlled Study of Methylnaltrexone (MNTX) for the Relief of Constipation Due to Opioid Therapy in Advanced Medical Illness  
Principal Investigator
- 2004-2005 UCB Pharma N02087  
A double-blind, randomized, placebo-controlled parallel-group, 16 week, multicenter trial evaluating the efficacy and safety of levetiracetam 500 mg tablets in BID administration (daily dosing range from 1000 mg to 3000 mg ) in adults (≥ 18 years or age) suffering from postherpetic neuralgia.  
Principle Investigator

Intramural Grants and Contracts

- 1978-1981 University of Utah Research Committee  
A process study of clinical pharmacist activity in a university teaching hospital, \$2,035, Principal Investigator.
- 1978-1981 Department of Health, Education and Welfare, Biomedical Research Support Grant  
Clinical Pharmacist Activity Outcome Study, Grant No. 507-RR-05738-07, \$5,372, Principal Investigator.
- 1991-1992 University of Utah Research Committee  
Software development and implementation of a data system for advanced cancer pain and its management, \$4,940, Principal Investigator.

Academic, Foundation, and Governmental Consultant Appointments

1971-1974	Hospice, Inc. (Comprehensive Terminal Care Program) National Cancer Institute Demonstration Project, New Haven, Connecticut - Drug Therapy and Pharmaceutical Services.
1975	American Society of Hospital Pharmacists, Food and Drug Administration - Class Labeling System Corticosteroid Review Panel.
1976-1977	American Academy of Pediatrics, Committee on Nutrition Subcommittee on Amino Acid Modified Diets.
1977-1994	Hospice of Salt Lake (Terminal Care Program) Drug Therapy in Advanced Disease.
1978-1981	National Center for Health Services Research, Health Services Development Grants Study Section.
1978	American Cancer Society Member, Workshop on Curriculum Development for Pharmacists.
1980-1887	Salt Lake Veterans Administration Medical Center, Development and Maintenance of Comprehensive Pharmaceutical Services and a Residency in Hospital Pharmacy.
1981-1982	Southeast Texas Hospice, Orange, Texas, Advisory Board.
1982	Joint Commission on Accreditation of Hospitals, Consultant Panel for Hospice Accreditation Standards.
1985	Federal Interagency Committee on Narcotics and Pain.
1990-1991	USPHS Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care, Guidelines Development Panel for the Management of Acute, Post-Operative Pain.
1990	National Cancer Institute, Workshop on Cancer Pain, Consultation to the Director of the Institute.
1991-1992	USPHS Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care, Guidelines Development Panel for the Management of Pain Associated with Malignancy.
1992	National Cancer Institute, Special Grant Review Panel.
1992-1999	ASHP Research and Education Foundation, Pain Management Traineeship Program Development Committee.
1992-1998	American Cancer Society National Advisory Group on Cancer Pain Relief
1994	National Institutes of Health, National Institute of Nursing Research, Special Grants Review Committee
1994	Astra Pharmaceuticals, Reviewer for Astra Clinical Pharmacy Grant Program
1994	National Institutes of Health, National Cancer Institute, Special Grant Review Committee
1996-1999	National Advisory Board, Vista Hospice Care Foundation.; Chairman
2000-2003	Joint Commission on Accreditation of Healthcare Organizations, Pain Management Performance Measures Expert Panel.
2002	US Food and Drug Administration and National Institutes of Health Analgesics Drug Development Workshop
2003	US Food and Drug Administration and National Institutes of Health. Analgesic Outcomes Studies
2003	US Food and Drug Administration Advisory Committee on Anesthetic and Life Saving Drugs, Opioid Risk-Management.
2004-present	Roche Foundation for Anemia Research Scientific Advisory Board
2004	Drug Enforcement Administration, Consultant on Prescription Pain Medications: Frequently Asked Questions and Answers for Health Care Professionals, and Law Enforcement Personnel
2004	National Cancer Institute, National Institutes of Health, Cancer-Related Pain Management Resources

EDITORIAL APPOINTMENTS

Editorships

2002-present Editor, Journal of Pain & Palliative Care Pharmacotherapy  
2002-present Editor, Palliative Care Department, American Pain Society Bulletin  
1991-2001 Editor, Journal of Pharmaceutical Care in Pain & Symptom Control  
1993-1995 Editor, Research Update Department, American Pain Society Bulletin  
1979-1989 Editor, Hospital Formulary

Editorial Board Appointments

2004-present *Opioid Pain Management*  
2001-present American Pain Society Bulletin  
2000-present American Journal of Hospice and Palliative Care  
1997-2002 Journal of Palliative Medicine  
1993 Consulting Editor, Analgesia  
1993-1995 American Pain Society Bulletin  
1990 Consulting Editor, Pain Management Update, 47th Annual Meeting of the American Society of Hospital Pharmacists  
1989-1993 The IHS Primary Care Provider  
1984-1996 American Journal of Hospice Care  
1984-1994 The Hospice Journal  
1978-1980 Consulting Editor, American Journal of Hospital Pharmacy  
1978-1979 Journal of Continuing Education in Hospital and Clinical Pharmacy  
1977-1978 Contributing Editor, Physician Assistant  
1973-1975 Editorial Staff, Connecticut Pharmacist  
1971-1977 Contributing Editor, International Pharmaceutical Abstracts

Reviewer Appointments

Referee for: American Journal of Pharmaceutical Education, American Journal of Hospice and Palliative Care, American Journal of Hospital Pharmacy, American Journal of Health-System Pharmacy, Drug Intelligence and Clinical Pharmacy, Hospital Pharmacy, Clinical Pharmacy, Life Sciences, Journal of Pain, Pain Medicine  
1977-present Reviewer, American Hospital Formulary Service  
1973-1976 Reference Panel, American Hospital Formulary Service  
1973-1978 Staff Consultant, Hospitals, J.A.H.A.  
1976-present Consultant, The Medical Letter on Drugs and Therapeutics  
1980-1997 Reviewer, American Pharmaceutical Association Handbook of Nonprescription Drugs

UNIVERSITY, PROFESSIONAL AND PUBLIC SERVICE

Memberships and Offices in Professional Societies – International

Federation Internationale Pharmaceutique  
Hospital Pharmacists' Section  
Academic Section  
International Association for the Study of Pain  
Subcommittee on Courses and Curriculum  
Subcommittee on Curriculum for Pharmacy Schools, Chairman

Memberships and Offices in Professional Societies – National

American Pharmaceutical Association  
Delegate from Rhode Island, Student Section, Annual Meetings, 1965, 1966  
Policy Committee on Professional Affairs, 1973-74, 1974-75  
Liaison Committee with American Academy of Physician's Assistants, 1974-75  
Committee on Developing a Statement on Pharmaceutical Services in Hospice Care, 1981-82

-continued-

Memberships and Offices in Professional Societies - National -continued

American Society of Health-System (formerly Hospital) Pharmacists

Delegate from Connecticut, House of Delegates, 1972, 1974

Commission on Goals, 1975-76

Council on Clinical Pharmacy and Therapeutics, 1976-77, 1977-78

Advisory Panel on Student Membership, 1977-81

Joint Committee with American Association of Colleges of Pharmacy, 1979-80

Vice Chairman, 1980-81

Council on Administrative Affairs, 1981-82

Board of Directors, 1982-85

Ad Hoc Commission on Pharmacy Practice and Cost Containment, Panel

Member, 1985-86

Task Force on SIG Program Assessment, 1985-86

Information Network for Students, 1985-present

Council on Therapeutics, Chairperson, 1988-89, 1989-90

American Society of Health-System Pharmacists Research and Education Foundation

Advisory Panel on Awards, 1976-77, 1977-78

Program Development Panel for Traineeship in Pain Management

American Pain Society

Professional Education Subcommittee on Analgesic Regulatory Issues, 1989-1991

APS Bulletin Editorial Board, 1993-1994

Analgesic Regulatory Affairs Committee, 1992-1997

Membership Committee, 1995-present

APS-American Academy of Pain Medicine Ethics Task Force, 1998-2001

Evidence-based Guidelines Committee, 2002-2004.

American Cancer Society

Workshop on Curriculum Development for Pharmacists, 1978

National Advisory Committee on Cancer Pain Relief, 1992-1993

Patient Services Advisory Group on Cancer Pain Relief, 1993-1997

American Alliance of Cancer Pain Initiatives

Board of Directors, 1997-2001

Program Committee 1997-1999

Drug Information Association

Committee on Publications, 1976-78

American Association of Colleges of Pharmacy

Distinguished Educator Award Committee, 1980-81

Section of Teachers of Clinical Instruction

Chairman, Issues Committee, 1978-79, 1979-80

College Liaison Representative, 1979-85

American Society of Hospice Care

National Advisory Board, 1985-87

National Hospice Organization

Delegate from Hospice of Salt Lake to Annual Meeting, 1980-81

Nominating Committee, 1980-81

Education and Training Committee, 1981-82

Evaluation and Selections Committee, chairman, 1993

Pharmacist Steering Committee of the Council of Hospice Professionals

United States Pharmacopeial Convention

Delegate from the Yale University School of Medicine, 1975-77

Delegate from the University of Utah College of Pharmacy, 1980-85

Hospital Bureau, Inc.

Chairman, National Pharmacy Advisory Committee, 1973-75

Memberships and Offices in Professional Societies - Regional, State and Local

- Connecticut Advisory Committee on Food and Drugs
  - Representing Yale University School of Medicine, 1975-76
  - Representing Connecticut Pharmaceutical Association, 1976-77
- Connecticut Hospital Association
  - Council on Shared Services and Facilities, 1975-76
  - Council on Clinical Practice, 1976-77
  - Committee on Purchasing, 1973-75
- Western (U.S.A.) Pain Society
  - Program Committee, 1994
- Connecticut Pharmaceutical Association
  - Executive Committee, 1975-77
  - Joint Committee with Extended Care Facilities, 1971-72
  - Public Relations Committee, 1971-72
  - Subcommittee for Definition of Outpatients, 1971-72
  - Subcommittee for Pharmacy Services to Health Maintenance Organization, 1971-72
  - Joint Conference Committee with the Connecticut Medical Society, 1972-3, 1973-4, 1974-5, Chairman, 1975-76, 1976-7
  - Liaison Committee with the Commission and the School of Pharmacy, 1972-73, 1973-74, 1974-75, Chairman, 1975-76
  - By-Laws Revision Committee, Chairman, 1973-74, 1974-75
- Connecticut Society of Hospital Pharmacists
  - Chairman, Group Purchasing Committee, 1970-71, 1971-72
  - Secretary, Hospital-Community Pharmacists Joint Committee, 1970-71
  - Chairman, Intra-Professional Relations Committee, 1971, 1972, 1973
  - Nominating Committee, 1971
  - Steering Committee, 1972
  - President-Elect and Program Chairman, 1973
  - President and Chairman of the Board of Directors, 1974
  - Legislative Committee 1975, 1976
  - Chairman, PSRO Liaison Committee, 1975-77
  - Chairman, Committee on Standards of Practice, 1975-77
- Utah Pharmaceutical Association
  - Board of Directors, 1978
  - Trustee, 1978-81
  - Interprofessional Relations Committee, Chairman, 1978-79
  - Committee on Professional Affairs, Chairman, 1979
- Utah Society of Hospital Pharmacists
  - Goals and Planning Committee, 1981, 1984
  - Chairman, 1981
  - Student Chapter Advisor, 1985-1992
- Utah Association of Health Professions
  - Delegate, 1979-80
  - Program Committee, 1979-80
- Salt Lake Regional Pharmaceutical Association
  - Board of Directors, 1977-78
  - Program Committee, 1977-78
- Utah Cancer Pain Initiative      Cancer Pain Relief-Utah
  - Steering Committee, 1991-present
  - Co-Chairman, 1991-1993
  - Vice President, 1993-1994
  - President, 1995
  - Chair, Role Model Program Planning Committee, 1996

-continued-

Memberships and Offices in Professional Societies - Regional, State and Local (continued)

Utah Division, American Cancer Society  
Board of Directors, 1981-1999  
Executive Committee, 1986-88  
Professional Education Committee, 1980-present  
Vice Chairman, 1984-86, Chairman, 1986-88  
Think Tank, 1990-present  
Chairman 1991-present

University Committees

1971-1977 Yale University Institutional Review Board-Human Investigation Committee  
1981-1982 University of Utah, Honors Program Advisory Committee  
1981-1984 University of Utah, University Senate  
Executive Committee, 1982-84  
1981-1982 University of Utah, Honors Program Advisory Committee  
1984 University of Utah, Health Sciences Center Primary Care Committee  
1984-1985 University of Utah, Health Sciences Prepaid Health Plan Committee  
1984-1985 University of Utah, Committee to Review the Structure and Function of the University Senate  
1984-1987 University of Utah Writing Board  
Education Committee, 1984-85  
Executive Committee, 1985-87  
1984-1987 University of Utah, Health Sciences Center Clinical Computing Control Committee  
1985-1987 University of Utah, Health Sciences Center Clinical Policy Council  
1988-1989 University of Utah, International Studies Program  
1996-1999 University of Utah, University Retention, Promotion, and Tenure Standards and Review Committee  
Chairman 1998-1999  
2004- University of Utah, University Retention Promotion and Tenure Standards Committee

School of Medicine Committee

1990-2002 Utah Physician Assistant Program Didactic Teaching Committee

College of Pharmacy Committees

1972-1973 Clinical Council, University of Connecticut School of Pharmacy  
1977-1987 Executive Committee, University of Utah College of Pharmacy  
1977-1987 Doctor of Pharmacy Committee, University of Utah College of Pharmacy  
Chairman, 1989-present  
1977-1978, Curriculum Committee, University of Utah College of Pharmacy  
1993-1997 Chairman, 1986-1988  
1977-1980 Research Committee, University of Utah College of Pharmacy  
1979-1985 ad hoc Committee for Clinical Scientist Training, University of Utah College of Pharmacy  
1980-1984 BS-MBA Committee, University of Utah College of Pharmacy  
1984-1985 Alumni Relations Committee, University of Utah College of Pharmacy  
1984-1986 Continuing Education Committee, University of Utah College of Pharmacy  
1989-1992 Scholastic Standards Committee, University of Utah College of Pharmacy  
1992-1993 Continuing Education committee  
1992-1993 Pharm.D. Task Force  
1994-1997 Strategic Planning Committee  
1995-1997 Dean's Task Force

-continued-

College of Pharmacy Committees (continued)

1995-1996 Professional Experience Program (PEP) Committee  
1998-2002 Computer Committee  
1999-2001 Accreditation Committee  
1999-2001 Pharm.D. Seminar Committee  
Chairman, 1999-2001  
2003-present Research and Graduate Programs Committee

Hospital Committees

1968-1970 Infection Control Committee, USPHS Hospital, Tuba City, Arizona  
1968-1979 Disaster Committee, USPHS Hospital, Tuba City, Arizona  
1970-1977 Pharmacy and Therapeutics Committee, Yale-New Haven Hospital  
1970-1977 Medical Service Representatives Committee, Yale-New Haven Hospital  
Secretary, 1970-71  
1973-1977 Patient Care Studies Committee, Yale-New Haven Hospital  
1977-1997 Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics  
Subcommittee on Outpatient Drug Availability, Chairman, 1985-1990  
Subcommittee on Aminoglycoside Monitoring, 1986-87  
1998-present Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics

CONTRIBUTED PAPERS

1. Medicine and Pharmacy Aboard New England Whaling Vessels, I: The Captain, An Apothecary-Surgeon at Sea, American Institute of the History of Pharmacy Annual Meeting, Dallas, TX, April 1966 (with G.E. Osborne).
2. Spectrophotofluorometric Determination of Cholesterol Auto-oxidation Products, original research, University of Michigan College of Pharmacy, 1968.
3. A Senior Level Course in the Contemporary Practice of Pharmacy, University of Michigan College of Pharmacy, February 1968.
4. Clinical Pharmacy Services to Ambulatory Patients, Area Pharmacy Officers Meeting, USPHS, Albuquerque, NM, May 1970.
5. The Care of the Dying Patient - An Interdisciplinary Approach, 6th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December 1971 (with G.M. McCart and D.F. Beste).
6. The Patient Health Record: A Major Means for Improving Outpatient Pharmacy Services, 7th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1972 (with J.H. Deffenbaugh, Jr.).
7. The Effect of Buffering on Cephalothin Induced Phlebitis, 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, July 1973.
8. Quality Control of Pharmaceutical Industry Representative Activities Within the Institution, 30th Annual Meeting, American Society of Hospital Pharmacists, Boston, MA, July 1973.
9. Drug Literature Abstract and Index Services, 31st Annual Meeting, American Society of Hospital Pharmacists, Chicago, IL, August 1974 (with B.R. Greenberg).
10. Critical Comparisons of Commonly Available Iodophor Solutions and Scrubs, 31st Annual Meeting of the American Society of Hospital Pharmacists, Chicago, IL, August 1974 (with M.J. Rubino).
11. The Effect of In-Line Filtration on the Incidence and Severity of Cephalothin-Induced Phlebitis, 10th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December 1975 (with E. Decker and J. Cote).
12. Utilization Review of Normal Serum Albumin, 11th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, December 1976 (with A.M. Vengrofski and R.F. Miller).
13. A Comparative Study of Prospective Surveillance and Voluntary Reporting in Determining the Incidence of Adverse Drug Reactions, 11th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, December 1976 (with B.S. Bennett).
14. Utilization Review of Nutritionally Complete Oral Liquid Diets, 11th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, December 1976 (with C.D. Ponte).
15. The Development of an Auxiliary Faculty of Practicing Pharmacist Role Models for the Provision of Meaningful Community and Hospital General Practice Externships, 79th Annual Meeting of the American Association of Colleges of Pharmacy, Orlando, FL, July 1978 (with J.D. McMahan).
16. An Integrated, Competency Based, Clinical Curriculum for Doctor of Pharmacy Students, 79th Annual Meeting of the American Association of Colleges of Pharmacy, Orlando, FL, July 1978 (with J.K. Devenport).
17. Planning for Decentralization of Pharmacy Services, 13th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, San Antonio, TX, December 1978 (with J.N. Bair and J. Russo, Jr.).
18. Medicine and Pharmacy Aboard New England Whaling Vessels, II: Drugs Used, Their Indications, Applications, Sources and Costs, American Institute of the History of Pharmacy Annual Meeting, Anaheim, CA, April 1979.
19. A Multidimensional Study of Clinical Pharmacist Process, American Society of Hospital Pharmacists 37th Annual Meeting, Anaheim, CA, April 1979 (with B. Page and J.K. Devenport).
20. Experience with a Graduate Program in Institutionalized Pharmacy Management Leading to an M.S. in Hospital Pharmacy, M.B.A. and Residency, American Association of Colleges of Pharmacy 80th Annual Meeting, Denver, CO, July 1979 (with J.N. Bair).
21. Iontophoresis of Lidocaine for Topical Anesthesia, 14th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1979 (with J. Russo, Jr., B. Page and R. Stephen).
22. A Postdoctoral Fellowship Program for Faculty Development in Clinical Pharmacy, American Association of Colleges of Pharmacy 81st Annual Meeting, Boston, MA, July 1980 (with H.H. Wolf).
23. Implementation of a Comprehensive Quality Assurance Program for Pharmaceutical Services, American Society of Hospital Pharmacists 15th Annual Midyear Meeting, San Francisco, CA, December 1980 (with J.N. Bair and L.G. Gisclon).

-continued-

CONTRIBUTED PAPERS (continued)

24. Education and Service Directed Toward Meeting the Needs of the Elderly, American Association of Colleges of Pharmacy 82nd Annual Meeting, Scottsdale, AZ, July 1981 (with M.D. Higbee and J.K. Devenport).
25. Patient Controlled Analgesia, Fourth World Conference on Pain, International Association for the Study of Pain, Seattle, WA, August 1984 (with R. Kleiman and B. Hare).
26. Identification of Criteria Which May Promote Consistent Documentation of Clinical Pharmacy Activities, American Society of Hospital Pharmacists 20th Annual Midyear Clinical Meeting, New Orleans, LA, December 1985 (with T.P. Lennon, G.E. Dukes and L.M. Strand).
27. Pharmacological and psychological considerations in the management of pain due to metastatic prostatic cancer. Ninth Annual Meeting of the Western U.S.A. Pain Society, Santa Fe, NM, May 1988 (with L.A. Czajkowski).
28. Development and implementation of standards of practice for a multiple institution system of hospitals and ambulatory care centers. American Society of Hospital Pharmacists 24th Annual Midyear Clinical Meeting, Atlanta GA, December, 1989 (with RM Church, RN Herrier, EB Smith, RW Boyce, and V Dwight).
29. A system for concurrent data collection and retrospective analysis of advanced cancer pain and its management. VIth World Congress on Pain, Adelaide, Australia, April, 1990 (with RG Twycross, S Johns and CD Cleeland).
30. Complications and Failed Pain Control with Chronic Epidural Pain Management: Mechanisms and Alternatives. American Pain Society 15<sup>th</sup> Annual Scientific meeting, Washington DC, November 1996 (with S DuPen, M Mauthier and D Coombs).
31. Evidence-Based Drug Therapy Symptom Control Guidelines for Palliative Care. First International Conference on Research in Palliative Care. National Institutes of Health and U.S. Cancer Pain Relief Committee, May 1998 (with L.S. Tyler)
32. Development and Implementation of Evidence-Based Medicine in Palliative Care. American Academy of Hospice and Palliative Medicine 11th Annual Assembly, Snowbird UT, June 1999 (with K Jackson).
33. A Successful Statewide Collaboration to Improve Care at the End of Life. American Academy of Hospice and Palliative Medicine 11th Annual Assembly, Snowbird UT, June 1999 (with J Jacobson and S Beck).
34. Clinical Practice Guidelines: Making Recommendations Using Imperfect Science and Multiple Experts, American Pain Society 18<sup>th</sup> Annual Scientific Meeting, Fort Lauderdale FL, October 1999. (with C Miaskowski and A Jacox).
35. Opioid Analgesic Use in Chronic Nonmalignant Pain.. American Society of Health-System Pharmacists 34<sup>th</sup> Annual Midyear Clinical Meeting, Orlando FL, December, 1999 (with K Jackson and C Rubingh).
36. Initial Efficacy Trial of topical Lidocaine Patches in the Management of Chronic Myofascial Pain. American Pain Society Annual Meeting, Atlanta GA, November 2000. (with A Dalpiaz and S Lorden)
37. The Role of the Treatment Outcomes of Pain Survey Monitoring health-Related Quality of Life. American Pain Society Annual Meeting, Atlanta GA, November 2000. (with D Carr, W Roger, M Ashburn, G Oderda and J Schein)
37. Clinical Beliefs about Opioid Indications and Barriers in Chronic Nonmalignant Pain Management, American Pain Society Annual Meeting, Atlanta GA, November 2000. (with P Grahmann and K Jackson)
38. Cost of Opioid Related Adverse Drug Events in Surgical Patients. American Society of Anesthesiologists, 2001 Annual Meeting, October 2001, New Orleans LA. (with GM Oderda, M Samore, R Evans, C Chen, MA Ashburn, J Burke)
39. Opioid-Related Adverse Drug Events and Costs in Surgical Patients. American College of Clinical Pharmacy Annual Meeting. Tampa, Florida, October 2001. (with GM Oderda, RS Evans, J Lloyd, C Chen C., MA Ashburn, J Burke and M Samore)
40. Cost of Opioid-Related Adverse Drug Events in Surgical Patients. American Society of Health Systems Pharmacists, New Orleans LA, December 2001. (Oncore Presentation). (with GM Oderda, RS Evans, J Lloyd, C Chen, MA Ashburn, J Burke and M Samore)
41. Topical Lidocaine Patch Therapy for Myofascial Pain. American Pain Society Annual Scientific Meeting, Baltimore MD, March 2002 (with A Dalpiaz and S Lorden)
42. Use of the TOPS as A Pain-Specific HRQOL Instrument. International Society for Pharmacoeconomics and Outcomes Research Fifth European Congress, Rotterdam, The Netherlands, November 2002. (with GM Oderda, MA Ashburn and W Stockdale)
43. Systematic Review of the Effects of Opioids and Pain on Human Immune Function. American Pain Society Annual Scientific Meeting, Chicago IL March 2003 (with K Fakata and S Mullen)

continued

CONTRIBUTED PAPERS (continued)

44. Age and Gender Stratified Differences in Quality of Life in Elderly Chronic Pain Patients. International Society for Pharmacoeconomics and Outcomes Research Eighth Annual International Meeting, Arlington, Virginia, May 2003. (with L Oderda, W Stockdale, GM Oderda, G Donaldson, MA Ashburn M, and D Brixner D)
45. Opioid- Induced Bowel Dysfunction: A survey of prevalence and risk factors in Chronic Non-Malignant Pain Patients. American and Canadian Pain Societies Joint Scientific Meeting, Vancouver, BC, Canada, Baltimore MD, May 2004 (with K Fakata, M-J Ho, and A Tuteja)

INVITED PRESENTATIONS

1. Clinical Pharmacy Services to Ambulatory Patients, Area Pharmacy Officers Meeting USPHS, Albuquerque, NM, May 1970.
2. The Drug Information Service - An Influence for Rational Drug Therapy, 18th Annual Seminar, New England Council of Hospital Pharmacists, Windsor, CT, May 1971.
3. Pharmaceutical Services to Extended Care Facilities, Connecticut Pharmaceutical Association Annual Convention, East Haddam, CT, June 1971.
4. Monitoring and Recording Drug Interactions in the Institution, University of Connecticut Drug Interaction Continuing Education Program, statewide closed circuit television presentation, November 1971.
5. Drug Information and Clinical Communications, 6th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December 1971.
6. Group Purchasing of Pharmaceuticals, New England Hospital Assembly, Boston, MA, March 1972.
7. Shared Services in Institutional Pharmacy Practice, Western Massachusetts Society of Hospital Pharmacists, Springfield, MA, June 1972.
8. Handling Drug Interactions and Adverse Drug Reports, Institute on General Practice of Hospital Pharmacy, American Society of Hospital Pharmacists, Boston, MA, July 1972.
9. Drug Information Services in a University Teaching Hospital, Institute on Drug Information and Clinical Communications, American Society of Hospital Pharmacists, Washington, DC, October 1972.
10. Drug Information Requests, Institute on Drug Information and Clinical Communications, American Society of Hospital Pharmacists, Washington, DC, October 1972.
11. Medical Service Representation Peer Review: A Method for Meeting the Needs of the Hospital and the Industry, Industrial Relations Day, Annual Assembly, New York State Council of Hospital Pharmacists, Cooperstown, NY, October 1972.
12. Parenteral Hyperalimentation, Annual Assembly, New York State Council of Hospital Pharmacists, Cooperstown, NY, October 1972.
13. The Drug Information Concept, Special Institute on Clinical Drug Information Services, Connecticut Hospital Association-Connecticut Regional Drug Information Service, New Haven, October 1972.
14. Clinical Case Reviews, 7th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1972.
15. The Pharmacist and Clinical Communications, The Mid-Hudson Valley Society of Hospital Pharmacists, Fishkill, NY, January 1973.
16. Drug Information Services in Connecticut: Current Status, Connecticut Regional Drug Information Service Institute, Farmington, CT, February 1973.
17. Interprofessional Communications, Connecticut Pharmaceutical Association Annual Continuing Education Seminar, Farmington, CT, April 1973.
18. Establishing Clinical Pharmacy Services in a Community Hospital, Worcester Area Hospital Pharmacists Meeting, Worcester, MA, May 1973.
19. Pharmacological Management of Gram Negative Sepsis, Association for Practitioners in Infection Control, New England Branch, New Haven, CT, June 1973.
20. The Pharmacist, The Dying Patient and the Family, Academy of General Practice of Pharmacy, 120th Annual Meeting, American Pharmaceutical Association, Boston, MA, July 1973.
21. Drug Information Utilization and Case Studies, 4th Annual Seminar, Rhode Island Society of Hospital Pharmacists, Seekonk, MA, September 1973.
22. Antibiotic Misuse, presented to the medical staff, W.W. Backus Hospital, Norwich, CT, October 1973.
23. Contemporary Antibiotic Therapy, Hospital Pharmacists of Western Massachusetts, Chicopee, MA, October 1973.
24. Professional Expectations, Connecticut Society of Hospital Pharmacists Annual Student Meeting, Storrs, CT, October 1973.
25. Drug Information Services and Clinical Communications, 8th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, New Orleans, LA, December 1973.

-continued-

INVITED PRESENTATIONS (continued)

26. Clinical Applications of Broad Spectrum Antibiotics, Delaware Valley Society of Hospital Pharmacists, Philadelphia, PA, February 1974.
27. Drug Therapy in the Terminally Ill Patient, New England Council of Hospital Pharmacists, New England Hospital Assembly, Boston, MA, March 1974.
28. Rational Antibiotic Therapy, presented to the medical staff, Veterans Memorial Hospital, Meriden, CT, April 1974.
29. Drug Literature Evaluation, Annual Assembly, New York State Council of Hospital Pharmacists, Grossinger, NY, October 1974.
30. How to Keep Current, Annual Assembly, New York State Council of Hospital Pharmacists, Grossinger, NY, October 1974.
31. Shared Pharmaceutical Services, New England Hospital Assembly, Boston, MA, October 1974.
32. Symptomatic Drug Therapy in Terminally Ill Patients, Oncology Nurse Education Project, Waterbury Hospital Health Center, Waterbury, CT, November 1974.
33. Professional Standards Review Organizations, Affiliated Chapter Officers Meeting, American Society of Hospital Pharmacists, Miami, FL, December 1974.
34. Drug Therapy in Terminally Ill Patients, 9th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Miami, FL, December 1974.
35. Drug Therapy Considerations, New England Assembly, American Academy of Physicians Assistants, New Haven, CT, February 1975.
36. Pain is Manageable, Nursing Home Administrator Group, Oncology Nurse Education Project, Waterbury Hospital Health Center, Waterbury, CT, April 1975.
37. Monitoring Drug Therapy, Connecticut Association of Health Care Facilities, Vernon, CT, July 1975.
38. Drug Utilization Review, New England Hospital Assembly, Boston, MA, September 1975.
39. Management of Poisoning and Drug Overdoses, presented to the medical staff, W.W. Backus Hospital, Norwich, CT, October 1975.
40. Rational Antibiotic Therapy of Gram Negative Infections, Annual Seminar of the Georgia Society of Hospital Pharmacists, Athens, GA, October 1975.
41. Establishing a Medical Service Representative Peer Review Program, University of Illinois College of Pharmacy - Hospital Pharmacy Service, Chicago, IL, October 1975.
42. Management of Pain in Cancer, statewide telelecture network, Oncology Nurse Education Project, Waterbury Hospital Health Center, Waterbury, CT, October 1975.
43. Prescriptive Practices of Physicians' Assistants and Nurse Practitioners, 4th Annual Conference on New Health Practitioners, Atlanta, GA, April 1976.
44. Monitoring Antibiotic Therapy, Health Facility Surveyor Improvement Conference, Region 4, DHEW, Daytona Beach, FL, June 1976.
45. Pharmaceutical Care in Terminal Illness, 11th Annual Seminar, Maryland Society of Hospital Pharmacists, Ocean City, MD, June 1976.
46. The Role of Drugs in Terminal Symptoms, Institute on Death and Dying, Southern Connecticut State College, New Haven, CT, June 1976.
47. Anticipated Effects of PSRO Programs on Hospital Services, 13th Annual Pharmacy Seminar, Central New York Society of Hospital Pharmacists, Syracuse, NY, September 1976.
48. Symptomatic Drug Therapy in Terminal Disease, presented to the medical staff, Stamford Hospital, Stamford, CT, September 1976.
49. Laboratory Parameters for Monitoring Drug Therapy, Seminar on Laboratory and Diagnostic Tests in the Long-Term Care Patient, Connecticut Pharmaceutical Association, Cromwell, CT, October 1976.
50. Reviewing Drugs for the Pharmacy and Therapeutics Committee, Institute on Effective Use of Clinical Drug Literature, American Society of Hospital Pharmacists, San Antonio, TX, October 1976.
51. Current Status and the Future of Drug Information Provision, Institute on Effective Use of Clinical Drug Literature, American Society of Hospital Pharmacists, San Antonio, TX, October 1976.
52. Use of Drugs by Patients, Seminar on Acute Medical Problems for Physician's Assistants, Maine Medical Center, Portland, ME, February 1977.

-continued-

INVITED PRESENTATIONS (continued)

53. The Drug Information Service and the Pharmacy and Therapeutics Committee, Annual Seminar of the Western Branches of the Canadian Society of Hospital Pharmacists, Banff, Alberta, Canada, March 1977.
54. Managing Pain in Advanced Neoplastic Disease, Annual Midyear Clinical Meeting, New York State Council of Hospital Pharmacists, Tarrytown, NY, March 1977.
55. Drug-Food Interactions, Seminar on Drug Interactions sponsored by the Rutgers University College of Pharmacy, Elizabeth, NJ, April 1977.
56. Drug-Diet Interactions, Annual Continuing Education Seminar, Connecticut State Dental Society - Connecticut Pharmaceutical Association, Berlin, CT, April 1977.
57. Establishing a Drug Information Center, 28th Annual Seminar of the Texas Society of Hospital Pharmacists, San Antonio, TX, April 1977.
58. Drug-Induced Impotence, Oncology Nurse Education Project, Waterbury Hospital and Health Center, Waterbury, CT, May 1977.
59. Rational Antibiotic Therapy, Annual Continuing Medical Education and Board Review Program for Physician's Assistants, New Haven, CT, September 1977.
60. Treatment of Pain, 5th Annual Maine Nurse-Hospital Pharmacist Conference, Portland, ME, October 1977.
61. Drug-Drug and Drug-Food Interactions, Utah Pharmaceutical Committee on Continuing Education Seminar on Drug Interactions, Salt Lake City, UT, November 1977.
62. The Department of Pharmacy and Drug Administration, Hospital Pharmacies Incorporated Seminar, Denver, CO, November 1977.
63. Changing Patterns in Antibiotic Usage, Hospital Pharmacies Incorporated Seminar, Denver, CO, November 1977.
64. Pharmacologic Approach to Chronic Cancer Pain, Cancer Rehabilitation Program Seminar on Pain Control in Cancer, Portland, OR, November 1977.
65. The Role of the Pharmacist in the Doctor-Patient Relationship, Seminar on Clinical Psychopharmacology, Yale University School of Medicine, Department of Psychiatry, New Haven, CT, December 1977.
66. Drug Therapy in Terminal Disease, Utah Society of Hospital Pharmacists, Salt Lake City, UT, May 1978.
67. Drug Therapy of Pain and Nausea in Cancer, Northern California Society of Hospital Pharmacists - American Cancer Society Program on Supportive Care of the Cancer Patient, Emeryville, CA, September 1978.
68. New Approaches in Pain Control for the Cancer Patient, Cancer Teaching Day, New York State Division, American Cancer Society, Syracuse, NY, November 1978.
69. Pharmacists and the Hospice Movement, 9th Annual Meeting, American Society of Consultant Pharmacists, Atlanta, GA, November 1978.
70. Pharmacology in Pain Control, Advances in Oncology, Interwest Regional Medical Education Center and the American Cancer Society, Salt Lake City, UT, February 1979.
71. Drug Therapy in Chronic Pain, Surgical Staff Conference, L.D.S. Hospital, Salt Lake City, UT, March 1979.
72. Chronic Pain Management, Medical and Nursing Staff, Holy Cross Hospital, Salt Lake City, UT, March 1979.
73. Pharmacists and the Hospice Movement, Academy of Pharmacy Practice, Section on Long Term Care, American Pharmaceutical Association 126th Annual Meeting, Anaheim, CA, April 1979.
74. The Role of Drug Therapy in Cancer Pain, Fourth Annual Midwest Oncology Workshop for Nurses and Pharmacists, Indianapolis, IN, April 1979.
75. Drug Therapy in the Terminally Ill Patient, 87th Annual Convention Utah Pharmaceutical Association, St. George, UT, May 1979.
76. Pharmacological Approaches to Symptom Control, Hospice Development Conference, Oregon Comprehensive Cancer Program, Portland, OR, May 1979.
77. Developing a Quality Assurance Program for Pharmacy Services, American Society of Hospital Pharmacists - Canadian Society of Hospital Pharmacists Institute on Practice, Vancouver, BC, Canada, August 1979.
78. Evaluating Pharmacists Performance, American Society of Hospital Pharmacists - Canadian Society of Hospital Pharmacists Institute on Practice, Vancouver, BC, Canada, August 1979.
79. Altered Pharmacokinetics in the Elderly and Drug Prescribing for the Elderly, Symposium on the Pharmacist and the Geriatric Patient, Colorado Pharmaceutical Association and the University of Colorado School of Pharmacy, Colorado Springs, CO, September 1979.

-continued-

INVITED PRESENTATIONS (continued)

80. Drug Therapy in Chronic Pain, Medical Staff Conference, FHP/Utah, Salt Lake City, UT, September 1979.
81. Planning for Decentralized Pharmacy Services, Fall Seminar, Idaho Society of Hospital Pharmacists, Sun Valley, ID, September 1979.
82. Infection Control - Drug Utilization Review, Seminar on Anaerobic Infections, Nebraska Society of Hospital Pharmacists, Omaha, NE, October 1979.
83. Approach to Chronic Pain, Medical Service Conference, Veterans Administration Medical Center, Salt Lake City, UT, October 1979.
84. Altered Pharmacokinetics in the Elderly and Drug Prescribing in the Elderly, Symposium on the Pharmacist and the Geriatric Patient, University of Washington School of Pharmacy and the Washington State Pharmaceutical Association, Seattle, WA, November 1979.
85. Symptom Control for the Terminally Ill, Community Home Health Agency, Pharmacists and Nurses Meeting, Longview, WA, November 1979.
86. Drug Therapy in Chronic Pain, Physicians Roundtable Meeting, St. John's Hospital, Longview, WA, November 1979.
87. Hospice: The Program and Its Function, Utah Society of Hospital Pharmacists, Salt Lake City, UT, November 1979.
88. Pain Management, Division of Oncology Conference, College of Medicine, University of Utah, Salt Lake City, UT, November 1979.
89. Drug Therapy in Chronic Pain Syndromes, Symposium on Chronic Pain Syndromes in Medical Practice: Expanded Options 1980, Eisenhower Medical Center and the Arthritis Foundation, Palm Springs, CA, March 1980.
90. Management of Severe, Chronic Pain, Medical Staff Quarterly Meeting, St. Benedicts Hospital, Ogden, UT, March 1980.
91. Pain and Symptom Management, National Hospice Organization Regional Seminar, San Antonio, TX, March 1980.
92. Pharmacology of Narcotic Analgesics in Terminal Pain: New Concepts, Tennessee Society of Hospital Pharmacists, Annual Meeting, Nashville, TN, March 1980.
93. Decentralization of Pharmaceutical Services, Missouri and Kansas Societies of Hospital Pharmacists, Annual Meeting, Kansas City, MO, April 1980.
94. Chronic Pain Management, St. Mark's Hospital Medical Grand Rounds, Salt Lake City, UT, April 1980.
95. Short and Long Term Pain Control, Annual Post Graduate Symposium of the University of Connecticut School of Pharmacy, Storrs, CT, April 1980.
96. Pharmacological Approaches to Pain Management, Symposium on Death and Dying in the Acute Care Hospital, Albert Einstein Medical Center, Philadelphia, PA, April 1980.
97. Treatment of Pain, Health Professionals Continuing Education Program on Care of the Terminally Ill, Oregon State University, Corvallis, OR, May 1980.
98. Pain and Pain Management in the Cancer Patient and Technical Pain Management in Advanced Disease, American Cancer Society, Utah Division, Conference on Human Values and Cancer, Salt Lake City, UT, May 1980.
99. Physiology and Management of Pain, Northwest Association of Physical Medicine and Rehabilitation, Newport, OR, May 1980.
100. Pharmaceutical Education and Health Planning (moderator), Section of Teachers of Clinical Instruction, American Association of Colleges of Pharmacy 81st Annual Meeting, Boston, MA, July 1980.
101. Update on Antibiotic Therapy, Intermountain Infectious Disease Symposium, Idaho Falls, ID, August 1980.
102. Justifying and Implementing Clinical Services, National Institute on Becoming an Effective Hospital Pharmacy Director, American Society of Hospital Pharmacists, Denver, CO, August 1980.
103. Management of Pain in the Terminally Ill Patient, First Annual Western Pharmacy Education Fair, California Pharmacist Association, Newport Beach, CA, September 1980.
104. Drug Therapy in Chronic Pain, Annual Meeting of the Kentucky Society of Hospital Pharmacists, Ft. Mitchell, KY, October 1980.
105. Symptom Control in Advanced Cancer, Annual Meeting of the National Hospice Organization, Los Angeles, CA, November 1980.
106. Rational Use of Non-Narcotic Analgesics, Dolowitz Memorial Workshop of Holy Cross Hospital, Salt Lake City, UT, November 1980.

-continued-

INVITED PRESENTATIONS (continued)

107. Drug Treatment of Anaerobic Infections, Anaerobic Infections Seminar, Idaho Society of Hospital Pharmacists and Area Health Education Consortium of Treasure Valley, Inc., Boise, ID, November 1980.
108. Symptom Control in Advanced Cancer, Hospice of Cache Valley, Logan, UT, January 1981.
109. Drug Therapy in Chronic Pain, Medical Staff Conference, Logan Regional Hospital, Logan, UT, January 1981.
110. Chronic Pain Management, Southeastern Idaho Center for Health Resources, Inc., Pocatello, ID, January 1981.
111. Pharmacological Management of Pain of Terminal Illness, *Conference on Palliative Care*, University of Minnesota School of Medicine, Department of Family Practice and Community Health and Hospice St. Paul-Bethesda Lutheran Medical Center, St. Paul, MN, February 1981.
112. Pharmacy Services and Drug Therapy to Patients with Advanced Irreversible Disease, Hospital Institute for Education, Training and Research, Inc., Yale University, New Haven, CT, March 1981.
113. Legitimizing Pharmacy Services, Massachusetts Society of Hospital Pharmacists Sixth Annual Spring Seminar, Framingham, MA, April 1981.
114. Management of Chronic Pain, Pain Symposium sponsored by the University of Pennsylvania School of Medicine, The Williamsport Hospital and the Susquehanna Pharmaceutical Profile Center, Williamsport, PA, April 1981.
115. Decentralized Pharmaceutical Services, Annual Meeting of Oklahoma Society of Hospital Pharmacists, Tulsa, OK, May 1981.
116. Symptom Control in Advanced Cancer, Ogden Surgical Society 35th Annual Medical Meeting, Ogden, UT, May 1981.
117. Drug-Nutrient Interactions, Nutrition-Dietetics Subdivision of the American Association on Mental Deficiency, 105th Annual Meeting, Detroit, MI, May 1981.
118. Drug-Induced Sexual Dysfunction, Psycho-Sexual Workshop sponsored by the Oregon Comprehensive Cancer Program, Portland, OR, June 1981.
119. Pain Management in Terminal Illness, St. Vincent's Hospital Medical Lecture Series and The Visiting Nurse Service, Santa Fe, NM, September 1981.
120. Problems and Therapy in Chronic Pain and Uses and Abuses of Marked Analgesics, *Continuing Education Program*, University of Utah College of Pharmacy, Salt Lake City, UT, September 1981.
121. New Approaches in Pain Control, Virginia Society of Hospital Pharmacists, Central Region, Richmond, VA, September 1981.
122. Expanding the Scope of Pharmacy Practice: The Pharmacist in Drug Use Control, 2nd Annual Western Pharmacy Education Fair, California Pharmacists Association, Palm Springs, CA, October 1981.
123. Symptom Control. Annual Fall Seminar, Oregon Council of Hospices, Portland, OR, October 1981.
124. Drug Therapy in Cancer Pain, Pain Conference, Oregon Comprehensive Cancer Program, Portland, OR, October 1981.
125. Managing Pain in Advanced, Irreversible Disease, Hospice Program, University of Illinois College of Medicine, Champaign, IL, October 1981.
126. Cancer Pain Control, Hospice Seminar, St. Francis Hospital, New Castle, PA, October 1981.
127. Symptom Control in Advanced Cancer, Whittier Hospital Hospice Symposium, City of Industry, CA, October 1981.
128. *Decentralizing for Drug Use Control*, Connecticut Society of Hospital Pharmacists, Newington, CT, October 1981.
129. Pain and Symptom Control, Lewis & Clark Rural Area Health Education Center Hospice Workshop, Yankton, SD, October 1981 (telelecture).
130. Hospice and the Pharmacist, Oregon Society of Hospital Pharmacists, Portland, OR, October 1981.
131. Chronic Pain Management, Southeastern Idaho Center for Health Resources, Inc., Idaho State University, and Idaho Falls Hospital, Idaho Falls, ID, November 1981.
132. Pharmaceutical Services in Hospice Care, National Hospice Organization Fourth Annual Meeting, St. Louis, MO, November 1981.
133. *Pain Control in the Hospice Patient*, Hospice Council for Northern Ohio Conference on Pain Management in Patients with Advanced Irreversible Disease, Cleveland, OH, November 1981.
134. Pain and Symptom Management in Terminal Cancer, University of California at San Francisco and Hospice of Marin, San Francisco, CA, November 1981.
135. The Problem of Pain: A Look at Terminal Illness, Boulder County Hospice, Inc., Boulder, CO, December 1981.

INVITED PRESENTATIONS (continued)

136. Decentralization of Pharmaceutical Services: Past, Present, Future, 16th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, New Orleans, LA, December 1981.
137. Drug Therapy for Symptom Control in Terminal Disease, Annual Meeting of the American Association for the Advancement of Science, Washington, DC, January 1982.
138. Current Concepts of Managing Pain in the Terminally Ill Patient, Nevada Pharmaceutical Association, Las Vegas, NV, March 1982.
139. Symptom Control in Advanced Cancer, Minnesota Society of Hospital Pharmacists, Farmington, MN, March 1982.
140. Supportive Services for the Terminally Ill Patient, Institute on Management of Chronic Disease States: Providing Ambulatory Pharmacy Services, American Society of Hospital Pharmacists, Las Vegas, NV, March 1982.
141. Hospice Care, Pan Pacific II Conference, Honolulu, HI, April 1982.
142. Decentralization for Improved Drug Use Control, Mississippi Society of Hospital Pharmacists, Jackson, MS, May 1982.
143. The Pharmacology of Analgesics for Chronic Pain Control, St. Luke's Hospital, Hospice Symposium, Duluth, MN, May 1982.
144. Symptom Control in Terminal Disease, Palliative Care Symposium, St. John Medical Center, Tulsa, OK, May 1982.
145. Management of Pain Caused by Cancer, 5th Annual Spring Seminar, Northwestern Memorial Hospital Department of Pharmacy, Chicago, IL, April 1982.
146. Control of Pain, University of Minnesota College of Pharmacy and Pharmacy Alumni Society, Minneapolis, MN, May 1982.
147. Control of Pain in Cancer Patients, Conference on Oncologic Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, October 1982.
148. Drug Therapy in the Management of Pain of Advanced, Irreversible Disease. The William M. Lees, MD, Memorial Conference on Hospice Care, Loyola University of Chicago Stritch School of Medicine, Chicago, IL, October 1982.
149. Pain Management in the Terminally Ill, American Society of Consultant Pharmacists, 13th Annual Meeting, New York, NY, November 1982.
150. New Directions in Cancer Pain Management, University of Michigan Medical School, Second Annual Clinical Oncology Program, Ann Arbor, MI, November 1982.
151. Pain: Where Do We Go From Here? Ontario Branch, Canadian Society of Hospital Pharmacists, Annual Meeting, Toronto, Ontario, Canada, December 1982.
152. Chronic Pain Management, University of North Dakota Medical School and the United Hospital, Grand Fork, ND, January 1983.
153. Pain Management Update, Greater Sacramento Cancer Council and University of California at Davis School of Medicine, Division of Hematology - Oncology, Sacramento, CA, January 1983.
154. Patient Education and Counseling, Utah Pharmaceutical Association, 2nd Annual Great Western Conference, Salt Lake City, UT, January 1983.
155. Arthritis Pain Management, Thirteenth Annual Pharmacy Seminar, Ferris State College School of Pharmacy, Big Rapids, MI, April 1983.
156. Pain Management Workshop, Community Care Hospice and Delta County Memorial Hospital, Delta, CO, April 1983.
157. Pain Management and Nonsteroidal Antiinflammatory Drugs, El Paso Society of Hospital Pharmacists and El Paso Pharmaceutical Association, El Paso, TX, May 1983.
158. New Advances in Pain Management, New Hampshire Society of Hospital Pharmacists, Merrimack, NH, June 1983.
159. Motivating Faculty, 84th Annual Meeting, American Association of Colleges of Pharmacy, Washington, DC, July 1983.
160. Current Pharmacologic Management of Cancer Pain, East Bay Cancer Program, Oakland, CA, September 1983.
161. Pain and Symptom Control, Hospital of Abilene, Hendrick Medical Center, Humana Hospital, and Taylor-Jones-Haskell County Medical Society, Abilene, TX, October 1983.
162. Pathophysiology and Management of Pain, Great Lakes Cancer Nursing Conference, Michigan Division, American Cancer Society, Lansing, MI, October 1983.
163. Contemporary Management of Chronic Pain, Greater Cleveland Academy of Pharmacy, Cleveland, OH, October 1983.

-continued-

INVITED PRESENTATIONS (continued)

164. Contemporary Pain Management in Cancer, John Muir Memorial Hospital, Walnut Creek, CA, November 1983.
165. Current Concepts in the Management of the Cancer Patient, Temple University School of Pharmacy and Pennsylvania Society of Hospital Pharmacists, Philadelphia, PA, November 1983.
166. DRGs from the Hospital Pharmacy Viewpoint, Montgomery Securities Health Care Industries Group, Los Angeles, CA, November 1983.
167. New Directions in Chronic Pain Management, Department of Medicine Conference, Wilmington Medical Center, Wilmington, DE, January 1984.
168. Tumor Conference Consultant on Symptom Control in Advanced Cancer, John Muir Hospital, Walnut Creek, CA, February 1984.
169. Pain Management in Cancer, Third Annual Oncology Seminar, Oncology Conferences and the University of California at San Francisco, February 1984.
170. Non-steroidal Antiinflammatory Drugs in Pain Management, Tidewater Area Society of Hospital Pharmacists, Portsmouth, VA, March 1984.
171. Drug Therapy in the Management of Pain in Advanced, Irreversible Disease, Lee Memorial Hospice Conference, Loyola University of Chicago School of Medicine, Oak Brook, IL, March 1984.
172. New Directions in Pain Control, Tidewater Society of Hospital Pharmacists, Norfolk, VA, March 1984.
173. Use of Analgesics in Mild to Moderate Pain, Mexican-American Physicians Association, San Antonio, TX, April 1984.
174. New Directions in Pain Management, Mississippi Society of Hospital Pharmacists, Jackson, MS, April 1984.
175. Cancer Pain Management, Department of Family Practice Residents Conference, Area Grand Rounds, Calgary General Hospital, Holy Cross Hospital, Calgary, Alberta, Canada, April 1984.
176. Drug Therapy in Chronic Pain, Calgary Pharmaceutical Association, Calgary, Alberta, Canada, April 1984.
177. Hospital Pharmacy in the United States, Association des Pharmaciens des Etablissements de Sante' du Quebec, Montreal, Quebec, Canada, April 1984.
178. Pain Management in Cancer, New Mexico Society of Hospital Pharmacists, Albuquerque, NM, April 1984.
179. Formulary System Controversies in the New Environment of DRGs, Centennial Conference, Montifiore Medical Center, New York, NY, May 1984.
180. Narcotic Analgesics in Cancer Pain Management, School of Pharmacy, University of the Pacific, Stockton, CA, May 1984.
181. Pain Control in Advanced Cancer, Hospice Symposium, Queen of the Valley Hospital, Nappa, CA, May 1984.
182. The Role of Pharmacists in Hospice Care, 105th Annual Meeting, Iowa Pharmacists Association, Des Moines, IA, June 1984.
183. Pain Management in Cancer, Annual Meeting, American Physical Therapists Association, Las Vegas, NV, June 1984.
184. Pain Management in the Cancer Patient, West Texas Cancer Conference, Midland, TX, June 1984.
185. DRGs: Their Impact on Clinical Pharmacy, Symposium on DRGs, University of North Carolina Schools of Medicine and Pharmacy, Chapel Hill, NC, August 1984.
186. Pain Management in Terminally Ill Patients, The Lilly Lecture, 37th Annual Meeting, Canadian Society of Hospital Pharmaceutics, Halifax, Nova Scotia, August 1984.
187. Management of Cancer Pain, 4th Annual Conference on Oncologic Pharmacy and Nursing, New York, NY, September 1984.
188. The Hospital Formulary and P&T Committee in the New Fiscal Environment, Annual Meeting, Arizona Society of Hospital Pharmacists, September 1984.
189. Philosophies of Pain Management, 6th Annual Pharmacy Symposium on Cancer Chemotherapy, The University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX, October 1984.
190. New Directions in Cancer Pain Management, 9th Annual Cancer Symposium for Nurses, Scripps Memorial Hospital, La Jolla, CA, October 1984.)
191. Drug Therapy for Chronic Pain, Orange County Pharmaceutical Association, Irvine, CA, October 1984.
192. Pain and Symptom Control: Practical Options for Nurses and Pharmacists, Preconference Seminar, Annual Meeting and Symposium, National Hospice Organization, Hartford, CT, November 1984.

INVITED PRESENTATIONS (continued)

193. Pharmacy Management Strategies in the Era of Prospective Reimbursement, Group Health of Puget Sound, Seattle, WA, December 1984.
194. An Overview of Pharmacological Methodologies in Relief of Pain, Conference on Pain Relief in the Last Phase of Life, Hospice Assistance Program, Portland, OR, January 1985.
195. Controlling Cancer Pain, Practical Oncology Seminar, Swedish Hospital Medical Center, Seattle, WA, January 1985.
196. The Structure and Function of the Pharmacy and Therapeutics Committee in 1985, Hoechst Lecture, Professional Practice Conference, Canadian Society of Hospital Pharmacists, Toronto, Ontario, February 1985.
197. New Approaches in Chronic Pain Drug Therapy, Pharmacy Colloquium, Lane County Pharmaceutical Association, Eugene, OR, February 1985.
198. Decentralization of Pharmaceutical Services for Drug Use Control, Pan Pacific III Conference, Hong Kong, February 1985.
199. Pain Management, Brown County Medical Society, Brownwood, TX, March 1985.
200. A Controlled Pain Study of Patient Controlled Analgesia in Severe Postoperative Pain, Department of Pharmacy Practice, University of Florida, Gainesville, FL, April 1985.
201. Pain Management in Cancer Patients, Northern Illinois Society of Hospital Pharmacists, Chicago, IL, April 1985.
202. Trends in Pharmacy Practice, Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Flagstaff, AZ, April 1985.
203. Pain Management in Cancer, Kaiser Foundation Hospital, Haywood, CA, April 1985.
204. Pain Therapy for the Pharmacist, New England Council of Hospital Pharmacists, New England Hospital Assembly, Boston, MA, April 1985.
205. Pain Teleconference, School of Nursing, Loyola University of Chicago, Chicago, IL, May 1985.
206. Analgesia in Mild to Moderate Pain, Ellsworth Air Force Base Hospital, Rapid City, SD, May 1985.
207. Advanced Pain and Symptom Management of the Terminally Ill Patient, Northern California Hospital Association, Berkeley, CA, May 1985.
208. Drug Therapy of Pain, Pfizer Dialogue, Association of Pharmacy Faculties of Canada Annual Meeting, Halifax, Nova Scotia, Canada, May 1985.
209. Cancer Pain Management, City of Hope National Medical Center, Oncology Conference, Anaheim, CA, June 1985.
210. Pharmacological Needs of a Hospice Program, The First Annual American Conference on Hospice Care, Boston, MA, June 1985.
211. The Pharmacist's Role in Death and Dying, California Pharmacists Association, Maui, HI, June 1985.
212. Integration of Clinical and Distributive Pharmacy Services, 85th Annual Meeting, American Association of Colleges of Pharmacy, San Francisco, CA, July 1985.
213. The Future of Health Care in America - Pharmacy Services, Marion Laboratories Health Care Symposium, Kansas City, MO, July 1985.
214. Acute and Chronic Pain Concepts, Meridian Park Hospital Pain Control Workshop, Tualatin, OR, September 1985.
215. Treatment of Cancer Pain, Practical Therapeutics 1985 Symposium, Rocky Mountain Drug Consultation Service, Denver, CO, September 1985.
216. Management of Pain, Iowa Academy of Family Physicians, Des Moines, IA, September 1985.
217. Administration of Pain Medication, Symposium on Pain Management, Sutter Community Hospitals, Sacramento, CA, October 1985.
218. The Hospital Formulary System, Pain Management, Annual Seminar, New Hampshire Society of Hospital Pharmacists, Manchester, NH, October 1985.
219. Rational Analgesia, Ninth Annual Cancer Symposium, Scripps Memorial Hospital Cancer Center, San Diego, CA, October 1985.
220. Pain Control - Pure and Simple, Fifth Annual Cancer Symposium for Nurses, Scripps Memorial Hospital Cancer Center, San Diego, CA, October 1985.
221. Pain Control in Cancer Patients, St. Lukes Hospital, Milwaukee, WI, November 1985.
222. Pain and Symptom Control: Practical Options for Nurses and Pharmacists, Preconference Seminar, National Hospice Organization Annual Meeting, Washington, DC, November 1985.

-continued-

INVITED PRESENTATIONS (continued)

223. Recent Advances in Pain Management, Utah Pharmaceutical Association Midyear Conference, Salt Lake City, UT, November 1985.
224. Pain Management of the Cancer Patient, Central Michigan Community Hospital, Mt. Pleasant, MI, November 1985.
225. Current Concepts in the Management of Pain, John Muir Memorial Hospital, Walnut Creek, CA, December 1985.
226. Formulary Evaluation as a Means to Cost Containment, 20th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, New Orleans, LA, December 1985.
227. Pharmacological Management of Pain, St. Mark's Hospital Pain Management Program, Salt Lake City, UT, January 1986.
228. Pain Management in the Geriatric Patient, Dade County Pharmacists Association, N. Miami Beach, FL, February 1986.
229. Drug Therapy for Chronic Pain, Pharmacy Service, Veterans' Administration Medical Center, La Jolla, CA, February 1986.
230. Pharmacological and Therapeutic Considerations in the Clinical Use of Nonsteroidal Anti-Inflammatory Drugs, Wake Area Health Education Center, Wake Medical Center, Raleigh, NC, March 1986.
231. Drug Indication Approval: Implications for the Health Care Provider, Seminar by the Sea, University of Rhode Island College of Pharmacy, Newport, RI, March 1986.
232. Formulary Systems in the New Fiscal Environment, Idaho Society of Hospital Pharmacists, Boise, ID, April 1986.
233. Pain Management in the Geriatric Patient, Tri Services Pharmacy Officers Meeting, Tripler Army Medical Center, Honolulu, HI, April 1986.
234. Pain Management in the Cancer Patient, Hilo Pharmacists Association, Hilo, HI, April 1986.
235. Drug Therapy for Clinical Pain, Seminar '86, Massachusetts Society of Hospital Pharmacists, Framingham, MA, May 1986.
236. Management of Pain, Tri-Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Flagstaff, AZ, May 1986.
237. Pharmacological and Pharmacokinetic Characteristics of Mixed Agonist Analgesics Buprenorphine Seminar, Annual Meeting, American Society of Health Pharmacists, Denver, CO, June 1986.
238. Pain and Symptom Management in Advanced Cancer, Second Annual American Conference in Hospice Care, San Francisco, CA, June 1986.
239. The Pharmacist's Role in Cancer Pain Management, Cancer Symposium, Wilmington Area Health Education Center, Wilmington, NC, September 1986.
240. Pain and Symptom Control in Cancer, Hospice Care Inc., Dallas, TX, September 1986.
241. Cancer Pain Management, Medical Grand Rounds, Baylor University Medical Center, Dallas, TX, September 1986.
242. Differential Management of Acute and Chronic Pain in Post-Operative and Cancer Patients, Surgical Grand Rounds, Baylor University Medical Center, Dallas, TX, September 1986.
243. Present Role and Effectiveness of the Pharmacy and Therapeutics Committee, Annual Meeting, Michigan Society of Hospital Pharmacists, Plymouth, MI, October 1986.
244. Pathophysiology of Pain, Staff Conference, St. Patrick Hospital, Missoula, MT, October 1986.
245. Drug Therapy Considerations in the Renally Compromised Patient, Annual Meeting, American Society of Consultant Pharmacists, New Orleans, LA, October 1986.
246. Drug Substitutions and the Formulary System, Houston-Galveston Area Society of Hospital Pharmacists, Houston, TX, November 1986.
247. Pain and Symptom Control: Practical Options for Pharmacists and Nurses, Preconference Seminar, Annual Meeting of the National Hospice Organization, Denver, CO, November 1986.
248. The Pharmacist's Involvement in Hospice Care, 21st Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1986.
249. Cancer Pain Management, University of Alabama Hospitals, Departments of Nursing and Pharmacy Services, Birmingham, AL, January 1987.
250. The Pharmacy and Therapeutics Committee, Oklahoma City Area Pharmacists and Hospital Administrators, Oklahoma City, OK, January 1987.
251. New Directions in Pain Management, Southeastern Florida Society of Hospital Pharmacists, Pompano Beach, FL, February 1987.

-continued-

INVITED PRESENTATIONS (continued)

252. Pharmacological Management of Pain, Medical Staff Conference, Imperial Point Medical Center, Fort Lauderdale, FL, February 1987.
253. Management of Cancer Pain, Family Practice Refresher Course, Utah Academy of Family Physicians, Salt Lake City, February 1987.
254. New Directions in Pain Management, County Pharmaceutical Association, Chico, CA, February 1987.
255. Pain and Symptom Management in Advanced Cancer, Hospice Continuing Education Program for Nurses, Stanford University Hospital, Palo Alto, CA, February 1987.
256. New Directions in Pain Management, Michigan Pharmaceutical Association/Michigan Society of Hospital Pharmacists Interim Meeting, Dearborn, MI, March 1987.
257. Cancer Pain Management, Section on Long Term Care, Wisconsin Pharmaceutical Association, Pewaukee, WI, April 1987.
258. The Pharmacist in Pain Management, Annual Spring Program, New Hampshire Pharmaceutical Association, Manchester, NH, May 1987.
259. Post-Operative Pain Management, Medical Grand Rounds, Bannock Regional Medical Center, Pocatello, ID, June 1987.
260. Management of Pain, Medical Staff Educational Program, Utah Valley Medical Center, Provo, UT, June 1987.
261. Pain and Symptom Control in Advanced Cancer, Third Annual American Conference on Hospice Care, Chicago, IL, June 1987.
262. Pain Management, Alabama Society of Hospital Pharmacists, 66th Annual Convention of the Alabama Hospital Association, Birmingham, AL, June 1987.
263. The Role of the Pharmacist in Managing Pain, Baytown Area Pharmacists, Baytown, TX, June 1987.
264. Pain Management in the Cancer Patient, 12th Annual Seminar in Oncology, City of Hope Medical Center, Costa Mesa, CA, June 1987.
265. Scientific and Clinical Advances in the Management of Pain, Keynote Address, Management of Pain Programme, Hospital Pharmacists' Section, Federation Internationale Pharmaceutique, 47th International Congress of Pharmaceutical Sciences, Amsterdam, The Netherlands, September 1987.
266. Nonsteroidal Antiinflammatory Agents as Analgesics, Second Annual Pharmacy Practice Seminar, The University of North Carolina and The North Carolina Pharmaceutical Association, Wilmington Area Health Education Center, Wrightsville Beach, NC, September 1987.
267. The Future of Health Care in America, keynote presentation, University of Rhode Island College of Pharmacy Continuing Education Seminar, Mansfield, MA, September 1987.
268. Postoperative Analgesia, Second Annual Surgical Chief Residents Conference, Berkeley, CA, October 1987.
269. Selection Criteria for Postoperative Opioid Analgesics, Preconference Symposium, Annual Meeting of the American College of Surgeons, San Francisco, CA, October 1987.
270. Cancer Pain Management, Auburn Faith Community Hospital Medical Staff Conference, Auburn, CA, November 1987.
271. Newer Methods of Administering Analgesics, Sacramento Valley Society of Hospital Pharmacists, Sacramento, CA, November 1987.
272. Advances in Pain Management, Sutter Memorial Hospital Medical Staff Conference, Sacramento, CA, November 1987.
273. Drug Therapy in Pain Management, Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Anchorage, AK, February 1988.
274. Changes in Pharmacy Practice - Opportunities or Treats? Keynote Address, Alaska Pharmaceutical Association 22nd Annual Convention, Anchorage, AK, February 1988.
275. Current Concepts in Pain Management, Alaska Pharmaceutical Association 22nd Annual Convention, Anchorage, AK, February 1988.
276. Symptom Management, Hospice Symposium, Kaiser Permanent Medical Care Program, Oakland, CA, March 1988.
277. Pharmacological Management of Pain, 47th Annual Meeting of the Southern Society of Hospital Pharmacists, Orlando, FL, May 1988.
278. Taking Pride in Our Profession: Sharing Experiences Through Presentation of Publications, U.S. Public Health Service, National Pharmacy Officers Meeting, Phoenix, AZ, May 1988.

-continued-

INVITED PRESENTATIONS (continued)

279. Formulary Review Process in the Current Fiscal Environment, 45th Annual Meeting of the American Society of Hospital Pharmacists, San Francisco, CA, June 1988.
280. Pharmacokinetics of Opioid Analgesics, International Hospice Institute Symposium, Granby, CO, July 1988.
281. Clinical Use of Nonsteroidal Antiinflammatory Analgesics, 12th Annual Snowbird Conference for Physicians Assistants and Nurse Practitioners, Snowbird, UT, August 1988.
282. Appropriate Use of Analgesics in Chronic Pain Management, Alaska Professional Licensing Boards, Anchorage, AK, October 1988.
283. Pain and Symptom Control: Options for Nurses/Pharmacists, National Hospice Organization, Annual Meeting and Symposium, Preconference Seminar, Orlando, FL, November 1988 (with M. McCaffery).
284. The Physician's Role in Hospice Care. Hospice House, Portland, OR, January 1989.
285. Patient Controlled Analgesia: Is it Appropriate in Cancer Pain Management? Conference on Barriers and Approaches to Cancer Pain Management, Good Samaritan Hospital and Medical Center Comprehensive Cancer Program, Portland, OR, January 1989.
286. Drug Therapy in Pain Management, Connecticut Society of Hospital Pharmacists, Hartford, CT, February 1989.
287. Drug Literature Evaluation, Department of Family and Internal Medicine Conference, Phoenix Medical Center, U.S. Public Health Service, Phoenix, AZ, March 1989.
288. Cancer Pain Update, Saint Marks Hospital, Salt Lake City, UT, March 1989.
289. Management of Chronic Pain, Medical Staff Conference, Phoenix Indian Medical Center, U.S. Public Health Service, Phoenix, AZ, April 1989.
290. Drug Literature Evaluation, Greater Phoenix Hospitals Pharmacists Journal Club, Phoenix, AZ, April 1989.
291. Newer Approaches in Drug Therapy of Pain, Salford and Trafford Health Authorities, Greater Manchester, England, April 1989.
292. The Changing Review Process for Antimicrobial Agents in American Hospitals, International Workshop on Clinical Pharmacoepidemiology of Antibiotic Drug Use, Herzelia, Israel, June 1989.
293. Symptom Management in Patients with Advanced, Irreversible Disease, Saint Catherine Hospital and Jeanne B. Corley Hospice, Garden City, KS, September 1989.
294. Managing Pain, Utah Pharmaceutical Association, American Fork, UT, October 1989.
295. Development of an Effective P & T Committee, Seminar 89, Annual Meeting of the California Society of Hospital Pharmacists, Anaheim, CA, October 1989.
296. New Findings in the Management of Pain, Family Practice Refresher Course, Utah Academy of Family Practice, Snowbird, UT, February 1990.
297. Management of Pain and Other Symptoms in the Hospice Setting, 137th Annual Meeting, American Pharmaceutical Association, Washington DC, March 1990.
298. Opioid Drug Therapy, Symposium on Pain and Cancer in the Pacific Basin, Australian Pain Relief Association and World Health Organization, Sydney, Australia, April 1990.
299. Pain Management in the Oncology Patient, Symposium on The Challenge of Caring for the Oncology Patient, Thomason Hospital, El Paso TX, May 1990.
300. Evolution of Clinical Pharmacy Services, Greater Cincinnati Society of Hospital Pharmacists, Cincinnati OH, May 1990.
301. Pharmaceutical Services in Chronic Pain Management, Department of Pharmacy Services, University of Cincinnati Hospital, May, 1990.
302. The Pharmacist's Role in Rational Therapeutics, Merrell Dow Lecture in Clinical Pharmacy, University of Manchester and Salford and Trafford Pharmaceutical Service, Manchester, England, May 1990.
303. A Data System for Cancer Pain and its Management, Department of Pharmacy, Faculty of Science, University of Manchester, Manchester, England, May 1990.
304. Problem-Based, Student-Centered Clinical Education, Department of Pharmacy clinical staff and post graduate students, Hope Hospital, Salford, England, May 1990.
305. Pain Management in the Cancer Patient, Twelfth Annual Symposium on Cancer Chemotherapy, The University of Texas M.D. Anderson Cancer Center, Houston
306. Newer Findings in the Management of Pain, Seminar on Pain Management, United Samaritans Medical Center, Danville IL, November 1990.

-continued-

INVITED PRESENTATIONS (continued)

307. Current Approaches to Pain Management in Advanced Cancer, Hospice medical directors and oncology pharmacists meeting, Kaiser Permanente Medical Centers, Oakland CA, February 1991.
308. High Tech, High Touch Pain Control, Regional Hospice Education Workshop, Kaiser Permanente Medical Centers, Oakland CA, February 1991.
309. Hospice Care: An Exciting Professional Opportunity for Pharmacists, 138th Annual Meeting, American Pharmaceutical Association, New Orleans LA, March 1991.
310. Hospice Care: The Pharmacist's Role in Drug Therapy for Terminally Ill Patients, 138th Annual Meeting, American Pharmaceutical Association, New Orleans LA, March 1991.
311. Management of Pain, Combined Federal Pharmacy Seminar, Phoenix AZ, May 1991.
312. Immunization Update, Combined Federal Pharmacy Seminar, Phoenix AZ, May 1991.
313. Drug Therapy Considerations in the Management of Cancer Pain, American Cancer Society, Albany County Unit, Albany NY, June 1991.
314. The Role of the Pharmacy and Therapeutics Committee in Formulary Management, 27th Annual Meeting, Drug Information Association, Washington DC, June 1991.
315. Chronic Pain Management, Portland Area Pharmacy Officers Meeting, USPHS Indian Health Service, Portland OR, September 1991.
316. Management of Chronic, Benign Pain, Practical Therapeutics, A Western Regional Seminar of the Rocky Mountain Drug Consultation Center, Denver CO, October 1991.
317. New Directions in the Management of Pain, Annual Meeting, Owen Healthcare, Houston TX, October 1991.
318. Management of Pain, Fifth Annual Symposium on Drug Therapy in the Elderly, Veterans Administration Medical Center at Martinez and University of California at San Francisco, Concord CA, October 1991.
319. Pain Management in the Cancer Patient, Indiana Society of Hospital Pharmacists Winter Meeting, Indianapolis IN, January 1992.
320. Hospice Care, Florida Pharmacy Association Research and Education Foundation Oncology Update '92, Destin Beach FL, January, 1992.
321. Role of the Hospice Pharmacist, American Pharmaceutical Association, 139th Annual Meeting, San Diego CA, March 1992.
322. The State of the Art in Pain Management, Symposium on Issues and Advances in Pain Management at the California Society of Hospital Pharmacists Focus '92 Meeting, Monterey CA, April 1992.
323. Pathophysiology of Pain Management, 14th Annual Cancer Symposium, Wake Area Unit of the American Cancer Society, Wake Area health Education Center and University of North Carolina School of Pharmacy, Raleigh NC, May 1992.
324. Opioid Analgesics in Contemporary Pain Management, 103rd Annual Convention, Oregon State Pharmacists Association, Ashland OR, June 1992.
325. Managing Chronic Pain of Non-Malignant Origin, 103rd Annual Convention, Oregon State Pharmacists Association, Ashland OR, June 1992.
326. NSAIDs: Are They All the Same? Annual Continuing Education Conference of the Utah Academy of Physician Assistants and Utah Nurse Practitioner Conference Group, Snowbird UT, August 1992.
327. Differentiating Acute Pain, Chronic Pain of Malignant Origin and Chronic Non-Malignant Pain. Scientific Symposium on Pain Management, Pharmacy World Congress '92, Lyons France, September, 1992.
328. Rational NSAID Therapy. Utah Academy of Physician Assistants and Utah Nurse Practitioner Group Annual Conference, Snowbird UT, September 1992.
329. The State of the Art in Pain Management and current Approaches to Cancer Pain Management, Symposium on Issues and Advances in Pain Management. Southeastern Michigan Society of Hospital Pharmacists and IMS LTD., Dearborn MI October, 1992.
330. Pain Management. 27th Annual Convention, Alaska Pharmaceutical Association, Anchorage AK, February, 1993.
331. Managing Anxiety and Depression in Palliative Care. Dimensions of Caring 1993: Symptom Management in Palliative Care. Scripps Clinic and Research Foundation and San Diego Hospice, San Diego CA, March 1993.
332. Managing the Symptom Complex of Pain, Anxiety and Depression. Dimensions of Caring 1993: Symptom Management in Palliative Care. Scripps Clinic and Research Foundation and San Diego Hospice, San Diego CA, March 1993.

-continued-

INVITED PRESENTATIONS (continued)

333. Current Concepts of Pain Theory. Effective Pain Management, Medical Staff Course. North Colorado Medical Center, Greeley CO, March 1993.
334. Managing Chronic, Malignant Pain. North Colorado Medical Center, Greeley CO, March 1993.
335. Clinical Practice Guidelines: Implications for Pharmacy. 38th Annual Ohio Pharmaceutical Seminar, Columbus OH, April, 1993.
336. Costs and Benefits of New Technology and Aggressive Interventions in Pain Management Associated with Advanced, Irreversible Disease. Florida Hospices Symposium, Orlando FL, April, 1993.
337. Update on Pain Management. U.S. Public Health Service Pharmacy Continuing Education Seminar, Phoenix AZ, May 1993.
338. Cancer Pain Management. 15th Midyear Conference, American Society of Consultant Pharmacists, Palm Springs CA, May, 1993.
339. Pain Management in the Cancer Patient, Plenary Session, Cancer Care in the 90s, University of Lethbridge and University of Calgary, Lethbridge, Alberta, Canada, May 1993.
340. New Directions in Pain Management. 50th Annual Meeting, American Society of Hospital Pharmacists, Denver CO, June 1993.
341. Management of Cancer Pain: Internal Medicine Grand Rounds. St. Joseph's Hospital and Medical Center, Phoenix AZ, June 1993.
342. New Directions in Pain Management. Washington State Pharmacists Association Annual Convention, Cour d'Alene ID, June 1993.
343. Management of Cancer Pain. The Jewish Hospital of Cincinnati. Cincinnati OH, June 1993.
344. Current Approaches to Cancer Pain Management, symposium on Issues and Answers in the Management of Pain in Association with the Arizona Society of Hospital Pharmacists Annual Meeting, Scottsdale AZ, July 1993.
345. The State of the Art in Pain Management, Florida Society of Hospital Pharmacists Annual Meeting, Orlando FL, August 1993.
346. Drug Therapy in Acute Pain Management, Utah Society of Pain Management Nurses, Salt Lake City UT, September 1993.
347. Pain Management in Long Term Care. Arizona Pharmacy Association Section of Consultant Pharmacists, Phoenix AZ, September 1993
348. Guidelines for Acute Pain and Cancer Pain, National Nurse Practitioner Annual Meeting, Baltimore MD, Oct 1993.
349. Converting the Federal Pain Management Guidelines into Practice, American College of Osteopathic Family Physicians Scientific Lecture Program, Boston MA, October 1993.
350. Converting Pain Management Principles into Practice, Annual Meeting of the American Academy of Family Physicians, Orlando FL, October 1993.
351. Guidelines on Cancer Pain Management. Preconference Symposium, National Hospice Organization Annual Symposium, Salt Lake City UT, October 1993.
352. Agency for Health Care Policy and Research: Acute and Cancer Pain Guidelines, American College of Osteopathic Internists Annual Convention and Scientific Sessions, Scottsdale AZ, October 1993.
353. Interdisciplinary Approaches to Cancer Pain Management, National Video Symposium on Cancer Pain Management, sponsored by the University of California at Los Angeles, Seattle WA October 1993.
354. Acute and Chronic Cancer Pain Guidelines. American Society of Consultant Pharmacists Annual Meeting, New Orleans LA, November 1993.
355. Rational Selection Criteria for Opioid Analgesics, New England Council of Hospital Pharmacists Annual Fall Seminar, Portsmouth NH, November 1993.
356. Current Perspectives on Pain Management. American Society of Hospital Pharmacists Midyear Clinical Meeting, Atlanta GA, December 1993.
357. Pharmacology of Analgesics and Adjuvants. American Academy of Pain Medicine Review Course in Pain Medicine, Orlando FL, February 1994.
358. Clinical Pain Management. Cache Valley Medical Society and Logan Regional Hospital, Logan UT, February 1994.
359. Pain Management in Long Term Care. Symposium on Geriatric Nursing in Long Term Care, S.D. Care Center, Phoenix AZ, Mar 1994.

-continued-

INVITED PRESENTATIONS (continued)

360. Using the AHCPR Clinical Practice Guidelines in Practice, Scientific Seminar on Pain Management, 31st Annual Convention and Scientific Seminar, Phoenix AZ, Mar 1994.
361. The Agency for Health Care Policy and Research Cancer Pain Management Guideline. Massachusetts Cancer Pain Initiative, Boston MA, Apr 1994.
362. Effective Professional Education for Cancer Pain Management. National meeting of State Cancer Pain Initiatives, Boston MA, Apr 1994.
363. Pharmacological Pain Management and the Guideline Development Process, Symposium on Federal Clinical Practice Guidelines, Western USA Pain Society, Newport Beach CA, Apr 1994.
364. Management of Chronic, Nonmalignant Pain, Institute for Rehabilitation and Research, Texas Medical Center, Houston TX, Apr 1994.
365. Symptom Control in Advanced, Irreversible Disease, Hospice of the Canyon, Malibu CA, Apr 1994.
366. The Federal Clinical Practice Guideline for Cancer Pain Management. Norris Cancer Center, University of Southern California, Los Angeles CA, Apr 1994.
367. The AHCPR Clinical Practice Guidelines for Acute Pain and Cancer Pain Management, American Society of Pain Management Nurses, Chicago IL, Apr 1994.
368. Pain Management Guidelines. American Society of Consultant Pharmacists Annual Meeting, Boca Raton FL, May 1994.
369. Acute and Cancer Pain Management. Southwest Regional Pharmacy Seminar, Indian Health Service, U.S. Public Health Service, Scottsdale AZ, May 1994.
370. Drug Therapy in Pain Management. American Association of Physicians Assistants Annual Meeting, San Antonio TX, May 1994.
371. Pain Management in Elderly Patients, Veterans Affairs Medical Center Symposium on Geriatric Care. Salt Lake City UT, June 1994.
372. Drug Therapy in Cancer Pain. Hospice of El Paso, El Paso TX, Sept 1994
373. Pain Management Issues and the Federal Clinical Practice Guidelines. Professional Continuing Education Program on Acute and Cancer Pain Management, College of Pharmacy, University of Utah, Salt Lake City UT, Sept 1994.
374. Current Approach to Managing Chronic, Nonmalignant Pain. Symposium on Contemporary Viewpoints on Managing Chronic Pain, McNeil Pharmaceutical, San Francisco CA, Oct 1994.
375. Acute Pain Management, Surgical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
376. Cancer Pain Management, Oncology-Hematology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
377. Clinical Pain Management. Department of Internal Medicine Conference, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
378. Pain Management Issues. Department of Pharmacy Conference, Cedars-Sinai Medical Center, Los Angeles CA, Oct 1994.
379. Pain Management in Critical Care Patients. Annual Seminar, Rhode Island Society of Hospital Pharmacists, Providence RI, Oct 1994.
378. The AHCPR Clinical Practice Guidelines for Acute and Cancer Pain Management, Pain Management Symposium, Memorial Medical Center, Las Cruces NM, Oct 1994.
379. Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, Ogden UT Oct 1994
380. The Agency for Health Care Policy and Research Chronic and Cancer Pain Guidelines. National Association for Home Care, 13th Annual Meeting, Chicago IL, Oct 1994.
381. The Future of the Consultant Pharmacist's Role in Pain Management. American Society of Consultant Pharmacists 25th Annual Meeting, Boston MA, Nov 1994.
382. Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, Provo UT Oct 1994
383. Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, Salt Lake City UT Oct 1994.
384. Acute, Post Surgical and Cancer Pain Management, Medical Staff Conference, Yavapai Regional Medical Center, Prescott AZ, Nov 1994.

-continued-

INVITED PRESENTATIONS (continued)

385. AHCPR Acute and Chronic Malignant Pain Management Guidelines, American College of Osteopathic Family Physicians, 99th Annual Convention, San Francisco CA, Nov 1994.
386. How the Practicing Clinician can use the Federal Clinical Practice Guidelines on Acute and Cancer Pain Management, Utah Medical Association, Salt Lake City UT Dec 1994.
387. Converting Pain Management into Practice. Harris County Pharmaceutical Association and Houston-Galveston Area Society of Hospital Pharmacists, Houston TX, Feb 1995.
388. Analgesic Pharmacology and Therapeutics, American Academy of Pain Medicine Review Course in Pain Medicine, Palm Springs CA, Feb 1995
389. Management of Acute and Chronic Pain, University Learning Systems, Las Vegas, NV, Feb 1995.
390. Pain Control- A Multidisciplinary Approach Columbus Hospital, Great Falls MT, Mar 1995.
391. Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, St. George UT, Mar 1995
392. Cancer Pain Management, Intercollegiate Center for Nursing Education, Spokane WA Mar 1995.
393. Management of Acute and Chronic Pain, University Learning Systems, Marco Island FL, Apr 1995.
394. Integrating the AHCPR Guidelines into Practice. Pain Management: An Interdisciplinary Approach, University of Utah College of Nursing and Utah Pain Management Nurses, Salt Lake City UT, May 1995.
395. Acute and Cancer Pain Management Guidelines. Academy of Managed Care Pharmacy Annual Meeting, Toronto, Ontario, Canada, May 1995.
396. Clinical Practice Guidelines for Managing Cancer Pain. Michigan Association of Osteopathic Physicians and Surgeons. Dearborn, MI, May 1995.
397. Differentiating Acute, Chronic Malignant and Chronic Nonmalignant Pain. Utah Society of Hospital Pharmacists Annual Meeting, Park City UT, May 1995.
398. The Importance of Pain and Symptom Control in a Changing Environment. American Society of Consultant Pharmacists Annual Midyear Conference, San Diego CA, May 1995.
399. The Physician Assistant's Role in Pain Management. American Academy of Physician Assistants 23rd Annual Conference, Las Vegas NV, June 1995.
400. Defining New Standards and Implications for Care for the Nurse Practitioner. American Academy of Nurse Practitioners 10th Annual National Conference, Hollywood CA, June 1995.
401. Understanding and Assessing Pain. First Annual Pain Management Seminar, University of Arizona Colleges of Pharmacy and Nursing and the Arizona Society of Hospital Pharmacists, Scottsdale AZ, July 1995.
402. Analgesic Drugs for Neuropathic and Sympathetically Maintained Pain. Pain Management in Elderly People sponsored by Sepulveda Department of Veterans Affairs Medical Center, Gerontological Society of America, and UCLA Multicampus Program of Geriatrics and Gerontology, Culver City CA, August, 1995.
403. Understanding and Improving Pain Management. Tenth Annual Pharmacy Management Conference, Walker Drug Company, Birmingham AL, August, 1995.
404. The Effective Assessment and Management of Chronic Pain, Maricopa County Pharmacy Association, Phoenix AZ, September, 1995.
405. Cancer Pain Management and the AHCPR Guideline. Northland Hospice, Flagstaff AZ, September, 1995
406. Chronic Nonmalignant Pain Syndromes. Illinois College of Clinical Pharmacy, Chicago IL September 1995.
407. The Importance of Pain and Symptom Control in a Changing Environment. 55th Annual Convention and Scientific Sessions, American College of Osteopathic Internists, Fort Lauderdale FL, October 1995.
408. Managing Chronic Malignant and Nonmalignant Pain in the Outpatient Environment. Seminar '95, California Society of Health-system Pharmacists, Palm Springs CA, October, 1995.
409. Nonsteroidal and Adjuvant Drugs in the Elderly. American Society of Consultant Pharmacists Annual Meeting. San Francisco CA, November 1995.
410. Dose Titration, Polypharmacy and the Role of the Pharmacist in Cancer Pain Management. Pain Resource Network Course, City of Hope Medical Center and Southern California Cancer Pain Initiative, Duarte CA, November 1995.
411. Adjuvant Pharmacotherapy in Cancer Pain. Pain Resource Network Course, City of Hope National Medical Center and the Southern California Cancer Pain Initiative, Duarte CA, November 1995.
412. Chronic Pain Management. El Paso Pharmaceutical Association, El Paso TX, December 1995.

-continued-

INVITED PRESENTATIONS (continued)

413. Case Studies in Pharmacotherapeutics. Utah Academy of Physician Assistants Recertification Review Course. Park City UT, January, 1996.
414. Cancer Symptom Control. Tumor Conference. St. Thomas Hospital, Nashville TN, February 1996.
415. Pain Management in Cancer and AIDS. Alive Hospice, Nashville TN, February 1996.
416. Pharmacology of Analgesics. American Academy of Pain Medicine Review Course, Orlando FL, February 1996.
417. Management of Cancer and AIDS Pain. Alive Hospice, Nashville TN, February 1996.
418. Cost of Pain to Society and the AHCPR Clinical Practice Guidelines on Pain Management, in Managing Chronic Nonmalignant Pain in Primary Care, University of Utah Health Sciences Center, Salt Lake City UT March 1995.
419. Pharmacist-Patient: Self Care and OTC Analgesics. American Pharmaceutical Association Annual Meeting, Nashville TN, March 1996.
420. Differentiating and Managing Acute, Chronic Malignant and Chronic Nonmalignant Pain. Montana Society of Hospital Pharmacists and University of Montana School of Pharmacy and Allied Health Sciences, Bozeman MT, March 1996.
421. Pain Control with Oral Agents. Society of Surgical Oncology 49th Annual Cancer Symposium, Atlanta GA March 1996.
422. Differentiating and Managing Chronic Pain. Memorial Hospitals Association, Modesto CA, April 1996.
423. The AHCPR Guideline: Cancer Pain. HealthInsight, Logan UT, May 1996.
424. Pain Management and Relief. Washington State Hospice Organization. Mt Vernon WA, May 1996.
425. New Approaches to Non-invasive Delivery of Symptom Management. Academy of Hospice Physicians 8th Annual Assembly, Snowbird UT, June 1996.
426. How Chronic Pain Affects the Patient. John C. Lincoln Hospital Pain Management Symposium, Carefree AZ, June 1996
427. Managing Chronic Pain. Mississippi Society of Health-System Pharmacists, Summer Seminar, Biloxi MS, July 1996.
428. Pain Management in the Home. Home Care '96, American Society of Health-System Pharmacists Annual Home Care Meeting, Orlando FL, July 1996.
429. Stumbling Blocks to Effective Pain Management. Visiting Nurse Services of the Northwest, Everett WA, August 1996.
430. Cancer Pain Management and the AHCPR Guidelines. Arizona State Cancer Pain Initiative, Tempe AZ, August 1996.
431. *Pharmaceutical Care in Pain Relief*, Symposium on Treatment of the Terminally Ill, World Pharmacy Congress, International Pharmaceutical Federation, Jerusalem Israel, September 1996.
432. Pharmacological Principles of Cancer Pain Management, Wyoming Medical Center and Wyoming Cancer Pain Coalition Education program, Casper WY October 1996.
433. Cancer Pain Management, National Invitational Pharmacists Pain Meeting, Fort Lauderdale FL, October 1996.
434. The Role of Opioids in Cancer Pain, American Academy of Osteopathic Internists 56<sup>th</sup> Annual Convention and Scientific Sessions, San Francisco CA, October 1996.
435. Opioid use in Chronic Nonmalignant Pain. Advances in the Management of Pain in the Acute and Chronic Setting. University of Utah School of Medicine, Salt Lake City UT October 1996.
436. Pathophysiology of Pain and the Management of AIDS and HIV Pain. Cancer pain Management Conference. Wyoming Medical Center, Casper WY, October 1996.
437. Drug Therapy of Neuropathic Pain. Symposium on Managing Pain: Managing Costs, held in conjunction with the American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans LA, December, 1996.
438. Differentiation and Management of Acute, Chronic Malignant and Chronic Nonmalignant Pain, Pharmacy Corporation of America National Teleconference, January 1977.
439. Pharmacotherapeutics Case Studies. Utah Academy of Physician Assistants 1997 Recertification Review Course, Park City UT, January 1997.
440. Nonopioid and Adjunctive medications. American Academy of Pain Medicine Review Course, Scottsdale AZ, February 1997.
440. Differentiating and Managing Chronic Pain. Frontiers in Pharmacy, El Paso Area Society of Health-System Pharmacists, El Paso TX, March 1997.

-continued-

INVITED PRESENTATIONS (continued)

441. Cancer Pain Management. National Invitational Meeting of Pain Management Pharmacists, San Antonio TX, April 1997.
442. Oxycodone Analgesia. Invitational Meeting of European Palliative Care Physicians, New York NY, April 1997.
443. Differentiating and Managing Pain in Primary Care. University of Montana School of Pharmacy and Rocky Mountain College Physician Assistant Program Continuing Education Symposium, Billings MT, April 1997.
444. New Findings in the Management of Nonmalignant pain. Medical University of South Carolina New Drug Update, Charleston SC, May 1997.
445. Pain Management Opportunities and Challenges, Invitational Physicians Meeting, New Orleans LA, May 1997.
446. Acute Pain Management Issues, Symposium on Cost-Effective Management of Acute Pain held in conjunction with the American Society of Health-Systems Pharmacists Annual Meeting, Minneapolis MN, June 1997.
447. Pharmacological Issues in Pain Management. Connecticut Hospital Association Interprofessional Education Program., Cromwell CT, June 1997.
448. Cancer Pain Management. Tumor Board Conference, University of Arkansas for the Health Sciences, Little Rock AR, June 1997.
449. Chronic Pain: Differentiating and Managing Chronic Malignant and Chronic Nonmalignant Pain. University Learning Systems, Kauai HI, July 1997.
450. Immunizations: Current Recommendations in Disease Prevention and Management. University Learning Systems, Kauai HI, July 1997.
451. Management of Chronic Nonmalignant Pain in Renally Impaired Patients. St Francis Medical Center, Honolulu HA, July 1997.
452. Pharmacological Advances in Neuropathic Pain Management. McKay Dee Hospital Center, Ogden UT, July 1997.
453. Differentiating and Managing Chronic Pain in Older Patients, Auburn University School of Pharmacy, Gulf Shores AL, July 1997 and Lake Guntersville AL, August 1997.
454. Contemporary Themes in Cancer Pain Management. American Society of Health System Pharmacist Home Care '97 Meeting, Reno NV, August 1997
455. Pain. Washington State Hospice Organization Fall Conference, Feral Way WA, September, 1997
456. Pharmacology in Pain and Symptom Control. Sandia Hospice, Albuquerque NM, September, 1997
457. Management of Chronic Pain Syndromes, Lovelace Health Systems, Albuquerque NM, September 1997.
459. Pain Management and Controlled Substance Prescribing. National Association of boards of Pharmacy/American Association of Colleges of Pharmacy District IV Annual Meeting, Detroit MI, November, 1997.
460. Pain Management in the Long Term Care Setting. American Society of Consultant Pharmacists 25<sup>th</sup> Annual Meeting, Philadelphia PA, November 1997.
461. The Management of Chronic Malignant Pain. South Carolina Society of Health-System Pharmacists and University of South Carolina, Winter Seminar, Greenville SC, November 1997.
462. Pain and Palliative Care Case Studies. Utah Academy of Physician Assistants Annual Review Course, Park City UT January 1998.
463. Chronic Pain. Utah Academy of Family Physicians, Park City UT, February 1998.
464. Pharmaceutical Care of Patients with Chronic Pain. Northeast Florida Society of Health-system Pharmacists, Jacksonville FL March 1998.
465. Advances in Pain Management. American College of Rheumatology Spring Meeting, Scottsdale AZ, April 1998.
466. Pharmacology of Opioids. Intermountain West Chapter, American Society of Pain Management Nurses Program on Health Care Providers Advocating for Pain Management, Salt Lake City Utah, April 1998.
467. Current Controversies in Managing Chronic Pain. American College of Clinical Pharmacy Practice and Research Spring Forum. Palm Springs CA, April 1998.
468. Pharmacological Management of Neuropathic Pain. Western Pain Society Annual Meeting, San Diego CA, May 1998.
469. Evidence-based Use of Opioids in Pharmaceutical Care. United Kingdom Clinical Pharmacy Association Spring Meeting, Leeds, England, May 1998.
470. Chronic Pain Management. Utah Academy of Family Physicians, Park City UT, February 1998.
471. Pharmaceutical Care of Patients with Chronic Pain. Northeast Florida Society of Health-system Pharmacists, Jacksonville FL March 1998.

-continued-

INVITED PRESENTATIONS (continued)

472. Advances in Pain Management. American College of Rheumatology Spring Meeting, Scottsdale AZ, April 1998. Pharmacology of Opioids Intermountain West Chapter, American Society of Pain Management Nurses Program on Health Care Providers Advocating for Pain Management, Salt Lake City Utah, April 1998.
473. Pharmacological Management of Neuropathic Pain. Western Pain Society Annual Meeting, San Diego CA, May 1998.
474. Evidence-based Use of Opioids in Pharmaceutical Care. United Kingdom Clinical Pharmacy Association Spring Meeting, Leeds, England, May 1998.
475. Pain Management in Primary Care. American Academy of Physician Assistants Annual Meeting. Salt Lake City UT May 1998.
476. Neuropathic Pain Pathophysiology and Management. American Alliance of Cancer Pain Initiatives Annual Meeting, Portland ME, June 1998.
477. Pain and Symptom Control in Palliative Care. Lovelace Clinic Continuing Education Program. Albuquerque MN, June 1998.
478. Evidence-based Medicine in Palliative Care. Pallayup Hospice, Pallyup WA, July, 1998
479. Effective Use of the Federal Acute and Cancer Pain Management Clinical Practice Guidelines Seattle Veterans Affairs Medical Center, Seattle WA, July 1998.
480. Pharmaceutical Care for Pain. Washington Society of Health-system Pharmacists, Seattle WA, July 1998
481. New Trends in the Treatment of Cancer Pain of Cancer Pain. 17<sup>th</sup> International Cancer Congress, Rio de Janeiro, Brazil, August, 1998.
482. Opioid Pharmacology, Pain Management Update Symposium, Memorial Hospital, Colorado Springs CO, September 1998.
483. Problem-based, Case-oriented Management of Neuropathic Pain. American Pain Society 17<sup>th</sup> Annual Scientific Meeting, San Diego CA, October 1998.
484. The Rationale Behind the AAPM-APS Consensus Statement on Opioids for the Treatment of Chronic Pain: A Blending of Science and Politics, American Pain Society 17<sup>th</sup> Annual Scientific Meeting, San Diego CA, October 1998.
485. Neuropathic Pain Management. Pharmacotherapy of neurological disorders Ednet Program, University of Utah College of Pharmacy, Salt Lake City UT, October 1998.
486. National Conference for Nurse Practitioners, Baltimore MD, November 1998.
487. Pain and Symptom Control in Chronic Disease at End-of-life. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
488. Pain Management in Arthritis. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
489. Refuting Opioid Mythology. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998..
490. COX-2 Inhibitors in the Management of Inflammatory Pain. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas NV, December, 1998.
491. Anticonvulsants in Neuropathic Pain. Neurology-Psychiatry Continuing Medical Education Program, Park City UT, Dec 1998.
492. Pharmacotherapy for Chronic Pain. Utah Academy of Physician Assistants 1997 Recertification Review Course, Park City UT, January 1999.
493. Pain Management in Long Term Care. Merck Long Term Care Meeting, Salt Lake City UT, February 1999.
494. The Management of Chronic Nonmalignant Pain in the Long Term Care Resident. NeighborCare, Plymouth Meeting PA, March 1999.
495. Rational Opioid Use in End of Life Care. The University of Arkansas for Medical Sciences Palliative Care Faculty Lecture Series. Little Rock AR, March 1999.
496. Pain and Symptom Management in Palliative Care. California Society of Health-System Pharmacists, Focus-'99. San Diego CA, March 1999.
497. Defining and Refuting Myths About Opioid Analgesia. American Association of Pain Management Nurses- Intermountain West Chapter, April 1999

-continued-

INVITED PRESENTATIONS (continued)

498. New Opportunities in the Treatment of Severe Pain. Symposium at the 22<sup>nd</sup> Annual Meeting of the Scandinavian Association for the Study of Pain. Reykjavik Iceland April 1999.
499. Pharmaceutical Care of the Acute Pain Patient. North Coast Society of Health-System Pharmacists, Santa Rosa CA, May 1999.
500. Pain Management is a Team Game. Southwest Regional Continuing Education Seminar, Indian Health Service, U.S. Public Health Service, Phoenix AZ, June 1999.
501. Nontraditional Analgesics for the Management of Neuropathic Cancer pain. The 10<sup>th</sup> national Meeting for State Cancer Pain Initiatives, American Alliance of Cancer Pain Initiatives, Salt Lake City UT, June 1999.
502. Clinical Advancements in the Management of Pain. American College of Apothecaries Annual Conference, Kansas City MO, September 1999.
503. Clinical Relevance of Opioid Pharmacokinetics and Metabolism, Symposium held at the American Pain Society 18<sup>th</sup> Annual Scientific Meeting, Fort Lauderdale FL, October 1999.
504. Oxycodone pharmacokinetics and pharmacodynamics. Pain Symposium, Stockholm, Sweden, October 1999.
505. Neuropathic Pain Management. Advances in End of Life Care, California Geriatric Education Center, University of California at Los Angeles, Woodland Hills CA, November 1999.
506. Pharmacological Treatment Options in Pain Management, Strategies for Pain Management in New Century, Baylor University Medical Center, Dallas TX, November, 1999.
507. Implications of the new JCAHO Pain Standards, American Society of Health-system Pharmacists 34<sup>th</sup> Annual Midyear Clinical Meeting, Orlando FL, December, 1999.
508. Cancer Pain Management. Radiation Oncology Resident Conference, University of Florida Shands Teaching Hospital, Gainesville FL, December 1999.
509. Pain and Symptom Management in Palliative Care. Northern California Hospice Programs, Kaiser Permanente, Oakland CA, December 1999.
510. Pain Management and Palliative Care, 6<sup>th</sup> Annual Recertification Review Course, Utah Academy of Physician Assistants, Salt Lake City UT, January 2000
511. Cancer Pain Management. good Samaritan Hospital, Phoenix Arizona, March 2000
512. Pharmaceutical Care of the Pain Patient. Seminar by the Sea, University of Rhode Island College of Pharmacy, Newport RI, March 2000
513. Myths about Opioids. Magic Valley Pharmaceutical Association, Twin Falls Idaho, April 2000
514. Pain Models and Analgesic Pharmacology. Certificate Program in Pain Management, American College of Apothecaries, Coronado CA, May 2000
515. Closing the Gap Between Current Practice and Knowledge in Pain Management. Internal Medicine Grand Rounds, Providence Hospital and Medical Center, Southfield MI, May 2000
516. Empowering Professionals and Patients to Improve Palliative Care, Southwest Florida Regional Medical Center, Fort Myers FL, May 2000
517. Myths and Facts about Opioid Analgesics. Sarasota Memorial Hospital, Sarasota FL, May 2000.
518. Differentiating and Managing Headaches, U.S. Public Health Service, Indian Health Service, Southwest Pharmacy Continuing Education Seminar, Scottsdale AZ, June 2000.
519. Common Opioid Myths, U.S. Public Health Service, Indian Health Service, Southwest Pharmacy Continuing Education Seminar, Scottsdale AZ, June 2000.
520. Nontraditional Analgesics in Cancer Pain Management, American Alliance of Cancer Pain Initiatives, Kansas City MO, June 2000
521. Pain Management in the Community Hospital. Sharp Health Care System, San Diego CA, June 2000
522. Cancer Pain Management - The 5<sup>th</sup> vital sign for the new Millennium. Hospice Center of Santa Fe, Santa Fe NM, June 2000
523. Management of Chronic Pain in the Elderly, New Mexico Pharmaceutical Association, 71<sup>st</sup> Annual Convention, Albuquerque NM, June 2000.
524. Opioid Pain Management. Worldwide Pain Conference, World Society of Pain Clinicians, San Francisco CA, July 2000.

-continued-

INVITED PRESENTATIONS (continued)

525. Is Age a Consideration in Opioid Therapy? Worldwide Pain Conference, World Society of Pain Clinicians, San Francisco CA, July 2000
526. The Management of Chronic Nonmalignant Pain. National Association of Boards of Pharmacy-American Association of Colleges of Pharmacy District 5 63<sup>rd</sup> Annual Meeting, Winnipeg Manitoba Canada August 2000.
527. Rational and Legal Use of Opioids in Chronic Pain. Garfield Memorial Hospital, Panguitch UT; Bear River Valley Hospital, Tremonton UT; Filmore Community Hospital, Filmore UT; Sanpete Community Hospital, Mt. Pleasant UT, August 2000.
528. Acute and Chronic Pain Medications- How to Decide Which to choose. Atlanta Academy of Institutional Pharmacists, Atlanta GA, August 2000.
529. Pain Management in Long Term Care. Western Medical Directors Association, Salt Lake City UT August, 2000.
530. Acute and Chronic Pain Management, Colegios Farmaceuticos de Puerto Rico, Rio Grande, Puerto Rico, August, 2000
531. Update and Dilemmas in Pain Management and Palliative Pharmaceutical Care. Carolina Seminar. North Carolina Association of Pharmacists and the University of North Carolina and Campbell University Schools of Pharmacy, Greensboro NC, October 2000.
532. Pharmacotherapy of Pain, Clarian Health Partners, Indianapolis IN, October 2000.
533. Pharmacists Role in Pain Management, Indiana College of Clinical Pharmacy, Indianapolis IN, October, 2000.
534. Clinical Use of COX-2 Inhibitors, 109<sup>th</sup> Annual Convention, Utah Pharmaceutical Association, St. George, UT, May 2001.
535. Myths and Facts about Opioids. 109<sup>th</sup> Annual Convention, Utah Pharmaceutical Association, St. George, UT, May 2001 .
536. Pain Management in 2001: The Imperative and the Challenges. Pain Management Update. Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Jamaica NY, June 2001.
537. Arthritis Pain Management Guidelines. Pri-Med Mid West Conference, University of Wisconsin-Madison School of Medicine, Rosemont IL, June 2001.
538. Pharmacological Management of Neuropathic Pain in Primary Care, Nurse Practitioner Symposium, University of Colorado School of Nursing. Keystone CO, July 2001
539. The Societal and JCAHO Mandate for Improved Pain Management. Scripps Memorial Hospital Medicine Grand Rounds, La Jolla CA, August 2001
540. Pain Management following Surgery and Trauma. Central Florida Podiatry Association, Orlando FL, September 2001.
541. *Opioid Pharmacology: Common Myths and Facts.* Pain Grand Rounds. M.D. Anderson Cancer Center and Sand Lake Hospital , Orlando Regional Health Care, Orlando FL, September, 2001.
542. Pain Management: A Mandate for Our Patients. Utah Nurses Association Annual Convention, Salt Lake City UT, September 2001.
543. New and Emerging Agents in Pain Management. Academy of Managed Care Pharmacy, Dallas TX, October, 2001.
544. Opioid Analgesics for Arthritic Pain. Symposium on Pain in Chronic Rheumatoid Disease. American College of Rheumatology Annual Meeting, San Francisco CA, November 2001.
545. The American Pain Society Arthritis Pain Management Guidelines. 36<sup>th</sup> Midyear Clinical Meeting, American Society of Health-System Pharmacists, New Orleans LA, December, 2001.
546. Evidence-Based Symptom Management in End-of-Life Care. Pain and Palliative Care Grand Rounds, University of Utah Health Sciences Center, Salt Lake City UT, January 2002.
547. Characterization and Management of Neuropathic Pain in Renal Disease. American Nephrology Nurses' Association Management/Advanced Practice Seminar, San Diego CA, January 2002.
548. Pain Management Procedures, Politics and Perceptions. American Society of Pain Management Nurses 2002 Annual Meeting, Salt Lake City UT, March 2002.
549. Safe and Legal Prescribing of Opioids. Oregon Pain Society 3<sup>rd</sup> Annual meeting. Eugene OR, April, 2002
550. Managing Acute and Chronic Pain. OSF St Francis Medical Center Pain Forum, Peoria IL, May, 2002
551. Evidence-Based Symptom Control. Indian Health Service Palliative Care Program, Albuquerque NM, May 2002.
552. Evidence-Based Medicine: NSAIDs in the management of Pain. McGill University and Université de Montréal, Montreal, Canada, May, 2002.

-continued-

INVITED PRESENTATIONS (continued)

553. Identifying and Managing Neuropathic Pain. *Medical Grand Rounds, Rosemont-Maisonneuve Hospital, Montreal, Quebec, Canada, May 2002.*
554. Clinical Practice Guideline for Arthritis Pain Management. *Laurentian Rheumatology Conference, Mont Tremblant, Quebec, Canada, May 2002.*
555. American Pain Society Guideline for Osteoarthritis, Rheumatoid Arthritis and Juvenile Chronic Arthritis Pain Management. *Canadian Pain Society 2002 Annual Conference, Winnipeg, Manitoba Canada, May 2002.*
556. Neuropathic Pain Management. *Kaiser- Permanente Medical Conference, Woodland Hills CA, May 2002.*
557. Differentiating and Managing Chronic Myofascial and Neuropathic Pain. *Indian Health Service, USPHS, Physician Assistant, Nurse Practitioner, and Pharmacist Annual Continuing Education Programs, Scottsdale AZ, June 2002.*
558. Principles of Pain Management. *Arizona Society of Health-System Pharmacists and Arizona Pharmacy Association, 2<sup>nd</sup> Annual Joint Meeting, Litchfield Park AZ, June 2002.*
559. Management of neuropathic Pain in the Primary Care Setting. *Nurse Practitioner Symposium, University of Colorado Health Sciences Center, Keystone CO, July 2002.*
560. COX-2 Selective NSAIDs: New therapeutic Options. *AmerisourceBergen Annual Meeting, Las Vegas NV, July 2002.*
561. Evidence-based Pain Management Guidelines. *Grand Rounds, Wyoming Medical Center, Casper WY, September 2002.*
561. COX-2 Selective NSAID Analgesia in Inflammatory Pain. *Pharmacy Conference, University of Ottawa Health System, Ottawa, Ontario, Canada, September 2002.*
562. Arthritis Pain Guideline. *Internal Medicine Grand Rounds, University of Utah Hospitals and Clinics, Salt Lake City UT September 2002.*
563. Evidence-based Guidelines for the Management of Arthritis Pain. *Rheumatology Rounds, Medical University of South Carolina, Charleston, SC, October 2002*
564. COX-2 Selective NSAID Therapy for Arthritis Pain. *Academy of Managed Care Pharmacy Annual Meeting, Washington DC, October 2002.*
565. Transdisciplinary End-of-Life Care. *Arizona Hospice and Palliative Care Organization Annual Meeting, Sun City AZ, October 2002.*
566. New Perspectives in Pain Management: An Expert Summit conference. *Las Vegas NV, Oct, 2002*
567. Symptom Management in Osteoarthritis. *Weber County Pharmaceutical Association, Ogden UT, October, 2002.*
568. Opioids in Arthritis: Safe and Effective? *American College of Rheumatology Annual Meeting, New Orleans, LA, Oct 2002.*
569. Legal and Ethical Opioid Use. *Utah Pharmaceutical Association, Midyear Meeting, Salt Lake City UT, Nov 2002.*
570. *Pharmacological management of pain. University of Utah School of Medicine and Utah Academy of Family Physicians Family Practice Primary Care Update, Salt Lake City UT, March 2003.*
571. Management of cancer pain. *Frontiers in Wyoming Medicine, Wyoming Medical Center, Jackson WY, March 2003*
572. *Evidence-based guidelines for arthritis pain management. University of Texas Southwestern Medical Center Rheumatology Grand Rounds, Dallas TX, April 2003.*
573. Acute pain management in adults. *Scott and White Health System Pharmacotherapy Conference, Temple TX, April 2003.*
574. Neuropathic pain management. *Physical Medicine and Rehabilitation Grand Rounds, Ottawa General Hospital, Ottawa, Ontario, Canada, May 2003.*
575. Chronic nonmalignant pain management in the elderly, *Canadian Geriatrics Society Annual Meeting, Ottawa, Ontario, Canada, May 2003.*
575. Chronic pain management in office practice, *St. Joseph's Hospital, Bellingham WA, June 2003.*
576. Methadone therapy: pros, cons and conversions. *Pain Management Symposium, Providence-Everett Medical Center, Everett WA, June 2003*
577. Pain in arthritic conditions – Do COX-2 inhibitors provide added value? *The Interurban Pain Association of Ontario, London Ontario, Canada, October 2003.*
578. Evidence-based management of pain in arthritis. *Medical Grand Rounds. St. Joseph's Hospital, Hamilton, Ontario, Canada, October 2003*
579. New trends in pain management. *McMaster University Rheumatology Grand Rounds, Hamilton, Ontario, Canada, October, 2003.*
580. Evidence-based management of chronic nonmalignant pain in the elderly. *Physiatry Rounds, McMaster University, Hamilton, Ontario, Canada, October 2003.*
581. Advances in cancer pain management. *London Regional Cancer Center, London, Ontario, Canada, October 2003.*
582. Opioid analgesia. *Grand Rounds, West Palm Beach Veterans Affairs Medical Center, West Palm Beach FL, March 2004.*
583. Risk management: balancing clinician, regulatory and patient care issues, *Advances in managing opioid analgesic therapy, Academy of Managed Care 16<sup>th</sup> Annual Meeting, San Francisco CA, April 2004.*

INVITED PRESENTATIONS (continued)

584. The incredible impact of pain on our health and mental health systems. Generations Conference, Salt Lake City UT, April 2004.
585. Evidence-based medicine: managing pain in arthritis patients. Division of Rheumatology, University of Alabama at Birmingham, Birmingham AL, April 2004.
586. Acute pain management: Nursing considerations. Nursing grand rounds, Scripps Green Clinic, La Jolla, CA, May 2004.
587. Acute Pain Management, Grand Rounds, Scripps Green Clinic, La Jolla CA, May 2004
588. Management of Inflammatory Pain. MedCenter One Grand Rounds, Bismarck ND, May, 2004.
589. New Evidence in the Management of Pain. Grand Rounds, West River Valley Regional Medical Center, Hettinger ND, May 2004.
590. Management of Chronic headaches. USPHS Indian Health Service Continuing Education Seminar, Scottsdale AZ, June 2004.
591. Pharmacotherapy for Chronic Nonmalignant Pain. 4<sup>th</sup> Annual Joint Meeting of the Arizona Society of Health-system Pharmacists and Arizona Pharmacy Association, Phoenix AZ, June 2004.
592. Opioids in Osteoarthritis: An Evidence-Based Analysis. International Congress of EULAR-European Congress on Rheumatology, Berlin, Germany, June 2004.
593. Managing Moderate to Severe Pain. Grand Rounds, St. Luke's Hospital, Duluth MN, July 2004.
594. Nontraditional and Adjunctive Analgesics. 2<sup>nd</sup> Annual Comprehensive Pain Board Review Symposium, University of Wisconsin Medical School, Madison WI, July 2004.
595. Evidence-Based Pain Management. Grand Rounds. Community Hospital, Grand Junction CO, August, 2004.
596. Advances in Pain Management: What the Studies Tell Us. Grand Rounds. Memorial Hospital, Montrose CO, August 2004.
597. Optimal Patient Satisfaction. Pain Management Conference. Creighton University Medical Center. Omaha NE, October 2004.
598. Managing Pain in Primary Care. Offutt Air Force Base, Omaha NE, October 2004.
599. Differentiating and Management Nociceptive and Neuropathic Pain Syndromes. New England Pain Association. Manchester NH, October 2004.
600. Monitoring and Managing Opioid Therapy. Warm Springs Health and Wellness Center, Indian Health Service, Warm Springs OR, November 2004.

Record of Testimony by Arthur G. Lipman

2004	McCallister et al v. Purdue Pharma et al. WV District Court expert witness for the defense	deposition
December 2004 January 27, 2005 September 21, 2005	Clifford Guzowski v. Stevens et al. followup telephonic deposition Wisconsin Superior Court, Ia Crosse WI expert witness for the defense	deposition  trial
2005	Joan & Brooks White v. Mayo Clinic Scottsdale et al. AZ Superior Court expert witness for the defense	deposition
September 19, 2005	Daniel B. Timmons v. The Purdue Pharma Co. et al U.S. District Court, Middle District of Florida, Tampa Division expert witness for the defense	deposition
October 31, 2005	Robert Weiss v. F. Craig Hazen et al Second Judicial District Court, Weber County, Utah expert witness for the defense	deposition
December 1, 2005	Denise Rodriguez v. Golden West Medical Center et al Superior Court of the State of Arizona expert witness deposition for the defense	deposition
October 31, 2006	DeRossett v. Bridgeman et al. Anderson County, So. Carolina Court of Common Pleas Expert witness for the plaintiff	deposition
December 21, 2006	Head v. Fayette Community Hospital et al State Court of Fayette County GA expert witness for the defense	deposition

... .. ) ... .. ) ... ..

## CURRICULUM VITAE

### STEPHEN P. LORDON, M.D.

Home  
1582 Orchard Drive  
Salt Lake City, UTAH  
84106

Office  
Summit Pain Management  
5250 South 320 West  
Atrium Bldg Suite 305  
Murray, Utah 84107

Home (801) 487-5635  
Fax (801) 463-7172  
Cell (801) 910-1182  
E-mail: [splordon@summitpain.com](mailto:splordon@summitpain.com)

Main 801-262-7246  
Fax 801-262-3696

### EDUCATION


Baccalaureate degree: University of California, Davis  
Major: Biochemistry  
Degree: BS  
Date of Graduation: 1978

Graduate work: University of Washington  
Department of Pharmacology  
One year towards Ph.D.  
1979-1980

Medical School: University of Health Sciences/Chicago  
Medical School  
Degree: MD  
Date of Graduation: June 1984

Residency: Family Practice Internship and one year of  
Residency  
University of California, Irvine  
Memorial Hospital-Long Beach, CA.  
1984-1986

Anesthesiology Residency  
University of Utah Health Sciences Center,  
Salt Lake City  
1986-1989



3/7/07

## **EDUCATION (continued)**

Fellowship: Pain Management, University of Utah  
Health Sciences Center, Salt Lake City  
August 1993 to July 1994

## **PROFESSIONAL EXPERIENCE**

August 1989 to July 1993 Full time Anesthesiologist  
FHP of Utah, Salt Lake City.

Clinical Assistant Professor (Volunteer),  
Department of Anesthesiology, University of Utah.

August 1993 to July 1994 Limited Term Instructor,  
Department of Anesthesiology,  
University of Utah.

August 1994 to March, 2002 Clinical Assistant Professor,  
Department of Anesthesiology,  
University of Utah.

April , 2002 to March 1<sup>st</sup>, 2004 Staff anesthesiologist and pain management  
physician  
St. Mark's Hospital  
Salt Lake City, Utah

April, 2004 to present Summit Pain Management, PC  
Murray, Utah

## **LICENSE AND CERTIFICATION**

State of Utah 86-174739-1205  
June 1986

Certifications Board Certified by The American  
Board of Anesthesiology, 1991.

Board Qualified in Pain  
Management by The American  
Board of Anesthesiology, 1994.

## ADMINISTRATIVE EXPERIENCE

### ADMINISTRATIVE POSITIONS

1991-1993	Vice-Chairman Department of Anesthesiology, FHP of Utah
November 1995 to March 2002	Medical and Program Director, Pain Rehabilitation Program, Pain Management Center, University of Utah.
February 1999 to March 2002	Associate Medical Director, Pain Management Center, University of Utah
February 2000 to August 2000	Associate Medical Director, Salt Lake County, Vistacare of Utah (hospice)

### PROFESSIONAL AND SCIENTIFIC COMMITTEES

September, 1997 to March, 2002	Committee member, University Hospital Cancer Committee
November, 1998 to November 2000	Committee member, Managed Care Task Force, American Pain Society

## MEMBERSHIP IN PROFESSIONAL SOCIETIES

American Medical Association  
Utah Medical Association  
American Society of Anesthesiology  
Utah Society of Anesthesiology  
American Pain Society  
American Academy of Pain Medicine  
American Society of Regional Anesthesia  
International Spinal Injection Society  
North American Neuromodulation Society

## TEACHING RESPONSIBILITIES/ASSIGNMENTS

July 1997 to May 1998: Instructor, School of Medicine "Art of Medicine" course to first and second year medical students. Lectures on pain management.

## COMMUNITY SERVICE

October 1997 to October 1998: volunteer anesthesiologist, Salt Lake City  
Donated Dental Services Clinic, Fourth Street Clinic.

November 2000: advisor on new JCAHO pain standards implementation to Davis  
North Community Medical Center, Layton, Utah.

April 2002 to present. Member of the "Utah Recovery Assistance Program",  
Physician Division, Department of Professional Licensing, State of Utah

July, 2004 to present. Member of the Utah Cancer Society's program "Knock-out  
colon cancer"

## PRESENTATIONS:

"Celiac Plexus Blockade", Department of Anesthesiology Grand Rounds, May 15,  
1996.

"Interdisciplinary Treatment Paradigm: 'Day Treatment'", University Pain  
Management Center Pain Grand Rounds, September 11, 1996.

"Fibromyalgia and Myofascial Pain Syndrome", Department of Anesthesiology  
Grand Rounds, October 16, 1996.

"Impact of Chronic Pain on Acute Post-Surgical Pain Treatment", Department of  
Anesthesiology Grand Rounds, February 19, 1997.

"Interdisciplinary Pain Management" Lakeview Hospital Grand Rounds, April 24,  
1997.

"Introduction to Chronic Pain Management for Primary Care Physicians",  
Department of Family Practice Grand Rounds, University of Utah, February 4, 1998.

"43rd Annual Postgraduate Course in Anesthesiology on Pain" Department of  
Anesthesiology, University of Utah. Moderator. February 20-24th, 1998

"Interdisciplinary Pain Management" Department of Physical Medicine and  
Rehabilitation, Grand Rounds, November 30, 1998

"Opioids in Chronic non-malignant pain" Lakeview Hospital Grand Rounds,  
December 3rd, 1998.

" Opioids in Chronic Non-Cancer Pain" University of Utah, Department of  
Physical Medicine and Rehabilitation, Grand Rounds, March 29, 1999.

## PRESENTATIONS (continued)

"Methodically sound approaches to opioid titration in chronic pain states"  
University of Utah Pain Grand Rounds, April 3, 1999.

"Myofascial Pain Syndrome and Primary Fibromyalgia" Department of Family  
and Preventative Medicine, University of Utah, Grand Rounds, February 23, 2000.

"New medications for the treatment of chronic pain" AORN Utah chapter annual  
meeting, March 11th, 2000

"Management of Chronic Pain with Opioids-medical/legal issues" 30th Annual  
Family Practice Refresher Course, University of Utah Department of Family and  
Preventive Medicine, March 28, 2000

"New developments in the treatment of chronic non-cancer pain" Davis-North  
Hospital grand rounds, Layton, UT August 10th, 2000.

"New medications for the treatment of chronic pain" Veterans Medical Center-  
Salt Lake City. Nurse Practitioner Weekly Grand Rounds, August 17th, 2000.

"Interdisciplinary treatment of chronic pain soft tissue pain disorders" and  
"Interdisciplinary treatment of Fibromyalgia and chronic soft tissue pain disorders".  
Program chairman. September 9th, 2000. University of Utah.

"Advances in the diagnosis and treatment of Myofascial Pain Syndrome".  
Interdisciplinary treatment of Fibromyalgia and chronic soft tissue pain disorders  
conference. September 9th, 2000. University of Utah.

"Practical vs. controversial issues in the treatment of Myofascial Pain Syndrome".  
Interdisciplinary treatment of chronic soft tissue pain disorders conference. September  
9th, 2000. University of Utah.

"New JCAHO standards for pain management/Practical considerations for using  
opioids" October 5th, 2000. Medical staff of St. John's Hospital, Jackson, Wyoming

"New JCAHO standards for pain management/Practical considerations for using  
opioids" October 6th, 2000. Nursing staff of St. John's Hospital, Jackson, Wyoming.

"New developments in the diagnosis and management of Myofascial Pain  
Syndrome" Moderator, American Pain Society, Professional Development Course,  
November 2nd, 2000, Atlanta, Georgia.

## PRESENTATIONS (continued)

"Pathophysiology, electrical stimulation, and Botulinum Toxin in Myofascial Pain Syndrome" in American Pain Society Professional Development Course: New developments in the diagnosis and management of Myofascial Pain Syndrome. November 2nd, 2000, Atlanta, Georgia.

"Opioids and function in the work place" Utah Department of Professional Licensing, monthly board meeting. November 17th, 2000, Salt Lake City, Utah.

"New medications for the treatment of chronic non-cancer pain" Fourth Street Indigent Care Clinic, Salt Lake City, Utah. January 9th, 2001.

"New JCAHO standards for pain management/Practical considerations for using opioids" Utah State Hospital. Provo, Utah February 8th, 2001.

"New Medications for the treatment of chronic non cancer pain" St. Marks Hospital, Family Practice Residency Grand Rounds, February 21th, 2001

"Introduction to Pain Management for Health Care Providers" North Valley Mental Health, Salt Lake City, Utah. February 26th, 2001.

"Cancer pain management outside WHO guidelines" Family Practice Refresher Course, University of Utah Dept of Family and Preventitive Medicine , Salt Lake City, Utah, March 21, 2001.

"New developments in the treatment and diagnosis of Myofascial Pain Syndrome" Family Practice Grand Rounds, University of Utah Department of Family and Preventitive Medicine. April 11, 2001.

"How to identify potential substance abuse patients" Eighth Annual Pharmacology Conference, University of Utah College of Nursing. Salt Lake City, June 2nd, 2001.

"Dispensing Controlled Substances" University of Utah College of Pharmacy Annual Conference, April 13th, 2002

"Rational Opioid Selection for Chronic Pain" University of Utah, Department of Anesthesiology Pain Management Grand Rounds, June 4<sup>th</sup>, 2004.

"I hurt all over" Westminster College, Department of Nursing. Division of Nurse Practitioners, teaching lecture. June 9<sup>th</sup>, 2004

## RESEARCH AWARDS

Morphine with Dextromethorphan: Conversion from other opioid analgesics.  
Algos Pharmaceutical Corporation, December 1997.

A usual use, open label, randomized, 3 month cohort, outcomes study in persistent back pain comparing Oxycontin q12 hours (controlled-release oxycodone) vs hydrocodone/apap q 4-6hours prn. Purdue Pharma. January, 1999.

Open-label Dose-titration Study of Subcutaneous Sufentanil for the Treatment of Chronic Pain. Durect Corporation February, 1999.

A randomized, double blind, parallel groups study of Morphelan (morphine sulfate oral extended release capsules) in patients with chronic, moderate to severe pain. Targon Corporation, August 1999.

An open-label, randomized, crossover study of the pharmacokinetics and safety of piroxicam administered to healthy human volunteers as a solid matrix dosage unit, a solid matrix dosage unit dissolved in water, or in capsule form. Anesta Corporation, November, 1999

Open label controlled trial of lidoderm patches to control myofascial pain. Endo Pharmaceuticals. 2000

Open label controlled trial of Matrix fentanyl patch to control knee osteoarthritis. ZARS Pharmaceuticals, 2004.

## EDITORIAL EXPERIENCE

Guest editor for pain related articles in Biomechanics Magazine.

Guest editor for Journal of Pharmaceutical Care in Pain and Symptom Control

Guest editor for Journal of Musculoskeletal Pain

## BIBLIOGRAPHY

Lordon S, Ashburn M: Acute pain service experience with patient controlled analgesia and intraspinal opioids for postoperative pain management. Journal of Pharmaceutical Care in Pain and Symptom Control Vol 3 (1), 1995.

Lordon S, Stanley T: Book Chapter "The Future of Intravenous Anesthesia" in: INTRAVENOUS ANESTHESIA, Paul White, M.D., Ph.D., (ed), Williams and Wilkins, 1996

## BIBLIOGRAPHY (continued)

Lordon S, Fine P. "Myofascial Pain Syndrome", Biomechanics Magazine, May 1998.

Lordon, S., book review of "The Pain Management Handbook-A Concise Guide to Diagnosis and Treatment". M.Eric Gershwin, Maurice E. Hamilton, editors. Humana Press, 1998. In "Clinical Journal of Pain"-September, 1998.

Lordon, S., book review of "The Neuroscience and Endocrinology of Fibromyalgia" by Stanley R Pillemer, MD. Hawthorn Medical Press. Journal of Pharmaceutical care in pain and symptom control, Haworth Medical Press, February, 2000.

Lordon, S. book review of "Myofascial pain and dysfunction: The trigger point manual" by Simons, Travell, and Simons. Baltimore, Williams, and Wilkins, 1999. In "Journal of Musculoskeletal Pain". Vol 8, No 4, 2000.

Lordon S, Cope D, Fine P book chapter "Invasive Pharmacologic and Non-Pharmacologic Modalities" in "Persistent pain in older adults: an interdisciplinary guide fro treatment". Weiner, Herr, Rudy eds. Springer Publishing, 2002.

Lordon, S. "Interventional Approach to Cancer Pain" for Current Headache and Pain Reports, Current Science, 2002.

Lipman A, Lordon S, Dalpiaz, A " Topical lidocaine patches for the treatment of myofascial pain syndrome-report of 26 case studies" poster presentation at American Pain Society annual meeting, Baltimore, March, 2002.

*[Faint, illegible handwriting at the top of the page]*

*[Faint, illegible handwriting at the top of the page]*



THE GEC GROUP

**NAME:** Cornelius A. Hofman

**EXPERTISE:** Economics and Finance

**EDUCATION:** University of Chicago  
*MBA, Economics and Finance*  
Chicago, IL  
1994

University of Pennsylvania  
*MA, Japanese Studies*  
Philadelphia, PA  
1992

Cornell University  
*BA, Asian Studies, Magna Cum Laude*  
Ithaca, NY  
1991


**THE GEC GROUP**  
SELECTED EXPERIENCE:

**Valuation Services**

*Business Valuation - Breach of Contract Litigation:* Calculated the fair market value of the division of a shipping logistics company in order to determine a bonus alleged to be owed to a broker stemming from the successful divestiture of the business.

*Business Valuation - Marital Dissolution:* Assessed the value of two service companies primarily engaged in insulation installation and asbestos removal.

*Business Valuation - Gift Tax Assessment:* Determined the fair market value of a large construction equipment part manufacturer.



**THE GEC GROUP**  
SELECTED EXPERIENCE:  
(continued)

*Business Valuation - Personal Injury Litigation:* Valued a furniture manufacturing and distribution company that failed due to an injury to the owner and key employee of the business.

*Business Valuation - Wrongful Death Litigation:* Valued a minority interest in a civil engineering and consulting firm owned by the survivor of a decedent who was an owner and key employee of the business.

*Business Valuation - Subsidiary Spin-off:* Valued a retail company that sells domestic and industrial fuel oils.

*Business and Stock Option Valuation - Minority Shareholder Buyout:* Performed a business valuation of a national manufacturer and distributor. Assessed the value of minority shareholders' stock options to determine the amount that the majority shareholders would have to pay the minority shareholders for their option to buy stock in the company for a set price at a specified date in the future.

*Preferred Stock Valuation - Gift Tax Assessment:* Calculated the value of an issue of junior preferred stock of a national pet supply company. Through the purchase agreement associated with the divestiture of his company, the seller acquired a preferred equity interest in the same company and then gifted a portion of this preferred interest.

**Economic Damages: Proving or Disproving**

*Causation and Lost Profits - Business Interruption Lawsuit:* Performed a forensic event study analysis showing statistical legitimacy of plaintiff's allegations regarding causation and liability. Determined the level of lost profits associated with the business interruption stemming from damage to and subsequent reconstruction of a portion of plaintiff's property.

*Causation and Lost Profits - Personal Injury Litigation:* Performed a forensic event study analysis and determined the falloff of plaintiff's construction business to be unrelated to the alleged wrongdoing by defendant.

**THE GEC GROUP**  
SELECTED EXPERIENCE:  
(continued)

*Causation and Lost Profits - Product Liability/Contract Dispute:* Evaluated causation by applying business economic theory to predict economic outcomes given defendant's actions. Determined the level of lost profits of a national wholesaler of sports accessories due to an alleged breach of contract. Reconstructed the company's past financial statements and projected future financial performance assuming the alleged breach had not occurred.

*Causation and Lost Profits - Malicious Prosecution:* Evaluated causation and liability by way of a forensic event study analysis. Calculated lost profits due to business interruption and interference stemming from a malicious law suit filed by defendant.

**Economic Damages: Quantifying**

*Lost Asset Value - Securities Litigation:* Performed and analyzed business valuations to determine the fair market value for the common stock interest in a telecommunications company before and after an initial public offering. Traced numerous financial transactions and determined the impact on value. Calculated the value of the preferred equity, a subsidiary's common equity, and the parent's common equity.

*Lost Profits - Insurance Bad Faith Lawsuit:* Performed a business valuation and determined the lost profits resulting from alleged delinquent insurance coverage of operating equipment that was damaged in a fire.

*Lost Profits and Business Valuation - Professional Liability/Contract Dispute:* Calculated lost profits of a snack food export company associated with the alleged wrongful packaging, handling and shipping of plaintiff's product.

*Lost Profits - Crop Loss Litigation:* Analyzed the productivity and profitability of plaintiff's farming operation. Calculated lost profits to be associated with allegations of lender liability.

**THE GEC GROUP**  
SELECTED EXPERIENCE:  
(continued)

*Lost Profits - Breach of Contract Litigation:* Calculated lost profits of seven concept shoe retail stores stemming from inventory shortages due to the alleged breach of contract by the shoe manufacturer/supplier.

**Wage Loss Litigation**

*International Wrongful Death Lawsuit:* Calculated the economic loss associated with the death of 27 passengers killed in a plane crash in Indonesia. Passengers were from Indonesia, Germany, Italy, Great Britain and the United States. Conducted labor market research and determined the economic loss associated with the death of each decedent based on the economic and financial factors, statistics, and conditions of his or her country.

*International Wrongful Death Lawsuit:* Calculated the economic loss associated with the death of a Japanese executive of an international company who was killed in a plane crash in the United States. Determined the economic loss based on Japanese economic and financial factors, statistics, and conditions, including: vital statistics, wage structure, government bond data, individual consumption patterns, fringe benefits, worklife expectancy, etc.

*Wrongful Death Lawsuit:* Valued the economic loss associated with the death of a nurse who was killed in a plane crash. Calculated lost earnings, fringe benefits and household services.

*Personal Injury Lawsuit:* Determined the economic loss to 11 factory workers who were injured from a chemical leak at a factory.

*Personal Injury Lawsuit:* Calculated the economic loss to a truck driver who was injured in an automobile crash.

*Medical Malpractice Lawsuit:* Determined the economic loss to a construction worker associated with alleged medical malpractice.

**THE GEC GROUP**  
SELECTED EXPERIENCE:  
(continued)

*Age Discrimination Lawsuit:* Calculated the lost wages and fringe benefits associated with the employment termination of four elderly workers.

*Gender Discrimination Lawsuit:* Calculated the lost wages and fringe benefits associated with the employment termination of three female workers.

*Breach of Contract Lawsuit:* Calculated the lost wages and fringe benefits associated with the alleged breach of an employment contract between a teacher and a school district.

**PROFESSIONAL  
ASSOCIATIONS:**

American Economics Association

Western Economic Association

Midwest Economics Association

Illinois Economics Association

National Association of Forensic Economics

National Association for Business Economists

National Social Science Association

International Atlantic Economic Society

**SERVICE  
ACTIVITIES:**

Director of Litigation Case Studies  
*Stanford Journal of Law, Business & Finance*  
1994 to 2000

Conference Discussant, "Issues in Forensic Economics"  
National Association of Forensic Economics/Midwest  
Economics Association  
1995

**SERVICE  
ACTIVITIES:**  
(continued)

Conference Discussant, "Forecasting Wages"  
National Social Science Association  
1995

Conference Discussant, "Firm and Organizational Behavior"  
Western Economic Association  
1996

Conference Chairperson, "Macroeconomic Theory"  
International Atlantic Economic Society  
1997

Conference Chairperson, "Career Development and Labor-  
Management Relations"  
International Atlantic Economic Society  
1998

Conference Discussant, "Topics in Labor: Employment  
Discrimination Against Disabled Workers"  
Midwest Economics Association  
2000

Conference Chairperson, "Productivity"  
Midwest Economics Association  
2000

Conference Discussant, "Economics of Immigration"  
Illinois Economics Association  
2005

Conference Chairperson, "Current Economic Conditions"  
Illinois Economics Association  
2005

**PUBLICATIONS /  
PRESENTATIONS:**

with Cornelius A. Hofman and Gary R. Wells, "The Impact of  
Education on the Value of Human Capital" *Social Science  
Perspectives Journal* April, 1994.

**PUBLICATIONS /  
PRESENTATIONS:**  
(continued)

“Risk Free Rates” in *Litigation Services Handbook*, 2nd edition,  
edited by Roman L. Weil, Michael J. Wagner, and Peter B.  
Frank (New York: John Wiley & Sons, 1995).

“Treasury Yields, Maturity Premiums and Inflation: Valuing  
Future Cash Flows” *Social Science Perspectives Journal* April,  
1995.

with Charles M. Linke, “Estimating Personal Consumption: A  
Regression Analysis of BLS Consumer Expenditure Data”  
Western Economic Association Annual Convention in San  
Francisco, CA (1996).

with Cornelius A. Hofman, “The Variation in Effective Tax  
Rates Across Household Income and Household Size”  
American Economic Association Annual Convention in New  
Orleans, LA (1997).

“Interest Rates on Government Bonds of Different  
Denominations” Western Economic Association Annual  
Convention in Seattle, WA (1997).

“Volume Discounted Yield Curves” *The Valuation Examiner*  
June/July 1997.

“Measuring Beta and Risk Premium in CAPM: Selecting a  
Financial Market” International Atlantic Economic Conference  
in Philadelphia, PA (1997).

“Market Portfolio Selection when Using the Capital Asset  
Pricing Model: A Summary” *International Advances in  
Economic Research* Vol 4, No. 2 (May 1998).

“Risk Adjusted Cost of Capital in a Non-Diversified Portfolio:  
Quantifying the Key Person Risk Premium” International  
Atlantic Economic Conference in Boston, MA (1998).

“Forensic Economics” Fall Conference of the American Board  
of Vocational Experts in Chicago, IL (1998).

**PUBLICATIONS /  
PRESENTATIONS:**  
(continued)

“Interpreting Fluctuations in Worker Populations Across Age and Occupation” Midwest Economics Association Conference in Chicago, IL (2000).

“Economic Analysis: Causation and Economic Damages” Difficult Issues for Business Lawyers - Business & Corporate Law Section of the Idaho State Bar Association in Boise, ID (2002).

with Cache Miller and Craig Clarke, “Interstate Earnings: An Analysis of Earnings from Idaho to Illinois” Illinois Economics Association Annual Meeting in Chicago, IL (2005).

with Cache Miller and Craig Clarke, “Productivity and Expected Yields: A Look at the Midwest Farmer.” Illinois Economics Association Annual Meeting in Chicago, IL (2005).

**LECTURES:**

“Calculating Economic Loss in the Legal Context: A Comparison Between Japan and the United States” University of Chicago Graduate School of Business. Chicago, IL

“Tort Law and the Recoverability of Economic Damages” University of Notre Dame Law School South Bend, IN

“Forensic Economics: The Role of the Economic Expert” University of San Diego School of Law San Diego, CA

“The Present Value of Projected Economic Losses: What Attorneys Should Know About Growing and Discounting” Arizona State University Law School Tempe, AZ

“Valuing Household Services” University of Utah College of Social and Behavioral Sciences Salt Lake City, UT

**LECTURES:**  
(continued)

*Contemporary Issues in Labor Economics*  
Idaho State University Department of Economics  
Pocatello, ID

“Applied Economics”  
Ricks College Department of Economics  
Rexburg, ID

*Principles in Economics*  
Idaho State University Department of Economics  
Pocatello, ID

“Feasibility Analysis: A Multidiscipline Process”  
Gigot Center for Entrepreneurial Studies  
Notre Dame College of Business Administration  
South Bend, IN

“Contract Valuation Analysis”  
Idaho State University, Economics Club  
Pocatello, ID

“Entrepreneurial Management: Growing a Multigenerational  
Family Business”  
Yale University, Yale Entrepreneurial Society  
New Haven, CT

“Expanding a Company Through a Small Business Initial Public  
Offering”  
Cornell University, Cornell Entrepreneur Organization  
Ithaca, NY

*Econometrics*  
Idaho State University Department of Economics  
Pocatello, ID

*Game Theory*  
Idaho State University Department of Economics  
Pocatello, ID

**LECTURES:**  
(continued)

*Economic Issues*  
Idaho State University Department of Economics  
Pocatello, ID

“Human Capital: Education, Wage Growth, Unemployment and Earnings”  
Roosevelt University Department of Economics  
Chicago, IL

**EMPLOYMENT:**

The GEC Group, Inc.  
*President*  
1995 to present

Provide a broad range of valuation and small business consulting services to businesses, governments, law firms, investment groups, and individuals in the context of mergers, expansions, acquisitions, divestitures, and litigation. Render expert testimony regarding economic damages and valuation issues. Valuation analyses include: lost wage analyses, business valuations, preferred stock valuations, lost profit calculations, economic impact studies. Litigation engagements include: breach of contract, crop damage, malicious prosecution, securities, professional liability, insurance bad faith, business interruption, patent infringement, antitrust, franchise disputes, personal injury, wrongful death, wrongful discharge, discrimination, medical malpractice, divorce.

Crowe, Chizek & Company  
*Economist, Special Projects Group*  
1993 – 1995

Engaged in a wide variety of projects that require an advanced, working knowledge in economics, finance, accounting, and statistics. Provided consulting services relating to business valuations, mergers and acquisitions, company divestitures, economic damage disputes, stock option valuations, preferred stock valuations. Rendered expert testimony in the context of personal injury and wrongful death litigation.

CURRICULUM VITAE  
Cornelius A. Hofman  
Page 11 of 11

**EMPLOYMENT:**  
(continued)

General Economic Consulting Company (GEC)  
*Analyst*  
1991 – 1993

Performed economic research and developed electronic economic models.

**HONORS AND  
AWARDS:**

Graduated *Magna Cum Laude*  
Cornell University

Cornell Tradition Award  
Cornell University

Foreign Language and Area Studies Award  
University of Pennsylvania



THE GEC GROUP

FEE SCHEDULE

Description	Cost
Retainer fee	Case specific
Hourly fees	Economist - Expert.....\$380
	Economist - Research.....\$200
	Senior Consultant.....\$160
	Consultant.....\$120
	Database/Software Analyst.....\$110
	Senior Analyst.....\$90
	Analyst.....\$60
	Research Assistant.....\$50
Office Assistant.....\$40	
Out-of-pocket costs	At cost

Fees and out-of-pocket costs will be billed every month during the periods of activity on your behalf. Invoices are payable upon presentation and any payment not received within 30 days of the invoice date will be billed monthly with interest compounded at 1.5% per month. In addition, you will be responsible for all attorney fees, court costs, and any other charges associated with the collection of any past due balance.

Rates and fees are subject to change at any time.



THE GEC GROUP

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2003	David E. Comstock Comstock & Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Ashcraft, et al. v. Great Western Chemical</i>	CV PI 00 00536D	District Court, Ada County, Idaho	Boise, ID	Deposition
2003	Richard H. Greener and Jon T. Simmons Cosho, Humphrey, Greener & Welsh 815 West Washington Street Boise, ID 83702	<i>Bank of America v. Hal Mcnee</i>	02 2 21116 0 SEA	Superior Court, King County, Washington	Seattle, WA	Deposition
2003	Joseph A. Bosco LaRose & Bosco 734 N. Wells Street Chicago, IL 60610	<i>Battle v. WLI Industries</i>	00 L 008455	Circuit Court, Cook County, Illinois	Chicago, IL	Deposition
2003	Timothy J. Helfrich 89 SW Third Avenue PO Box S Ontario, OR 97914	<i>Bedortha v. Commercial Tire</i>	CV PI 01 00536D	District Court, Ada County, Idaho	Boise, ID	Trial
2003	John T. Lezamiz Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Benson v. Magic Valley Partners</i>	CV 02 3541	District Court, Twin Falls County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167  
Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2003	Michael R. Mahony Attorney at Law PO Box 220 280 A Street East Vale, OR 97918	<i>Bruce v. State of Idaho</i>	CV OC 0207209D	District Court, Ada County, Idaho	Boise, ID	Trial
2003	Loretto M. Kennedy Holland & Knight 131 S. Dearborn, 30th Floor Chicago, IL 60603	<i>Coyle v. Sundstrand</i>	98 L 11157	Circuit Court, Cook County, Illinois	Chicago, IL	Deposition
2003	Rebecca A. Broadbent Finch & Broadbent 103 W. Idaho Boise, ID 83702	<i>Degen v. White</i>	CV-00-00739	District Court, Gooding County, Idaho	Gooding, ID	Trial
2003	T. Guy Hallam Jr. White Peterson Canyon Park at the Idaho Center 5700 E. Franklin Road, Suite 200 Nampa, ID 83687	<i>Engine Protector v. Energy Release</i>	CV OC 0203300D	District Court, Ada County, Idaho	Nampa, ID	Deposition
2003	T. Guy Hallam Jr. White Peterson Canyon Park at the Idaho Center 5700 E. Franklin Road, Suite 200 Nampa, ID 83687	<i>Engine Protector v. Energy Release</i>	CV OC 0203300D	District Court, Ada County, Idaho	Boise, ID	Trial
2003	James L. Farina Hoey, Farina & Downes 542 South Dearborn, Suite 1010 Chicago, IL 60605	<i>Greenwood v. Eastern Joliet &amp; Elgin Railroad</i>		Federal Court, Indiana	Hammond, IN	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

108

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2003	James L. Farina Hoey, Farina & Downes 542 South Dearborn, Suite 1010 Chicago, IL 60605	<i>Greenwood v. Eastern Joliet &amp; Elgin Railroad</i>		Federal Court, Indiana	Hammond, IN	Trial
2003	Shelby H. Kanarish Harvey L. Walner & Associates 123 North Wacker Drive, Suite 880 Chicago, IL 60606	<i>Hinchley v. Central DuPage Hospital</i>	01 L 00517	Circuit Court, DuPage County, Illinois	Chicago, IL	Deposition
2003	David E. Comstock Comstock & Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Hofman v. Goldsberry</i>	CV PI 02 00021A	District Court, Bannock County, Idaho	Boise, ID	Deposition
2003	Ronald L. Lipinski Seyfarth Shaw 55 E. Monroe Street, Suite 4200 Chicago, IL 60603	<i>Miroballi Shoe v. Nine West</i>	02 C 1388	Federal Court, Illinois	Chicago, IL	Deposition
2003	David E. Comstock Comstock & Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Morton v. Sinclair</i>	CV 02 3074	District Court, Twin Falls County, Idaho	Boise, ID	Deposition
2003	John T. Lezamiz Hepworth, Lezamiz & Jaris 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Paulson v. Pioneer Club</i>	CV 02 1662	District Court, Twin Falls County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2003	Raymond D. Powers Hall, Farley, Oberrecht & Blanton 702 West Idaho, Suite 700 PO Box 1271 Boise, ID 83701	<i>Smith v. West Valley Medical Center, et al.</i>	CV2000 9638	District Court, Canyon County, Idaho	Boise, ID	Deposition
2003	Tom Loucks Childress & Zdeb 515 N. State Street, Suite 2200 Chicago, IL 60610	<i>Srejec v. Russo</i>	00 L 12123	Circuit Court, Cook County, Illinois	Chicago, IL	Deposition
2003	Timothy S. Harris Quarles & Brady 500 West Madison Street, Suite 3700 Chicago, IL 60661	<i>Taag v. Roper Whitney</i>	99 C 50032	Federal Court, Illinois	Chicago, IL	Deposition
2003	Loretto M. Kennedy Holland & Knight 131 S. Dearborn, 30th Floor Chicago, IL 60603	<i>Wilson, et al. v. Sundstrand</i>	99 C 6946 consolidated into 99 C 6944	Federal Court, Illinois	Chicago, IL	Deposition
2004	John A. Bush Comstock and Bush 199 North Capitol Blvd., Suite 500 PO Box 2774 Boise, ID 83701	<i>Barton v. R.C. Willey</i>	02 0544 S LMB	Federal Court, Idaho	Boise, ID	Deposition
2004	Sam Johnson Johnson & Monteleone 405 South Eighth Street, Suite 250 Boise, ID 83702	<i>Callow v. Riveriew Marina</i>	03 129 S BLW	Federal Court, Idaho	Boise, ID	Trial

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2004	Michael R. McBride Signature Law Group 1495 East 17 <sup>th</sup> Street Idaho Falls, ID 83404	<i>Crane v. Columbia Eastern Idaho Regional Medical Center, et al.</i>	CV 00 4741	District Court, Bonneville County, Idaho	Boise, ID	Deposition
2004	James M. Urtis Law Office of James M. Urtis 20 N Clark Street, Suite 2550 Chicago, IL 60602	<i>Hayes v. Luken</i>			Chicago, IL	Deposition
2004	Benjamin J. Cluff Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Henstock v. Faulkner Land &amp; Livestock Co., et al.</i>	CV 03 00279	District Court, Gooding County, Idaho	Boise, ID	Deposition
2004	Benjamin J. Cluff Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Henstock v. Faulkner Land &amp; Livestock Co., et al.</i>	CV 03 00279	District Court, Gooding County, Idaho	Gooding, ID	Trial
2004	David E. Comstock Comstock and Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Hofman v. Goldsberry</i>	CV PI 02 0021A	District Court, Bannock County, Idaho	Pocatello, ID	Trial
2004	James L. Farina Hoey, Farina & Downes 542 South Dearborn, Suite 200 Chicago, IL 60605	<i>Jesus Martinez</i>	00 C 2723	Federal Court, Illinois	Chicago, IL	Trial

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2004	John A. Bush Comstock and Bush 199 North Capitol Blvd., Suite 500 PO Box 2774 Boise, ID 83701	<i>King v. R.C. Willey</i>	02 0544 S LMB	Federal Court, Idaho	Boise, ID	Deposition
2004	David E. Comstock Comstock & Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Klaus v. St. Alphonsus</i>	CV PI 0300335 D	District Court, Ada County, Idaho	Boise, ID	Deposition
2004	Miles J. Zaremski Kaminsky & Rubinstein 7250 N. Cicero Av. Lincolnwood, Illinois 60712	<i>Kochert v. Bochenek</i>	4: 01CV0027AS	Federal Court, Illinois	Boise, ID	Deposition
2004	D. Samuel Johnson Johnson & Monteleone 405 S. 8th Street, Suite 250 Boise, ID 83702	<i>Lemez v. Wal-Mart Stores, Inc.</i>		District Court, Ada County, Idaho	Boise, ID	Deposition
2004	John C. Keenan Goicoechea Law Office 308 - 12th Avenue Road Nampa, ID 83686	<i>Loper v. Hungerford</i>	CV PI 0100514D	District Court, Ada County, Idaho	Boise, ID	Trial
2004	John M. Ohman 510 "D" Street P.O. Box 51600 Idaho Falls, ID 83405-1600	<i>Puccinelli v. AFLAC</i>	CV-02-5209	District Court, Bonneville County, Idaho	Salt Lake City, UT	Arbitration

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167  
 Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2004	John M. Ohman 510 "D" Street P.O. Box 51600 Idaho Falls, ID 83405-1600	<i>Puccinelli v. AFLAC</i>	CV-02-5209	District Court, Bonnevillie County, Idaho	Boise, ID	Deposition
2004	Tim J. Helfrich Yturri Rose 89 SW Third Avenue PO Box 'S' Ontario, OR 97914	<i>Puckett v. Verska</i>	CV PI 0200348D	District Court, Ada County, Idaho	Boise, ID	Trial
2004	Walter H. Bithell Holland and Hart 101 South Capitol Blvd., Suite 1400 P.O. Box 2527 Boise, ID 83701-2527	<i>Rountree v. Freightways, et al.</i>	CV PI 01-00622D	District Court, Ada County, Idaho	Boise, ID	Deposition
2004	Tim J. Helfrich Yturri Rose 89 SW Third Avenue PO Box 'S' Ontario, OR 97914	<i>Schmid v. Morgan</i>	CV PI 01-00492D	District Court, Ada County, Idaho	Boise, ID	Deposition
2004	Steven B. Andersen Holland and Hart 101 South Capitol Blvd., Suite 1400 P.O. Box 2527 Boise, ID 83701-2527	<i>Smith v. Minnehan, et al.</i>	CV OC 02091520	District Court, Ada County, Idaho	Boise, ID	Trial

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2004	Steven B. Andersen Holland and Hart 101 South Capitol Blvd., Suite 1400 P.O. Box 2527 Boise, ID 83701-2527	<i>Smith v. Minnehan, et al.</i>	CV OC 02091520	District Court, Ada County, Idaho	Boise, ID	Trial
2004	Walter H. Bithell Holland and Hart 101 South Capitol Blvd., Suite 1400 P.O. Box 2527 Boise, ID 83701-2527	<i>Stanger v. CRST International</i>	CIV PI 02-1	District Court, Jerome County, Idaho	Jerome, ID	Trial
2004	Guy Delson Geleerd, Jr. Coughlin & Geleerd 30 North LaSalle Street, Suite 3400 Chicago, IL 60602	<i>Stein v. Rosenberg</i>	00 L 10718		Chicago, IL	Deposition
2004	Christopher C. Burke 815 West Washington Street Boise, ID 83702	<i>Vuittonet v. Hayes Lemmerz International, et al.</i>	CV PI 0100323D	District Court, Ada County, Idaho	Boise, ID	Deposition
2005	John T. Lezamiz Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303-0389	<i>Batcha v. Cheney, et al.</i>			Twin Falls, ID	Trial
2005	James T. Farnan Guth, Reinke & Farnan 161 North Clark, Suite 2900 Chicago, IL 60601 Fax: 312-855-0629	<i>Carr v. St. Francis Hospital</i>			Chicago, IL	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2005	James W. Ford Brenner, Ford, Monroe & Scott 33 North Dearborn St, Suite 300 Chicago, IL 60602-3102	<i>Coburn v. The Salvation Army</i>	03 L 224	Circuit Court, Lake County, Illinois	Chicago, IL	Deposition
2005	Brian J. Cheney Dial, May & Rammell 216 W Whitman PO Box 370 Pocatello, ID 83204-0370	<i>Emerson v. Hartford</i>			Pocatello, ID	Arbitration
2005	John R. Kormanik White Peterson 5700 E. Franklin Rd., Suite 200 Nampa, ID 83687-7901	<i>Goff v. Washington County</i>		Federal Court, Idaho	Boise, ID	Trial
2005	James M. Urtis Law Office of James M. Urtis 20 North Clark St., Suite 2550 Chicago, IL 60602	<i>Hayes v. Luken</i>			Chicago, IL	Trial
2005	John R. Kormanik White Peterson 5700 E. Franklin Rd., Suite 200 Nampa, ID 83687-7901	<i>Henrickson v. St. Alphonsus Regional Medical Center</i>	CV OC 0304896D	District Court, Ada County, Idaho	Boise, ID	Trial
2005	Donald W. Lojek 199 W Main PO Box 1712 Boise, ID 83701	<i>Keeney v. Kent</i>	CV PI 0400143D	District Court, Ada County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2005	Steven B. Andersen Holland & Hart 101 S Capitol Blvd., Suite 1400 PO Box 2527 Boise, ID 83702	<i>Mallory v. Smith</i>	CV OC 0003575 D	District Court, Ada County, Idaho	Boise, ID	Deposition
2005	John T. Lezamiz Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303-0389	<i>Martin and Shorts v. Grant</i>	CV 04 1007	District Court, Blaine County, Idaho	Twin Falls, ID	Deposition
2005	Tim J. Helfrich Yturri Rose 89 SW Third Avenue PO Box 'S' Ontario, OR 97914	<i>Puckett v. Verska</i>	CV PI 0200348D	District Court, Ada County, Idaho	Boise, ID	Trial
2005	Paul C. EchoHawk Nathan R. Long EchoHawk Law Offices 151 N 4 <sup>th</sup> Ave., Suite A PO Box 6119 Pocatello, ID 83205-6119	<i>Scissons v. United States of America, et al.</i>	CV 03-531-S-EJL	Federal Court, Idaho	Boise, ID	Deposition
2005	David E. Comstock 199 N Capitol Blvd., Suite 500 PO Box 2774 Boise, ID 83701	<i>Steed v. Walmart</i>	2:03CV00814 DB	Federal Court, Utah	Salt Lake City, UT	Trial

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2005	Guy D. Geleerd Coughlin & Geleerd 30 N LaSalle St, Suite 3400 Chicago, IL 60602	<i>Stein v. Rosenberg</i>	00 L 10718		Chicago, IL	Deposition
2005	Donald W. Lojek Lojek Law Offices 1199 W. Main PO Box 1712 Boise, ID 83701	<i>Storm v. RJT Farming, Inc.</i>	CV 2004-0001188	District Court, Minidoka County, Idaho	Boise, ID	Deposition
2005	John R. Kormanik White Peterson 5700 E. Franklin Rd., Suite 200 Nampa, ID 83687-7901	<i>Ward v. Sorrento Lactalis, Inc.</i>	CIV 04-006-S- BLW	Federal Court, Idaho	Boise, ID	Trial
2006	Tomas Petkus Tobin Petkus & Munoz Three First National Plaza, Suite 1950 Chicago, IL 60602	<i>Alexander v. Four Points Sheraton, et al.</i>	05 L 6854	Circuit Court of Illinois, Cook County	Chicago, IL	Deposition
2006	Jon T. Simmons Greener Banducci Shoemaker The Banner Bank building 950 W Barnock Street, Suite 900 Boise, ID 83702	<i>Bredeson v. Gritman Medical Center, Inc.</i>	CV 2003-00581	District Court, Latah County, Idaho	Boise, ID	Deposition
2006	John T. Lezamiz Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Cafferty v. State of Idaho, et al.</i>	CV PI 0400446 D	District Court, Ada County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2006	Yturri Rose Tim Helfrich 89 SW Third Avenue PO Box Box "S" Ontario, Oregon 97914	<i>Cox v. McKay</i>	CV 04-10959	District Court, Canyon County, Idaho	Boise, ID	Deposition
2006	John T. Lezamiz Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Cranney v. Mutual of Enumclaw Insurance Company, et al.</i>	CV-2004-256*D	District Court, Cassia County, Idaho	Twin Falls, ID	Arbitration
2006	Bruce C. Jones Blackburn & Jones 1673 W. Shoreline, Suite 200 PO Box 7808 Boise, ID 83707	<i>General Auto Parts v. Genuine Parts Company, et al.</i>	CV 04-379-S-EJL	Federal Court, Idaho	Boise, ID	Deposition
2006	William H. Thomas Huntley Park 250 South 5th Street, Suite 660 Boise, ID 83702	<i>Haga v. IKON Office Solutions</i>	CV04-172-SEJL and CV05-048-S-EJL	Federal Court, Idaho	Boise, ID	Deposition
2006	G. Lance Nalder Nalder Law Office 591 Park Avenue, Suite 201 Idaho Falls, ID 83402	<i>Hendricks v. Eastern Idaho Regional Medical Center</i>	CV-05-2046	District Court, Bonneville County, Idaho	Boise, ID	Deposition
2006	Andrew Gardner Stoel Rives 900 SW Fifth Avenue, Suite 2600 Portland, OR 97204	<i>JSH Farms, Inc. v. T&amp;J Kosmos Farms, et al.</i>	CV 001265		Pendleton, OR	Arbitration

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2006	David W. Cantrill Cantrill, Skinner, Sullivan & King 1423 Tyrell Lane PO Box 359 Boise, Idaho 83701	<i>Juarez, et al. v. Dick and Nick's Quality Tire Service, et al.</i>	05-384-E BLW	Federal Court, Idaho	Boise, ID	Deposition
2006	Kevin E. Dirius White Peterson Canyon Park at the Idaho Center 5700 E Franklin Road, Suite 200 Nampa, ID 83687	<i>Lee v. City of Boise</i>	CV OC 0506775	District Court, Ada County, Idaho	Nampa, ID	Deposition
2006	Gregory C. Tollefson Stoel Rives 100 S Capitol Blvd., Suite 1900 Boise, Idaho 83702	<i>Lickfold v. 24 Hour Fitness</i>			Coeur d'Alene, ID	Arbitration
2006	T. Guy Hallam White Peterson Canyon Park at the Idaho Center 5700 E. Franklin Road, Suite 200 Nampa, ID 83687	<i>Loomis v. Heritage Propane</i>	CV-04-617-S-EIL	Federal Court, Idaho	Boise, ID	Deposition
2006	Robyn Brody Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Matey v. Ford Motor Company, et al.</i>	CV 2005 - 400	District Court, Blaine County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2006	David M. Comstock Comstock & Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Neiwert v. Sinclair and Rea</i>	CV-04-3002	District Court, Twin Falls County, Idaho	Boise, ID	Deposition
2006	David E. Comstock Comstock & Bush 199 N. Capitol Blvd., Suite 500 P.O. Box 2774 Boise, ID 83701-2774	<i>Neiwert v. Sinclair, et al.</i>	CV 04-3002	District Court, Twin Falls County, Idaho	Twin Falls, ID	Trial
2006	Paul C. EchoHawk Nathan R. Long EchoHawk Law Offices 151 N 4 <sup>th</sup> Ave., Suite A PO Box 6119 Pocatello, ID 83205-6119	<i>Scissons v. United States of America, et al.</i>	CV 03-531-S-EJL	Federal Court, Idaho	Boise, ID	Trial
2006	James L. Farina Hoey & Farina 542 South Dearborn, Suite 200 Chicago, IL 60605	<i>Sitkowski v. F.H Paschen</i>	02 L 9761	Circuit Court of Illinois, Cook County	Chicago, IL	Deposition
2006	Brent O. Roche Racine, Olson, Nye, Budge & Bailey Center Plaza - Corner First & Center PO Box 1391 Pocatello, ID 83204-1391	<i>Skinner v. Super 8 Motel</i>	CV-051574	District Court, Twin Falls County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167  
Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years

Date	Client	Case	Case Number	Court	Location	Type
2006	Benjamin J. Cluff Hepworth, Lezamiz & Janis 133 Shoshone Street North P.O. Box 389 Twin Falls, ID 83303-0389	<i>Stewart, et al. v. Wilkes Transport, Inc., et al.</i>	CV 03-1837	District Court, Cassia County, Idaho	Boise, ID	Deposition
2006	John T. Edwards Brown, Edwards & Harrison 1221 W Hays Boise, ID 83702	<i>Stoddard v. Low's Ready Mix, et al.</i>	CV PI 0400253D	District Court, Ada County, Idaho	Boise, ID	Deposition
2006	Robert A. Braun Brenner Ford Monroe & Scott 33 N Dearborn, Suite 300 Chicago, IL 60602	<i>Struif v. WALSH</i>	03 L 3576	Circuit Court of Illinois, Cook County	Chicago, IL	Depo
2006	John E. Rumel Idaho Education Association 620 North Sixth Street P.O. Box 2638 Boise, ID 83701	<i>Swanson v. Troy School District, et al.</i>	CV 2005-481	District Court, Latah County, Idaho	Moscow, ID	Trial
2006	Joel A. Beck Hepworth, Lezamiz & Janis 133 Shoshone Street North PO Box 389 Twin Falls, ID 83303	<i>Whitehead, et al. v. Brown, et al.</i>	CV 2004-894	District Court, Gooding County, Idaho	Boise, ID	Deposition

Boise Office | 12000 New Hope Road | Star, ID 83669 | Tel: 208-286-0166 | Fax: 208-286-0167

Chicago Office | 211 E. Ontario, Suite 1800 | Chicago, IL 60611 | Tel: 312-922-8001 | Fax: 312-922-8002

ORIGINAL

Richard E. Hall  
ISB #1253; reh@hallfarley.com  
Keely E. Duke  
ISB #6044; ked@hallfarley.com  
HALL, FARLEY, OBERRECHT & BLANTON, P.A.  
702 West Idaho, Suite 700  
Post Office Box 1271  
Boise, Idaho 83701  
Telephone: (208) 395-8500  
Facsimile: (208) 395-8585  
WA212-404.531BYRNE EXPERT DISCLOSURE.DOC

DISTRICT COURT  
TWIN FALLS CO., IDAHO  
FILED

2007 JUN 18 PM 2:03

BY \_\_\_\_\_  
CLERK  
DEPUTY

Attorneys for Defendant Thomas J. Byrne

IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT  
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS

VAUGHN SCHMECHEL, individually,  
and as Surviving Spouse and Personal  
Representative of the Estate of ROSALIE  
SCHMECHEL, deceased, and ROBERT P.  
LEWIS, KIM HOWARD and TAMARA  
HALL natural children of ROSALIE  
SCHMECHEL, deceased,

Plaintiffs,

vs.

CLINTON DILLE, M.D., SOUTHERN  
IDAHO PAIN INSTITUTE, an Idaho  
corporation, THOMAS BYRNE, P.A. and  
JOHN DOE, I through X,

Defendants.

Case No. CV-05-4345

**DEFENDANT THOMAS J. BYRNE'S  
DISCLOSURE OF EXPERT  
WITNESSES**

COMES NOW defendant Thomas J. Byrne, P.A., by and through his counsel of record Hall, Farley, Oberrecht & Blanton, P.A., and hereby discloses the following expert witnesses whom he may call at the trial of this matter:

1. Chris J. Kottenstette, PA-C  
8405 E. Hampden Ave., Apt. 23-C  
Denver, CO 80231  
(970) 215-0903

Mr. Kottenstette is a physician assistant practicing pain medicine in Denver, Colorado. Mr. Kottenstette has been formally retained by counsel for defendant Thomas J. Byrne. Mr. Kottenstette's Curriculum Vitae is attached hereto as Exhibit A. Mr. Kottenstette charges for his work as an expert are as follows: \$150/hour to review records, \$200/hour for depositions in Denver, Colorado, and \$1,500/day for testimony outside of Denver, Colorado. It is unknown at this time what cases, if any, Mr. Kottenstette has provided deposition or trial testimony within the preceding four years, and, if available, such information will be provided at a later date.

Subject Matter:

Applicable medical principals, liability, causation, and damages

Substance of Facts:

A list of case materials Mr. Kottenstette reviewed is attached hereto as Exhibit B. In addition to the case specific items Mr. Kottenstette may use in his review of this case and the opinions he renders in this case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once those deposition have been taken. He may also rely on relevant medical research and/or literature related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert disclosure, or depositions taken in this case. He will also be provided all documents plaintiffs' expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those documents to Mr. Byrne's counsel).

Substance of Opinions:

It is expected Mr. Kottenstette will testify regarding issues within his expertise, and will testify that all opinions he expresses are held with reasonable medical certainty. It is anticipated Mr. Kottenstette will testify that Mr. Byrne met the standard of care applicable to a physician assistant practicing pain management medicine in September and October 2003 in Twin Falls, Idaho in all aspects of his care and treatment of Mrs. Schmechel.

Mr. Kottenstette will testify that he is familiar with the applicable standard of care based on his years of practice as a physician assistant in pain management medicine, along with his review of the care provided to Mrs. Schmechel by the Southern Idaho Pain Institute and the depositions of Mr. Byrne and Dr. Dille, which include their explanation of what the applicable standard of care was for their respective specialties and positions in September and October of 2003 in Twin Falls, Idaho. It is further anticipated Mr. Kottenstette will testify that based on his review of those items, it is his opinion that the applicable standard of care for Mr. Byrne, as Mr. Byrne and Dr. Dille practiced it and explained it, is consistent with the standard of care as Mr. Kottenstette understood it to be for such similar providers as was applicable in out-patient pain management clinics in Denver, Colorado in 2003 and, therefore, he has actual knowledge regarding such standard of care. In addition, it is also anticipated Mr. Kottenstette will testify that he has reviewed the affidavits of Dr. Rodde Cox, Dr. William Binegar, and Dr. Bradford Hare and, based on those affidavits believes he is adequately familiar with the applicable standard of care and that such standard was no different in September and October 2003 in Twin Falls, Idaho than in Denver, Colorado. It is also anticipated that Mr. Kottenstette will testify that he also reviewed the affidavits of Arthur Lipman, Pharm-D, as well as the disclosures of the plaintiffs' expert witnesses who profess to have knowledge of the standard of care applicable to Mr. Byrne and Dr. Dille. It is anticipated Mr. Kottenstette will testify that based

on his reading of those affidavits (and Dr. Hare's affidavit) and his personal knowledge of a physician assistant's practice in Salt Lake City, Utah which he learned during his enrollment in the University of Utah Physician Assistant program, that the applicable standard of care is no different between Salt Lake City, Utah and Denver, Colorado.

It is anticipated Mr. Kottenstette will testify that Mr. Byrne met the standard of care in all aspects of his care and treatment of Mrs. Schmechel. Specifically, it is anticipated Mr. Kottenstette will testify that based upon his review of the records and deposition transcripts, it is apparent to him that Mr. Byrne was an appropriately trained and experienced physician assistant and had an appropriate understanding for a physician assistant of the use and prescription of Methadone. As such, it is anticipated Mr. Kottenstette will testify that he disagrees with Dr. Lipman's assertion that Mr. Byrne appeared to lack the appropriate level of understanding of the pharmacologic properties of Methadone; rather, it is anticipated Mr. Kottenstette will testify Mr. Byrne had an appropriate understanding of the pharmacology of Methadone and prescribed it appropriately..

It is also anticipated Mr. Kottenstette will testify that Mr. Byrne complied with the standard of care in obtaining an appropriately thorough history regarding Mrs. Schmechel. In providing this opinion, it is anticipated Mr. Kottenstette will testify that Mr. Byrne performed an adequate and thorough examination of Mrs. Schmechel that included a physical examination, review of her past medical conditions (including her history of obstructive sleep apnea), past medical treatment (including her use of C-pap), current condition, current and past medications, her reasons for going to the Southern Idaho Pain Institute, and her goals for treatment. It is also anticipated he will testify that Mr. Byrne verified that Mrs. Schmechel had an objective basis for pain for which she complained by obtaining her latest MRI, which showed arachnoiditis which would account for such neuropathic pain, and by obtaining her latest orthopedic surgery consult which indicated that there

was no surgical intervention in terms of spinal surgery available to her. In providing these opinions, it is also anticipated Mr. Kottenstette will testify that the standard of care allows a provider to use his discretion and judgment as to when and what records are necessary to obtain. It is further anticipated Mr. Kottenstette will testify that the standard of care did not require that Mr. Byrne obtain Mrs. Schmechel's prior treatment records from any provider (or discuss Mrs. Schmechel with any of her prior providers) because he determined Mrs. Schmechel was a competent historian and he determined that he obtained the necessary information from her from which he was able to formulate an appropriate treatment plan. It is anticipated Mr. Kottenstette will further testify, as addressed above, that it was appropriate for Mr. Byrne to obtain the orthopedic surgeon's records so he could evaluate whether the surgeon felt there was an operative component to Mrs. Schmechel's pain, which records indicated no surgical treatment option available. It is anticipated he will further testify that the standard of care did not require Mr. Byrne to contact Dr. Vorse, or obtain her records prior to initiating treatment and that based on his review of Dr. Vorse's records there is nothing in those records which would have suggested that Mr. Byrne not proceed with the treatment he implemented.

It is further anticipated Mr. Kottenstette will testify that Mr. Byrne complied with the applicable standard of care in 2003 when he elected to discontinue Mrs. Schmechel's Oxycontin and utilize Methadone as a long-acting opioid, to continue her use of Hydrocodone as a break-through pain medication, and also appropriately reduced the Amitriptyline dose she was taking, which was a conservative and reasonable approach to Mrs. Schmechel's treatment. It is anticipated that Mr. Kottenstette will further testify that the change to Methadone was within the standard of care because it is a widely used and accepted medication for the treatment of chronic pain, was a good choice for Mrs. Schmechel given that she complained her pain was not well-controlled on her prior pain regimen, it was thought that Methadone had a good effect for neuropathic pain such as Mrs.

Schmechel's, and because it is often times appropriate to change a patient's pain medication from one opioid to another (opioid rotations) as such change can provide better pain relief.

It is further anticipated Mr. Kottenstette will testify that Mr. Byrne's dosing of Methadone was also appropriate and in fact, conservative. It is anticipated that Mr. Kottenstette will testify that even had Mr. Byrne elected to start Mrs. Schmechel on 15 mg of Methadone twice a day, this would have been a reasonable and appropriate starting dose for her and that such dose would have complied with the standard of care. However, it is anticipated Mr. Kottenstette will testify that Mr. Byrne was more conservative by starting her on lower doses and titrating up to the reasonable starting dose of 30 mg a day.

It is also anticipated Mr. Kottenstette will testify that Mr. Byrne's initial prescription for 90 Methadone and 70 Hydrocodone met the standard of care. Specifically, it is anticipated Mr. Kottenstette will testify that writing a month long supply of such prescriptions is within the standard of care given her history (including her use of Hydrocodone and OxyContin), her condition (including the need to switch from one long-term pain management regimen to another), the information she was provided as to how much of both Methadone and Hydrocodone to take, and the anticipation her long-term pain management therapy would continue. As it is anticipated Mr. Kottenstette will testify, it was anticipated Mrs. Schmechel would be on the medications for the long-term given her history of chronic pain and that her orthopedic surgeon concluded there was not a surgical component to her pain. In addition, it is anticipated that Mr. Kottenstette will testify the record does not indicate Mrs. Schmechel was failing to follow Mr. Byrne's advice regarding her Methadone treatment and, rather, the records affirmatively establishes she was following Mr. Byrne's directions regarding her newly initiated therapy.

It is further anticipated Mr. Kottenstette will testify that Mr. Byrne complied with and exceeded the standard of care in all aspects of his follow-up care with Mrs. Schmechel. Specifically, it is anticipated he will testify that Mr. Byrne called Mrs. Schmechel on the Monday following his Friday visit and initiation of therapy with Mrs. Schmechel and that such call was appropriate. It is anticipated he will further testify that Mr. Byrne's direction to Mrs. Schmechel to call him the next day, and the fact she called him the next day, was excellent follow up by Mr. Byrne. In providing these opinions, it is also anticipated Mr. Kottenstette will testify that Mr. Byrne would have met the standard of care had he followed up with her one week after initiating her therapy (so, the following Friday). It is anticipated Mr. Kottenstette will also testify that the applicable standard of care does not require that Mr. Byrne follow-up with Ms. Schmechel every day, as Mr. Keller will allegedly testify. It is anticipated Mr. Kottenstette will explain that Mr. Keller's position regarding the follow-up care related to the initiation of Methadone is not consistent with the training Mr. Kottenstette received at the University of Utah, his practice as a physician assistant in Denver, Colorado, or with any standard of care of which Mr. Kottenstette is aware as each relates to a patient with Mrs. Schmechel's pain management history and medical condition. It is further anticipated that Mr. Kottenstette will testify that Mrs. Schmechel knew how to reach the Southern Idaho Pain Institute if she felt she needed to and that there is nothing in the medical records which suggests that she was having any problems with her new pain management therapy.

It is anticipated Mr. Kottenstette will also testify, to the extent admissible, that there is a factual dispute regarding whether Mrs. Schmechel talked with Mr. Byrne over the weekend to allegedly discuss some problems (edema and pain in her legs) her family alleges she was having. It is further anticipated Mr. Kottenstette will testify that even had those concerns been brought to Mr. Byrne's attention, that such concerns were likely not related to Methadone use but more probably

than not related to her history of edema in her legs due to other conditions. It is further anticipated Mr. Kottenstette will testify that the medical records strongly support the position that Mrs. Schmechel made no such calls to Mr. Byrne or the Southern Idaho Pain Clinic.

It is further anticipated that Mr. Kottenstette will testify that Mr. Byrne's titration of Mrs. Schmechel's Methadone dosage on Monday September 29 and Tuesday September 30, 2003 was appropriate based upon the original conservative dose, Mr. Byrne's follow up with Mrs. Schmechel on the following Monday and Tuesday, and what Mrs. Schmechel communicated to him during those two follow-up conversations. It is further anticipated he will testify that Mr. Byrne's verbal and written dosing instructions were clear and that Mrs. Schmechel was following those instructions. Specifically, it is anticipated Mr. Kottenstette will testify that if Mrs. Schmechel had not been following Mr. Byrne's instructions regarding her dosing, it is reasonable to expect that she would have notified Mr. Byrne on Monday, once he asked her to increase her dose from 5 mg twice a day to 10 mg twice a day, that she was already taking the higher dose. Mr. Kottenstette is also anticipated to testify that his opinions are further supported by the medical records which indicated that on Tuesday Mrs. Schmechel reported to Mr. Byrne that she was doing well and had increased her dose the Monday evening before to 15 mg. It is anticipated that Mr. Kottenstette will testify that as such, the records do not reflect that Mrs. Schmechel was not complying with Mr. Byrne's treatment plan; rather, they establish that she was in fact following his advice with respect to increasing her dose from 5mgs to 10mgs to 10-15mgs twice a day as he instructed her on September 26, 2003. It is anticipated Mr. Kottenstette will testify that in the event Mrs. Schmechel was not following Mr. Byrne's instructions and failed to inform him of her failure to follow his directions, Mr. Byrne is certainly not responsible for her actions or inaction and that she did not give him any indication that she was not following his treatment plan that he had explained to her.

It is further anticipated Mr. Kottenstette will testify that obstructive sleep apnea is a very common problem and in September and October of 2003 there was no information generally available to pain management physicians and physician assistants that there was any special concern or problem with Methadone in patients with obstructive sleep apnea that was any different than any other narcotic including those that Mrs. Schmechel had been on for a long period of time prior to seeing Mr. Byrne. It is further anticipated Mr. Kottenstette will testify that the standard of care did not require Mr. Byrne to inquire further regarding the exact degree of obstructive sleep apnea or examine her sleep study testing. It is anticipated Mr. Kottenstette will further testify that the fact that for years Mrs. Schmechel had been on higher equivalent doses of Oxycontin than the dose of Methadone that Mr. Byrne put her on (even assuming a starting dose of 30 mg) indicates that Mr. Byrne appropriately complied with the standard of care in how he treated Mrs. Schmechel and the extent to which he considered her sleep apnea, i.e., that it was being treated by C-pap, as there was nothing that would have made Mr. Byrne believe that Methadone posed any greater risk with respect to the sleep apnea to Mrs. Schmechel.

It is also anticipated Mr. Kottenstette will testify that the cause of Mrs. Schmechel's death is uncertain and that another condition she had was just as, if not more, likely to have caused her death than the Methadone and Hydrocodone. In providing this opinion, it is anticipated Mr. Kottenstette will rely on the descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's various co-morbid medical conditions and personal habits.

It is further anticipated Mr. Kottenstette will testify that the case specific documents he has reviewed, along with the depositions of Mr. Byrne and Dr. Dille, establish a thorough, careful, and compassionate job performed by Mr. Byrne.

It is anticipated Mr. Kottenstette will be deposed in this matter and may testify regarding any issue addressed during the course of his deposition.

Mr. Kottenstette is expected to respond to and/or rebut opinions provided by medical expert witnesses called by plaintiffs, including, but not limited to, Mr. James Keller, Arthur Lipman, Pharm-D, Stephen Lordon, M.D., and Kimberly Vorse, M.D.

It is anticipated Mr. Kottenstette will address, explain and render expert opinions with regard to relevant medical subjects within his expertise, including, but not limited to, Class II narcotics (including OxyContin and Methadone), Hydrocodone, Amitriptyline, sleep apnea (including obstructive sleep apnea), opioid use (including long-term use), and any clinical findings and laboratory evaluations performed on Mrs. Schmechel.

2. Rodde Cox, M.D.  
1000 N. Curtis, Suite 202  
Boise, Idaho 83706  
(209) 377-3435

Dr. Cox is a physician practicing in Boise, Idaho who practices Physical Medicine and Rehabilitation with an active part of his practice in pain management. Dr. Cox has been formally retained by counsel for defendant Thomas J. Byrne. Dr. Cox's Curriculum Vitae is attached hereto as Exhibit C. Dr. Cox charges \$300/hour for record review and \$500/hour for testimony. It is unknown at this time what cases, if any, Dr. Cox has provided deposition or trial testimony within the preceding four years, and, if available, such information will be provided at a later date.

Subject Matter:

Applicable medical principals, liability, causation, and damages

Substance of Facts:

A list of case materials Dr. Cox reviewed is attached hereto as Exhibit D. In addition to the case specific items Dr. Cox may use in his review of this case and the opinions he renders in this

case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once those deposition have been taken. He may also rely on relevant medical research and/or literature related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert disclosure, or depositions taken in this case. He will also be provided all documents plaintiffs' expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those documents to Mr. Byrne's counsel).

Substance of Opinions:

It is expected Dr. Cox will testify as to all opinions and items contained within the Affidavit of Rodde Cox, M.D. dated June 11, 2007, which is attached as Exhibit E. It is further anticipated he will testify that all opinions he expresses are held with reasonable medical certainty. It is anticipated Dr. Cox will testify that Mr. Byrne met the standard of care applicable to a physician assistant practicing pain management medicine in September and October 2003 in Twin Falls, Idaho in all aspects of his care and treatment of Mrs. Schmechel.

It is anticipated Dr. Cox will testify that Mr. Byrne met the standard of care in all aspects of his care and treatment of Mrs. Schmechel. Specifically, it is anticipated Dr. Cox will testify that based upon his review of the records and deposition transcripts, it is apparent to him that Mr. Byrne was an appropriately trained and experienced physician assistant and had an appropriate understanding for a physician assistant of the use and prescription of Methadone. As such, it is anticipated Dr. Cox will testify that he disagrees with Dr. Lipman's assertion that Mr. Byrne appeared to lack the appropriate level of understanding of the pharmacologic properties of Methadone; rather, it is anticipated Dr. Cox will testify Mr. Byrne had an appropriate understanding of the pharmacology of Methadone and prescribed it appropriately..

It is also anticipated Dr. Cox will testify that Mr. Byrne complied with the standard of care in obtaining an appropriately thorough history regarding Mrs. Schmechel. In providing this opinion, it is anticipated Dr. Cox will testify that Mr. Byrne performed an adequate and thorough examination of Mrs. Schmechel that included a physical examination, review of her past medical conditions (including her history of obstructive sleep apnea), past medical treatment (including her use of C-pap), current condition, current and past medications, her reasons for going to the Southern Idaho Pain Institute, and her goals for treatment. It is also anticipated he will testify that Mr. Byrne verified that Mrs. Schmechel had an objective basis for pain for which she complained by obtaining her latest MRI, which showed arachnoiditis which would account for such neuropathic pain, and by obtaining her latest orthopedic surgery consult which indicated that there was no surgical intervention in terms of spinal surgery available to her. In providing these opinions, it is also anticipated Dr. Cox will testify that the standard of care allows a provider to use his discretion and judgment as to when and what records are necessary to obtain. It is further anticipated Dr. Cox will testify that the standard of care did not require that Mr. Byrne obtain Mrs. Schmechel's prior treatment records from any provider (or discuss Mrs. Schmechel with any of her prior providers) because he determined Mrs. Schmechel was a competent historian and he determined that he obtained the necessary information from her from which he was able to formulate an appropriate treatment plan. It is anticipated Dr. Cox will further testify, as addressed above, that it was appropriate for Mr. Byrne to obtain the orthopedic surgeon's records so he could evaluate whether the surgeon felt there was an operative component to Mrs. Schmechel's pain, which records indicated no surgical treatment option available. It is anticipated he will further testify that the standard of care did not require Mr. Byrne to contact Dr. Vorse, or obtain her records prior to initiating treatment and that based on his review of Dr.

Vorse's records there is nothing in those records which would have suggested that Mr. Byrne not proceed with the treatment he implemented.

It is further anticipated Dr. Cox will testify that Mr. Byrne complied with the applicable standard of care in 2003 when he elected to discontinue Mrs. Schmechel's Oxycontin and utilize Methadone as a long-acting opioid, to continue her use of Hydrocodone as a break-through pain medication, and also appropriately reduced the Amitriptyline dose she was taking, which was a conservative and reasonable approach to Mrs. Schmechel's treatment. It is anticipated that Dr. Cox will further testify that the change to Methadone was within the standard of care because it is a widely used and accepted medication for the treatment of chronic pain, was a good choice for Mrs. Schmechel given that she complained her pain was not well-controlled on her prior pain regimen, it was thought that Methadone had a good effect for neuropathic pain such as Mrs. Schmechel's, and because it is often times appropriate to change a patient's pain medication from one opioid to another (opioid rotations) as such change can provide better pain relief.

It is further anticipated Dr. Cox will testify that Mr. Byrne's dosing of Methadone was also appropriate and in fact, conservative. It is anticipated that Dr. Cox will testify that even had Mr. Byrne elected to start Mrs. Schmechel on 15 mg of Methadone twice a day, this would have been a reasonable and appropriate starting dose for her and that such dose would have complied with the standard of care. However, it is anticipated Dr. Cox will testify that Mr. Byrne was more conservative by starting her on lower doses and titrating up to the reasonable starting dose of 30 mg a day.

It is also anticipated Dr. Cox will testify that Mr. Byrne's initial prescription for 90 Methadone and 70 Hydrocodone met the standard of care. Specifically, it is anticipated Dr. Cox will testify that writing a month long supply of such prescriptions is within the standard of care given her

history (including her use of Hydrocodone and OxyContin), her condition (including the need to switch from one long-term pain management regimen to another), the information she was provided as to how much of both Methadone and Hydrocodone to take, and the anticipation her long-term pain management therapy would continue. As it is anticipated Dr. Cox will testify, it was anticipated Mrs. Schmechel would be on the medications for the long-term given her history of chronic pain and that her orthopedic surgeon concluded there was not a surgical component to her pain. In addition, it is anticipated that Dr. Cox will testify the record does not indicate Mrs. Schmechel was failing to follow Mr. Byrne's advice regarding her Methadone treatment and, rather, the records affirmatively establishes she was following Mr. Byrne's directions regarding her newly initiated therapy.

It is further anticipated Dr. Cox will testify that Mr. Byrne complied with and exceeded the standard of care in all aspects of his follow-up care with Mrs. Schmechel. Specifically, it is anticipated he will testify that Mr. Byrne called Mrs. Schmechel on the Monday following his Friday visit and initiation of therapy with Mrs. Schmechel and that such call was appropriate. It is anticipated he will further testify that Mr. Byrne's direction to Mrs. Schmechel to call him the next day, and the fact she called him the next day, was excellent follow up by Mr. Byrne. In providing these opinions, it is also anticipated Dr. Cox will testify that Mr. Byrne would have met the standard of care had he followed up with her one week after initiating her therapy (so, the following Friday). It is anticipated Dr. Cox will also testify that the applicable standard of care does not require that Mr. Byrne follow-up with Ms. Schmechel every day, as Mr. Keller will allegedly testify. It is anticipated Dr. Cox will explain that Mr. Keller's position regarding the follow-up care related to the initiation of Methadone is not consistent with the training Dr. Cox received at the University of Utah, his practice as a physician assistant in Denver, Colorado, or with any standard of care of which Dr. Cox is aware as each relates to a patient with Mrs. Schmechel's pain management history and medical

condition. It is further anticipated that Dr. Cox will testify that Mrs. Schmechel knew how to reach the Southern Idaho Pain Institute if she felt she needed to and that there is nothing in the medical records which suggests that she was having any problems with her new pain management therapy.

It is anticipated Dr. Cox will also testify, to the extent admissible, that there is a factual dispute regarding whether Mrs. Schmechel talked with Mr. Byrne over the weekend to allegedly discuss some problems (edema and pain in her legs) her family alleges she was having. It is further anticipated Dr. Cox will testify that even had those concerns been brought to Mr. Byrne's attention, that such concerns were likely not related to Methadone use but more probably than not related to her history of edema in her legs due to other conditions. It is further anticipated Dr. Cox will testify that the medical records strongly support the position that Mrs. Schmechel made no such calls to Mr. Byrne or the Southern Idaho Pain Clinic.

It is further anticipated that Dr. Cox will testify that Mr. Byrne's titration of Mrs. Schmechel's Methadone dosage on Monday September 29 and Tuesday September 30, 2003 was appropriate based upon the original conservative dose, Mr. Byrne's follow up with Mrs. Schmechel on the following Monday and Tuesday, and what Mrs. Schmechel communicated to him during those two follow-up conversations. It is further anticipated he will testify that Mr. Byrne's verbal and written dosing instructions were clear and that Mrs. Schmechel was following those instructions. Specifically, it is anticipated Dr. Cox will testify that if Mrs. Schmechel had not been following Mr. Byrne's instructions regarding her dosing, it is reasonable to expect that she would have notified Mr. Byrne on Monday, once he asked her to increase her dose from 5 mg twice a day to 10 mg twice a day, that she was already taking the higher dose. Dr. Cox is also anticipated to testify that his opinions are further supported by the medical records which indicated that on Tuesday Mrs. Schmechel reported to Mr. Byrne that she was doing well and had increased her dose the Monday

evening before to 15 mg. It is anticipated that Dr. Cox will testify that as such, the records do not reflect that Mrs. Schmechel was not complying with Mr. Byrne's treatment plan; rather, they establish that she was in fact following his advice with respect to increasing her dose from 5mgs to 10mgs to 10-15mgs twice a day as he instructed her on September 26, 2003. It is anticipated Dr. Cox will testify that in the event Mrs. Schmechel was not following Mr. Byrne's instructions and failed to inform him of her failure to follow his directions, Mr. Byrne is certainly not responsible for her actions or inaction and that she did not give him any indication that she was not following his treatment plan that he had explained to her.

It is further anticipated Dr. Cox will testify that obstructive sleep apnea is a very common problem and in September and October of 2003 there was no information generally available to pain management physicians and physician assistants that there was any special concern or problem with Methadone in patients with obstructive sleep apnea that was any different than any other narcotic including those that Mrs. Schmechel had been on for a long period of time prior to seeing Mr. Byrne. It is further anticipated Dr. Cox will testify that the standard of care did not require Mr. Byrne to inquire further regarding the exact degree of obstructive sleep apnea or examine her sleep study testing. It is anticipated Dr. Cox will further testify that the fact that for years Mrs. Schmechel had been on higher equivalent doses of Oxycontin than the dose of Methadone that Mr. Byrne put her on (even assuming a starting dose of 30 mg) indicates that Mr. Byrne appropriately complied with the standard of care in how he treated Mrs. Schmechel and the extent to which he considered her sleep apnea, i.e., that it was being treated by C-pap, as there was nothing that would have made Mr. Byrne believe that Methadone posed any greater risk with respect to the sleep apnea to Mrs. Schmechel.

It is also anticipated Dr. Cox will testify that the cause of Mrs. Schmechel's death is uncertain and that another condition she had was just as, if not more, likely to have caused her death than the

Methadone and Hydrocodone. In providing this opinion, it is anticipated Dr. Cox will rely on the descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's various co-morbid medical conditions and personal habits.

It is further anticipated Dr. Cox will testify that the case specific documents he has reviewed, along with the depositions of Mr. Byrne and Dr. Dille, establish a thorough, careful, and compassionate job performed by Mr. Byrne.

It is anticipated Dr. Cox will be deposed in this matter and may testify regarding any issue addressed during the course of his deposition.

It is further anticipated Dr. Cox will testify that Dr. Dille's care and treatment of Mrs. Schmechel met the standard of care in all respects and that Dr. Dille appropriately supervised Mr. Byrne.

Dr. Cox is expected to respond to and/or rebut opinions provided by medical expert witnesses called by plaintiffs, including, but not limited to, Mr. James Keller, Arthur Lipman, Pharm-D, Stephen Lordon, M.D., and Kimberly Vorse, M.D.

It is anticipated Dr. Cox will address, explain and render expert opinions with regard to relevant medical subjects within his expertise, including, but not limited to, Class II narcotics (including OxyContin and Methadone), Hydrocodone, Amitriptyline, sleep apnea (including obstructive sleep apnea), opioid use (including long-term use), and any clinical findings and laboratory evaluations performed on Mrs. Schmechel.

3. Keri L. Fakata, Pharm.D  
3838 S. 700 E., Suite 202  
Salt Lake City, Utah 84106

Dr. Fakata is a Pharm.D practicing at Lifetree Pain Clinic in Salt Lake City, Utah. Dr. Fakata has been formally retained by counsel for defendant Thomas J. Byrne. Dr. Fakata's Curriculum

Vitae is attached hereto as Exhibit F. Dr. Fakata charges \$250/hour for her work on this case. Dr. Fakata has not testified as an expert witness within the last four years.

Subject Matter:

Applicable medical principals, liability, causation, and damages

Substance of Facts:

A list of case materials Dr. Fakata reviewed is attached hereto as Exhibit G. In addition to the case specific items Dr. Fakata may use in her review of this case and the opinions she renders in this case, she will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once those deposition have been taken. She may also rely on relevant medical research and/or literature related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert disclosure, or depositions taken in this case. She will also be provided all documents plaintiffs' expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those documents to Mr. Byrne's counsel).

Substance of Opinions:

It is expected Dr. Fakata will testify as to all opinions and items contained within the Affidavit of Keri Fakata, Pharm.D. dated June 4, 2007, which is attached as Exhibit H. It is further anticipated she will testify that all opinions she expresses are held with reasonable medical certainty.

It is anticipated that Dr. Fakata will testify regarding the pharmacologic properties, including the pharmacokentic and pharacodynamic properties, of Methadone, OxyContin, Hydrocodone, and other medications which had been prescribed for Mrs. Schmechel by Mr. Byrne and other healthcare providers. It is further anticipated she will testify regarding what information was reasonably known in September and October 2003 regarding Methadone, Hydrocodone, OxyContin, and other medications provided to Mrs. Schmechel by Mr. Byrne or other healthcare providers.

It is further anticipated she will testify that obstructive sleep apnea is a very common problem and in September and October of 2003 there was no information generally available to pain management physicians and physician assistants that there was any special concern or problem with Methadone in patients with obstructive sleep apnea that was any different than any other narcotic including those that Mrs. Schmechel had been on for a long period of time prior to seeing Mr. Byrne. It is anticipated Dr. Fakata will testify that the fact that for years Mrs. Schmechel had been on higher equivalent doses of Oxycontin than the dose of Methadone that Mr. Byrne put her on (even assuming a starting dose of 30 mg) indicates that Mr. Byrne appropriately complied with the standard of care in how he treated Mrs. Schmechel and the extent to which he considered her sleep apnea, i.e., that it was being treated by C-pap, as there was nothing that would have made Mr. Byrne believe that Methadone posed any greater risk with respect to the sleep apnea to Mrs. Schmechel.

It is anticipated Dr. Fakata will testify that the cause of Mrs. Schmechel's death is uncertain and that another condition she had was just as, if not more, likely to have caused her death than Methadone and/or Hydrocodone. In providing this opinion, it is anticipated Dr. Fakata will rely on the descriptions provided regarding the scene of death and her knowledge of Mrs. Schmechel's various co-morbid medical conditions and personal habits. It is anticipated she will also testify regarding the blood levels of Methadone and Hydrocodone pre-death and post-death.

It is further anticipated that if Dr. Lipman is permitted to testify regarding standard of care and whether Dr. Dille and/or Mr. Byrne complied with the standard of care, then Dr. Fakata will testify that Mr. Byrne met the standard of care applicable to a physician assistant practicing pain management medicine in September and October 2003 in Twin Falls, Idaho in all aspects of his care and treatment of Mrs. Schmechel. In addition, it is anticipated she will testify consistent with the disclosure provided above for Mr. Kottenstette.

Dr. Fakata will also be called to rebut the testimony of plaintiffs' experts to the extent it involves her field of practice as a Pharm.D.

It is anticipated Dr. Fakata's deposition will be taken in this case and it is anticipated she will testify at trial regarding what is discussed in her deposition.

4. T.J. Byrne, P.A.  
Hall, Farley, Oberrecht & Blanton, P.A.  
702 W. Idaho, Ste. 700  
Boise, Idaho 83701

Mr. Byrne is a physician assistant who is a named defendant in this matter. Mr. Byrne may provide expert testimony regarding his care and treatment of Mrs. Schmechel, including, but not limited to, his examination, his meetings with her, his conversations with her, his observations, monitoring, his record, his orders, relevant standards of health care practice, causation, and response and rebuttal to medical expert witnesses called by plaintiffs. Mr. Byrne was deposed in this matter and he is anticipated to testify consistent with the testimony provided during the course of his deposition, which transcript and exhibits are incorporated herein by this reference, and may testify as to all issues covered during the course of said deposition.

In addition, Mr. Byrne is anticipated to address medical subjects within his expertise and to rely upon his medical education and experience, his continuing medical education, his knowledge of medical literature applicable to the matter at issue, his review of the medical records of Mrs. Schmechel, his review of the discovery and litigation record in this matter, and deposition testimony taken in the course of discovery in this matter. In addition, Mr. Byrne may testify to and rely upon personal interactions with health care providers, Mrs. Schmechel, and his personal knowledge of the medical care and treatment he provided to Mrs. Schmechel.

5. Clinton Dille, M.D.  
Givens Pursley  
601 W. Bannock St.  
Boise, Idaho 83701

Dr. Dille is a physician who is a named defendant in this matter. Dr. Dille may provide expert testimony regarding Mr. Byrne's care and treatment of Mrs. Schmechel, including, but not limited to, the role and supervision of a physician assistant at the Southern Idaho Pain Institute including during September and October 2003, Mr. Byrne's care and treatment of Mrs. Schmechel, along with relevant standards of health care practice, causation, and response and rebuttal to medical expert witnesses called by plaintiffs. He may also testify regarding his interactions with Mr. Byrne as they related to patients, including Mrs. Schmechel, that Mr. Byrne cared for while at the Southern Idaho Pain Institute. Dr. Dille was deposed in this matter on and he is anticipated to testify consistent with the testimony provided during the course of his deposition, which transcript and exhibits are incorporated herein by this reference, and Dr. Dille may testify as to all issues covered during the course of said deposition.

In addition, Dr. Dille is anticipated to address medical subjects within his expertise and to rely upon his medical education and experience, his continuing medical education, his knowledge of medical literature applicable to the matter at issue, his review of the medical records of Mrs. Schmechel, his review of the discovery and litigation record in this matter, and deposition testimony taken in the course of discovery in this matter.

6. James Smith, M.D.  
Boise Heart Clinic  
287 W. Jefferson  
Boise, ID 83702

Dr. Smith is a board-certified physician specializing in cardiology and internal medicine. Dr. Smith has been retained by counsel for Mr. Byrne and counsel for Dr. Dille and the Southern Idaho

Pain Institute. Dr. Smith's hourly charge for his services as an expert is \$300/hour. Dr. Smith's curriculum vitae is attached hereto as Exhibit I.

Subject Matter:

Applicable medical principals, causation, and damages

Substance of Facts:

A list of case materials Dr. Smith reviewed is attached hereto as Exhibit J. In addition to the case specific items Dr. Smith used in his review of this case and the opinions he renders in this case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once those deposition have been taken. He may also rely on relevant medical research and/or literature related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert disclosure, or depositions taken in this case. He will also be provided all documents plaintiffs' expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those documents to Mr. Byrne's counsel).

Substance of Opinions:

It is anticipated Dr. Smith will testify that the cause of Mrs. Schmechel's death is uncertain and that another condition she had was just as, if not more, likely to have caused her death than Methadone and/or Hydrocodone. In providing this opinion, it is anticipated Dr. Smith will rely on the descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's various co-morbid medical conditions and personal habits. It is also anticipated that Dr. Smith will testify regarding Mrs. Schmechel's reduced life expectancy given her medical condition and personal habits. In discussing these issues, it is anticipated that Dr. Smith will testify regarding certain risk factors Mrs. Schmechel had that would have reduced her life expectancy.

Dr. Smith will also be called to rebut the testimony of plaintiffs' experts to the extent it involves Mrs. Schmechel's cause of death and her life expectancy.

It is anticipated Dr. Smith's deposition will be taken in this case and it is anticipated he will testify at trial regarding what is discussed in his deposition.

7. Scott Phillips, M.D., F.A.C.P.  
Toxicology Associates  
2555 S Downing Street, Ste. 260  
Denver, Colorado 80210

Dr. Phillips is board certified in Medical Toxicology and Internal Medicine. He is currently an Assistant Clinical Professor at the University of Colorado Health Sciences Center, Denver. Dr. Phillips also serves as an editorial reviewer for several peer-reviewed medical journals, including the *Archives of Internal Medicine*. Dr. Phillips has been retained by counsel for Mr. Byrne and counsel for Dr. Dille and the Southern Idaho Pain Institute. Dr. Phillip's curriculum vitae is attached hereto as Exhibit K.

Subject Matter:

Applicable medical principals, causation, and damages

Substance of Facts:

A list of case materials Dr. Phillips reviewed is attached hereto as Exhibit L. In addition to the case specific items Dr. Phillips used in his review of this case and the opinions he renders in this case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once those deposition have been taken. He may also rely on relevant medical research and/or literature related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert disclosure, or depositions taken in this case. He will also be provided all documents plaintiffs' expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those documents to Mr. Byrne's counsel).

Substance of Opinions:

It is anticipated Dr. Phillips will testify that the cause of Mrs. Schmechel's death is uncertain and that another condition she had was just as, if not more, likely to have caused her death than Methadone and/or Hydrocodone. In providing this opinion, it is anticipated Dr. Phillips will rely on the descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's various co-morbid medical conditions and personal habits.

It is also anticipated Dr. Phillips will testify regarding the pharmacologic properties, including the pharmacokinetic and pharmacodynamic properties, of Methadone, OxyContin, Hydrocodone, and other medications which had been prescribed for Mrs. Schmechel by Mr. Byrne and other healthcare providers. It is further anticipated he will testify regarding what information was reasonably known in September and October 2003 regarding Methadone, Hydrocodone, OxyContin, and other medications provided to Mrs. Schmechel by Mr. Byrne or other healthcare providers. It is anticipated he will also testify regarding the blood levels of Methadone and Hydrocodone pre-death and post-death.

Dr. Phillips will also be called to rebut the testimony of plaintiffs' experts to the extent it involves Mrs. Schmechel's cause of death and her life expectancy.

It is anticipated Dr. Phillips's deposition will be taken in this case and it is anticipated he will testify at trial regarding what is discussed in his deposition.

8. Janat E. O'Donnell, M.D.  
Idaho Pulmonary Associates  
901 N. Curtis, Ste. 401  
Boise, Idaho 83706  
(208) 323-0031

Dr. O'Donnell has been retained by counsel for Mr. Byrne and by counsel for Dr. Dille and the Southern Idaho Pain Institute. Please see Dr. Dille's and Southern Idaho Pain Institute's

disclosure of experts for a description of her anticipated opinions and testimony, which is incorporated herein as it pertains to Dr. O'Donnell.

9. In addition to the above-listed experts, Mr. Byrne may also call as his experts and/or fact witnesses in this case, any and all healthcare providers, including physicians, nurses, health care providers, or consultants, who at any time provided care, treatment, advice, or consultation to Mrs. Schmechel. Such individuals may be called to testify regarding facts or opinions within their scope of knowledge, experience and/or expertise or otherwise as to any matter to which they are competent to testify.

10. Mr. Byrne also reserve the right to call any persons appropriately disclosed by plaintiffs and/or co-defendants (including Dr. Hare and Dr. Binegar) as experts in this case to discuss any matter for which they are competent to testify, including any matter within the scope of their expertise based upon their training, education and/or experience.

11. Insofar as discovery in this matter is ongoing, Mr. Byrne reserves the right to amend or supplement this list to include the designation of additional expert witnesses as may be necessitated by further discovery.

12. Any expert witnesses Mr. Byrne elect not to call at trial are declared to be consulting witnesses only, whether deposed or not. No other party may call such consulting expert without Mr. Byrne's permission.

DATED this 18<sup>th</sup> day of June, 2007.

HALL, FARLEY, OBERRECHT  
& BLANTON, P.A.

By Keely E. Duke  
Keely E. Duke - Of the Firm  
Attorneys for Defendant Thomas J. Byrne

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on the 19<sup>th</sup> day of June, 2007, I caused to be served a true copy of the foregoing **DEFENDANT THOMAS J. BYRNE'S DISCLOSURE OF EXPERT WITNESSES**, by the method indicated below, and addressed to each of the following:

David Comstock  
Law Offices of Comstock & Bush  
199 N. Capitol Blvd., Ste. 500  
P.O. Box 2774  
Boise, Idaho 83701  
*Attorney for Plaintiffs*  
Fax No.: (208) 344-7721

U.S. Mail, Postage Prepaid  
 Hand Delivered  
 Overnight Mail  
 Telecopy

Steven J. Hippler  
GIVENS PURSLEY  
601 W. Bannock ST.  
PO Box 2720  
Boise ID 83701-2720  
*Attorneys for Clinton Dille, M.D. and  
Southern Idaho Pain Institute*

U.S. Mail, Postage Prepaid  
 Hand Delivered  
 Overnight Mail  
 Telecopy

  
\_\_\_\_\_  
Keely E. Duke



# CHRIS J. KOTTENSTETIE, PA-C

8405 E. Hampden Ave., Apt 23-C, Denver, CO 80231

Home (970) 215-0903

Cell (970) 215-0903

E-mail - Ckotten@Bigfoot.com

## CAPABILITIES

- ✦ Nationally recognized leader in Pain Management
- ✦ 5+ years experience in a busy Pain Management/Spine Rehab/Interventional Clinic
- ✦ Experience in hospital rounding, Pre & Post OP care, charting and records excellence
- ✦ Demonstrated excellence in pump and stim programming and management
- ✦ Extensive medication management experience
- ✦ In office procedures and surgical assisting
- ✦ National lecturer, conference presenter, and consultant in pain management
- ✦ Hands-on, execution oriented leader and team builder
- ✦ Experience in administrative management, HR management, coding, marketing, and billing
- ✦ Ability to use technology to an advantage- computer networking, problem solving, repair
- ✦ Founder and Pres. PAs in Pain Management, A Special Interest Group of the AAPA
- ✦ Previous service as an appointed member of the Board of Examiners for the Malcolm Baldrige National Quality Award
- ✦ Member, National Expert Panel for the Clinical Practice Guideline Panel in Opioids for Non-Cancer Pain, a Joint project of the APS and AAPM
- ✦ Demonstrated strong leadership and team building skills. Dedicated. Dependable.

- Additional PA Experience in Orthopedic Surgery, Emergency Room, and Family Practice.
- Board Certified in General Medicine and Surgery: Licenses active in CO, and MI.
- Expertise includes management/supervision, quality improvement, problem assessment, solution integration, and marketing. Proven teaching & problem-solving skills
- 7 years experience as an Athletic Trainer, 3 at the college level.
- Seventeen years experience as a paramedic/manager in an urban/rural 911-access system
- Experienced instructor for: ACLS, PALS, PHTLS, CPR, EMT classes
- Certified in supervision and total quality management, Colorado State University
- Technical proficiency in many computer, network, Internet programs, web design, and multimedia use, to include Word, WordPerfect, and many other leading programs
- Golden Key Honor Society lifetime member
- Selected member of Empire's Who's Who Executive and Professional Registry
- Past President, State PA Academy, and previously Student Academy Director-at-Large, AAPA

## EXPERIENCE

3/07 - Present

### Alpharma Branded Products Division– Medical Science Liaison

Provide education to providers, managed care organizations, associations, groups, and sales staff in proper pain management. Identify and communicate with key opinion leaders in pain management.

6/03-Present

### Denver Pain Management– Physician Assistant

Physician Assistant, Clinical Manager for an interventional pain management practice – Pre/Post Op Care, On-Call, Medication Management, Refill and Programming of implanted Pumps and Stim devices, clinical operation management. Transitioned to Per-Diem Status 3/1/07 with PA only responsibilities

4/01 – 4/03

### Northern Colorado Pain Management, LLP– Physician Assistant

Physician Assistant in a spine and interventional pain management practice – Hospital duties, Pre/Post Op Care, On-Call, Medication Management, Refill and Programming of implanted Pumps and Stim devices. Administrative duties to include; Office Management Duties, Computer and Network management, Systems and Quality Development and Implementation, and Marketing - References Available

3/00 – 4/01

### Foothills Family Care, LLC– Physician Assistant

Physician Assistant in a family practice setting. Administrative duties to include; contract review, supply purchasing, computer and network management.

10/99 – 10/00

### Big Thompson Emergency Physicians, PC.– Physician Assistant

Physician Assistant in an emergency room setting

# CHRIS J. KOTTENSTETIE, PA-C

## EXPERIENCE

8/99 – 8/00

Continued...

**Physician Extender Services, Inc. – Physician Assistant / Surgical Assist**

Assist in surgery as required. Assisted Dr. Louis Tartaglia, M.D. Orthopedic Surgeon primarily

1990- Present

**Front Range Community College- EMS Instructor – Part time (off an on)**

Over the years I taught EMS Classes to the public, and continuing education to other agencies.

1986-2000

**Poudre Valley Health Care, Inc. - Paramedic Supervisor**

Supervised operations of the service for an assigned shift. Responsible for SOP, legal issues, government regulations, and various resources to maintain the operational continuity of the service with other agencies and service providers. Responsible for patient care/operations for a 2200 sq. mile area including an urban area of 100,000+ population and rural areas. Full time 4/86-9/97, Part-time 10/99-9/00 (hiatus to attend PA School)

1990-1996

**Air Life of Greeley - Per-Diem Flight Paramedic**

Responsible for dynamic/advanced paramedic level care involved in helicopter transport service.

1984-1986

**Colorado State University - Athletic Trainer**

Assisted in the prevention, evaluation, care, and rehabilitation of collegiate athletes. - Volunteer (1500 hours towards professional certification)

1981-1986

**Reed Ambulance (Currently Action Care) - Supervisor/Dispatcher**

Responsible for supervision of 30 Paramedics and dispatchers in greater Denver metro area. Similar duties as Poudre Valley Health Care.

## EDUCATION

1997-1999

**Utah Physician Assistant Program (UPAP)- University of Utah Medical School – PA Certificate (a masters equivalent program in hours and coursework)**

1984-1986

**Colorado State University**- Certified Vocational Instructor, Supervisor's Development Certificate Program (110 hrs) - Spring '92, Total Quality Management Certificate Program (38 hrs) - Fall '95, 125-quarter (83 sem) hours towards graduation in a bachelors of science program at Colorado State University, Ft. Collins, CO.

## INVOLVEMENT

**Appointed Member, Malcolm Baldrige National Quality Award Board of Examiners 2003-2004**

-- The Baldrige Award is given by the President of the United States to businesses, manufacturing and service, small and large, and to education and health care organizations that apply and are judged to be outstanding in seven areas: leadership, strategic planning, customer and market focus, information and analysis, human resource focus, process management, and business results. A focused fund of companies who have won the award have outpaced the S&P by 15% consistently in ROI.

**Past-President, Past Webmaster (www.coloradopas.org)**

**Colorado Academy of Physician Assistants (CAPA)**

A professional volunteer organization for Colorado PAs. Created, published and managed the web site with 32,000+ hits/month ([www.coloradopas.org](http://www.coloradopas.org)). Created current website, Instrumental in changing cosignature requirement with the BME. Various other roles since 1999. President 2003-2004. Past-President Term 6/04-6/05

**South Central Regional Representative – Constituent Relations**

**Committee of the American Academy of Physician Assistants (AAPA)–**

The AAPA is a professional member organization of PA's. Appointed office. 2001 Term

**SAAAPA Board of Directors - Director-at-Large - 1998-1999 Term**

**Student Representative to the Assembly of Representatives of SAAAPA from the Utah Physician Assistant Program. Elected office. 1998**

## ORGANIZATIONAL MEMBERSHIPS

**Organizational memberships:** American Academy of Physician Assistants (AAPA), Colorado Academy of Physician Assistants (CAPA), American Academy of Pain Management (American Pain Society (nominated for Director-at-large), Founding Member of PAs in Pain Management, a special interest group with the AAPA, Board Member, American Academy of Pain Educators

## CONSULTANT/ SPEAKER

Purdue Pharma, Cephalon, Pfizer, Lilly, Colorado Academy of PA's, AAPA, Continuing Education, Inc. University at Sea.



CHRIS J. KOTTENSTETTE, PA-C  
SCHMECHEL V. BYRNE, ET AL  
2.404.53

DOCUMENTS REVIEWED

DEPOSITIONS	
	TJ Byrnes
	Clinton Dille, MD
	Vaughn Schmechel
	Robert Lewis
	Tamara Hall
	Kim Howard
MEDICAL RECORDS	
	Southern Idaho Pain and Rehabilitation Center
	Records of Kenneth Harris, MD
	Records of Kimberly Vorse, MD
	Sun Valley Sports Medicine
	Sun Valley Spine Institute
	Idaho Diagnostic Sleep Lab
	Wood River Medical Center
	Magic Valley Medical Center
	Records of Timothy Johans, MD
PLEADINGS	
	Plaintiffs' Disclosure of Expert Witnesses w/attachments
MISC.	
	Twin Falls County Sheriff's Dept. Report
	Twin Falls County Coroner's Report



**CURRICULUM VITAE**

**RODDE D. COX, M.D.**  
1000 N. Curtis, Suite 202  
Boise, Idaho 83706  
(208) 377-3435

EDUCATION

Residency: Physical Medicine and Rehabilitation  
University of Washington, Seattle, Washington  
Internship completed 1989  
Residency completed June 30, 1992

Medical: University of Utah, School of Medicine  
Salt Lake City, Utah  
M.D., 1988

Undergraduate: University of Idaho, Moscow, Idaho, 1981-1984  
BS in Bacteriology  
Lewistown State College, Lewiston, Idaho, 1980-1981

High School: Lewiston High School, Lewiston, Idaho, 1980

MEDICAL/PROFESSIONAL LICENSURE

Licensed Physician and Surgeon, State of Idaho, 1994

Licensed Physician and Surgeon, State of Oregon, 1992

Diplomat of the National Board of Medical Examiners, 1989

SPECIALTY BOARD STATUS

American Board of Independent Medical Examiners, December 1997

American Board of Electrodiagnostic Medicine, certified April 1996

American Academy of Physical Medicine and Rehabilitation, certified May 1992, recertified July 2003

ADDITIONAL EXPERIENCE

Participant in St. Alphonsus Occupational Health Services design team, 1996-2000

Medical Director, Industrial Rehabilitation Program, STAARS, 1996-2000

Clinical Director, Injured Workers Program, Oregon Rehabilitation Center, 1/93-6/94

Development of Occupational Medicine Program, Sacred Heart General Hospital, Eugene, Oregon, 1994

Chief Resident in Department of Rehabilitation Medicine, University of Washington, 7/91-6/92

Perform electromyographic studies for Diabetes Controls and Complications Trial, Pacific Medical Center, Seattle, Washington, 1990-1992

Assistant for Biophysics and Kinesiology/biomechanics courses, University of Washington, Department of Rehabilitation Medicine, Seattle, Washington

*Page 2*  
*Curriculum Vitae*  
*Rodde Cox, M.D.*

AWARDS AND HONORS

Outstanding Resident Award, Department of Rehabilitation Medicine, University of Washington, 1992

Alpha Omega Alpha Medical Honor Society, University of Utah School of Medicine, 1988

PRACTICE AND HOSPITAL AFFILIATIONS

Boise Physical Medicine and Rehabilitation, Boise, Idaho, 1994-present  
Karehcr Estates, Nampa, Idaho, Medical Director, Rehabilitation Services, 12/94-12/97  
Hillcrest Care Center, Boise, Idaho, Rehabilitation Director, 1994-present  
St. Alphonsus Regional Medical Center, Boise, Idaho, Active Staff, 1995-present  
Elk's Rehabilitation Hospital, Boise, Idaho, Active Staff, 1995-present  
St. Luke's Regional Medical Center, Boise, Idaho, Active Staff, 1995-present  
Mercy Medical Center, Nampa, Idaho, Courtesy Staff, 1995-present  
West Valley Medical Center, Caldwell, Idaho, Courtesy Staff, 1995-present  
Rehabilitation Medicine Associates, Eugene, Oregon, 1992-1994  
Sacred Heart General Hospital, Eugene, Oregon, Active Staff, 1992-1994  
McKenzie-Willamette Hospital, Springfield, Oregon, Active Staff, 1992-1994  
River Park Living Center, Medical Director, Rehabilitation Services, Eugene, Oregon, 1993-1994

PROFESSIONAL ORGANIZATIONS

American Board of Independent Medical Examiners  
American Board of Electrodiagnostic Medicine  
Academy of Physical Medicine and Rehabilitation  
American Medical Association  
Idaho Medical Association  
Ada County Medical Association  
Northwest Association of Physical Medicine and Rehabilitation  
Physiatric Association of Spine, Sports and Occupational Rehabilitation

UNIVERSITY AFFILIATIONS

University of Washington, Clinical Faculty, Department of Rehabilitation Medicine, 1992-present

PUBLICATIONS

Book Review, American Journal of Physical Medicine and Rehabilitation; Volume 73; September/October 1994

Latex hypersensitivity following exposure to gloves during electromyography, Massagli, TC, Cox, RD, Muscle and Nerve; Volume 16; May, 1993



**RODDE COX, MD  
SCHMECHEL V. BYRNE, ET AL  
2.404.53**

**DOCUMENTS REVIEWED**

<b>DEPOSITIONS</b>	
	TJ Byrnes
	Clinton Dille, MD
	Vaughn Schmechel
	Robert Lewis
	Tamara Hall
	Kim Howard
<b>MEDICAL RECORDS</b>	
	Southern Idaho Pain and Rehabilitation Center
	Records of Kenneth Harris, MD
	Records of Kimberly Vorse, MD
	Sun Valley Sports Medicine
	Sun Valley Spine Institute
	Idaho Diagnostic Sleep Lab
	Wood River Medical Center
	Magic Valley Medical Center
	Records of Timothy Johans, MD
<b>PLEADINGS</b>	
	Plaintiffs' Disclosure of Expert Witnesses w/attachments



Richard E. Hall  
ISB #1253; reh@hallfarley.com  
Keely E. Duke  
ISB #6044; ked@hallfarley.com  
HALL, FARLEY, OBERRECHT & BLANTON, P.A.  
702 West Idaho, Suite 700  
Post Office Box 1271  
Boise, Idaho 83701  
Telephone: (208) 395-8500  
Facsimile: (208) 395-8585  
WA202-404.53\AFF - DR. COX.DOC

Attorneys for Defendant Thomas J. Byrne

IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT  
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS

VAUGHN SCHMECHEL, individually,  
and as Surviving Spouse and Personal  
Representative of the Estate of ROSALIE  
SCHMECHEL, deceased, and ROBERT P.  
LEWIS, KIM HOWARD and TAMARA  
HALL natural children of ROSALIE  
SCHMECHEL, deceased,

Plaintiffs,

vs.

CLINTON DILLE, M.D., SOUTHERN  
IDAHO PAIN INSTITUTE, an Idaho  
corporation, THOMAS BYRNE, P.A. and  
JOHN DOE, I through X,

Defendants.

Case No. CV-05-4345

**AFFIDAVIT OF RODDE COX, M.D.**

STATE OF IDAHO            )  
  )ss  
COUNTY OF \_\_\_\_\_ )

**RODDE COX, M.D.**, being first duly sworn on oath, deposes and states as follows:

1. I am over the age of 18 and I make the following statements based upon my own personal knowledge and belief.

2. I am a physician practicing in Boise, Idaho. I practice Physical Medicine and Rehabilitation with an active part of my practice in pain management. I have been practicing in Boise, Idaho since 1994. I obtained my undergraduate degree in Bacteriology from the University of Idaho in 1984. In 1988 I graduated from the University of Utah, School of Medicine. I completed my Physical Medicine and Rehabilitation internship and residency at the University of Washington in 1989 and 1992 respectively. My Curriculum Vitae is attached as Exhibit A.

3. I make this affidavit based upon my own personal knowledge.

4. I have been retained by counsel for defendant T.J. Byrne, P.A. in this matter to render testimony as an expert in Physical Medicine and Rehabilitation, including pain management.

5. I have reviewed a number of case specific documents which are detailed in the attached Exhibit B.

6. All of the opinions set forth in this Affidavit are opinions which I hold to a reasonable degree of medical certainty and I hold these opinions on a more probable than not basis.

7. I have had experience in supervising physician assistants during the course of my practice.

8. I am adequately familiar with the standard of care for physician assistants practicing pain management medicine in Twin Falls, Idaho in September and October 2003. I gained such familiarity through a variety of ways. I have had many interactions with physicians and physician

assistants in Twin Falls, Idaho, who practice pain management medicine and have discussed with them their practices in Twin Falls, Idaho from 1994 through 2006. Specifically, I have discussed with these various physicians and physician assistants their evaluation, treatment, and follow-up with patients. In addition to those interactions, I have also been involved in the medical care of patients receiving pain management therapy from Twin Falls' physicians and physician assistants during the years 1994 to the present. As a treating physician for such patients, I am familiar with the medical care these patients received, including the use of pain relievers such as Oxycontin, Methadone, Hydrocodone, Amitriptyline, and others. I have also read the depositions of T.J. Byrne and Dr. Clinton Dillé which discuss the standard of care for a physician assistant practicing pain management medicine in September and October 2003. Based on my involvement since 1994 with physicians, physician assistants, and patients from Twin Falls, Idaho, along with my review of the depositions of Mr. Byrne and Dr. Dillé, I am adequately familiar with the standard of care for a physician assistant practicing in Twin Falls, Idaho in September and October 2003 and opine that such standard of care was the same in Boise, Idaho as it was in Twin Falls, Idaho in September and October 2003.

9. Based on my education, training, experience in pain management medicine, and knowledge of the standard for a physician assistant practicing pain management medicine in Twin Falls, Idaho in September and October 2003, it is my opinion that Mr. Byrne met the standard of care in all respects in his care and treatment of Mrs. Schmechel.

10. Specifically, it is my opinion that Mr. Byrne met the standard of care in the following aspects of his care and treatment of Mrs. Schmechel:

- a. His examination of Mrs. Schmechel. Mr. Byrne performed a thorough examination of Mrs. Schmechel that included a review of her past medical conditions, past medical treatment, current condition, current and past

medications, her reasons for going to the Southern Idaho Pain Institute, and her goals for treatment.

- b. His review of Mrs. Schmechel's intake paperwork and his September 26, 2003, discussion with her in which he appropriately discovered information related to her past and current medical condition. Specifically, the standard of care did not require that Mr. Byrne obtain Mrs. Schmechel's prior treatment records from any provider (or discuss Mrs. Schmechel with any of her prior providers) because he determined Mrs. Schmechel was a good historian and he determined that he obtained the necessary information from her from which he was able to formulate an appropriate treatment plan. However, it was appropriate for him to obtain the orthopedic surgeon's records so he could evaluate whether the surgeon felt there was an operative component to Mrs. Schmechel's pain. Those records indicated that there was not an operative component. With respect to Dr. Vorse's records, I have reviewed Dr. Vorse's records and it is my opinion that there is nothing within Dr. Vorse's chart (or any of the medical providers' charts I have reviewed) that should have changed Mr. Byrne's treatment of Mrs. Schmechel. As such, nothing in those records would change my opinion that Mr. Byrne met the applicable standard of care in his care and treatment of Mrs. Schmechel.
- c. His decision to reduce her Amitryptiline. Amitryptiline has been linked to an increased chance of arrhythmias and Mr. Byrne appropriately reduced Mrs. Schmechel's moderate dose she was taking through Dr. Vorse.

- d. His determination that Mrs. Schmechel's Oxycontin should be discontinued and his decision to prescribe Methadone for Mrs. Schmechel. When Mrs. Schmechel presented on September 26, 2003, she complained that her current pain regimen was not working for her and she was complaining of 10 out of 10 pain. Given her complaints, it was reasonable for Mr. Byrne to change her pain management regimen. Methadone is a widely used and accepted medication for the treatment of chronic pain. Methadone was a good choice for Mrs. Schmechel given that Methadone is a Class II narcotic whose pharmacokinetic and pharmacodynamic properties allow it to be long acting. Methadone is good for neuropathic pain, which is the type of pain for which Mrs. Schmechel complained. In addition, Mr. Byrne knew of Mrs. Schmechel's obstructive sleep apnea and that she was using a CPAP machine to treat that condition. Methadone was an appropriate medicine to choose for Mrs. Schmechel, particularly given her long term use of Oxycontin and her complaints that the current pain regimen was not working for her.
- e. His decision to start Mrs. Schmechel on 5mgs twice a day and titrate up to 10mgs-15mgs twice a day. Mrs. Schmechel was not opioid naïve. She had been on Oxycontin for over 4 years and, at the time she saw Mr. Byrne, was taking 60mgs of Oxycontin a day. She had also been on Hydrocodone for numerous years and, at the time she saw Mr. Byrne, was taking 30-37.5 mgs a day. Mr. Byrne appropriately started Mrs. Schmechel on a conservative dose of methadone and then, after each conversation with her, appropriately increased her dose to the dose range he wanted her on.


- f. His follow-up with Mrs. Schmechel. Mr. Byrne met the standard of care in his follow-up care and treatment of Mrs. Schmechel given that he spoke with her by phone on both Monday September 29 and Tuesday September 30 to discuss how she was doing. It is my opinion that Mr. Byrne would also have met the standard of care had he just followed up with Mrs. Schmechel one to two weeks after starting her on the Methadone.
- g. Increasing her dose on Monday the 29<sup>th</sup> and Tuesday the 30<sup>th</sup>. Mr. Byrne's titration of Mrs. Schmechel's Methadone dosage on Monday September 29 and Tuesday September 30, 2003 was appropriate based upon the original conservative dose and Mr. Byrne's follow up with Mrs. Schmechel on the following Monday and Tuesday. It is also my opinion that his verbal and written dosing instructions were clear. If Mrs. Schmechel had not been following Mr. Byrne's instructions regarding her dosing, it is reasonable to expect that she would have notified Mr. Byrne on Monday, once he informed her of the increase in her dose from 5mgs twice a day to 10mgs twice a day, that she was already taking the higher dose. This is even further supported by the records which indicated that on Tuesday, Mrs. Schmechel reported to Mr. Byrne that she was doing well and had increased her dose the evening before to 15mgs. The records do not reflect that Mrs. Schmechel was not complying with Mr. Byrne's treatment plan; rather, they establish that she was in fact following his advice with respect to increasing her dose from 5mgs to 10mgs to 10-15mgs twice a day as he instructed her on September 26, 2003. In the event Mrs. Schmechel was not following Mr. Byrne's instructions and failed


to inform him of her failure to follow his directions, Mr. Byrne certainly cannot be held responsible for her actions.

Further your Affiant sayeth naught.

  
\_\_\_\_\_  
RODDE COX, M.D.

SUBSCRIBED AND SWORN TO before me this 11<sup>th</sup> day of June, 2007.



  
\_\_\_\_\_  
Notary Public for Idaho  
Residing at: Ada County  
My Commission Expires: 11-30-07

CERTIFICATE OF SERVICE


I HEREBY CERTIFY that on the 11<sup>th</sup> day of June, 2007, I caused to be served a true copy of the foregoing AFFIDAVIT OF RODDE COX, M.D., by the method indicated below, and addressed to each of the following:

David Comstock  
Law Offices of Comstock & Bush  
199 N. Capitol Blvd., Ste. 500  
P.O. Box 2774  
Boise, Idaho 83701  
*Attorney for Plaintiffs*  
Fax No.: (208) 344-7721

U.S. Mail, Postage Prepaid  
 Hand Delivered  
 Overnight Mail  
 Telecopy

Steven J. Hippler  
GIVENS PURSLEY  
601 W. Bannock ST.  
PO Box 2720  
Boise ID 83701-2720  
*Attorneys for Clinton Dillé, M.D. and  
Southern Idaho Pain Institute*

U.S. Mail, Postage Prepaid  
 Hand Delivered  
 Overnight Mail  
 Telecopy

  
\_\_\_\_\_  
Keely J. Duke



**CURRICULUM VITAE**

**RODDE D. COX, M.D.**  
1000 N. Curtis, Suite 202  
Boise, Idaho 83706  
(208) 377-3435

EDUCATION

Residency: Physical Medicine and Rehabilitation  
University of Washington, Seattle, Washington  
Internship completed 1989  
Residency completed June 30, 1992

Medical: University of Utah, School of Medicine  
Salt Lake City, Utah  
M.D., 1988

Undergraduate: University of Idaho, Moscow, Idaho, 1981-1984  
BS in Bacteriology  
Lewis Clark State College, Lewiston, Idaho, 1980-1981

High School: Lewiston High School, Lewiston, Idaho, 1980

MEDICAL/PROFESSIONAL LICENSURE

Licensed Physician and Surgeon, State of Idaho, 1994

Licensed Physician and Surgeon, State of Oregon, 1992

Diplomat of the National Board of Medical Examiners, 1989

SPECIALTY BOARD STATUS

American Board of Independent Medical Examiners, December 1997

American Board of Electrodiagnostic Medicine, certified April 1996

American Academy of Physical Medicine and Rehabilitation, certified May 1992, recertified July 2003

ADDITIONAL EXPERIENCE

Participant in St. Alphonsus Occupational Health Services design team, 1996-2000

Medical Director, Industrial Rehabilitation Program, STAARS, 1996-2000

Clinical Director, Injured Workers Program, Oregon Rehabilitation Center, 1/93-6/94

Development of Occupational Medicine Program, Sacred Heart General Hospital, Eugene, Oregon, 1994

Chief Resident in Department of Rehabilitation Medicine, University of Washington, 7/91-6/92

Perform electromyographic studies for Diabetes Controls and Complications Trial, Pacific Medical Center, Seattle, Washington, 1990-1992

Assistant for Biophysics and Kinesiology/biomechanics courses, University of Washington, Department of Rehabilitation Medicine, Seattle, Washington

Page 2  
*Curriculum Vitae*  
*Rodde Cox, M.D.*

AWARDS AND HONORS

Outstanding Resident Award, Department of Rehabilitation Medicine, University of Washington, 1992  
Alpha Omega Alpha Medical Honor Society, University of Utah School of Medicine, 1988

PRACTICE AND HOSPITAL AFFILIATIONS

Boise Physical Medicine and Rehabilitation, Boise, Idaho, 1994-present  
Karoher Estates, Nampa, Idaho, Medical Director, Rehabilitation Services, 12/94-12/97  
Hillcrest Care Center, Boise, Idaho, Rehabilitation Director, 1994-present  
St. Alphonsus Regional Medical Center, Boise, Idaho, Active Staff, 1995-present  
Elk's Rehabilitation Hospital, Boise, Idaho, Active Staff, 1995-present  
St. Luke's Regional Medical Center, Boise, Idaho, Active Staff, 1995-present  
Mercy Medical Center, Nampa, Idaho, Courtesy Staff, 1995-present  
West Valley Medical Center, Caldwell, Idaho, Courtesy Staff, 1995-present  
Rehabilitation Medicine Associates, Eugene, Oregon, 1992-1994  
Sacred Heart General Hospital, Eugene, Oregon, Active Staff, 1992-1994  
McKenzie-Willamette Hospital, Springfield, Oregon, Active Staff, 1992-1994  
River Park Living Center, Medical Director, Rehabilitation Services, Eugene, Oregon, 1993-1994

PROFESSIONAL ORGANIZATIONS

American Board of Independent Medical Examiners  
American Board of Electrodiagnostic Medicine  
Academy of Physical Medicine and Rehabilitation  
American Medical Association  
Idaho Medical Association  
Ada County Medical Association  
Northwest Association of Physical Medicine and Rehabilitation  
Physiatric Association of Spine, Sports and Occupational Rehabilitation

UNIVERSITY AFFILIATIONS

University of Washington, Clinical Faculty, Department of Rehabilitation Medicine, 1992-present

PUBLICATIONS

Book Review, American Journal of Physical Medicine and Rehabilitation; Volume 73; September/October 1994  
Latex hypersensitivity following exposure to gloves during electromyography, Massagli, TC, Cox, RD, Muscle and Nerve; Volume 16; May, 1993



RODDE COX, MD  
SCHMECHEL V. BYRNE, ET AL  
2.404.53

DOCUMENTS REVIEWED

DEPOSITIONS	
	TJ Byrnes
	Clinton Dille, MD
	Vaughn Schmechel
	Robert Lewis
	Tamara Hall
	Kim Howard
MEDICAL RECORDS	
	Southern Idaho Pain and Rehabilitation Center
	Records of Kenneth Harris, MD
	Records of Kimberly Vorse, MD
	Sun Valley Sports Medicine
	Sun Valley Spine Institute
	Idaho Diagnostic Sleep Lab
	Wood River Medical Center
	Magic Valley Medical Center
	Records of Timothy Johans, MD
PLEADINGS	
	Plaintiffs' Disclosure of Expert Witnesses w/attachments



---

## CURRICULUM VITAE

---

Keri L. Fakata, Pharm.D

Executive Clinical Research Scientist  
Lifetree Clinical Research ®  
3838 S. 700 E., Suite 202  
Salt Lake City, Utah 84106

Clinical Pharmacist Practitioner  
Lifetree Pain Clinic  
3838 S. 700 E., Suite 200  
Salt Lake City, UT 84106  
Email: [kerif@lifetrepain.com](mailto:kerif@lifetrepain.com)

### EDUCATION:

1989-1994	Bachelor of Science/ Biology University of Nebraska Omaha, Nebraska
2000-2001	Doctor of Pharmacy University of Nebraska Medical Center Pharmacy (UNMC) Omaha, Nebraska
2001-2002	Residency in Pharmacy Practice University of Utah Hospitals and Clinics Salt Lake City, Utah
2002-2004	Fellowship in Pain Management University of Utah Health Sciences Pain Management Center/College of Pain Management and Palliative Care-Pharmacotherapy

### PROFESSIONAL EXPERIENCE:

2006-present	Executive Clinical Scientist Lifetree Clinic Research Salt Lake City, UT
--------------	--

- 2004-present    Pain Management Clinical Pharmacist Practitioner  
Life Tree Pain Clinic  
Salt Lake City, UT
  
- 2002-2005    Clinical Instructor in Pharmacy Practice  
University of Utah College of Pharmacy  
Salt Lake City, UT
  
- 2002-2005    Clinical Pharmacist (pm)  
University of Utah Health Sciences Center  
Salt Lake City, UT
  
- 2001-2003    Community Pharmacist (prn) Walgreens  
Salt Lake City, UT.
  
- 2003            Adjunct Faculty Member  
Pharmacology, LDS Business College  
Salt Lake City, UT
  
- 1994-2000    Research Technologist, Pediatrics/Toxicology  
University of Nebraska Medical Center, Omaha Nebraska

**PROFESSIONAL AFFILIATIONS:**

- 2005-present    American Society of Pain Educators ASPE Faculty
  
- 2005-present    Professional Consultant for Elan Pharmaceutical    Inc.
  
- 2002-2004    Reviewer for Cochrane, Collaboration Pain,  
Palliative Care and Supportive
  
- 2002-2004    Reviewer for the *Journal of Pain & Palliative Care Pharmacotherapy*
  
- 2002-2004    Drug and Justice interdisciplinary working group,  
Department of Philosophy, University of Utah
  
- 2002-2005    American Pain Society
  
- 2002-2004    American College of Clinical Pharmacy
  
- 2002-2004    Utah Society of Health-Systems Pharmacists
  
- 1999-2001    American Society of Health-Systems Pharmacists
  
- 1999-2001    Chairperson and volunteer for SHARING  
(Student Health Alliance Reaching Indigent and Needy Groups)  
Clinic, University of Nebraska Medical Center
  
- 1997-2001    American Pharmaceutical Association Academy of Students of Pharmacy

**HONORS:**

- 2003-2005    National Institutes of Health (NIH) Clinical Research Loan Repayment  
Award (:21,000/year for up to four years)
  
- 2004            Alan S. Scott Scholarship Neurotoxin Institute

- 2004 American Pain Society Scholar Award
- 2004 American Pharmaceutical Association Academy of Pain Management Faculty Scholarship
- 2001 The Cunningham Memorial Award for Excellence and Interest in Pharmacodynamics, UNMC College of Pharmacy
- 2001 Phi Lambda Sigma Pharmacy Leadership Society, UNMC College of Pharmacy
- 2000 American Pharmaceutical Association/ Merck Student Project Award, UNMC College of Pharmacy
- 2000 Academy of Student of Pharmacy Scholarship, UNMC College of Pharmacy

#### PEER-REVIEWED PUBLICATIONS:

Fakata KL, B.E. Cole, Therapeutic Advances for Optimizing Opioid Tolerability in J of Family Practice 2007, to be published June 2007 issue (in press)

Webster LR, Fakata KL, Cherapata S, Fisher R, Minehart M, Open-label, Multicenter Study of Combined Intrathecal Morphine and Ziconotide: Addition of Morphine in Patients Receiving Ziconotide for Severe Chronic Pain. Pain Medicine (in press)

Fakata KL, Lipman AG: Anti-inflammatory Agents for Musculoskeletal Pain and Arthritis. Current Pain and Headache Reports. 2004; June 8(3):173-7,

Fakata KL, Lipman AG: Pharmacotherapy for pain in Rheumatological Conditions: The neuropathic component. Current Pain and Headache Reports 2003, June 7(3): 197-206

Sommers O, Fakata KL, Swanson SA Stemmer PM: Modulation of the Phosphatase Activity of Calcineurin by Oxidants and Antioxidants *in vitro*. European Journal of Biochemistry 2000; 267; 2312-2322,

Fakata KL, Eimquist WF, Swanson SA, Vorce RL, Prince C., Stemmer PM: Cyclosporin A has low potency as a calcineurin inhibitor in cells expressing high levels of P glycoprotein, Life Sciences 1998 62(26): 2441-2448.

Fakata KL , Swanson SA, Vorce RL Prince C, Stemmer PM: Pyrethroid insecticides as Phosphatase Inhibitors, Biochemical Pharmacology 1998; 55:2017-2022

#### BOOK CHAPTERS:

Fakata KL, Lipman G: Gastrointestinal Opioid Physiology and Pharmacology in *Opioid, Bowel Dysfunction*. Binghamton NY, Haworth Medical Press, 2005.

Fakata KL, Lipman AG: Gastrointestinal Opioid Effects in Acute and Chronic Pain Patients, In *Opioid Bowel Dysfunction*. Binghamton NY, Haworth Medical Press, 2005.

Joish VN, Fakata KL, Lipman AG, Arthritis Pain, Outcomes, and Evidence, In Evidence, Outcomes and Quality of Life in Pain Treatment, Wittink H, Carr DB, editors, Amsterdam, Elsevier, 2004: in press.

Fakata KL, Miaskoski C. Lipman AG. *Chronic Malignant Pain Management*, In *Pain Management for Primary Care Clinicians*. Bethesda MD, American Society of Health

Systems Pharmacists, 2004

Fakata KL, Lipman AG. Cancer Pain Management: Adjuvant Analgesics in Cancer Related Bone Pain. In *Encyclopedia Reference of Pain*, Springer-Verlag 2006

**OTHER PUBLICATIONS:**

Authored 1.5 hour Symposium, A Class Review of Peripherally Acting Opioid Antagonists: A focus on the management of opioid-induced adverse events, Power point presentation presented at American Academy of Pain Medicine New Orleans Feb 9<sup>th</sup> 2007.

Authored 1.5 hour symposium for APS Novel Peripheral Acting Opioid Antagonists: A focus on the management of opioid induced gastrointestinal adverse events to be presented in Washington DC at the American Pain Society Meeting May 4<sup>th</sup> 2007.

Practical Issues of Reimbursement for Intrathecal Drug Delivery: The Ziconotide Model by William Stuart and Keri L Fakata PharmD in *Practical Pain Management*. (in press)

Webster LR, Fakata KL: Ziconotide for Chronic Severe Pain. *Practical Pain Management* 2005 May 5(4) 47-56

**ABSTRACTS/POSTERS:**

Webster LR, Fakata KF, Grant BJB, Stoddard G. Patterns of Sleep Disordered Breathing in Chronic Pain Patients on Opioid Therapy vs Primary Care Patients not Opioid Therapy presented American Academy of Pain Medicine, 23 February 2006. San Diego Ca

Webster LR, Grant BJB, Fakata KL, and Choi Y. Sleep Apnea Associated with Methadone and Benzodiazepine Therapy poster presented at American Academy of Pain Medicine, 23 February 2006. San Diego Ca

Lipman AG, Fakata KL, Mullin S. Systematic Review of the Effects of Opioids and Pain on Human Immune Function- *J Pain* 2003; 4: Suppl 1. 56

Fakata KL, Lipman AG, Tuteja A, Ho, MJ. Opioid- Induced Bowel Dysfunction: A survey of prevalence and risk factors in Chronic Non-Malignant Pain Patients.- Submitted for poster. American Pain Society/Canadian Pain Society Annual Meeting May 2004 Vancouver BC. *J pain* 2004; 5(3) Supp.1 S45

**NATIONAL AND REGIONAL PRESENTATIONS:**

American Academy of Pain Medicine Feb 9<sup>th</sup> 2007, New Orleans, titled: A Class Review of Peripherally Acting Opioid Antagonists: A focus on the management of opioid-induced adverse events.

Colorado Pain Society Annual Meeting November 10<sup>th</sup> 2005, Denver Colorado Titled: Clinical Use of Ziconotide in Chronic Severe Pain.

**LICENSURE:**

Pharmacist, Utah, by examination, 2001- present 4946621-1701  
Pharmacist, Controlled Substance Schedule 2-5 4946621-8911  
Pharmacist, Montana by reciprocity 5411

**CLINICAL RESEARCH EXPERIENCE:**

A Pivotal Study of the Euphoria-Blocking Effects of Naltrexone HCl Co-Administered with Oxycodone HCl in Non-Dependent, Opioid-Preferring Subjects.

Safety, Tolerability, and Pharmacokinetics of Oral Study Medication with Estimation of the Maximally Tolerated Dose (MTD), in Healthy Male and Female Volunteers Using a Double-Blind, Placebo-Controlled, Single Ascending Dose, Sequential Cohort Study.

A Pilot Study to Select a Dose of Naltrexone Hydrochloride That Will Reduce Subjective Euphoric Effects of Oxycodone Hydrochloride in Non-Dependent, Opioid-Preferring Subjects.

An Evaluation of a Modified Immunoassay Urinalysis Used with a Dose Compliant Algorithm to Discriminate Between Multiple Clinically-Relevant Doses of Hydrocodone in Naltrexone-Blocked Opioid Naïve Healthy Volunteers.

A Double-Blind, Placebo-Controlled, Single Dose, Ascending, Sequential Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneous Study Medication in Healthy Male Volunteers.

7/01/02 to 06/30/04- Pain and the Defense Response - To study the effects of pharmacological manipulated noradrenergic arousal on the on the defense response. Research Associate.

2/02/03 to 12/11/03 - A double-blind placebo-controlled study of Study Medication for the relief of symptomatic constipation due to chronic opioid therapy in patients with advanced medical illness, Co-Investigator.

12/03 to 02/04 - A double-blind, placebo-controlled, multi-center phase IIB study to evaluate the efficacy and safety of multiple study medication dosage regimens for the treatment of opioid induced bowel dysfunction in subjects with chronic pain of nonmalignant origin. Co-investigator.

01/04 to 01/05 - A Double Blind Phase 3, Two-Week, Placebo Controlled Study of Study Medication for the Relief of Constipation Due to Opioid Therapy in Advanced Medical Illness Co-investigator

02/04 to 02/05 - A double-blind, randomized, placebo-controlled parallel-group, 16 week, multicenter trial evaluating the efficacy and safety of Study Medication 500 mg tablets in BID administration (daily range from 1000 mg to 3000 mg) in adults (18 years or age) suffering from post herpetic neuralgia. Co-investigator.

8/04-11/04 - Documentation of pharmacy costs in the preparation of chemotherapy infusion in academic and community-based oncology practices. Co-investigator.

4/04 to 4/05 - An open label, long term, multicenter, intrathecal study medication effectiveness and safety trial in patients with chronic severe pain. Co-investigator

2/05 to 6/05 - A randomized placebo-controlled crossover trial evaluating the effect of Study medication at 1, 3 and 6 mg dose levels on the abuse potential of 40 mg Study medication in non-dependent, opioid preferring subjects. Co-investigator

6/05-present - A double-blind, placebo controlled, ascending dose ranging study to evaluate the Safety tolerability and pharmacokinetics of subcutaneous study medication in Healthy male volunteers using an up and down design. Co-investigator.

03/06-present - A double-blind, placebo-controlled, single and multiple dose study to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of study Medication in healthy elderly volunteers. Co-investigator.

12/06 to present - Opioid Sparring effects of Intrathecal (IT) Ziconotide (PRIALT) in combination with IT Hydromorphone vs. Hydromorphone alone in Patients with Chronic Severe Pain. Principal Investigator

**CERTIFICATIONS:**

American Heart Association AC LS Certification  
Adult and Adolescent Immunization Certification

**PROFESSIONAL COMMUNITY SERVICE ACTIVITIES:**

Olympic Village Polyclinic Specialist- Volunteer Pharmacist 2002 Olympics, SLC, UT  
Peoples Health Clinic -Volunteer Pharmacist- Student preceptor - Park City, UT 2003-2004.



KERI L. FAKATA, PHARM.D  
 SCHMECHEL V. BYRNE, ET AL  
 2.404.53

DOCUMENTS REVIEWED

DEPOSITIONS	
	TJ Byrnes
	Clinton Dille, MD
	Vaughn Schmechel
	Robert Lewis
	Tamara Hall
	Kim Howard
MEDICAL RECORDS	
	Southern Idaho Pain and Rehabilitation Center
	Records of Kenneth Harris, MD
	Records of Kimberly Vorse, MD
	Sun Valley Sports Medicine
	Sun Valley Spine Institute
	Idaho Diagnostic Sleep Lab
	Wood River Medical Center
	Magic Valley Medical Center
	Records of Timothy Johans, MD
PLEADINGS	
	Plaintiffs' Disclosure of Expert Witnesses w/attachments
MISC.	
	Twin Falls County Sheriff's Dept. Report
	Twin Falls County Coroner's Report



Richard E. Hall  
 ISB #1253; reh@hallfarley.com  
 Keely E. Duke  
 ISB #6044; ked@hallfarley.com  
 HALL, FARLEY, OBERRECHT & BLANTON, P.A.  
 702 West Idaho, Suite 700  
 Post Office Box 1271  
 Boise, Idaho 83701  
 Telephone: (208) 395-8500  
 Facsimile: (208) 395-8585  
 W 032-404.53VAFF - DR FAKATA.DOC

Attorneys for Defendant Thomas J. Byrne

IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT  
 OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS

VAUGHN SCHMECHEL, individually,  
 and as Surviving Spouse and Personal  
 Representative of the Estate of ROSALIE  
 SCHMECHEL, deceased, and ROBERT P.  
 LEWIS, KIM HOWARD and TAMARA  
 HALL natural children of ROSALIE  
 SCHMECHEL, deceased,

Plaintiffs,

vs.

CLINTON DILLE, M.D., SOUTHERN  
 IDAHO PAIN INSTITUTE, an Idaho  
 corporation, THOMAS BYRNE, P.A. and  
 JOHN DOE, I through X,

Defendants.

Case No. CV-05-4345

**AFFIDAVIT OF KERI FAKATA,  
Pharm.D**

STATE OF UTAH )  
COUNTY OF Salt Lake )<sup>ss</sup>

KERI FAKATA, Pharm.D, being first duly sworn on oath, deposes and states as follows:

1. I am over the age of 18 and I make the following statements based upon my own personal knowledge and belief.

2. I am a Pharm.D practicing at Lifetree Pain Clinic in Salt Lake City, Utah. I have a Bachelor of Science in Biology from the University of Nebraska and obtained my Doctor of Pharmacy in 2001 from the University of Nebraska. I completed a Residency in Pharmacy Practice at the University of Utah Hospitals and Clinics in 2002 and performed a Fellowship in Pain Management at the University of Utah Health Sciences from 2002 to 2004.

3. During my time at the University of Utah in the Residency and Fellowship programs, I had an opportunity to work with Dr. Lipman and became acquainted with his practice as a Pharm.D.


4. Based upon my personal observations of Dr. Lipman's practice from 2002 through 2004, along with the training he provided in my Residency and Fellowship program at the University of Utah, Dr. Lipman has limited his practice to pharmacology workup. As such, Dr. Lipman does not provide medical diagnoses for patients and does not examine patients, or provide treatment to patients for purposes of diagnosis. Rather, based on diagnoses he is provided by a physician or physician assistant, Dr. Lipman provides physicians or physician assistants with pharmacologic treatment recommendations. However, Dr. Lipman does not make the decision as to what medications upon which a patient will be placed; that decision rests with the physician or physician assistant who will either accept or reject Dr. Lipman's recommendation(s). In addition, Dr. Lipman is not directly involved in the initiation of the medications for the patient and is not involved in

monitoring the patient or in the patient's follow-up care to evaluate how the patient is responding to the medications. As a Pharm.D, Dr. Lipman is also not permitted by law to prescribe medications to patients in the state of Utah.

*Keri F. Fakata*

KERI FAKATA, Pharm.D

Subscribed and sworn to before me this 4 day of June, 2007.



*[Signature]*

Notary Public for Utah

Residing at:

My Commission Expires:

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on the 4<sup>th</sup> day of June, 2007, I caused to be served a true copy of the foregoing AFFIDAVIT OF KERI FAKATA, PharmD, by the method indicated below, and addressed to each of the following:

David Comstock  
Law Offices of Comstock & Bush  
199 N. Capitol Blvd., Ste. 500  
P.O. Box 2774  
Boise, Idaho 83701  
*Attorney for Plaintiffs*  
Fax No.: (208) 344-7721

- U.S. Mail, Postage Prepaid
- Hand Delivered
- Overnight Mail
- Telecopy

Steven J. Hippler  
GIVENS PURSLEY  
601 W. Bannock ST.  
PO Box 2720  
Boise ID 83701-2720  
*Attorneys for Clinton Dille, M.D. and  
Southern Idaho Pain Institute*

- U.S. Mail, Postage Prepaid
- Hand Delivered
- Overnight Mail
- Telecopy

  
\_\_\_\_\_  
Keely E. Duke









SCOTT PHILLIPS, MD  
SCHMECHEL V. BYRNE, ET AL  
2.404.53

DOCUMENTS REVIEWED

DEPOSITIONS	
	TJ Byrnes
	Clinton Dille, MD
	Vaughn Schmechel
	Robert Lewis
	Tamara Hall
	Kim Howard
MEDICAL RECORDS	
	Southern Idaho Pain and Rehabilitation Center
	Records of Kenneth Harris, MD
	Records of Kimberly Vorse, MD
	Sun Valley Sports Medicine
	Sun Valley Spine Institute
	Idaho Diagnostic Sleep Lab
	Wood River Medical Center
	Magic Valley Medical Center
	Records of Timothy Johans, MD
	Twin Falls County Sheriff's Report
	Twin Falls County Coroner's Report
PLEADINGS	
	Plaintiffs' Disclosure of Expert Witnesses w/attachments